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293-HEK (human embryonic kidney) has traditionally been the packaging cell 
line of choice for the production of adenoviral vectors for gene therapy protocols.  
With an increase in demand for these vectors for clinical trials, it is necessary to 
address the need for development of robust and efficient cell culture process for vector 
production. 
A low glutamine fed-batch platform was developed for suspension culture of 
293-HEK cells.  The aim was to tighten the control on glutamine metabolism and 
hence reduce ammonia and lactate accumulation.  This fed-batch system was 
implemented using a commercial medium (293 SFM II), an in-house serum-free 
chemically-defined medium (SF-CDM) and finally an in-house protein-free 
chemically-defined medium (PF-CDM).  Reduction in glutamine and glucose 
consumption, as well as production of waste metabolites like lactate, ammonia, alanine 
and glycine, were observed in the fed-batch cultures.  Consequently, there were 
general improvements in maximum cell concentrations attainable in fed-batch cultures 
ranging from 4-6 million cells/mL, a 2 to 4 fold improvement over parallel batch 
cultures.  These improvements were translated into enhancement of virus titers up to 3 
X 1011 pfu/mL in the PF-CDM fed-batch platform.  These results demonstrated for the 
first time that the control of only glutamine at low levels in cultures is sufficient to 
reduce lactate and ammonia production and yield significant improvements in both cell 
concentrations and viral production. 
Transcriptional profiling was performed on cells from the mid-exponential, late 
exponential and stationary phases of both batch and fed-batch cultures of 293-HEK 




of genes related to glutamine/glutamate metabolism indicating a general reduction in 
glutaminolysis and a more efficient glutamine metabolism in the fed-batch cultures.  It 
also showed repression of TCA cycle coupled with an increase in electron transport 
chain activity and a reduction in proton leakage in the fed-batch, indicative of a more 
energetically efficient metabolic state.  There were also differences in the cell cycle 
regulation between the two modes of culture revealed by the transcriptional analysis, 
most notably the down-regulation of anti-proliferative (growth arrest) genes and genes 
that are related to DNA replication initiation in the fed-batch.  These results 
demonstrated that the microarray platform can effectively be utilized as a tool to 
monitor transcriptional events in mammalian cells in culture enabling significantly 
regulated genes to be identified as potential targets for cell lines improvements.  
However, future insights into the transcriptional regulatory network in its entirety may 
only be revealed with time when more genomic information becomes publicly 
available. 
Genetic intervention to reduce glutamine metabolism at the molecular level 
should dispense with the need for complicated fed-batch instrumentations.  Antisense 
down-regulation of the main glutaminolytic enzyme, glutaminase, was achieved and 
glutamate, alanine, proline, aspartic acid and asparagine profiles were observed to be 
different in the antisense clones compared to the untransfected cells.  These differences 
were attributed to a compensatory up-regulation of gamma-glutamyltransferase (γ-
GT).  The up-regulation of this alternative glutamine catabolic pathway is proposed to 
be in response to the down-regulation of glutaminase expression.  Although the 
strategy was unable to restrict glutamine metabolism by way of reducing glutamine 
uptake and ammonia production, it was established that γ-GT could play a significant 




mammalian cell bioprocessing.  Thus, to effectively modulate glutamine metabolism in 
cell culture, there may be a need to down-regulate both glutaminase and γ-GT.  The 
significance of γ-GT in other industrially important cell lines, such as CHO and BHK, 
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The heydays of gene therapy begun in 1990 with the first clinical trial to 
correct a life-threatening congenital defect through introduction of adenosine 
deaminase gene into immune cells (Culliton 1990).   It had brought with it the promise 
of a cure for a wide variety of genetic diseases and even cancer.  The euphoria 
dissipated however when Jesse Gelsinger, a University of Pennsylvennia clinical trial 
subject, died after receiving a dosage of adenoviral vector to correct a rare genetic liver 
disorder.  The US FDA suspended all viral vector gene therapy trials and placed the 
entire field under extreme scrutiny (Fox 2000).  Clinical trials were subsequently 
allowed to resume, albeit under new revised guidelines and since then much emphasis 
has been place on the safety of these vectors.  From this shift in paradigm, there 
emerged the second and third generation adenoviral vectors with improved safety 
profiles (Krougliak and Graham 1995; Wang et al. 1995; Yeh et al. 1996; Brough et 
al. 1996; Hardy et al. 1997; Kochanek et al. 2001).  More recently in late 2003, the 
gene therapy field received its greatest endorsement yet with the first approval of a 
commercial gene therapy product in China.  This anti-cancer gene therapy protocol is 
based on the adenoviral vector delivery of p53 tumor-suppressor gene for head and 
neck tumors (Pearson et al. 2004).  These developments have continued to sustain 
interest in adenoviral vector production which has traditionally been conducted in 293-





The major disadvantages of the first generation adenoviral vectors are being 
addressed with new developments in recombinant viral vector design.  To meet the 
growing demand of adenovirus vectors for gene therapy programs, parallel 
development of efficient, scalable and robust production processes is crucial and is the 
main motivation behind the work detailed in this thesis. 
Mammalian cell cultures are widely used for the production of 
biopharmaceutical therapeutics and the cultivation of mammalian cells has 
traditionally been dependent on undefined additives such as serum or other protein 
hydrolysates.  The inconsistencies of these materials and their potential for harboring 
harmful adventitious agents, plus additional complications introduced in downstream 
processes, have provided a strong push for their elimination from industrial cell culture 
processes (Lubiniecki 1999; Froud 1999).  Outbreaks of prion diseases in recent years 
have provided additional impetus for elimination of these animal-derived components 
for biotherapeutics production.  Although the use of vegetable-based protein 
hydrolysates (eg. soybean protein hydrolysate) as serum and protein replacements 
provides a means to achieve this, it relinquishes chemical definition by re-introduction 
of these chemically complex mixtures (Franek et al. 2000; Burteau et al. 2003).  The 
elimination of undefined components such as hydrolysates, has obvious advantages of 
yielding a “cleaner” and more consistent process that lends itself well to guidelines 
from the regulatory agencies and savings on downstream processing (eg. purification).  
Despite the prevalence of commercial protein-free, chemically defined media (PF-
CDM), the inaccessibility of information on their formulation places a limitation on the 





With insights from advancements in genomic expression analyses, genetic 
engineering of cells for improved culture characteristics is emerging as a feasible 
avenue of cell line improvement.  Information gleaned from microarray analyses have 
been successfully applied to the engineering of E. coli for resistance to anti-microbial 
agents and for hypersecretion of α-hemolysin (Gill et al. 2002; Lee and Lee 2005).  
However, much of these early works were conducted in less complex prokaryotic or 
lower eukaryotic (eg. yeast) systems due to the more complete genomic information 
available.  With the completion of the sequencing of the human genome, it remains to 
be seen if this vast amount of new genomic information can be exploited in a similar 
fashion.  An understanding of the transcriptional changes associated with metabolic 
improvements in culture should provide insights into important cellular processes that 
will be valuable in a rational approach to engineering of robust cell lines with 
improved cellular metabolism. 
1.3 Thesis Objectives 
Most fed-batch strategies reported in current literature focus mainly on the 
control of glucose at low level to achieve an alternate metabolic state.  Glutamine is a 
major protein component and implicated in a number of important biosynthetic 
pathways for purine, pyrimidine, amino sugars and nicotiamide nucleotide synthesis in 
cells.  Additionally, it is also one of the major intermediates of the anaplerotic 
pathways that provide alternative carbon sources that help maintain the carbon flux in 
the Tri-Carboxylic Acid (or TCA) cycle for energy production.  The metabolism of 
glutamine involves deamination to glutamate before conversion to the TCA cycle 
intermediate, 2-oxoglutarate.  This results in the formation of ammonia as a secondary 
metabolite.  Formation of lactate can also occur via the partial oxidation of pyruvate 




potentially lead to production of inhibitory levels of both lactate and ammonia.  
Accumulation of ammonia in mammalian cultures has a number of deleterious 
consequences and has been widely studied and reported (Schneider et al. 1996; 
Mirabet et al. 1997). 
The central theme of this thesis is the investigation, understanding and 
manipulation of cellular metabolism in 293-HEK cells to improve cell growth and 
hence adenovirus production.  Specifically, it is hypothesized that the control of only 
glutamine at low levels in culture is sufficient to restrict overflow glutamine 
metabolism leading to the formation of inhibitory waste metabolites, like lactate and 
ammonia, and result in improvements in viable cell concentrations and 
correspondingly higher adenoviral vector production titers.  The above hypothesis was 
investigated by comparison of batch and low glutamine fed-batch cultures conducted 
in a suspension system utilizing (A) a commercial serum-free medium (293 SFM II), 
(B) an in-house serum-free chemically defined medium (SF-CDM) and (C) an in-
house protein-free chemically defined medium (PF-CDM).  The protein-free 
chemically defined medium (PF-CDM) platform was developed to ascertain if 
additional improvements from the serum-free system were possible when cellular 
dependence on proteinaceous or undefined components were eliminated and better 
nutrient control of the fed-batch process implemented.  A transcriptional analysis using 
DNA microarray was also performed to decipher the transcriptional changes associated 
with alterations in cellular metabolism and the insights gleaned from this study assisted 
in identification of genetic targets for metabolic engineering of cell lines for improved 
growth and adenovirus production.  Finally, metabolic engineering to modulate 




metabolism can be effected at the molecular level without the implementation of 
complicated online fed-batch strategies and instrumentations. 
1.4 Thesis Organization 
This thesis comprises of 8 chapters.  Chapter 1 provides a brief introduction 
and outlines the theme and objectives of this thesis.  Chapter 2 consists of a literature 
review on adenoviruses, adenoviral gene therapy vectors, 293-HEK cells, dynamic 
nutrient-controlled fed-batches, protein-free chemically-defined media for mammalian 
cell cultures, DNA microarray and metabolic engineering of cells for improved cellular 
efficiency.  Chapter 3 details the materials and methods employed in this thesis.  
Chapter 4 highlights the results from low glutamine fed-batch cultures in commercial 
and in-house serum-free medium for improving cell concentrations and adenovirus 
production.  The development and implementation of a PF-CDM fed-batch platform 
for further improvements of culture performance is reported in Chapter 5.  Chapter 6 
presents the results from a transcriptional profiling study focused on cellular 
metabolism to decipher the genetic regulatory mechanism unlying the fed-batch 
process.  Chapter 7 presents the results from the metabolic engineering of 293-HEK 
cells to reduce cellular glutamine metabolism at the molecular level without the use of 
complex fed-batch instrumentations.  Finally, Chapter 8 consists of a summary of the 





2 LITERATURE REVIEW 
2.1 Adenoviruses 
Adenoviruses are widespread in nature and the different serotypes are known to 
be capable of infecting a wide spectrum of avian or mammalian hosts.  They are non-
enveloped double-stranded DNA viruses whose capsid is mainly composed of pentons 
(penton base and fiber monomers) and hexons (Figure 2.1).  The typical infection cycle 
begins with the attachment of the fiber to a suitable cellular receptor, eg. MHC (Major 
Histocompatibility Complex) class I molecule or CAR (Coxsackievirus and 
Adenovirus Receptor).  After receptor-mediated endocytosis, the toxicity of the 
pentons mediates the rupturing of the phagocytic membrane resulting in the release of 
the viral particle into the cytoplasm.  The viral particle then undergoes uncoating and 
migrates to the nucleus where the viral DNA enters and viral transcription and 
replication begins.  Completion of the virus infection cycle triggers cell death and the 
release of virion progeny (Figure 2.2).  Once in the host cell nucleus, the viral DNA 
forms a complex with the host cell histones and triggers off a series of viral genes 
transcription events.  The sequence of events leads firstly to sequestering of the host 
cell machinery for virus replication and eventually to the release of virion progeny 
(Figure 2.3). 
 The early region of the adenovirus type 5 was first identified with the potential 
to transform rodent cell in vitro in 1973 (Graham and van der Eb 1973).  Subsequent 
studies demonstrated that two of the earliest products of viral gene transcription, ie. 
Early 1A (E1A) and Early 1B (E1B), have the ability to interact with host cell tumor 
suppressors leading to cellular transformation and immortalization.  E1A has been 


































Figure 2.3  Adenovirus genes transcriptional events during infection cycle 
(Extracted from http://www.tulane.edu/~dmsander/WWW/335/Adenoviruses. 
html). 
 
to immortalise primary cells in vitro (Whyte et al. 1988).  The E1B product is known 
to bind the p53 tumor suppressor, however it does not transform cells on its own but 
cooperates with E1A to effect the stable transformation of cells (Yew and Berk 1992). 
2.2 Adenoviral gene therapy vectors 
The use of replication-deficient recombinant adenovirus in gene therapy is 
currently undergoing extensive research and some of these products are presently 
undergoing early clinical trials.  Currently, 26% of all gene therapy protocols 
undergoing clinical trials use adenoviral vectors.  This is second only to the use of 
retroviral vectors which comprises 27% of on-going gene therapy clinical trial 






Figure 2.4  Vectors used in gene therapy clinical trials (Extracted from 
http://www.wiley.co.uk/genetherapy/clinical/). 
 
There are many advantages of using adenovirus as gene delivery vectors.  
Firstly, they can be readily produced in suitable packaging cell lines (eg. 293-HEK and 
PER.C6) and purified for clinical applications.  Secondly, the deletion of the E1 and 
other less essential region of the viral DNA effectively created space in the capsid for 
the insertion of recombinant genes.  Recombinant viral vectors can accommodate large 
segments of foreign DNA up to 7.5kb.  And since the viral genome remains 
extrachromosomal, there is less risk of insertional mutagenesis.  However, this is a 
potential drawback if sustained expression of therapeutic gene is required.  
Furthermore, the E1-deficient adenoviral vectors retain some level of cytotoxicity, 
making them particularly well suited for destructive gene therapy strategies.  Last, but 
certainly not least, is the ability of the adenovirus to infect both quiescent as well as 
dividing cells as opposed to retrovirus which requires actively dividing cells for its 




Many of the existing adenoviral gene therapy protocols utilize first generation 
replication-incompetent adenoviral vector.  These vectors have their critical E1 region 
deleted to prevent the progression of virus infection in-vivo after dosing and yet allow 
easy expansion of viral stocks using a suitable packaging cell line expressing the viral 
E1 polypeptide (eg. 293-HEK).  They frequently have their E3 region removed as well 
to create space for the therapeutic gene to be introduced.  These first generation vectors 
can however sometimes regain the E1 region of their genome through homologous 
recombination events and become replication-competent.  The emergence of these 
mutant replication-competent adenoviruses (RCAs) in viral stocks can potentially 
compromise patient safety and poses a serious safety issue.  An additional 
complication with the use of first generation adenoviral vectors is the induction of 
inflammatory response by the presence of the remaining viral genes which can 
potentially trigger host immune response in subjects during clinical application and 
render repeated dosing difficult, if not impossible. 
New cell lines have been developed with the expressed purpose of eradicating 
this problem by elimination of the overlapping homologous region between the vector 
and helper cell line.  The human embryonic retinoblastoma cell line, PER.C6, was the 
result of such an effort (Fallaux et al. 1998).  The cellular-viral junction from the 
human adenovirus type 5 transformed 293 cell line has also been sequenced in a bid to 
better understand the integration of the viral DNA into the cell and hence the 
emergence of RCA.  This information may then be utilized in the design of vector/cell 
systems that reduces or prevents the occurrence of RCAs (Louis et al., 1997). 
Second generation adenoviral vectors have additional genes implicated in viral 
replication deleted so as to minimize synthesis of adenoviral proteins which can trigger 




vectors lacking both the E1/E3 and/or the E2 and E4 region of the viral genome 
(Krougliak and Graham 1995; Wang et al. 1995; Yeh et al. 1996; Brough et al. 1996).  
These vectors also have the added advantage of increased transgene capacity up to 10 
kb.  They have significantly improved safety for clinical use as well since no 
overlapping sequences exist in the E1-/E4- vectors and its complementary cell line and 
double recombination events are necessary for viruses to regain replication 
competency (Brough et al. 1996). 
Third generation ‘gutless’ adenovirus vectors have their entire viral genome 
removed and thus do not possess the capacity to replicate and require the presence of 
helper viruses to support replication and packaging.  Advantages over earlier 
generation viruses includes increased transgene capacity, reduced toxicity and 
immunogenicity, and increased persistence of transgene expression (Hardy et al. 1997; 
Kochanek et al. 2001). 
The major disadvantages of the first generation adenoviral vectors are being 
addressed with these new developments in recombinant viral vector design with 
improved genetic payload and safety profiles.  To meet the growing demand of 
adenovirus vectors for gene therapy programs, parallel development of efficient, 
scalable and robust production processes is crucial. 
2.3 293-HEK (Human Embryonic Kidney) cells 
The developments in gene therapy have fueled interest in the 293-Human 
Embryonic Kidney (293-HEK) cell line that has traditionally been used in the 
production of E1-deficient adenoviruses.  These cells were first derived in 1977 via 
transformation of primary kidney fibroblast from aborted human fetus with 
mechanically sheared fragments of the DNA from human adenovirus serotype 5 




contains two transcription units, E1A and E1B, whose products are necessary and 
sufficient for mammalian cell transformation by adenovirus.  The 293 cells express 
E1A and E1B viral gene products that are essential for the replication of adenovirus 
deficient in the E1 region.  As a result, they are used extensively in the production of 
E1-deficient recombinant viral vectors.  The resultant immortalized cell line was 
designated as 293-HEK and has since developed into one of the industrially important 
cell lines for both adenoviral vector and recombinant protein production. 
Being fibroblast of origin, the original 293-HEK cells were naturally adherent 
cells and were first developed as adherent monolayer cultures propagated in a serum-
supplemented complex medium.  The requirement of an anchorage surface for the 
adherent cells presents spatial constraints to the scaling up of the culture system.  
Theoretically, the virus infection kinetics of the adherent system is also believed to be 
less efficient than that of the suspension system since infection is a surface-dependent 
phenomenon and adherent cells have effectively 50% unexposed surface area.  Thus, 
adaptation of cells from surface-dependent growth to suspension growth offers a very 
big advantage in terms of bioprocessing. 
One of the challenges facing the adaptation of cells to suspension culture has 
been the development of aggregates that can render the accurate determination of cell 
numbers difficult.  This inaccuracy in the determination of cell count can pose a 
problem in subsequent targeting of cell concentrations for sub-culturing of the cells.  
Furthermore, it is believed that the infection of a highly aggregated culture will not be 
as efficient as that of a homogeneous mono-cellular culture since it will be difficult to 
expose cells located deep within the core of an aggregate to the virus. 
The 293-HEK cells were adapted to suspension growth by the originator of the 




adenovirus production (Graham 1987).  The feasibility of suspension culture of 293 
cells was investigated with an adenovirus expression system used for the production of 
Protein Tyrosine Phosphatase 1C and found to support high recombinant protein 
production (Ganier et al., 1994). 
More recent evidence of continued interest in this cell line includes attempts by 
numerous investigators to adapt these cells to serum-free growth in an effort to 
improve compliance with regulatory guidelines (Cote et al. 1998; Jayme et al. 1999; 
McAllister et al. 1999).  Other related work on comparisons of virus production 
techniques (Iyer et al. 1999) and attempts at online monitoring of the viral vector 
production process (Cote et al. 1997) have also been reported.  Industrial interest in the 
cell line also led to investigation on scaling-up of the culture process (Schoofs et al. 
1998) and development of high yielding perfusion process for adenoviral vector 
production (Henry et al. 2004).  Perhaps the greatest endorsement of its importance in 
the biotech industry is the employment of 293-HEK as the production cell line for the 
anti-sepsis drug XigrisTM (activated human protein C) by Eli Lilly. 
There is also fresh interest in the adoption of this cell line for rapid transient 
expression of moderate quantities of large number of potential drug candidates for 
evaluation during the drug discovery process.  The 293-EBNA cell line (Invitrogen) 
was developed for this specific purpose and supports high transient production of 
recombinant proteins.  This cell line constitutively expresses the Epstein-Barr Virus 
Nuclear Antigen (EBNA) that supports the episomal replication of plasmid vectors 
containing the viral oriP motif.  This permits extrachromosomal plasmid replication 
and maintains high transgene copy number for efficient transient recombinant protein 
expression without the need to select for stably transfected clones (Young et al. 1988; 




and ensures a robust drug discovery pipeline for industrial organizations and ensures 
continued industrial relevance of the 293 cell line.  
2.4 Dynamic nutrient-controlled fed-batch 
 
Glucose and glutamine concentrations in typical mammalian cell culture media 
are usually higher than concentrations required by cells for energy production and 
biomass assimilation.  This excess of glucose and glutamine induces an unnecessarily 
high uptake of these nutrients, resulting in the production of inhibitory levels of waste 
metabolites like lactate and ammonia.  The accumulation of inhibitory metabolites has 
been known to pose a limitation on the maximum attainable cell and product yields in 
mammalian cell batch cultures (Glacken 1988; Hassell et al. 1991; Mirabet et al. 
1997). 
The restriction of cells to a more efficient metabolic state via the control of 
principal metabolites in cell culture had been reported extensively in literature.  The 
accompanying improvements in cell and product yield have also been reported with 
varying degree of success by various authors.  Extensive work has been done on the 
use of dynamic nutrient feeding to maintain either glucose or both glucose and 
glutamine at low levels in fed-batch cultures.  This strategy has been shown to reduce 
the overflow of glucose and glutamine metabolism and shift cell metabolism to an 
efficient state with reduced waste metabolites production and thus achieve a higher cell 
concentration for enhance productivity.  The said approach has been successfully 
implemented in the fed-batch culture of hybridoma cells through the control of low 
glucose level in the culture via estimation of glucose consumption rate from online 
oxygen uptake rate (OUR) measurements, resulting in an improvement in both cell 




developed to maintain both glucose and glutamine at low levels and lactate, ammonia 
and alanine productions were all significantly reduced, allowing the hybridoma cell 
concentration to reach the reported level of 1x107 cells/mL (Zhou et al. 1996).  
Improvements in cell concentrations and product formation were achieved by other 
investigators with myeloma (Gambhir et al. 1999) and baby hamster kidney (BHK-21) 
cells (Cruz et al. 2000) using similar strategies.  Although there might be concerns that 
limiting glucose and/or glutamine can affect product glycosylation in fed-batch 
cultures, as both nutrients play a major role in forming the precursors of glycan 
structures, it has been reported that optimizing set-point nutrient levels could prevent 
loss of product glycosylation (Wong et al., 2005a). 
Although similar low glucose cultures of 293 cells have been studied before, 
significant improvements in cell concentration have not been achieved, even though 
lactate production was observed to have reduced (Siegwart et al. 1999).  The elevation 
of cell concentration and adenovirus vector production were however achieved by 
other researchers through the control of glucose and glutamine.  This was despite a 
fractionally lower specific productivity of virus that was attributed to a possible 
decrease in infection efficiency due to aggregate formation (Wong et al. 1999). 
2.5 Protein-free chemically-defined media for mammalian cell 
culture 
In 1885, Wilhelm Roux’s demonstration that embryonic chicken cells could be 
maintained alive in vitro in a warm physiological solution heralded the birth of cell 
culture.  Traditional cell culture relied heavily on poorly defined crude animal-derived 
extracts, most common of which are equine or bovine serum, to supply the necessary 
macromolecular nutrients, including certain growth factors.  Serum is costly and 




it is also highly subjected to lot-to-lot variability and risks of contamination by 
adventitious agents (eg. bacteria and viruses), their by-products (eg. bacteria 
endotoxin) and other contaminants such as prions.  The inconsistencies of these 
materials and their potential for harboring harmful agents, plus additional 
complications introduced in downstream processes, have provided a strong push for 
their elimination from industrial cell culture processes (Lubiniecki 1999; Froud 1999). 
Cell culture media development took a big step forward with the first 
description of a chemically-defined, synthetic medium with the ability to support the 
clonal growth of certain mammalian cells (Ham 1965).  Better understanding of the 
growth promoting properties of serum permitted the creation of a chemically-defined, 
serum-free medium through substitution of serum with specific hormones (Hayashi 
and Sato 1976).  Other reports demonstrated that refinement of nutrients and trace 
metals supplements supported clonal growth of CHO cells (Hamilton and Ham 1977; 
Gasser et al. 1985).  Nonetheless, a universal serum-free formulation remained elusive 
and serum-free media formulations continues to be highly cell line specific due to the 
fastidious nature of different cell lines (Hayashi and Sato 1976; Barnes and Sato 1980). 
As culture techniques are gradually refined, it soon became apparent that a 
mixture of four important factors, selenium, insulin, transferrin and ethanolamine, are 
critical for many cell lines’ survival in the absence of serum.  Selenium, a trace 
element usually supplemented in the form of sodium selenite, is thought to be an 
important co-factor in cellular processes to combat oxidative stress.  Insulin and 
transferrin are both protein components and are involved in stimulating cell 
proliferation and iron transport respectively.  Ethanolamine is required for fatty acid 
metabolism and assembly and was found to be essential in serum-free cultures of 




With outbreaks in prion diseases in recent years, the use of animal-derived 
components for biotherapeutics production has come under close scrutiny from the 
regulatory authorities.  This has in part provided some of the impetus towards the 
development of protein-free media.  Since insulin and transferrin are frequently the 
only two remaining protein components in many existing serum-free formulation, 
efforts were concentrated around the systematic substitution of each of these protein 
components with chemically simpler structures.  Growth of certain human tumour cell 
lines have been reported in transferrin-free media supplemented with an alternate iron 
source, ferric citrate (Neumannova et al 1995).  Hybridoma cultures in protein-free 
chemically-defined media were also reported with some degree of success (Stoll et al. 
1996). 
Other researchers adopting an alternative approach resorted to the use of 
vegetable-based protein hydrolysates (eg. soybean protein hydrolysate) as serum and 
protein replacements.  This effectively makes the media protein and animal 
component-free but relinquishes chemical definition by re-introduction of these 
chemically complex mixtures of protein hydrolysates (Franek et al. 2000; Burteau et 
al. 2003).  The elimination of undefined components such as hydrolysates has obvious 
advantages of yielding a “cleaner” process that lends itself well to guidelines from the 
regulatory agencies and savings on downstream processing (eg. purification).  An 
additional advantage of having a fully defined system is the ease with which process 
optimization can be executed.  Hence, there is a clearly perceptible shift in the industry 
towards the use of protein-free chemically-defined media which is apparent in the wide 





The recent advent of new and more sensitive analytical techniques and 
development of high throughput analysis coupled with high capacity computation 
enabled a more rational approach to media development.  However, media 
development work remains highly laborious and manpower intensive and continues to 
be dominated by commercial entities.  These biopharmaceutical and media companies 
protect their formulations under trade secrets and the inaccessibility of formulation 
information places a limitation on the ability to conduct process optimization since the 
nutrient environment is unknown. 
2.6. DNA microarray 
The DNA microarray is one technological approach that has the potential to 
measure changes in global mRNA expression levels.  It involves the use of 
immobilized DNA “targets” spotted on coated glass slides at extremely high density of 
up to 40000 spots per glass slide in a patterned grid known as an array.  Each spot on 
the array contains purified DNA from a unique representative section of a discrete 
gene of the organism of interest and the whole array functions like multiple concurrent 
Southern blots.  This technology has in part been made available in recent years 
through advancement in mechatronics allowing for construction of highly precise 
robotic systems capable of printing the DNA arrays of such dense patterns onto glass 
slides.  It has also become a reality in part through the massive sequencing efforts that 
provided the necessary genomic information for the design of these “targets”. 
For study of genomic expression differences, known "target" DNA, either 
cDNAs (500~5,000 bases) or oligonucleotides (20~70 bases), are first spotted onto 
microscope slides.  mRNA from two populations of cells at different states (eg. batch 
vs fed-batch, disease vs normal tissue, etc.) will then have to be isolated.  The mRNA 




in the cell at two distinctly different physiological states.  In a traditional dual dye 
system, the mRNA populations are then reverse transcribed in vitro into cDNA and 
labeled separately with individual fluorescent dyes (eg. Cy3 and Cy5) that have 
different, non-overlapping emission spectras.  The two differently labeled cDNA 
populations are then mixed and used as a “probe” for the array printed on the slide.  
The “probe” is then hybridized to the array and excess “probe” DNA removed by 
washing before it is scanned using a laser or white light scanner.  The difference in 
expression of different genes in the dissimilar states is reflected as differences in the 
ratio of fluorescent intensities of the two dyes.  It is thus possible to quantify the 
difference in gene expression between the two physiological states. 
2.6.1. Transcriptional profiling using microarray 
The concept of microarray as a tool for monitoring of genome-wide 
transcriptional patterns was first reported in 1995.  This proof-of-concept study was 
performed on Arabidopsis thaliana, a flowering plant with one of the smallest known 
plant genomes commonly employed in genomic studies, and established the efficacy of 
this new genomic tool (Schena et al. 1995).  Since its inception, microarray has gained 
widespread employment in many aspects of biomedical research, especially in the 
cancer arena (MacGregor and Squire 2002; Clarke et al. 2004; Stoughton 2005). 
Most of the initial transcriptional profiling work was carried out in the yeast, 
Saccharomyces cerevisiae, due to the amount of genomic information available on this 
lower eukaryotic organism after its genome has been sequenced.  This facilitated the 
construction of whole genome DNA microarray for yeast studies (Lashkari et al. 
1997).  An excellent example that clearly demonstrated the power of this genomic tool 
in metabolism studies is the study of alteration in metabolism during diauxic shift yeast 




respiration of ethanol (DeRisi et al., 1997).  Part of the extension of this work includes 
the deciphering of the gene transcriptional regulation of phosphate metabolism and the 
translational response to rapid transfer from fermentable (glucose) to nonfermentable 
(glycerol) carbon source (Ogawa et al. 2000; Kuhn et al. 2001). 
Microarray was quickly adopted for the study of basic cellular processes in 
higher organisms (eg. human cell culture systems).  Transcriptional profiling of the 
responses of human fibroblasts to serum withdrawal revealed clusters of gene with 
related functions showing coordinated temporal expression patterns.  Furthermore, 
previously unknown genes were observed with expression regulated in highly specific 
temporal patterns, leading to speculations of their possible functions (Iyer et al. 1999).  
Two other subsequent studies focused on deciphering of the cellular program behind 
cell cycle regulation in a bid to further understanding of this basic cellular process 
(Cho et al. 2001, Whitfield et al. 2002). 
In the context of bioprocessing, much of the work to date has predominantly 
been conducted in prokaryotic systems or lower eukaryotics like the yeast.  
Transcriptional profiling of metabolic response to glucose in B. subtilis, protein 
overproduction and during high cell concentration culture in E. coli have been reported 
(Blencke et al. 2003, Oh and Liao 2000, Yoon et al. 2003).  However, not much has 
been reported with respect to mammalian cell cultures, with the exception of 
expression profiling of hybridoma in metabolically shifted cultures using a 
combination of both microarray and proteomic analyses (Korke et al. 2004). 
With the insights gained from advancement in genomic expression analysis, 
genetic engineering of cells for improved culture characteristics is emerging as a 
feasible avenue of cell line improvement.  It is by no means an immature technology as 




microarray analysis has been applied to the engineering of E. coli for resistance to anti-
microbial agents (Gill et al. 2002) and for hypersecretion of Α-hemolysin through 
manipulation of translation rate via rare codon usage (Lee and Lee 2005).   
2.7. Metabolic engineering of cells for improved cellular efficiency 
Genetic manipulation of the metabolic pathways involving ammonia and 
lactate presents an alternative approach to regulate the accumulation of lactate and 
ammonia.   Various strategies have been reported in literature for the construction of 
stable cell lines with reduced ammonia and/or lactate formation through genetic 
manipulation of critical genes in the metabolic network. 
Overexpression of glutamine synthetase (GS) was originally conceived as a 
novel selection marker system for selection and amplification of transgene expression 
for recombinant protein production in mammalian cell culture.  GS catalyses the 
formation of glutamine from glutamate and ammonia and thus imparts transfected cells 
with the ability to proliferate in glutamine-free media.  It has also been demonstrated to 
possess the additional benefit of reducing ammonia accumulation in NS0, hybridoma 
and CHO cell cultures (Cockett et al. 1990; Bebbington et al. 1992; Birch et al. 1994). 
 Other studies have reported the reduction of the level of accumulated ammonia 
by concurrent overexpression of carbamoyl phosphate synthetase I (CPS I) and 
ornithine transcarbamoylase (OTC) in CHO cells.  CPS I and OTC catalyze the first 
and second step of the urea cycle in the liver respectively.  Ammonium ions produced 
by deamination reactions are converted to carbamoyl phosphate by CPS I and then to 
citrulline by OTC resulting in lower accumulation of this toxic waste metabolite (Park 
et al. 2000). 
Strategies to limit the production of lactate includes introduction of a cytosolic 




cytosol provides a shunt from pyruvate to malate that enters the TCA cycle in the 
mitochondria.  This shunt reaction competes directly with lactate dehydrogenase 
(LDH) for the cytosolic pyruvate pool and hence reduces lactate accumulation.  This 
approach was demonstrated to reduce lactate accumulation in BHK-21 cells and also 
improve recombinant protein production (Irani et al. 1999; Irani et al. 2002).  This 
same strategy was established for two other cell lines:  293-HEK and High-Five insect 
cell line (Elias et al. 2003). 
An alternative approach to limiting lactate production is to directly target the 
gene responsible for lactate formation from pyruvate, LDH.  Gene targeted knock-out 
via homologous recombination was performed on a hybridoma cell line, however only 
partial disruption of the LDH-A (LDH isozyme A) was achieved.  However, despite 
having only partial disruption, the resultant downregulation of LDH was sufficient to 









3 MATERIALS AND METHODS 
3.1 Cell Cultivation 
The 293 Human Embryonic Kidney cell line (293H from GibcoBRL, Life 
Technologies, Maryland) was single-cell cloned into serum-free, suspension culture by 
the company prior to commercialization.  They were adapted to grow in three different 
media during the entire course of the experiments, namely (A) 293 SFM II, (B) in-
house serum-free chemically defined medium (SF-CDM) and (C) in-house protein-free 
chemically defined medium (PF-CDM).  The details of the three different media are as 
follows: 
(A) 293 SFM II is a commercial low protein serum-free medium (GibcoBRL, Life 
Technologies, Maryland).  The medium was supplemented with 4 mM L-glutamine 
(Sigma Cat No. G5763) prepared in a 200 mM stock solution with 4.5 % NaCl (Sigma 
Cat No. S5886).  The medium formulation is proprietary to Gibco and thus the exact 
composition of the medium is not known. 
(B) The in-house serum-free chemically defined medium (SF-CDM) was 
formulated based on a custom modified calcium-free DMEM/F12 medium (Hyclone, 
Logan, Utah) supplemented with SITE (selenium, insulin, transferrin and 
ethanolamine) liquid media supplement (Sigma Cat No. 4920).  Cells were adapted to 
this SF-CDM to minimize the complications in data analysis introduced by working 
with an undefined commercial medium or from undefined components like 
hydrolysates.  Dextran sulphate MW 5000 (Sigma Cat No. D7037) was found to 
alleviate cell aggregation issues encountered in the SF-CDM.  The in-house SF-CDM 
formulation is proprietary to Bioprocessing Technology Institute (BTI) and protected 




(C) The in-house protein-free chemically-defined medium (PF-CDM) was the 
result of further modifications to the SF-CDM formulation.  The basal medium 
formulation (as mentioned above) was further supplemented with top-up of glucose, 
glutamine, aspartate, serine, methionine and leucine.  Protein components, insulin and 
transferrin, were removed or replaced with a chemically-defined component of non-
proteinaceous nature.  The in-house PF-CDM formulation is proprietary to 
Bioprocessing Technology Institute (BTI) and protected as a trade secret. 
Cells were grown in shaker flasks at 37 oC incubator with 8 % CO2 atmosphere 
and sub-cultured every 3 days to 3-3.5 x 105 cells/mL.  Inoculum for the bioreactor 
was prepared in shaker flasks using the abovementioned conditions.  Fed-batch 
cultures in the bioreactor were started using 0.3-0.5 mM glutamine and controlled at 
between 0.1-0.3 mM in the culture.  Control batch cultures in 2 L bioreactors were 
started at 4 mM glutamine in 293 SFM II, 2.5 mM glutamine in SF-CDM and 4mM 
glutamine in PF-CDM respectively, with the normal amount of glucose typically found 
in these media (25 mmol/L in 293 SFM II and PF-CDM; 17.5 mmol/L in SF-CDM).  
All inoculums were spun down and spent media removed before resuspension in fresh 
media prior to inoculation. 
The anchorage dependent 293 Human Embryonic Kidney (HEK) cell line used 
for the metabolic engineering work was purchased from American Type Culture 
Collection (ATCC CRL-1573).  The cell line was grown in DMEM medium 
(Invitrogen) supplemented with 10% (v/v) fetal calf serum (Hyclone).  These cells 
were chosen for transfection primarily because attached cells have higher transfection 
efficiency.  Cells were adapted to suspension growth in serum-free medium, 293 SFM 
II supplemented with 4 mM glutamine (Sigma Cat No. G5763) after transfection.  




Suspension cells were subcultured every 3-4 days in shaker flasks.  Both types of cells 
were grown at 37°C with 8% CO2 atmosphere. 
3.1.1 Batch Bioreactor Operations 
Batch cultures were conducted in a 2 L double-walled, round-bottom glass 
vessel (B. Braun, Melsungen, Germany) with a heated water jacket.  The reactors were 
inoculated at an initial working volume of 2 L with a 3-3.5 X 105 cells/mL seeding 
density.  Bubble-less aeration was effected through the use of a silicone membrane 
tubing basket (B. Braun, Melsungen, Germany) and the dissolved oxygen 
concentration (DO) maintained at 50 % of air saturation at 1 atm using an Air/N2 mix 
(early phase) or O2/Air mix (late phase) set at 1 L/min.  Agitation rate was set at 120 
rpm using a 3-blade segmented impeller.  pH in the culture was maintained at 7.10 
using intermittent CO2 addition to the gas mix or 7.5 % (w/v) NaHCO3 (Sigma Cat No. 
S5761) solution.  It should be noted that a comparison of these batch cultures with 
shaker flask cultures showed no significant differences in maximum cell concentration 
attainable (results not shown).  Batch cultures conducted in 2 L and 5 L bioreactor 
vessels also achieved comparable specific growth rates and maximum cell 
concentrations (Appendix A). 
3.1.2 Fed-Batch Bioreactor Operations 
The fed-batch cultures were conducted in a 5 L double-walled, round-bottom 
glass vessel (B. Braun, Melsungen, Germany) with a heated water jacket.  The reactors 
were inoculated with a seeding density of 3-3.5 X 105 cells/mL at an initial working 
volume of 4 L.  Aeration, agitation and pH control were implemented as described 




The glutamine and glutamate concentrations in the culture were tracked online 
using an automated aseptic online sampling loop.  The flowrate of the sampling loop 
was set at 1-3 L/hr.  A 10 μm stainless steel spin-filter (B. Braun, Melsungen, 
Germany) mounted on the impeller shaft excludes 99 % of the cells from the 
recirculation loop.  A Biopem online filtration unit fitted with a 0.2 μm filter 
membrane (B. Braun, Melsungen, Germany) further downstream ensures a cell-free 






















Cell free sample withdrawn from spin filter, 10 micron
 
Figure 3.1  Bioreactor fed-batch system set-up.  Where:  DCU = Digital Control 
Unit;  MFCS = Multi-Fermenter Control System; DOT = Dissolved Oxygen 
Tension. 
 
Initial cultures were conducted to determine a baseline glutamine consumption 
rate to establish a suitable online sampling and feeding time interval for the fed-batch 




maintaining glutamine level as low as 0.1 mM in culture and implemented in the fed-
batch system.  Online YSI monitoring of glutamine/glutamate level was done every 1.5 
hours and the measured value transmitted back to the Biostat MD Digital Control Unit, 
DCU (B. Braun, Melsungen, Germany), which was then relayed to the Multi-
Fermenter Control System, MFCS (B. Braun, Melsungen, Germany).  An online 
algorithm calculated the amount of concentrated feed required to maintain culture at 
pre-set glutamine level (Figure 3.2 and Table 3.1). 
Feed injection was effected via a peristaltic pump (Watson-Marlow, Cornwall, 
England) set at 11 mL/min under the control of the DCU and injection quantity was 
controlled via the use of a weighing balance (Mettler Toledo, Columbus, OH, USA) 
communicating directly with the MFCS.  The feed medium for the 293 SFM II cultures 
was prepared from a custom formulated 10X calcium-free, glucose-free and glutamine-
free DMEM/F12 with 1X salt (Hyclone, Logan, UT, USA).  Feed medium was then 
supplemented with 10 g/L of Hysoy (Quest International, Hoffman Estate, IL, USA) 
soybean protein hydrolysate and 20 mM of glutamine (Sigma Cat No. G5763).  The 
feed medium for the SF-CDM fed-batch culture was similar except for the exclusion of 
Hysoy since cells used were adapted to hydrolysate-free growth. 
The 293 SFM II and SF-CDM fed-batch were also spiked with 100X SITE 
(selenium, insulin, transferrin and ethanolamine) media supplement concentrate 
(Sigma Cat. No. 4920) at 72 hours to a final concentration of 1X in the cultures.  This 
SITE spike was essential to ensure high cell yields in the fed-batch cultures as the 
starting amount present in the media was not sufficient to support growth at the much 
higher cell concentrations and needed to be replenished.  It was however excluded in 
the PF-CDM fed-batches with no deleterious effects since cultures were already 





Figure 3.2  Flowchart of control algorithm for automatic fed-batch system.  See 
Table 3.1 for detailed description of parameters. 
Start BatchAge
Timer = Abs(Cos(BatchAge * π / SamplingInterval))
TimerTrig =  
Timer > 0.99 
Count1 = (Count1 + 1) * 
TimerTrig End
Const1 =  
Count1 = 1 
End
Const2 = (Gln 
< GlnSetpt) * TimerTrig 
End
YSIVolLoss = YSIVolLoss + 
(3.32/1000) * Const1 Count2 = (Count2 + 1) * Const2 
Const3 = 
Count2 = 1 End
Pump = ScaleMod > Mass 
Subs1 = 50 * Pump 
End
RxtrVol = VolIni + (- ScaleMod) / 













AmtGlnFeed = (GlnSetpt – Gln) * RxtrVol * Const3 
MassFeed = (AmtGlnFeed / GlnFeed) * 1000 
Mass = Mass – MassFeed 




Table 3.1  Parameters from flowchart of online fed-batch control algorithms 
Parameter Description 
BatchAge Reactor run time from inoculation 
Abs Absolute function 
Cos Cosine function 
SamplingInterval Time interval for automatic online sampling (set at 90 mins) 
Timer  Timer for automatic online sampling 
TimerTrig Constant for triggering of online calculations at online sampling when Timer1 > 
0.99 at the end of 90 minutes cycle 
Count1 Self-resetting counter to ensure single pass calculation for YSI volume loss at 
each sampling interval 
Const1 Constant for triggering of YSI sampling loss calculation 
YSIVolLoss Sampling volume loss from YSI online sampling 
Gln Online glutamine concentration value (from YSI) 
GlnSetpt Glutamine concentration setpoint value 
Const2 Constant for triggering of feed calculations at Gln < GlnSetpt 
Count2 Self-resetting counter to ensure single pass calculation for feeding at each 
sampling interval 
Const3 Constant for triggering of feed calculations 
RxtrVol Culture volume in reactor 
AmtGlnFeed Amount of glutamine required to bring concentration level back to setpoint 
GlnFeed Glutamine concentration in feed 
MassFeed Mass of required feed (equivalent to volume since specific gravity of feed ~ 1.0) 
Mass Online calculated cumulative mass 
Scale Actual measured mass from weighing scale 
FeedOffset Mass offset value to cater for feed manipulations during run 
ScaleMod Modified scale reading after accounting for offset 
Pump Trigger for feed pump 
Subs1 Activation of substrate pump at 50% power output 
VolIni Initial culture volume in reactor at start of run 





The feed medium was modified from the SF-CDM feed for the PF-CDM fed-
batch cultures with the exclusion of sodium chloride, NaCl, and elevation of all other 
salts in the feed to 10X of the level found in DMEM/F12.  This was to allow 
supplementation of important trace elements that might run out during the fed-batch 
without running into osmolality issues from introduction of too much NaCl.  Calcium 
chloride, CaCl2 (Sigma Cat No. C2661), was maintained at 20 µM level in the feed to 
avoid clumping issue associated with high calcium levels in the culture.  Ferric citrate 
trihydrate, C6H5FeO7.3H2O (BDH Cat No. 283814C), was supplemented at 500 uM in 
the feed as an iron source to substitute transferrin.  Concentrated glucose solution was 
spiked into the reactor to bring the glucose level up to 2 g/L whenever it fell below 0.5 
g/L to ensure that it was not depleted in the fed-batches.  The glutamine concentration 
was successfully maintained at the desired set-points in the cultures as can be 
demonstrated by the online glutamine concentration profiles showing that residual 
level at the end of each 1.5 hours sampling cycle were not depleted at any point of the 
cultures (Figure 3.3). 
3.1.3 Cell Concentration Determination 
The cell concentration in the culture was determined by cell counting using an 
Improved Neubauer haemocytometer (Weber, England).  Cell viability was estimated 
using the trypan blue exclusion method.  An additional complication with clumpy cells 
at high cell concentration in the latter stages of the 293 SFM II and SF-CDM fed-batch 
cultures entailed the need to disperse the cells with the use of a 0.23-gauge hypodermic 
needle.  This method was employed as prior attempts to disperse the cells using trypsin 
proved unsuccessful.  This might be attributed to a clumping mechanism independent 
of cell surface proteins and hence explains the impotence of trypsin to de-aggregate the 





























Figure 3.3  Glutamine concentration profiles of batch (broken lines) and fed-
batch cultures (solid lines) conducted at different glutamine levels in (A) 293 SFM 
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treatment with the syringe was detrimental to cells, viability was instead estimated 
using trypan blue on an untreated sample.  This clumping issue was however not 
observed in the PF-CDM fed-batches until culture viability started to fall below 80%. 
3.1.4 Metabolite Analysis 
The glucose, lactate, glutamine and glutamate concentrations in the culture 
supernatent were determined using a YSI 2700 biochemical analyzer (Yellow Springs 
Instruments, Youngstown, OH, USA).  The glucose and lactate were determined 
offline from a sample of culture supernatent.  The glutamine and glutamate 
concentrations were determined online via an aseptic online sampling loop connected 
to the YSI biochemical analyzer. 
 Amino acid analysis of the culture was determined from offline samples by 
reverse-phase HPLC using a Shimpack VP-ODS column (Shimadzu, Kyoto, Japan).  
Amino acid derivatization prior to the HPLC analysis was performed using the Waters 
AccQ Fluor Reagent Kit (Millipore, Milford, MA, USA).  Detection was done at 395 
nm with a fluorescent detector (Shimadzu, Kyoto, Japan). 
Ammonia assay was performed with a UV spectrophotometric kit  as per 
manufacturer’s instructions (Sigma Cat. No. 171-C).  A 5X dilution of the culture 
supernatent with MilliQ water was done before the assay to bring the ammonia level 
within detection range of the assay kit. 
3.1.5 Specific Rates 
The average specific growth rate (μ) was obtained from the gradient of a 
straight line fit to the logarithmic plot of cell concentration versus time over the 




Specific rates, q, of individual metabolites were determined from the 




1  f(t)N, 
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  q 12         (3.1) 
 
Where specific rate, q, is calculated from the concentration of metabolite at earlier time 
point (t1), C1, concentration at subsequent time point (t2), C2, and the cell 
concentration time profile, N,f(t).  A 4th-order polynomial was first fitted to the cell 
concentration data to obtain the cell concentration as a function of time before 
mathematical integration was performed.  A polynomial fit was utilized instead of an 
exponential curve because it affords a better fit to the data, especially towards the 
stationary phase of the culture where growth slows. 
3.1.6 Microarray Sample Collection and Storage 
Cells were collected from mid-exponential, late exponential and stationary 
phases of both PF-CDM batch and fed-batch cultures for the microarray experiments.  
Cells from the common inoculum used to seed both cultures were collected for use as a 
reference (Control) sample.  By hybridizing samples from each phase against the 
common reference, it allows for the construction of temporal gene expression profiles 
for comparison of significantly regulated genes in the two cultures with the 
progression of the culture.  Samples of culture with 3 X 107 cells were taken from the 
bioreactors and centrifuged at 1000 rpm (or average RCF = 160 g) for 10 minutes in a 
swinging bucket centrifuge (Beckman).  Supernatent was removed and cell pellets 
stored in -80 oC prior to RNA extraction.  All samples were collected at viabilities > 
90% to ensure that RNA isolated from the cell pellets will be of sufficiently good 




3.2 Virus Infection 
The adenoviral vector, Ad5 CMV-GFP (Q-biogene, Carlsbad, CA, USA), used 
was a human adenovirus serotype 5 carrying a reporter gene expressing the green 
fluorescent protein (GFP) under the control of the Cytomegalovirus (CMV) promoter.  
It is an E1-deleted adenovirus and is hence replication deficient in normal cells.  It 
requires the E1 polypeptides that are expressed in 293-HEK cells to be able to 
reproduce virion progeny.  The virus stock titer was typically 1 X 109 (± 10%) plaque 
forming unit/mL (pfu/mL).  The use of a model virus carrying the GFP reporter gene 
was to facilitate subsequent virus quantification using the end-point dilution titering 
method. 
In the bioreactor, the batch cultures were infected at a cell concentration of 1-
1.5 X 106 cells/mL and the fed-batch cultures were infected at 3-4 X 106 cells/mL.  
The cultures were infected at cell concentrations well before peak concentrations to 
ensure that the cultures were in good condition necessary for virus propagation.  
Infection experiments conducted in shake flask cultures were conducted at 1 X 106 
cells/mL after culture was spun-down and media exchange conducted.  This was done 
to ensure the cultures are in optimal nutrient environment for the virus production 
phase.  It was however not a feasible practice for bioreactor cultures since there is no 
efficient protocol for effecting media exchange for large volumes without 
compromising the cultures.  All cultures were infected with a MOI (Multiplicity of 
Infection) of 5 pfu/cell to ensure synchronous infection. 
3.2.1 Virus Titer 
The virus productivity was quantified using TCID50 (Tissue Culture Infectious 
Dosage 50 %) assay via end-point dilution.  Samples harvested from the reactor were 




293-HEK cells (ATCC #:  CRL-1573) were grown to confluency in DMEM 
(GibcoBRL, Rockville, MA, USA) with 10% Fetal Bovine Serum (Hyclone, Logan, 
UT, USA) in T-75 flasks.  The cells were then trypsinized and counted.  A cell 
suspension of 1 X 105 cells/mL was obtained by dilution with fresh media.  A serial 
dilution of the virus samples was prepared with fresh media.  Virus dilutions of 10-5 – 
10-11 were mixed with equal volumes of cell suspensions and then plated into 96-well 
titer plates.  Each dilution was plated into 16 wells of 100 μL each.  Plates were 
incubated for 6 days at 37 oC and 5 % CO2.  Plates were manually scored for 
fluorescence on the 6th day using a fluorescent microscope.  The 6th day scoring was 
chosen to allow sufficient time for cells to reach confluence and virus infection, and 
progression, to take place so that the cells will start expressing GFP.  However, some 
of the GFP gradually loses its fluorescence beyond that time frame and titer scores 
drops after day 6.  Scores were tabulated and TCID50 values were then calculated 
according to the method of Reed and Muench (Reed and Muench 1938).  TCID50/mL 
values were converted to pfu/mL by multiplication with a factor of 0.69, which was 
obtained assuming a Gaussian distribution (O’Reilly et al. 1994). 
3.3 DNA Microarray Platform Development 
Most of the microarray protocols used were adapted from protocols employed 
by Dr. Patrick Brown’s laboratory, Stanford University (http://cmgm.stanford.edu/ 
pbrown).  A summary of the microarray experimental workflow is presented in Figure 
3.4. 
3.3.1 Slide Coating 
Glass microscope slides were coated with poly-L-lysine prior to spotting of 





Figure 3.4  Outline of microarray workflow 
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to which nucleic acid can adhere electrostatically prior to permanent fixation via cross-
linking.  3” X 1” microscope slides (Gold Seal) arranged in slide racks were cleaned 
by soaking with 2.5M NaOH in 57% ethanol for 2 hours to remove trace amounts of 
oils  and  debris.    The  slides  were  then  rinsed  by  repeated  plunging  into  multiple 
changes of deionised water (minimum 10 litres).  Slides should not be exposed to air 
for extended periods at any point to avoid formation of water-stains. 
 Coating was done by gently shaking the slides in poly-L-lysine solution (for 1 
rack: 70 mL poly-L-lysine + 40 mL tissue culture PBS + 300 mL deionised water) for 
1 hour.  The poly-L-lysine solution should not be prepared in glass containers to avoid 
unnecessary loss due to coating of containers.  Polyethylene containers were used for 
both preparation of the poly-L-lysine solution and for coating the slides.  The slides 
were then rinsed as described previously.  The coated slides were then spun in a 
centrifuge at 600 rpm (or average RCF = 60 g) for 10 minutes to dry.  The slides were 
dried further in a 42 OC vacuum oven for 10-15 minutes to dry (to minimize exposure 
of the slides to dust, the rack was wrapped in aluminum foil from this point onward).  
The dried slides were then stored in clean plastic slide box for minimum of 14 days 
before printing. 
3.3.2 Preparation of DNA for printing 
The probe DNA used in the construction of the microarray was purchased from 
Compugen.  The oligonucleotide library consists of 18,861 oligos, representing 18,656 
unique genes (LEADSTM cluster).  1 nmol of each oligo, between 55-70 bases long 
(with a 5'-C6 amino modifier), was supplied lyophilized in 96-wells format comprising 
a total of 197 plates.  The oligos were reconstituted in-situ with 20 ul of filtered 0.1 M 
NaPO4 buffer (pH 7.5) to 50 μM and this was designated the master plate.  5 μL was 




to 25 μM with 5 μL 0.1 M NaPO4 buffer (pH 7.5).  5 μL was transferred from the 
working plate to the printing plate (384-well) and further diluted to 12.5 μM with 5 μL 
of 2X printing buffer (2 M Betaine + 20% DMSO in 6X SSC).  384-well printing 
plates were used due to compatibility with the microarray printer.  All plates were 
covered with aluminum microplate seal (Axygen), spun-down and stored in -20 oC 
until use.  All liquid transfers were effected with a liquid handling system (Tecan).     
3.3.3 Array design, printing and post-processing 
19,584 element (including landing lights and additional controls) microarrays 
were spotted from the 384-well printing plates onto poly-L-lysine coated slides.  
Landing lights are oligos labeled with each of the Cy3 or Cy5 dyes prior to printing to 
facilitate easy orientation of the slide image and spots alignment after scanning.  Each 
96-well plate from the manufacturer came with a control in the form of 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) but additional controls were 
included in the microarray (Table 3.2). 
Printing or spotting of the microarray was done using a Virtek SDDC-3 array 
printer (Bio-Rad Laboratories, CA) equipped with 48 quill-type steel pins (Telechem, 
Sunnyvale, CA) in a 12 X 4 configuration (Figure 3.5).  Spots were printed in a left-to-
right, top-to-bottom fashion at a nominal centre-to-centre spacing of 185 μm to obtain 
a microarray with 48 sub-arrays consisting of 408 spots each (Figure 3.6). 
Printed slides were baked at 80°C for 2 hours and blocked with succinic 
anhydride and 1,2 dichloroethane as described in previous publication (Diehl et al. 
2001).  The purpose of the baking was to fix the oligos to the poly-L-lysine coat by 
cross-linking to it and thus ensures that the target DNAs are not removed during post-
hybridization washing steps.  The blocking step serves to reduce the amount of 




Table 3.2  List of additional controls included in the microarray 
Control Gene Description 
K01391 B. subtilis tryptophan (trp) operon Cy3 landing light at top left hand corner 
of each sub-array.  Bacterial gene with 
no known homolog in Human. 
X17013 B. subtilis lys gene for diaminopimelate 
decarboxylase 
Cy5 landing light at bottom right hand 
corner of each sub-array.  Bacterial gene 
with no known homolog in Human. 
M24537 B. subtillis sporulation protein 
(spoOB), GTP-binding protein (obg), 
phenylalanine biosynthesis associated 
protein (pheB), and monofunctional 
prephenate dehydratase (pheA) genes 
Negative control.  Bacterial gene with no 
known homolog in Human. 
NM_001614 H. sapiens actin, gamma 1 (ACTG1) Positive control.  High abundance 
Human gene. 
NM_001402 H. sapiens eukaryotic translation 
elongation factor 1 alpha 1 (EEF1A1) 
Positive control.  High abundance 
Human gene. 
NM_001658 H. sapiens ADP-ribosylation factor 1 
(ARF1) 
Sensitivity control.  Low abundance 
Human gene. 
NM_001659 H. sapiens ADP-ribosylation factor 3 
(ARF3), mRNA 
Sensitivity control.  Low abundance 
Human gene. 
PolyA N.A. Negative control.  Check for unspecific 
binding due to oligo-dT on cDNA. 
HumanCot1 N.A. Negative control.  Check for unspecific 
binding to Human DNA. 
Printing Buffer N.A. Negative control.  Check for background 



















Figure 3.5  Virtek SDCC3 Array Printer (inset bottom left:  Brass print-head 













Figure 3.6  Schematic layout of microarray slide. 
 
   The identity of each spot in the array on the slides was mapped out by the 
array visualization software Clonetracker (BioDiscovery) and a reference file created 
for spot alignment and subsequent extraction of data from the scanned images. 
3.3.4 RNA Purification, Reverse Transcription and cDNA Labeling 
Total RNA were extracted from cell pellet samples (3 x 107 cells) using Trizol 
reagent as per manufacturer’s instructions (Invitrogen).  Quantity and quality of total 
RNA extracted was then verified with the use of a capillary UV-spectrophotometer, 
GeneQuantTM Pro RNA/DNA Calculator (Amersham Biosciences, Piscataway, NJ).  A 
UV absorbance ratio of 260nm/280nm > 1.8 was considered of sufficient purity.   1st-
strand cDNA targets were then prepared by oligo-dT priming of 50ug of total RNA 
(per microarray hybridization) using Superscript II reverse-transcriptase (Invitrogen) 
and amino-allyl dUTP.  Oligo-dT priming ensured that the 1st-strand cDNA was a 
representation of only the mRNA population and hence only the genes that were 
actively expressed and transcribed by the cells.  Following the reverse-transcription, 






NHS-ester Cy3 (PA23001) and Cy5 dye (PA25001, Amersham Biosciences, 
Piscataway, NJ).   
3.3.5 Array Hybridization and Scanning 
Hybridization of the targets onto the slides was conducted in a manual 
hybridization chamber (Telechem) for a minimum of 16 hrs at 42oC.  Four slides per 
experimental time point were used, with 2 forward and 2 reversed-dye labeling.  
Essentially, two hybridizations were carried out with the Test sample labeled with Cy5 
and Control sample labeled with Cy3 and another two replicates with the dyes 
switched around.  This reversed-dye labeling is to account for any possible dye bias 
that might skew the results.  Hybridized arrays were then washed to remove 
unspecifically bound DNA on the slide and scanned using an ArrayWorx scanner 
(Applied Precision).  The emission wavelengths from both dyes are different and thus 
the slide was scanned at two different channels and the composite image stitched 
together by the software.  An example of a scanned composite image of a section of a 
hybridized microarray is shown in Figure 3.7.  The raw intensity values from the scans 
can then be extracted using the software in conjunction with the Reference File that 
maps out the spots’ identities and location on the array. 
3.3.6 Data Processing and Analysis 
Intensity values data obtained from the scanner were then uploaded to an in-
house microarray data processing system, Microarray Discovery System (MDS).  Raw 
data normalization was conducted in the MDS using Lowess normalization and scale 
normalized between the slides conducted using median absolute deviation (MAD). 
Compared to other techniques, like housekeeping-based normalization, global 





Figure 3.7  Composite scan image of a section of a hybridized microarray.  (Note:  
With respect to Control, green denotes down-regulation in sample; red denotes 
up-regulation in sample; yellow denotes no change) 
 
constantly expressed housekeeping genes may not hold.  The fundamental assumption 
in global normalization is that majority of genes do not undergo change in expression 
and thus the overall mean expression ratio serves as the normalization standard.  This 
is a valid assumption since transcriptional changes of only small proportion of the 
entire genome is necessary for cells to achieve alternate physiological/phenotypic 
states. 
Locally Weighted Linear Regression (Lowess) Normalization 
One of the most widely used global normalization techniques is the Locally 
Weighted Linear Regression (Lowess) method, which was first applied to microarray 
data by Yang et al. (2002).  Subsequent microarray studies have demonstrated the 
robustness of fit of this method in the presence of a few extreme outliers.  The main 
idea behind this non-linear correction procedure was to utilize a locally weighted 
polynomial regression of the intensity scatterplot in order to obtain the calibration 




determining the value of the calibration factor.  However, it was suggested that a log2-
based scatterplot of the mean log intensity (A) versus the transformed ratio (M) should 
be used instead of the simple log2-based intensity scatterplot as the former is capable 
of removing any intensity dependent effects in the log ratio values.  This type of 
scatterplot is commonly known as a Bland-Altman plot in the statistics literature.  The 
values for A and M are given as: 
 










M 2log         (3.3) 
where  Ir = red channel (ie. Cy5) intensity 
 Ig = green channel (ie. Cy3) intensity 
 
Normalization was achieved by first employing a non-linear polynomial 
regression between A and M.  The normalized log ratios (MNormalized) were then 
obtained by subtracting the estimated log ratio (MLowess, obtained from the Lowess fit) 
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An illustration of the normalization process shows more symmetrical spread of the 








Figure 3.8  M-A plots of microarray data before (left) and after (right) Lowess 
normalization. 
 
Median Absolute Deviation (MAD) Scaling 
Normalized intensity ratios from the slides can still have different data spread.  
Therefore, before meaningful comparison of the data can be conducted between the 
different replicates, these inherent discrepancies in the spread of the data have to be 
eliminated first.  Inter-slide scale normalization of the data was conducted using the 
Median Absolute Deviation (MAD) method.  This algorithm scales each array based 
on an estimated scaling factor, αi, for each slide which was derived from the median 
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An illustration of the scaling process shows more even spread of the data after MAD 








Figure 3.9  Box plots of microarray data before (left) and after (right) MAD scale 
normalization. 
 
Determination of Statistical Significance 
The reliability of the data was reflected in its reproducibility and that was 
ascertained via a t-test.  The t-test was conducted on the normalized and scaled log 
intensity ratios using the following: 
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The probability value, p-value, was calculated based on Student’s t-distribution from 
the t-value, tg, using Java program provided by JSCI maths package 
(http://jsci.sourceforge.net/).  The p-value allows for rapid isolation of genes with good 
reproducibility for in-depth analysis and further literature mining. 
 Methods described above were adapted from previous publication (Yang et al., 
2002).  Gene expression values herein are expressed as the log2 intensity ratio of each 
phase with respect to the Control.  Resulting log ratios were then filtered at a 
significance fold-change cut-off of 1 (ie. 2-fold) or 0.58 (ie. 1.5-fold).  A statistical 
confidence level of p-value ≤ 0.05 was used.  Genes were deemed to be significantly 
regulated if the expression value satisfies these criteria at any one of the three phases 
(ie. mid-exponential, late exponential and stationary) of batch and fed-batch.  List of 
significantly regulated genes at 1.5-fold and p-value ≤ 0.05 is included in Appendix B.  
Significantly regulated genes were grouped by function using available databases such 
as Entrez Gene (www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=gene) and KEGG 
(www.genome.jp/kegg) (Kanehisa et al. 2002) and visualized using TreeView 
(http://rana.lbl.gov/EisenSoftware.htm).  Clustering of the microarray data was also 
attempted using Cluster (http://rana.lbl.gov/EisenSoftware.htm) and visualized using 
TreeView.  The aim of this was to try to isolate clusters of genes with similar 
expression profiles and attempt to elucidate the functions of some of the as yet 




A further pathway-oriented analysis of the dataset at a less stringent fold 
change criteria of 1.5-fold (at p < 0.05) was conducted using the GenMAPP software 
(www.genmapp.org) (Dahlquist et al., 2002).  However, in order to better appreciate 
the differences in the transcriptional regulation of these genes with time, low fold 
change values were included in the gene expression profiles to ensure continuity. 
3.4 Quantitative Real-Time PCR 
Selected gene expression results from microarray data were validated using 
quantitative real-time PCR (qRT-PCR).  Primers were either obtained from 
PrimerBank (http://pga.mgh.harvard.edu/primerbank/) or designed using the Primer 
Express software (PE Applied Biosystems) when not available.  List of primer 
sequences used is included in Table 3.3. 
cDNA samples from Control (inoculum) and each sampling point were 
obtained from oligo-dT priming of equal loading of total RNA (30ug) to minimize 
non-uniform loading for the qRT-PCR runs.  qRT-PCR runs were conducted with 
these cDNA samples (1 μL in 25 μL final reaction mix per well) using Biorad iTaq 
mastermix (Biorad) in an ABI Prism 7000 (PE Applied Biosystems).  Duplicate runs 
were conducted for each sample.  Relative fold change in gene expression to Control 
was calculated using the delta-delta threshold cycle method (Livak and Schmittgen 
2001).  The threshold cycle of each gene was normalized against the threshold cycle of 
Eukaryotic Translation Elongation Factor 1 Alpha 1, EEF1A1 (Genbank accession:  








Table 3.3  Primer sequences used for quantitative real-time PCR 
Gene ID Description Accession Forward Primer (5' - 3') 
Reverse Primer 
(5' - 3') 
EEFIA1 
Eukaryotic translation 





ACTB Actin beta NM_001101 CATGTACGTTGCTATCCAGGC 
CTCCTTAATGTCA
CGCACGAT 
ACTG1 Actin gamma 1 NM_001614 TCACCCACACTGTGCCCATCTACGA 
CAGCGGAACCGC
TCATTGCCAATGG 
ASNS Asparagine synthetase NM_001673 GAATACCAGACCAAAGTGGATGG 
GCGGAGTGCTTC
AATGTAACAAG 

















































3 ; CHOP 
NM_004083 GAAACAGAGT GGTCATTCCC C 
TCGATTTCCTGCT
TGAGCC 






3.5 Construction of Antisense Glutaminase Plasmids 
The pGA104 recombinant plasmid containing the rat kidney phosphate 
activated glutaminase (PAG) cDNA (Genbank Accession number: M65150) was 
kindly provided by Dr. Norman P. Curthoys (Colorado State University).  Three 
fragments were obtained after restriction with EcoRI and HindIII.  The fragment sizes 
were 1.6 kb, 1.1 kb and 0.28 kb.  The 3’-end sequences, 1.6 kb and 0.28 kb, were 
subcloned in their antisense orientations into the pcDNA3.1 vector containing a 




of the high sequence similarity found amongst cDNAs coding for C-terminal ends of 
known glutaminases, including human glutaminase (Lobo et al., 2000).  The sequences 
selected for antisense targeting were specific to kidney glutaminase and do not show 
homology to other genes, as verified by NCBI BLAST.  This ensures that the antisense 
constructs target the gene-of-interest specifically and does not cause any peripheral 
effects by affecting the expression of other genes.  The resulting constructions were 
designated pPAG1.6AS and pPAG0.28AS. 
3.6 Generation of Antisense Glutaminase Stable Cell Lines 
293-HEK cells were transfected using Lipofectamine™ 2000 reagent 
(Invitrogen), as per manufacturer’s instructions, to obtain the stable cell lines 293-
1.6AS (1.6kb antisense fragment) and 293-0.28AS (0.28kb antisense fragment).  G418 
(Sigma Cat No. G8168) was added at a concentration of 700 μg/mL and drug resistant 
cells were collected after 2-3 weeks for single cell cloning, in which cells were diluted, 
and seeded in 96-well plates at one cell per well.  Wells that contained more than one 
cell were marked and excluded from further investigation.  50% of the medium in each 
well was replaced twice a week.  After 4-6 weeks, surviving clones reached confluency 
and were expanded for banking.  Selected clones were adapted to suspension and 
serum-free culture for ease of handling.  All subsequent cell line characterizations were 
conducted using these suspension cultures. 
3.7 Detection of Antisense Transcripts using RT-PCR 
The presence of antisense transcripts expression in the 293-1.6AS and 293-
0.28AS clones was verified using RT-PCR.  The primers used were designed to 
amplify a 200 base-pair amplicon overlapping the 3’ restriction site on the antisense 




-3’) primes near the 3’ region of both antisense transcripts (which are identical) and the 
reverse primer (5’-CAACAGATGGCTGGCAACTA-3’) primes the vector backbone 
region adjacent to the 3’ restriction site.  Hence only cells containing either one of the 
antisense plasmid vector and actively expressing antisense transcripts will show a band 
on RT-PCR. 
Total RNA were extracted from cell pellet samples (3 x 107 cells) using Trizol 
reagent as per manufacturer’s instructions (Invitrogen).  1st-strand cDNA was 
synthesized by reverse transcription of total RNA (30 ug) using ImProm-II reverse 
transcriptase (Promega) and anchored oligo-dT28.  0.5 μL of resulting first-strand 
cDNA was used as the template for the 40 cycles PCR amplication reaction conducted 
using Taq DNA polymerase (Fermentas).  5 μL of PCR products were subjected to 
electrophoresis on a 1.5% agarose gel, stained with 0.5 μg/μL of ethidium bromide and 
visualized with the use of a UV-light box (BioRad). 
3.8 Detection of Glutaminase by Western Blot 
Transfected and non-transfected 293-HEK cells, on the third day of growth, 
were pelleted by centrifugation, washed once with ice-cold PBS, and lysed on ice in 
RIPA buffer [50mM Tris HCl (pH 7.4), 150nM NaCl, 1mM EDTA, 1% (v/v) Triton 
X-100, 1% (w/v) sodium deoxycholate, 0.1% (w/v) SDS], with added protease 
inhibitors, PMSF (0.2mM), pepstatina (1.0µg/mL), Leupeptin (10µg/mL) and aprotinin 
(1.0µg/mL).  Cell lysates were clarified by centrifugation at 14K rpm (or average RCF 
= 14500 g) for 10mins in the cold room.  Total cell proteins [25µg; determined by 
BCA protein assay (Pierce)] with NuPAGE LDS Sample Buffer (Invitrogen) were 
boiled at 95oC for 5 minutes, electrophoresed on 4-12% Bis-Tris HCl/polyacrylamide 
gels (Invitrogen), and transferred to nitrocellulose membranes. The membranes were 




of 1:10000 (kindly supplied by Prof. J. C. A. Ramos of Malaga University, Spain), 
followed by a second incubation with a goat anti-rabbit IgG horseradish-peroxidase 
antibody (Abcam Ab6721; dilution 1:5000). The glutaminase bands were then detected 
using ECL Kit from Amersham and recorded onto chemiluminescent detection film 
(Roche).  The same membrane was washed and the β-actin bands were detected using 
mouse anti-actin (Abcam Ab8226; dilution 1:5000) and anti-mouse-HRP (Abcam 
Ab6728; dilution 1:5000). 
3.9 Assay of γ-glutamyltransferase (γ-GT) 
A diagnostics kit for γ-GT (Sigma Cat No. 419) was used for the quantitative 
determination of enzyme activity.  γ-GT catalyzes the transfer of the glutamyl group 
from L-γ-glutamyl-3-carboxy-4-nitroanilide (substrate) to glycylglycine with the 
formation of γ-glutamylglycylglycine and 5-amino-2-nitrobenzoate (product).  The 
substrate is colorless while the product of the reaction absorbs light strongly at 405 nm.  
The rate of increase in absorbance at 405 nm is directly proportional to γ-GT activity in 
the sample.  The procedure and calculation of enzyme activity were conducted as per 




4 ENHANCED 293-HEK CELL GROWTH AND 
ADENOVIRUS PRODUCTION 
 Most fed-batch strategies reported in current literature focus mainly on the 
control of glucose at low level to achieve an alternate metabolic state.  However, 
glutamine is a major protein component and implicated in a number of important 
biosynthetic pathways for purine, pyrimidine, amino sugars and nicotiamide nucleotide 
synthesis in cells.  Additionally, it is also one of the major intermediates of the 
anaplerotic pathways that provide alternative carbon sources that help maintain the 
carbon flux in the Tri-Carboxylic Acid (or TCA) cycle for energy production.  The 
metabolism of glutamine involves deamination to glutamate before conversion to the 
TCA cycle intermediate, 2-oxoglutarate.  This results in the formation of ammonia as a 
secondary metabolite.  Formation of lactate can also occur via the partial oxidation of 
pyruvate derived from TCA cycle intermediates.  Thus, if present in excess, glutamine 
can potentially lead to production of inhibitory levels of both lactate and ammonia.  
Accumulation of ammonia in mammalian cultures has a number of deleterious 
consequences and has been widely studied and reported (e.g. Schneider et al. 1996; 
Mirabet et al. 1997). 
 Although low glucose cultures of 293 cells have been investigated, significant 
improvements in cell density have not been achieved despite the fact that lactate 
production was observed to have reduced (Siegwart et al. 1999).  The elevation of cell 
density and adenovirus vector production were however achieved by other researchers 
through the control of both glucose and glutamine (Wong et al. 1999).  The main 




production can be achieved via the control of only glutamine at low levels in the 
culture. 
 An online sampling system was developed to allow continuous online 
monitoring of glutamine levels in the culture via a continuous cell-exclusion system 
that allows for aseptic, cell-free sampling of the culture broth.  A feedback control 
algorithm was used to maintain the glutamine concentration at a level as low as 0.1 
mM with a concentrated glucose-free feed medium.  Feedback control via direct 
measurement of glutamine is a better reflection of the metabolic demand of glutamine 
in the fed-batch cultures than predictive feeding based on projected cell growth and 
consumption rates.  The glucose in the fed-batch was started at the same level as the 
control batch cultures and maintained at above 0.5 g/L via addition of concentrated 
glucose stock.  This is to ensure that improvements in the fed-batches were due to the 
low glutamine conditions.  This was tested in two media:  (A) a commercial serum-free 
formulation (293 SFM II) and (B) an in-house developed serum-free chemically 
defined (SF-CDM) formulation based on DMEM/F12 medium.  Protein hydrolysates, 
present in the 293 SFM II feed, were eliminated from the SF-CDM feed to assess the 
robustness of the fed-batch platform in the absence of these supplements.  In addition, 
an infection study on the high density fed-batch culture using Adenovirus-Green 
Fluorescent Protein (Ad-GFP) construct was also done to ascertain the production 
capacity of the low glutamine cultures. 
 Reductions in waste metabolites accumulation and improvements in both cell 
densities and adenoviral vector production were achieved and the metabolic alterations 
observed during fed-batch cultures will be discussed in this chapter.  Further 




comparison of batch and fed-batch cultures in the PF-CDM will be described in 
Chapter 5. 
4.1 293-HEK Cell Growth in Batch and Fed-batch Cultures 
Prior to the fed-batch experiments, batch cultures were conducted to determine 
a baseline glutamine consumption rate and establish a suitable online sampling and 
feeding time interval for the fed-batch cultures.  The concentration of glutamine in the 
culture was maintained at the respective targeted set-points using the feedback system 
described Section 3.1.2 of Materials and Methods.  The glutamine concentration was 
successfully maintained at the desired set-points in the cultures as demonstrated by the 
glutamine concentration profiles shown in Figure 3.3. 
The 293 SFM II fed-batch cultures controlled at 0.2 mM and 0.1 mM glutamine 
were started at initial glutamine levels of 0.5 mM and 0.3 mM respectively.  The SF-
CDM fed-batch culture controlled at 0.3 mM glutamine was started with an initial 
glutamine concentration of 0.5 mM.  These low initial glutamine levels were to 
facilitate early initiation of feeding in the fed-batch cultures and maximize the cells’ 
exposure to the low glutamine environment.  If the cultures were started at the original 
high level found in the media (ie. 4mM in 293 SFM II and 2.5mM in SF-CDM), the 
glutamine level would not fall to a low enough level to initiate automatic feeding until 
very late in the culture which would deny the cultures the benefits of the low glutamine 
fed-batch platform.  Furthermore, a higher glutamine set-point was necessary in the 
SF-CDM culture to prevent depletion of the glutamine during the 1.5 hours sampling 
interval as a result of a higher glutamine consumption rate probably due to the leaner 
nature of the medium.  Feeding for both 293 SFM II fed-batches were initiated 
automatically at between 40 and 45 hours and the SF-CDM fed-batch at about 15 














Figure 4.1  Feed profiles of fed-batch cultures controlled at low glutamine 
concentration in 293 SFM II and SF-CDM. 
 
Typically, the batch cultures reached maximum cell concentrations of 2.5 X 106 
cells/mL (293 SFM II) and 1.5 X 106 cells/mL (SF-CDM) respectively (Fig. 4.2).  The 
fed-batches consistently reach a maximum cell concentration of between 4 X 106 – 4.5 
X 106 cells/mL (Fig. 4.2).  This represents a 1.8-2.8 folds increase in cell 
concentrations of fed-batch over batch cultures.  There was no depletion of any amino 
acids in the 293 SFM II batch culture and it was able to reach peak cell concentration 
of 2.5 X 106 cells/mL.  Conversely, there was depletion of a number of amino acids, 
including serine and methionine at 40 hours and leucine at 60 hours, in the SF-CDM 
batch and the culture was only able to attain 1.5 X 106 cells/mL.  As a result, the 
improvements in cell concentrations of fed-batch over batch cultures were more 
pronounced in the SF-CDM when assessed against the lower cell concentration in the 
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Figure 4.2  Cell concentration profiles of batch (broken line) and fed-batch (solid 
lines) cultures controlled at 0.2 mM (▲) and 0.1 mM (♦) glutamine conducted in 
293 SFM II and controlled at 0.3 mM (■) glutamine in SF-CDM.   Error bars 
represent standard deviation of triplicate measurements. 
 
Table 4.1  Comparison of cell concentrations and growth rates 
 293 SFM II SF-CDM 
 Batch Fed-Batch 1 Fed-Batch 2 Batch Fed-Batch 
Initial glutamine conc. 
(mmol/L) 
4.0 0.5 0.3 2.5 0.5 
Glutamine set-point conc. 
(mmol/L) 
- 0.2 0.1 - 0.3 
Initial glucose conc. 
(mmol/L) 
25.0 25.0 25.0 17.5 17.5 
Initial cell conc.* 
(106 cells/mL) 
0.3 0.3 0.3 0.35 0.35 
Max. viable cell conc. 
(106 cells/mL) 
2.53 4.49 4.10 1.51 4.11 
Specific growth rate, μ 
(hr-1) 
0.025 0.031 0.025 0.027 0.029 
Total feed volume added 
(mL) 
- 346 277 - 518 
Specific yield of biomass 
per glutamine** (cell/mmol) 
700 2296 2654 527 1951 
*Cultures conducted using SF-CDM required a slightly higher seeding density to overcome the presence 
of a long lag phase in the culture. 





































































Additionally, the specific growth rate (µ) calculated over the exponential 
growth phase of the cultures, obtained via fitting a straight line to the logarithmic plot 
of cell concentration versus time, indicates that there was no adverse effect on the 
growth due to the low-glutamine environment (Table 4.1).  The fed-batch cultures 
achieved higher yields of biomass per glutamine consumed when compared to their 
respective batch cultures indicating a more efficient usage of glutamine.  It should be 
noted that the cultures conducted using SF-CDM required a higher seeding density of 
3.5 X 105 cells/mL to overcome the presence of a long lag phase in the culture. 
4.2 Cellular Metabolism in Batch and Fed-batch Cultures 
The batch and fed-batch cultures employing 293 SFM II were started with 25 
mM of glucose and glucose were not depleted throughout the entire duration of the 
experiments (Figure 4.3a).  These batch and fed-batch cultures employing SF-CDM 
were started with 17.5 mM of glucose, as this medium was formulated based on 
DMEM/F12.  The fed-batch culture employing SF-CDM was depleted of glucose at 85 
hours, the end of the exponential growth phase (Figure 4.3b).  Glucose concentration 
was restored to 9 mM with a concentrated glucose solution, however, the cells were 
already in stationary phase and growth rate did not appear to increase again. 
Ammonia concentration profiles for batch and fed-batch exhibited remarkable 
differences in 293 SFM II cultures (Figure 4.3c) but not in the SF-CDM cultures 
(Figure 4.3d).  A general reduction in the production of ammonia was observed right 
from the onset of the 293 SFM II fed-batch cultures.  This concurs with reported 
results obtained from offline glutamine controlled cultures of Madin-Darby Canine 
Kidney (MDCK) cells (Glacken et al. 1985) and predictive feeding glutamine 
controlled cultures of hybridoma cells (Ljunggren and Haggstrom 1994).  In a low-






Figure 4.3  Glucose, lactate and ammonia concentration profiles of batch (broken 
line) and fed-batch (solid lines) cultures controlled at 0.2 mM (▲) and 0.1 mM (♦) 
glutamine conducted in 293 SFM II and controlled at 0.3 mM (■) glutamine in 






































































































































































functions like nucleotides  and  amino  sugars  production  to  support  cell  growth and 
division, thus there is less excess glutamine to metabolise via glutaminolysis, hence 
reducing ammonia production. 
 Lactate production were observed in the early exponential phase of both batch 
and fed-batch cultures, but consumption was only observed in the fed-batch cultures, 
after 90 hours in the 293 SFM II fed-batch cultures and 72 hours in SF-CDM fed-batch 
culture respectively (Figure 4.3e and f).  Similar patterns of lactate consumptions have 
been reported for BHK-21 cells (Cruz et al. 2000), however this was achieved via the 
control of both glucose and glutamine at low levels whereas similar results were 
obtained here using the control of just glutamine.  The consumption of lactate when 
glucose is maintained at a low level could be due to the restriction of the glycolytic 
pathway resulting in the cells utilizing an alternative carbon source (lactate) to 
maintain the flux through pyruvate going into the TCA cycle.  However, it was not 
immediately obvious why lactate consumption occurred with 9 mM of glucose still 
remaining in the 293 SFM II fed-batch cultures at 90 hours.  It has been reported that 
ammonia can enhance glycolysis via the activation of a key glycolytic enzyme, 
phosphofructokinase (PFK) (Uyeda and Racker 1965).  Thus, it was speculated that the 
presence of less ammonia in the 293 SFM II fed-batch cultures has reduced the 
activation of PFK and resulted in lowered glycolytic activities.  Therefore, lactate 
consumption in the fed-batch cultures could be the combined result of a less active 
glycolytic pathway and the reduction of glutaminolysis in a low-glutamine 
environment. 
Average specific rates of the main metabolites were calculated (Figure 4.4).  
The specific consumption rate of glutamine in both 293 SFM II and SF-CDM fed-




the fed-batch cultures were also drastically reduced.  This could serve as evidence of 
restriction of overflow metabolism of glutamine.  The low glutamine environment 
limits the amount of excess glutamine available for energy production via 
glutaminolysis, which is known to be the main contributor of ammonia in culture 
(Street et al. 1993).  It is proposed that concomitantly reduction of ammonia 
production led to reduced PFK activation, accounting for the lower observed glucose 
consumption rate (Figure 4.4) which is much more obvious in the 293 SFM II fed-
batch due to a much lower ammonia accumulation (Figure 4.3c). 
Figure 4.4  Average specific consumption/production rates of major metabolites 
in batch and fed-batch cultures calculated from exponential growth phase.  
Glucose and lactate rates for fed-batch cultures were taken from late exponential 
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Specific rates of consumption or production of most of the other amino acids in 
the batch and fed-batch cultures were found to be fairly similar in both media (Figure 
4.5).  However, this observation is contradictory to reports of serum supplemented, 
low glutamine 293 fed-batch cultures exhibiting higher specific amino acid 
consumption rates than batch cultures (Nadeau et al. 2000).  Note that glutamate is not 
represented in Figure 4.5 due to its extremely erratic production and consumption 
pattern rendering the allocation of an average specific rate meaningless. 
Figure 4.5  Specific consumption/production rates of all other amino acids in 
batch and fed-batch cultures.  Negative rates represent consumption. 
 
Alanine is commonly considered one of the main overflow metabolites from 
excessive glutaminolysis.  The formation of α-ketoglutarate from glutamate can occur 
either via deamination by glutamate dehydrogenase, forming an additional ammonia, 
or transamination by an aminotransferase, leading to the production of alanine.  It has 
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accumulated in HeLa and CHO cells from glutamine metabolism (Street et al. 1993).  
Thus, alanine is generally seen to accumulate in the batch cultures and the results agree 
with these findings.  It was however observed to have reverted to consumption in the 
293 SFM II fed-batch cultures.  Consumption of alanine had also been reported in 
glucose limited hybridoma cultures (Europa et al. 2000) and glutamine limited 
hybridoma cultures (Ljunggren and Haggstrom 1994).  This could be attributed to a 
lower requirement for ammonia detoxification in the fed-batch cultures and serves as 
further evidence of the restriction of the cells’ overflow metabolism of glutamine. 
 Glycine production were observed in the early exponential phase of both batch 
and fed-batch cultures, and glycine consumption was observed during the late 
exponential and stationary phases of the SF-CDM batch, SF-CDM fed-batch and 293 
SFM II fed-batch cultures (Figure 4.5).  This reversion to consumption could be a 
result of increased demand for purine synthesis from glycine to support cell division at 
a high density in the fed-batch cultures.  However, glycine consumption observed in 
the SF-CDM batch culture (Figure 4.5) was hypothesized to be the result of serine 
depletion in the culture triggering the reverse of the serine transhydroxymethylase 
reaction leading to the synthesis of serine from glycine. 
 The average stoichiometric yields of lactate from glucose and ammonia from 
glutamine were calculated from the final accumulation of each waste metabolite and 
the total cumulative consumption of each nutrient.  The ratios of ΔNH4/ΔGlutamine 
were similar for batch and fed-batch cultures (Figure 4.6).  This observation was 
supported by reported data from hybridoma culture grown under low-glutamine 
conditions (Ljunggren and Haggstrom 1994).  It signifies that the only avenue open to 
ammonia reduction appears to be reduction in overall glutamine consumption.  The 





Figure 4.6  Average ammonia yield from glutamine and lactate yield from glucose 
between batch and fed-batch.  Calculated from entire growth phase of respective 
cultures. 
 
(Figure 4.6).  It was speculated that this was the result of a restriction in both 
glycolysis and glutaminolysis due to reasons discussed above. 
From the results, it was deduced that the restriction of glutamine metabolism in 
the low-glutamine fed-batch culture resulted in a lower ammonia production.  The 
reduction in ammonia reduces the requirement for detoxification and hence lowered 
the alanine production.  The lower ammonia level also means that the PFK enzyme is 
less activated and hence a lower glycolytic rate was observed.  Finally, the combined 
reduction in both glycolysis and glutaminolysis resulted in a lower accumulated lactate 
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4.3 Virus Production in Batch and Fed-batch Cultures 
An infection study was conducted using parallel batch and fed-batch cultures.  
The fed-batch cultures were started with an initial glutamine concentration of 0.3 mM 
and controlled at 0.1 mM.  The results obtained from virus infection of parallel batch 
and fed-batch bioreactor runs are shown in Figure 4.7.  The fed-batch cultures 
achieved a virus titer of 5.2 X 109 pfu/mL whereas the batch cultures achieved a virus 
titer of only 3.4 X 108 pfu/mL.  The improvement in virus titer was approximately 10-
fold. 
Figure 4.7  Virus production in batch cultures (×) and fed-batch cultures (♦).  
Results from 2 sets of simultaneous batch and fed-batch infection runs conducted 
in 293 SFM II.  Error bars represent standard deviation of duplicate experiments. 
 
 
 The fed-batch culture was infected at 3 million cells/mL in an attempt to 
harness the capacity of cells at the stationary phase, at high cell concentration and 


























previous results is only capable of half the maximum cell concentration, was infected 
at 1.5 million cells/mL.  The lower virus titer in the batch culture was attributed to the 
fact that when the infection was initiated at 1.5 million cells/mL, the subsequent 
requirement of nutrients for virus production was not met.  This was not the case in the 
fed-batch cultures where feeding continued after infection and maintained the essential 
nutrients at the level necessary to support the additional metabolic load for virus 
infection to progress in the culture.  Thus, it has been demonstrated that restriction of 
substrate of the cells does not compromise its virus production capacity as long as 
sufficient nutrients are accessible to the cells during the infection phase. 
4.4 Conclusions 
An online fed-batch system incorporating sampling coupled with automatic 
feedback control was successfully developed to control glutamine concentration at a 
low and steady level in cultures.  This fed-batch system was implemented using a 
commercial medium (293 SFM II) and an in-house serum-free chemically-defined 
medium (SF-CDM).  Consequently, there were improvements in maximum cell 
concentrations attainable in fed-batch cultures ranging from 4-4.5 million cells/mL, a 
1.8 to 2.8 fold improvement over parallel batch cultures.  These improvements were 
translated into enhancement of virus titers up to 5.2 X 109 pfu/mL in the 293 SFM II 
fed-batch cultures. 
The restriction of cells to a more efficient metabolic state via the control of 
glucose and glutamine had been reported extensively in literature with varying degress 
of success in improving cell and product yields.  However, the results have amply 
demonstrated for the first time that the restriction of glutamine overflow metabolism 
alone is sufficient to reduce accumulation of major waste metabolites like ammonia 




the extent of ‘metabolic malleability’ of 293-HEK cells to manipulation solely through 






5 PROTEIN-FREE CHEMICALLY DEFINED 
MEDIUM FOR 293-HEK CELL GROWTH AND 
ADENOVIRUS PRODUCTION 
This chapter focuses on media development and outlines the progression of the 
cell culture system from an undefined serum-free commercial medium (293 SFM II) to 
an in-house serum-free chemically defined medium (SF-CDM) and finally to an in-
house protein-free chemically defined medium (PF-CDM).  Low glutamine fed-batch 
cultures and virus production in PF-CDM are also discussed in this chapter. 
Additional complications introduced in downstream processes by proteins and 
recent outbreaks of prion diseases have provided a strong push for the elimination of 
animal-derived protein components from industrial cell culture processes.  One 
alternative is the use of vegetable-based protein hydrolysates (eg. soybean protein 
hydrolysate) as serum and protein substitutes is possible but it relinquishes chemical 
definition by re-introduction of these chemically complex mixtures.  Thus, the 
elimination of all undefined components such as hydrolysates, has obvious advantages 
of yielding a more consistent process that will be more in accordance with regulatory 
guidelines.  Despite the prevalence of commercial PF-CDM, the inaccessibility of 
information on their formulation places a limitation on the ability to conduct process 
optimization hence the necessity for development of an in-house PF-CDM. 
An additional issue that was addressed was the formation of cellular aggregates 
that can render cell concentration determination inaccurate and compromise nutrient 
transfer and progression of virus infection during adenovirus production.  Dextran 




production and was employed in both the in-house media (SF-CDM and PF-CDM) 
before the reactor runs were conducted. 
The chemically-defined nature of the SF-CDM facilitated the efforts to isolate 
and systematically substitute the proteinaceous components with chemically simpler 
compounds.  A factorial experiment was conducted to isolate the crucial proteinaceous 
component present in SITE (selenium, insulin, transferrin and ethanolamine).  Cells 
exhibited dependence on only transferrin but not insulin and insulin was eliminated 
from the medium formulation.  An inorganic iron source, ferric citrate, was identified 
as a substitute for transferrin.  Cell growth and virus productivity in the final PF-CDM 
medium was evaluated against the commercial 293 SFM II and in-house SF-CDM 
medium in shake flask cultures.  Low-glutamine fed-batch cultures were also 
conducted utilizing the PF-CDM platform and improvements in cell concentrations 
and virus production titers were achieved. 
5.1 Elimination of Cellular Aggregation in SF-CDM and PF-CDM 
Commercially obtained 293-HEK suspension cells originally growing in 
commercial 293 SFM II medium were adapted to chemically-defined serum-free 
medium formulation (SF-CDM) to facilitate further identification of crucial nutrient 
factors.  The absence of serum from the medium generally requires supplementation 
with certain proteins, hydrolysates or defined peptides.  In this case, the medium was 
supplemented with SITE (Sigma Cat No. S4920), a mixture of selenium, insulin, 
transferrin and ethanolamine, which was first reported in the culture of serum-free 
cultures of hybridoma cells (Murakami et al 1982).  Cells were adapted to this medium 
and long-term stability of the cells in this medium was ascertained with repeated 
passaging.  Cells were able to grow normally and cryofreezing and subsequent revival 




The cells grown in SF-CDM without dextran sulphate had a tendency to form 
large aggregates and thus render determination of cell concentration both tedious and 
time-consuming.  Formation of large aggregates can also potentially hinder the transfer 
of nutrient and progression of infection during adenovirus production.  Dextran 
sulphate had successfully been utilized in the induction of single-cell suspension 
cultures in insect cells (Dee et al 1997a; Dee et al. 1997b; Schuler and Dee 1998).  The 
mechanism of cell dispersion is not well understood but was postulated to be an 
interference of cellular interaction with lysed membrane fragments through 
competitive binding (Dee et al. 1997a). 
Different concentration levels of dextran sulphate were tested in culture and 10 
mg/L was sufficient to alleviate the problem of cell aggregation in SF-CDM (Figure 
5.1) whereas 5 mg/L was found to be ineffective (results not shown).  In 
unsupplemented cultures, cells exist predominantly as large aggregates of between 50-
200 cells with very few singular cells observed.  However, cultures supplemented with 
dextran sulphate at concentration as low as 10 mg/mL were deaggregated within the 
first passage and formed well-dispersed cultures consisting mainly of doublet or triplet 
cells by the second or third passage. 
Dextran sulphate has been reported to be cytotoxic to insect cells at high 
concentrations in culture.  Since the cytotoxic level was never established in 293-HEK 
cultures before, it was thus necessary to ascertain the level used will not be detrimental 
to the culture.  Comparison of cell growth in cultures supplemented with 10 and 20 
mg/L dextran sulphate with that of unsupplemented cultures were conducted to ensure 
that the cultures are not operating near the cytotoxicity level of dextran sulphate in the 
cultures (Figure 5.2).  Both supplemented cultures reached comparable peak cell 





Figure 5.1  293-HEK cells in SF-CDM without dextran sulphate forms large 































Figure 5.2  293-HEK cell growth in cultures with 10 mg/L (■) and 20 mg/L (♦) 
dextran sulphate, and unsupplemented SF-CDM (×).  Error bars represent 
standard deviation of triplicate measurements. 






however only reached 1.5 million cells/mL in the same time.  The apparent attenuated 
growth is attributable to a difficulty in cell number determination due to the presence 
of large cell clumps in this culture or higher cell death in the aggregates as a result of 
limitation in mass transfer of nutrients. 
Dextran sulphate has also been reported to interfere with HIV, cytomegalovirus 
and baculovirus infection processes (Baba et al. 1990, Neyts et al. 1992, Dee et al. 
1997b), and this property may potentially extend to adenoviral infection process.  
Thus, it was necessary to ensure that the concentration of dextran sulphate effective for 
reducing aggregation does not compromise the virus infection process.  To ensure that 
any difference in virus infection/production is not due to the presence of cellular 
aggregates, cells growing in SF-CDM supplemented with 10 mg/L dextran sulphate 
were used as the common innoculum for the experiment.  Cultures were spun-down 
and resuspended into fresh medium with and without dextran sulphate before infection 
at 1 millions cells/mL at MOI = 5 pfu/mL.  Both cultures exhibited almost identical 
virus production levels of 2.2 X 1010 pfu/mL showing no compromise in virus 
productivity in the presence of 10 mg/L of dextran sulphate (Figure 5.3).  Thereafter, 
the optimal level of 10 mg/L of dextran sulphate was used in both the SF-CDM and 
PF-CDM formulations. 
5.2 Isolation and Substitution of Protein Supplements in SF-CDM 
An in-house PF-CDM formulation was developed in order to facilitate further 
optimization of the fed-batch process by elimination of cellular dependence on protein 
























Figure 5.3  Virus production in SF-CDM without dextran sulphate (×) and in SF-
CDM supplemented with 10 mg/L dextran sulphate (♦). 
 
defined components.  A PF-CDM platform will also have the added advantages of 
having better compliance with regulatory guidelines and being economically more 
viable through exclusion of costly protein supplements (eg. insulin) and reduction in 
purification cost. 
 A factorial experiment was conducted to establish the importance of the 
individual protein components, insulin and transferrin, in SITE (selenium, insulin, 
transferrin, ethanolamine).  All cultures supplemented with transferrin (T, IT, STE) 
demonstrated comparable growth to fully supplemented SF-CDM (SITE) whereas 
cultures lacking transferrin (I, SIE, -ve Control) showed reduced growth (Figure 5.4).  
Contrary to common belief that insulin is essential in culture, only transferrin was 





Figure 5.4  293-HEK cultures containing transferrin (solid lines) exhibit 
comparable growth to culture supplemented with SITE (ie. SF-CDM).  All 
cultures without transferrin (broken lines) showed reduced growth similar to 
unsupplemented cultures (-ve Control).  Error bars represent standard deviation 
of triplicate measurements. 
 
 These results clearly suggested that insulin may be eliminated from the medium 
whereas a suitable chemically-defined, non-proteinaceous substitute for transferrin has 
to be identified.  Growth of certain human tumour cell lines have been reported in 
transferrin-free media supplemented with an alternate iron source, ferric citrate, with 
feasible concentrations ranging from 5 to 500 µmol/L (Neumannova et al 1995). 
 To determine the optimal ferric citrate concentration, 293-HEK cells were 
adapted to growth in PF-CDM with ferric citrate concentrations ranging from 0 to 50 
µmol/L.  Cultures were repeatedly passaged in each concentration at seeding 
concentration of 0.3 million cells/mL every 2-3 days depending on cell growth (Figure 









































Figure 5.5  Repeated passages of 293-HEK cell in PF-CDM with 0 µmol/L, 5 
µmol/L, 25 µmol/L and 50 µmol/L ferric citrate.  Error bars represent standard 
deviation of triplicate measurements. 
 
carry-over of iron from the inoculum culture possibly as intracellular store, since 
cultures were all spun-down and supernatant discarded before  resuspension  into  fresh 
media (Figure 5.5a).  Cultures supplemented with 5 µmol/L ferric citrate survived 
long-term passaging but exhibited attenuated growth reaching 1 million cells/mL at 
each passaging (Figure 5.5b).  Cultures supplemented with 25 and 50 µmol/L of ferric 
citrate showed similar growth characteristics reaching cell concentrations of 1.5-2 
million cells/mL (Figure 5.5c and 5.5d respectively).  This indicates that 5 µmol/L is 
below minimum threshold level of ferric citrate for normal cell growth and levels > 25 
µmol/L is already in excess.  25 µmol/L of ferric citrate was deemed to be the optimal 
















































































































l)(a)  0 μmol/L Ferric Citrate 
(c)  25 μmol/L Ferric Citrate (d)  50 μmol/L Ferric Citrate 




osmolality.  Higher culture osmolality may be a potential problem when the PF-CDM 
is adopted for fed-batch processes, since fed-batches are usually prone to osmolality 
issues as a result of feeding of concentrated nutrient solutions. 
5.3 Cell Growth and Virus Production in PF-CDM in Shake Flask 
Cell growth and viral productivity in PF-CDM were evaluated against 
commercial 293 SFM II and SF-CDM.  Cell growth in all three media exhibited 
similar growth potential, reaching a maximum peak cell concentration of between 1.5-
2 million cells/mL in 4-5 days from a seeding density of 0.35 million cells/mL.  
Infection experiments conducted in shake flask were first spun-down and complete 
media exchange effected before infection at 1 million cells/mL at an MOI = 5 pfu/cell.  
The media exchange was conducted to ensure the most conducive nutrient 
environment for virus production.  Titers of culture samples collected 24, 48, 72 and 
96 hours post-infections showed that virus production in all 3 media were similar 
(Figure 5.6) indicating that the PF-CDM can perform as well as protein-supplemented 
cultures with regards to virus production. 
5.4 Cell Growth and Metabolism in PF-CDM Batch and Fed-batch 
Cultures 
A PF-CDM fed-batch platform utilizing the online fed-batch system described 
in Section 3.1.2 was developed based on the PF-CDM medium (Chapter 3.3).  Fed-
batch cultures conducted using the PF-CDM platform reached cell concentrations of 6 
million cells/mL in repeated runs, representing a 4X improvement in cell concentration 






Figure 5.6  293-HEK cell growth and virus production in 293 SFM II (×), SF-



















Figure 5.7  Viable cell concentrations of repeated batch (broken lines) and low 
glutamine fed-batch (solid lines) cultures in PF-CDM.  Error bars represent 



























































































The batch and fed-batch cultures were also observed to be metabolically 
different as evident in the reduced specific glutamine and glucose consumption rates 
and lactate and ammonia production rates (Figure 5.8).  Similar results have been 
observed in low glutamine SF-CDM and 293 SFM II fed-batch cultures discussed in 
Chapter 4.  The reduction in inhibitory waste metabolite production was postulated to 
be the primary reason for the significant improvements in cell growth and virus 
production in the fed-batch cultures compared to the batch cultures. 
Figure 5.8  Average specific consumption/production rates of major metabolites 
in batch (□) and fed-batch (■) cultures calculated from exponential growth phase.  
Glucose and lactate rates for fed-batch cultures were taken from late exponential 
phase.  Negative rates represent consumption.  Error bars represent standard 
deviation of duplicate experiments. 
 
 The average stoichiometric yields of lactate from glucose and ammonia from 
glutamine were also calculated from the final accumulation of each waste metabolite 





























Figure 5.9  Average ammonia yield from glutamine and lactate yield from glucose 
between batch and fed-batch.  Calculated from ratio of total accumulated 
ammonia or lactate over total glutamine or glucose consumed.  Error bars 
represent standard deviation of duplicate experiments. 
 
approximately 70% reduction in ΔNH4/ΔGlutamine ratio in PF-CDM fed-batch 
cultures compared to the batch cultures.  This was however not the same  for  SF-CDM 
and 293 SFM II cultures (Chapter 4) where decreases in ammonia production were 
matched by corresponding decreases in glutamine consumption rates with no reduction 
in ΔNH4/ΔGlutamine ratios.  It was not obvious why this significant improvement in 
ΔNH4/ΔGlutamine ratio is possible only in the PF-CDM cultures but not in the serum-
free ones, however, there is a strong possibility that in the absence of exogenous 
sources of peptide intermediates (hydrolysates or protein), glutamine is channeled 
more efficiently towards important cellular processes to support cell growth and 
division rather than the anaplerotic pathway as an alternative energy source.  The 




























batch cultures.  It was a larger improvement compared to the 50% reduction observed 
in the serum-free cultures.  These improvements in ΔLactate/ΔGlucose were proposed 
to be the result of restrictions in both glycolysis and glutaminolysis (Chapter 4). 
The specific rates of consumption or production of most amino acids in the 
cultures were similar, with the obvious exception of glycine, alanine and proline 
(Figure 5.10).  There were significant reductions in the production rates of alanine and 
proline, and reversion of glycine production to consumption in the PF-CDM fed-batch 
compared to the batch.  The reduction in alanine production and reversion of glycine 
production to consumption in low glutamine fed-batch cultures have previously been 
discussed in Chapter 4.  However, the reduction in proline production has thus far only 
been observed in the PF-CDM fed-batch cultures.  Proline accumulation in mammalian 
cells is a result of arginine and glutamate catabolism.  However, since there was little 
difference in arginine consumption rates between the batch and fed-batch (Figure 
5.10), the reduction in proline production is likely a direct consequence of the lower 
availability of glutamate as a result of lower glutaminolysis in the fed-batch. 
5.5 Virus Production in PF-CDM Batch and Fed-batch Cultures 
An infection study was conducted in duplicate batch and fed-batch runs.  Batch 
cultures were infected at 1 million cells/mL and fed-batch at 4 million cells/mL at a 
MOI (multiplicity of infection) of 5 pfu/mL.  Virus samples were collected at 24-hours 
interval up to 144 hours post-infection and titered.  Results showed there was at least 
10,000-fold improvement in volumetric virus production in the fed-batch cultures 
compared to batch, reaching a titer of 3 x 1011 pfu/mL (Figure 5.11). 
The lower titers exhibited by the batch cultures were attributed to poor culture 
conditions at the late stage of the cultures with limited nutrient resources to support the 
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Figure 5.10  Specific consumption/production rates of all other amino acids in 
batch and fed-batch cultures.  Negative rates represent consumption.  Results 
calculated from duplicated batch and fed-batch runs.  Error bars represent 
standard deviation of duplicate experiments. 
 
Figure 5.11  Virus production in batch (▲) and fed-batch (x) cultures.  Results 
from duplicate batch and fed-batch infection runs conducted in PF-CDM.  Note:  

























probably the combined results of both a much better nutrient environment and the 
much higher cell concentration at the time of infection.  There was also significant 
improvement over previously reported titer of 5 x 109 pfu/mL using the same cell line 
and fed-batch system in 293 SFM II medium (Figure 4.7), and this can well be 
attributed to ease of optimizing the fed-batch using PF-CDM.  Since the cells are 
independent of any proteinaceous or undefined components, there is no necessity to 
replenish these components in the culture.  Thus, only the other defined components of 
the medium needed to be replenished and this affords better control of feeding of 
nutrients in the fed-batch cultures.  Thus far, the highest adenoviral vector titer 
reported in literature for 293 cells in suspension system is 4 x 1010 pfu/mL (Henry et 
al. 2004). 
5.6 Summary of Cell Growth and Virus Productivity 
 Cell growth and viral productivity in PF-CDM were evaluated against 
commercial 293 SFM II and SF-CDM where complete media exchange were 
conducted for all three flasks just before infection to ensure the most conducive 
nutrient environment for virus production.  Results showed that the PF-CDM and SF-
CDM performed as well as commercial 293 SFM II medium (Table 5.1). 
Table 5.1  293-HEK cell growth and virus productivity in shake flask 
 293 SFM II SF-CDM PF-CDM 
Initial cell conc. 
(106 cells/mL) 
0.35 0.35 0.35 
Max. viable cell conc. 
(106 cells/mL) 
1.80 1.77 1.96 
Virus titer* 
(108 cells/mL) 
259 299 335 




 Low glutamine fed-batch cultures conducted using the PF-CDM platform 
performed better than those conducted in 293 SFM II or SF-CDM reaching cell 
concentrations of 6.65 million cells/mL (Table  5.2). 
Table 5.2  293-HEK cell growth and virus productivity in bioreactors 
 293 SFM II SF-CDM PF-CDM 
 Batch Fed-Batch Batch Fed-Batch Batch† Fed-Batch† 
Initial glutamine conc. 
(mmol/L) 
4.0 0.3 2.5 0.5 4.0 0.5 
Glutamine set-point conc. 
(mmol/L) 
- 0.1 - 0.3 - 0.3 
Initial glucose conc. 
(mmol/L) 
25.0 25.0 17.5 17.5 25.0 25.0 
Initial cell conc. 
(106 cells/mL) 
0.3 0.3 0.35 0.35 0.35 0.35 
Max. viable cell conc. 
(106 cells/mL) 
2.53 4.10 1.51 4.11 1.67 6.65 
Specific growth rate, μ 
(hr-1) 
0.025 0.025 0.027 0.029 0.026 0.023 
Stoichiometric yield of 
ammonia/glutamine 
0.694 0.705 0.784 0.678 0.892 0.262 
Stoichiometric yield of 
lactate/glucose 
0.995 0.660 1.260 0.738 1.243 0.220 
Specific yield of biomass per 
glutamine** (cell/mmol) 
700 2296 527 1951 399 1090 
Virus Titer* 
(108 pfu/mL) 
3.4 52 - - 0.25 3540 
*Average from duplicated independent infection runs.  Media exchange was not conducted as there was 
no efficient protocol to do so in the bioreactor. 
**See Appendix D for calculations. 
† Average from duplicated runs. 
 
As discussed earlier, this improvement is possible primarily because better 
control of the feeding of nutrients in the PF-CDM fed-batch.  The stoichiometric yields 
of ammonia from glutamine and lactate from glucose were also much lower in the PF-




efficient utilization of glutamine with reduced proportion of this nutrient shunted to 
anaplerotic reactions.  Finally, virus production titers in PF-CDM fed-batches were 
also higher than that achieved in 293 SFM II fed-batches by approximately 70-folds 
(ie. 3740 X 108/52 X 108) due to a higher cell concentration attainable and better 
control of feeding of nutrients (Table 5.2). 
5.7 Conclusions 
 An effective PF-CDM for suspension 293-HEK cell culture and adenovirus 
production was established via systematic substitution of proteinaceous medium 
components with chemically-defined ones.  Insulin was found to be non-essential and 
eliminated from the culture whereas transferrin in the culture was successfully 
substituted with an alternative iron supplement, iron citrate.  Initial cell aggregation 
issues were also resolved utilizing dextran sulphate as a deaggregating agent.  The low 
glutamine fed-batch system developed earlier was verified in the PF-CDM platform 
resulting in improved viable cell concentration up to 6 million cells/mL and virus 
productivity up to 3 X 1011 pfu/mL.  In addition, there was general reduction in 
consumption of the 2 main cellular carbon sources of glucose and glutamine and 
reduction in production of a number of common waste metabolites like lactate, 
ammonia, alanine and glycine in the nutrient-controlled fed-batch cultures implying an 








6 TRANSCRIPTIONAL PROFILING OF 293-HEK 
BATCH AND FED-BATCH CULTURES 
 It was highlighted in Chapters 4 and 5 that limiting glutamine metabolism via 
low culture glutamine levels resulted in physiological changes that translated to an 
improvement in cell and virus yields.  In this chapter, an investigation of the 
transcriptional regulation of the metabolic changes associated with the batch and the 
low-glutamine fed-batch cultures using DNA microarray is reported.  This analysis 
should provide better understanding of the transcriptional regulatory mechanism 
resulting in the observed physiological changes. 
Transcriptional profiling of cells from the mid-exponential, late exponential 
and stationary phases of both the batch and fed-batch were undertaken using an 18,000 
element human chip and gene profiles at the different time points from each culture 
were obtained.  Transcriptional profiles were ontologically classified and clustered 
using self-organizing maps (SOM) to provide a global view of the genetic changes.  
Furthermore, a pathway-oriented analysis focusing on metabolism and cell cycle was 
conducted to reveal the dynamic regulation of genes related to amino acid metabolism, 
tRNA synthetases, TCA cycle, electron transport chain, glycolysis and cell cycle.  It is 
envisaged that insights to cellular metabolism will be valuable in a rational approach to 







6.1 Global Transcriptional Changes in Batch and Fed-batch 
Cultures 
 Microarray experiments were conducted on cells collected from mid-
exponential, late exponential and stationary phases of both batch and fed-batch PF-
CDM cultures (Figure 6.1).  The common inoculum was used as a reference (Control).  
The significantly regulated genes were then shortlisted using a significance criteria of 
absolute fold-change > 2-fold (ie. 1 < log2 intensity ratio < -1) with statistical 
significance criteria of p-value < 0.05. 
Figure 6.1  Viable cell concentration profiles of batch (▲) and fed-batch (x) 
cultures.  Arrows indicate growth phases where samples were collected for 
microarray analysis.  All samples were collected at viability > 90%.  Error bars 














































6.1.1 Ontological Distribution of Significantly Regulated Genes 
Based on these significance criteria, 204 of the most significantly regulated 
genes in the dataset were categorized according to their ontology and their expression 
data presented in the form of a heat map (Figure 6.2).  General expression patterns 
indicated that there were significant differences in gene expression profiles between 
the fed-batch and batch.  Since both cultures were essentially started using the same 
inoculum and basal medium, these differences could only be attributed to the low 
glutamine fed-batch process.  However, despite the comprehensiveness of the public 
human genome database, about half of the differentially expressed genes were 
unknown genes (90, 44%) or do not have a known functional ontology associated with 
them.  Their role in the cellular transcriptional program remains unknown until more 
information becomes available in the public domain.   
The three largest functional categories found to be differentially regulated were 
transcriptional regulation (20, 10%), protein processing (18, 9%) and metabolism 
genes (17, 8%).  Transcriptional regulation genes form the basic transcriptional control 
mechanism by which the cells control gene expression.  Majority of these significantly 
regulated transcriptional regulation genes had lower expression in the mid and late 
exponential phases of the fed-batch compared to the batch (Figure 6.2, group A).  The 
large number of differentially regulated transcriptional regulation genes provided 
evidence of active transcriptional control of cell physiology in the fed-batch cultures 
and implies that the metabolic differences observed between the batch and fed-batch 
cultures were not solely due to enzyme kinetics resulting from differences in substrate 
concentrations.  A large percentage of genes found to be significantly regulated were 
related to metabolism (Figure 6.2, group C).  Furthermore, these genes are generally 





         A. Transcription regulation (20, 10%) 
 
B. Protein processing (18, 9%) 
 
C. Metabolism (17, 8%) 
 
D. Stress response (11, 5%) 
 
E. Signal transduction (11, 5%) 
 
F. Transport (11, 5%) 
 




NM_001806 CEBPG CCAAT/enhancer binding protein (C/EBP), gamma 
X52357 ZNF29 zinc finger protein 29 (KOX 26) 
AF161342 SF1 splicing factor 1 
NM_003431 ZNF124 zinc finger protein 124 (HZF-16) 
NM_005455 ZNF265 zinc finger protein 265 
NM_003440 ZNF140 zinc finger protein 140 (clone pHZ-39) 
NM_004089 DSIPI delta sleep inducing peptide, immunoreactor 
NM_004432 ELAVL2 ELAV (embryonic lethal, abnormal vision, Drosophila)-like 2 
NM_005080 XBP1 X-box binding protein 1 
NM_005870 SAP18 sin3-associated polypeptide, 18kDa 
NM_014571 HEYL hairy/enhancer-of-split related with YRPW motif-like 
S53686 TAL1 T-cell acute lymphocytic leukemia 1 
X78924 ZNF266 zinc finger protein 266 
X94440 TEAD2 TEA domain family member 2 
AK024092 CHD2 chromodomain helicase DNA binding protein 2 
AL110188 ZNF10 zinc finger protein 10 (KOX 1) 
NM_004024 ATF3 activating transcription factor 3 
NM_004516 ILF3 interleukin enhancer binding factor 3, 90kDa 
NM_004992 MECP2 methyl CpG binding protein 2 (Rett syndrome) 
AK024431 AKNA AT-hook transcription factor AKNA 
NM_007235 XPOT exportin, tRNA (nuclear export receptor for tRNAs) 
NM_006276 SFRS7 splicing factor, arginine/serine-rich 7, 35kDa 
AK023636 MIR c-mir, cellular modulator of immune recognition 
AB037802 COG1 component of oligomeric golgi complex 1 
NM_012414 RAB3-GAP150 rab3 GTPase-activating protein, non-catalytic subunit (150kD) 
AF147326 TM4SF2 transmembrane 4 superfamily member 2 
NM_014265 ADAM28 a disintegrin and metalloproteinase domain 28 
NM_002429 MMP19 matrix metalloproteinase 19 
NM_003605 OGT O-linked N-acetylglucosamine (GlcNAc) transferase 
NM_003619 PRSS12 protease, serine, 12 (neurotrypsin, motopsin) 
NM_003963 TM4SF5 transmembrane 4 superfamily member 5 
NM_001907 CTRL chymotrypsin-like 
AB039947 APBA2BP amyloid beta (A4) precursor protein-binding, family A, member 2 binding protein 
AK000724 KPNA6 karyopherin alpha 6 (importin alpha 7) 
AK000770 B3GNT7 UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 7 
AK026340 ARIH1 ariadne homolog, ubiquitin-conjugating enzyme E2 binding protein, 1 (Drosophila) 
Y11162 RPL18A ribosomal protein L18a 
NM_006223 PIN4 protein (peptidyl-prolyl cis/trans isomerase) NIMA-interacting, 4 (parvulin) 
NM_001673 ASNS asparagine synthetase 
NM_002047 GARS glycyl-tRNA synthetase 
NM_001902 CTH cystathionase (cystathionine gamma-lyase) 
AF113132 PSAT1 phosphoserine aminotransferase 1 
NM_003986 BBOX1 butyrobetaine (gamma), 2-oxoglutarate dioxygenase 1 
AK023963 MARK3 MAP/microtubule affinity-regulating kinase 3 
AK022317 UCK1 uridine-cytidine kinase 1 
U58514 CHI3L2 chitinase 3-like 2 
AL049442 FLJ14431 hypothetical protein FLJ14431 
NM_003129 SQLE squalene epoxidase 
NM_012079 DGAT1 diacylglycerol O-acyltransferase homolog 1 (mouse) 
NM_000408 GPD2 glycerol-3-phosphate dehydrogenase 2 (mitochondrial) 
AF131756 SLC1A2 solute carrier family 1 (glial high affinity glutamate transporter), member 2 
AK021975 ALDH2 aldehyde dehydrogenase 2 family (mitochondrial) 
NM_000434 NEU1 sialidase 1 (lysosomal sialidase) 
NM_007180 TREH trehalase (brush-border membrane glycoprotein) 
NM_000035 ALDOB aldolase B, fructose-bisphosphate 
NM_005346 HSPA1B heat shock 70kDa protein 1B 
NM_001280 CIRBP cold inducible RNA binding protein 
NM_006472 TXNIP thioredoxin interacting protein 
NM_005546 ITK IL2-inducible T-cell kinase 
D86964 DOCK2 dedicator of cytokinesis 2 
NM_002185 IL7R interleukin 7 receptor 
AF216292 HSPA5 heat shock 70kDa protein 5 (glucose-regulated protein, 78kDa) 
NM_001925 DEFA4 defensin, alpha 4, corticostatin 
NM_002258 KLRB1 killer cell lectin-like receptor subfamily B, member 1 
NM_018289 FLJ10979 hypothetical protein FLJ10979 
NM_018319 TDP1 tyrosyl-DNA phosphodiesterase 1 
NM_002531 NTSR1 neurotensin receptor 1 (high affinity) 
NM_000510 FSHB follicle stimulating hormone, beta polypeptide 
NM_003604 IRS4 insulin receptor substrate 4 
NM_004864 GDF15 growth differentiation factor 15 
AB018283 RHOBTB1 Rho-related BTB domain containing 1 
NM_000842 GRM5 glutamate receptor, metabotropic 5 
NM_004313 ARRB2 arrestin, beta 2 
NM_014011 SOCS5 suppressor of cytokine signaling 5 
AF113223 SNX25 sorting nexin 25 
AF086183 APLP2 amyloid beta (A4) precursor-like protein 2 
NM_005242 F2RL1 coagulation factor II (thrombin) receptor-like 1 
AF052169 KCTD12 potassium channel tetramerisation domain containing 12 
NM_003234 TFRC transferrin receptor (p90, CD71) 
NM_005183 CACNA1F calcium channel, voltage-dependent, alpha 1F subunit 
D79998 KCTD2 potassium channel tetramerisation domain containing 2 
NM_000721 CACNA1E calcium channel, voltage-dependent, alpha 1E subunit 
NM_000811 GABRA6 gamma-aminobutyric acid (GABA) A receptor, alpha 6 
NM_000835 GRIN2C glutamate receptor, ionotropic, N-methyl D-aspartate 2C 
NM_000891 KCNJ2 potassium inwardly-rectifying channel, subfamily J, member 2 
NM_006028 HTR3B 5-hydroxytryptamine (serotonin) receptor 3B 
NM_016529 ATP8A2 ATPase, aminophospholipid transporter-like, Class I, type 8A, member 2 
AF086298 THSD2 thrombospondin, type I, domain 2 
NM_005542 INSIG1 insulin induced gene 1 
AJ132084 DNAH7 dynein, axonemal, heavy polypeptide 7 
X62468 IFNG interferon, gamma 
NM_015714 G0S2 putative lymphocyte G0/G1 switch gene 
AF216381 CCNB1IP1 cyclin B1 interacting protein 1 
NM_002826 QSCN6 quiescin Q6 
NM_002388 MCM3 MCM3 minichromosome maintenance deficient 3 (S. cerevisiae) 











































H. Apoptosis (6, 3%) 
 
I. Translation regulation (2, 1%) 
 
J. Others (11, 5%) 
 





AK026945 C20orf97 chromosome 20 open reading frame 97/tribbles homolog 3 (Drosophila)  TRIB3 
NM_001188 BAK1 BCL2-antagonist/killer 1 
AF174487 BOK BCL2-related ovarian killer 
NM_002759 PRKR protein kinase, interferon-inducible double stranded RNA dependent 
NM_005092 TNFSF18 tumor necrosis factor (ligand) superfamily, member 18 
NM_017745 BCOR BCL6 co-repressor 
NM_004095 EIF4EBP1 eukaryotic translation initiation factor 4E binding protein 1 
NM_004178 TARBP2 TAR (HIV) RNA binding protein 2 
AF070599 PPP1R11 protein phosphatase 1, regulatory (inhibitor) subunit 11 
AL355694 AP4E1 adaptor-related protein complex 4, epsilon 1 subunit 
AF000562 UPK2 uroplakin 2 
NM_005750 C4orf6 chromosome 4 open reading frame 6 
NM_001614 ACTG1 actin, gamma 1 
AF286598 AMOT angiomotin 
AF086347 WNT4 wingless-type MMTV integration site family, member 4 
M96843 ID2B inhibitor of DNA binding 2B, dominant negative helix-loop-helix protein 
AB045292 TMEM8 transmembrane protein 8 (five membrane-spanning domains) 
NM_006768 BRAP BRCA1 associated protein 
NM_005323 HIST1H1T histone 1, H1t 
L36587 unknown unknown 
AB002437 TIGA1 TIGA1 
Z36874 unknown unknown 
AK023781 unknown CDNA FLJ13719 fis, clone PLACE2000433 
AL110141 unknown MRNA; cDNA DKFZp564D0164 (from clone DKFZp564D0164) 
NM_016303 LOC51186 pp21 homolog 
U50539 unknown Human BRCA2 region, mRNA sequence GT605. 
AK021889 unknown unknown 
AK024914 unknown unknown 
AF086369 unknown unknown 
AF083117 unknown unknown 
AF075082 unknown Full length insert cDNA YQ80H06 
AL049680 LOC343068 hypothetical protein LOC343068 
X81896 TMEM16C transmembrane protein 16C 
U92017 unknown unknown 
AL049244 unknown unknown 
AF090932 unknown unknown 
Y10206 unknown unknown 
AK001398 unknown CDNA FLJ10536 fis, clone NT2RP2001094 
AK021601 FLJ11539 hypothetical protein FLJ11539 
AK022594 unknown MRNA; cDNA DKFZp686B15184 (from clone DKFZp686B15184) 
M34428 PVT1 Pvt1 oncogene homolog, MYC activator (mouse) 
M91159 H3F3A H3 histone, family 3A 
NM_006808 SEC61B Sec61 beta subunit 
AF181286 unknown unknown 
AB007975 unknown MRNA, chromosome 1 specific transcript KIAA0506. 
AF086535 NOR1 oxidoredunknownnitro domainunknowncontaining protein 
AK024517 unknown CDNA: FLJ20864 fis, clone ADKA01825 
AK026195 unknown CDNA clone IMAGE:30402226, partial cds 
AL137383 unknown MRNA; cDNA DKFZp434L1626 (from clone DKFZp434L1626) 
NM_005382 NEF3 neurofilament 3 (150kDa medium) 
AL109698 unknown hypothetical protein DKFZp547K1113 
NM_004709 CXorf1 chromosome X open reading frame 1 
AL049231 unknown unknown 
AK026385 unknown unknown 
AL117570 unknown unknown 
U00684 unknown unknown 
U03241 unknown unknown 
U58666 unknown unknown 
AB023223 STXBP5L syntaxin binding protein 5unknownlike 
AF052106 C6orf106 chromosome 6 open reading frame 106 
AF075028 unknown Full length insert cDNA YI38B04 
AF085891 unknown Full length insert cDNA clone YP91F02 
AF086468 unknown Full length insert cDNA clone ZD86H05 
AF090944 unknown Clone HQ0663 PRO0663 mRNA, partial cds 
AF161441 unknown Similar to HSPC323 (LOC284422), mRNA 
AK000792 unknown CDNA FLJ20785 fis, clone COL02504 
AK023283 unknown CDNA FLJ12795 fis, clone NT2RP2002047 
AK023501 unknown Hypothetical gene supported by AK023501 (LOC399876), mRNA 
AK023940 unknown CDNA FLJ13878 fis, clone THYRO1001411 
AK024303 unknown CDNA FLJ14241 fis, clone OVARC1000533 
AK024662 unknown CDNA: FLJ21009 fis, clone CAE04083 
AK026493 unknown CDNA: FLJ22840 fis, clone KAIA4709 
AK027199 unknown CDNA: FLJ23546 fis, clone LNG08361 
AL050288 APG4B APG4 autophagy 4 homolog B (S. cerevisiae) 
AL080200 unknown DKFZP434F122 protein 
AL133052 C1orf37 chromosome 1 open reading frame 37 
AL137343 NSE1 NSE1 
D87446 RW1 RW1 protein 
NM_016947 C6orf48 chromosome 6 open reading frame 48 
NM_017638 FLJ20045 TRAP/mediator complex subunit p28b 
NM_018011 FLJ10154 hypothetical protein FLJ10154 
NM_018250 FLJ10871 hypothetical protein FLJ10871 
NM_020347 LZTFL1 leucine zipper transcription factorunknownlike 1 
U80232 unknown Similar to dJ153G14.3 (novel C2H2 type Zinc Finger protein) (LOC346157), mRNA 
U81557 unknown Similar to Zinc finger protein 345 (Zinc finger protein HZF10) (LOC401915), mRNA 
X52341 ZNF17 zinc finger protein 17 (HPF3, KOX 10) 
X84370 unknown Immunoglobulin heavy chain variable region (VH4) mRNA, VH4unknown59 allele, partial cds 
NM_016940 C21orf6 chromosome 21 open reading frame 6 
AY007113 AMMECR1 Alport syndrome, mental retardation, midface hypoplasia and elliptocytosis chromosomal region, gene 1 
AK001857 unknown unknown 
AK021771 unknown unknown 
AK022963 unknown unknown 
Z83947 unknown unknown 
X64982 unknown unknown 
AF009288 unknown unknown 
NM_018626 unknown unknown 
AL137450 unknown MRNA; cDNA DKFZp434J0428 (from clone DKFZp434J0428) 
NM_018360 CXorf15 chromosome X open reading frame 15 
















































Figure 6.2  Categorization of 204 most significantly regulated genes (significance 
criteria: fold change > 2 and p-value < 0.05 from at least one phase) according to 
functional ontologies.  Numbers shown in parentheses beside each category 
indicate number of genes and percentage of total significantly regulated genes 
respectively. 
 
stationary phase, possibly resulting in lowered substrate utilization and waste 
metabolite production, indicative of a more efficient metabolic state.  One other 
obvious difference between the fed-batch and batch is the higher expression of 
transport genes during the mid-exponential phase in the fed-batch cultures (Figure 6.2, 
group F).  This could be a sign of higher molecular traffic and thus higher cellular 
activities in the fed-batch cultures. 
6.1.2 Clustering of Significantly Regulated Genes 
 Clustering is one of the commonly used methods for analysis of microarray 
data and it has been shown to efficiently group together genes of similar functions by 
their expression patterns.  Thus, grouping together poorly characterized or novel genes 
with well characterized ones, may provide a means to elucidate the function of many 
of these genes for which there is little or no information in the public domain (Eisen et 
al. 1998).  Additionally, genes with similar expression profiles can be hypothesized to 
be controlled by common transcriptional regulatory elements which may provide a 
AJ002969 unknown unknown 
AK000807 unknown unknown 
AK024615 unknown unknown 
NM_013307 unknown unknown 
AL359650 unknown unknown 
AB019565 unknown unknown 
AK021614 unknown CDNA FLJ11552 fis, clone HEMBA1003021 
AK025215 C13orf18 chromosome 13 open reading frame 18 
AK026671 FLJ23018 hypothetical protein FLJ23018 
AL049452 unknown MRNA; cDNA DKFZp586C1322 (from clone DKFZp586C1322) 
AK023936 unknown unknown 
Fold Change 
 3          2        1:1        -2        -3 






































simple means for multi-gene targeting via manipulation of a small number of “master 
regulator genes” associated with a desired phenotype (DeRisi et al. 1997). 
 The 204 most significantly regulated genes identified from the significance 
analysis were subjected to clustering into ten self-organizing maps (SOM).  The 
clustering was performed on all six time points (three phases each from batch and fed-
batch) from the microarray analysis simultaneously.  This allows concurrent 
identification of genes with similar profiles across both cultures and improves the 
stringency of the analysis.  The fidelity of the clustering will be enhanced since gene 
expression profiles across all phases of both cultures will have to be similar before 
they can be grouped together (Figure 6.3). 
 From the results, Cluster C showed consistently lower expression pattern in the 
fed-batch compared to the batch, especially in the late exponential phase (Figure 6.3).  
This cluster consists of 22 genes out of which a remarkable 9 (41%) of the genes were 
functionally annotated for transcriptional regulation.  Of the remaining 13 genes, only 
3 (14%) had an assigned function and 10 (45%) were unknown genes.  This suggests 
the possibility that the remaining 10 unknown genes may be involved in transcriptional 
regulation as well.  However, verification of the elucidated function of these genes has 
to be done individually before this hypothesis can be confirmed. 
The results from the remaining clusters were however much more difficult to 
interpret since there are genes of various different functional catergories in each of 
them.  It is possible that these genes may share common genetic regulatory elements 
that may be revealed by a detailed analysis of the upstream portion of the genes’ open 
reading frame (ORF).  However, much of the regulatory motifs for these genes are 
currently not available in the public domain.  Thus much of these data will have to be 








NM_003431 transcription regulation 




NM_002388 cell cy cle 
U81557 unknown 
AK024092 transcription regulation 
AL110188 transcription regulation 
U80232 unknown 
NM_016303 unknown 
NM_004024 transcription regulation 
X52341 unknown 
NM_004516 transcription regulation 
NM_004992 transcription regulation 
NM_005092 apoptosis 
AK023636 protein ubiquitination  
X64982 unknown 





NM_005242 signal transduction 
AK000807 unknown 









NM_014571 transcription regulation 
AF174487 apoptosis 
AF070599 enzyme regulation 
AF181286 unknown 
NM_018319 stress response 
D86964 stress response 
AB039947 protein metabolism 
AK024431 unknown 
NM_016947 unknown 
NM_006276 RNA metabolism 
NM_003605 protein metabolism 
L36587 unknown 
NM_005080 transcription regulation 
AK026945 apoptosis 
AK022317 metabolism 
NM_004095 translation regulation 
AK023963 phosphate metabolism 
NM_001902 amino acid metabolism 
AF083117 unknown 
NM_007235 transport 
AF147326 protein metabolism 
AL049680 unknown 
NM_001280 stress response 
NM_001673 amino acid metabolism 
AK021975 carbohy drate metabolism 
NM_015714 cell cycle 
AF216381 cell cycle 
NM_001806 transcription regulation 
AL110141 unknown 
NM_002047 amino acid metabolism 
AB002437 unknown 
AF113132 amino acid metabolism 
AF161441 unknown 
NM_016940 unknown 
NM_004089 transcription regulation 
NM_004313 signal transduction 
NM_003986 vitamin metabolism 
AB037802 protein transport 
AK021771 unknown 
AB018283 signal transduction 
NM_002826 cell cy cle 
NM_002258 stress response 
NM_004432 transcription regulation 




NM_018289 stress response 
NM_018011 unknown 
U58666 unknown 
X78924 transcription regulation 
AK023940 unknown 
NM_018250 unknown 




NM_012079 lipid metabolism 
NM_006472 stress response 











NM_001925 stress response 
NM_002429 protein metabolism 
NM_000811 ion transport 
D79998 ion transport 
NM_003963 protein metabolism 
NM_000835 ion transport 
AB045292 cell adhesion 
NM_005750 development 
NM_004178 translation regulation 
AK000792 unknown 
S53686 transcription regulation 
AK023936 stress response 
NM_014011 signal transduction 
NM_016529 ion transport 
NM_006028 ion transport 
NM_007180 carbohy drate metabolism 
AF090944 unknown 








NM_005323 nucleosome assembly   
AK024303 unknown 
AK027199 unknown 
NM_003234 ion transport 
AK024662 unknown 
NM_005346 stress response 
NM_000721 ion transport 
AJ132084 cell growth and/or maintenance
NM_003129 lipid metabolism 
NM_005546 stress response 
NM_003604 signal transduction 
X81896 unknown 
NM_000434 carbohy drate metabolism 
AF052169 ion transport 
AF131756 glutamate transport 
NM_014265 protein metabolism 
AF086347 cell-cell signaling  























































































Figure 6.3  Clustering of 204 most significantly regulated genes using Self-
Organizing Maps (SOM).  Data was clustered into 10 SOM with the gene ID and 
function displayed on the right. 
 
6.2 Pathway-Oriented Analysis of Batch and Fed-batch Cultures 
using GenMAPP 
 Due to the complexity of the overwhelmingly large datasets generated by 
microarray experiments, a problem compounded by the large proportion of unknown 
genes, physiological significance of transcriptional expression data is frequently only 
possible through a pathway-oriented analysis of the results.  Using a more stringent 
fold change criterion of 2-fold, 204 genes were found to be significantly regulated.  
However, when a fold change criterion of 1.5-fold was used, 1554 genes were 
shortlisted as significantly regulated (Figure 6.4).  Therefore, a less stringent fold 
change criterion of 1.5-fold might be more appropriate for subsequent pathway-
oriented analysis in order to have sufficient genes in the pathways represented to make 
M96843 cell motility
NM_002759 apoptosis 
AF113223 signal transduction 
NM_001907 protein metabolism 
NM_012414 protein transport 
AL359650 unknown 
Y11162 protein metabolism 
AF009288 unknown 




AK000770 protein metabolism 
Z83947 unknown 
NM_001614 cy toskeleton 
AL049452 unknown 
NM_000510 signal transduction 
AF000562 development 
AF090932 unknown 
NM_002185 stress response 
AK001398 unknown 
Y10206 unknown 









NM_004864 signal transduction 
NM_000035 carbohy drate metabolism 
NM_005183 ion transport 
AF216292 stress response 
AF161342 transcription regulation 
AK026340 protein metabolism 
AK022594 unknown 








AL355694 endocy tosis 
NM_005455 transcription regulation 
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the analysis meaningful.  Moreover, fold-change criteria of less than 2-fold have been 
reported as biologically relevant in literature utilizing mammalian cell cultures 
(Mulligan et al. 2002, Pandini et al. 2003, Korke et al. 2004). 
 
 
Figure 6.4  Number of differentially regulated genes of both batch (□) and fed-
batch (■) cultures at each of the 3 culture phases using 2 different significance 
criteria:  Fold change > 2 (left) or 1.5 (right) at p-value < 0.05. 
 
The focus of this analysis was primarily on metabolism and the classes of genes 
that were found to be significantly regulated were related to amino acid metabolism, 
tRNA synthetases, TCA cycle, electron transport chain and glycolysis.  The study was 
however extended to include cell cycle pathway analysis as well as there were 
significant numbers of cell cycle related genes that were found to be differentially 
expressed and the cell cycle pathway is a well characterized one.  The heat maps 
representing the expression data of those genes identified from the GenMAPP analysis 
are shown in Figure 6.5.  The implications of these results are discussed in greater 
detail in the following sections. 
 
























































(at least 1 of 3 phases):
Batch       = 75
Fed-batch = 155
Total         = 204
























































(at least 1 of 3 phases):
Batch       = 637
Fed-batch = 1205





I. Amino Acid Metabolism 
 
 
II. tRNA Synthetase 
 
 
III. TCA Cycle 
 
 




















Figure 6.5  Genes involved in amino acid metabolism, tRNA synthetases, TCA 
cycle, electron transport chain, glycolysis and cell cycle that were identified to be 
significantly regulated using GenMAPP (significance criteria:  fold change > 1.5 
and p-value < 0.05 from at least one phase). 
 
6.2.1 Amino Acid Metabolism Genes (Figure 6.5, group I) 
In general, most of the amino acid metabolism genes are seen to be down-
regulated in the fed-batch compared to the batch.  This is especially obvious in the late 
exponential to stationary phases of the cultures.  Among the genes that were down-
regulated were those involved in glutamine/glutamate, serine/glycine/cysteine and 
arginine/polyamine metabolism.  The general down-regulation of these amino acid 
NM_004446 EPRS  glutamyl-prolyl-tRNA synthetase 
NM_002047 GARS  glycyl-tRNA synthetase 
NM_004184 WARS  tryptophanyl-tRNA synthetase 
NM_006513 SARS  seryl-tRNA synthetase 
NM_003680 YARS  tyrosyl-tRNA synthetase 
NM_005896 IDH1  isocitrate dehydrogenase 1 (NADP+), soluble 
U87972 IDH3B  NAD+-isocitrate dehydrogenase 
AF131748 SUCLG2  clone 25191 GTP-specific succinyl-CoA synthetase beta subunit 
NM_001152 SLC25A5  solute carrier family 25 (mitochondrial carrier; adenine nucleotide translocator), member 5 
AF076617 SLC25A6  ADP/ATP translocase 
NM_001863 COX6B  cytochrome c oxidase subunit Vib 
NM_004541 NDUFA1  NADH dehydrogenase (ubiquinone) 1 alpha subcomplex 
NM_007103 NDUFV1  NADH dehydrogenase (ubiquinone) flavoprotein 1 
U28480 UCP1  uncoupling protein 1 (mitochondrial, proton carrier) 
NM_001924 GADD45A (anti)  growth arrest and DNA-damage-inducible, alpha 
NM_004083 GADD153 (anti)  DNA-damage-inducible transcript 3 
NM_004725 BUB3 (anti)  budding uninhibited by benzimidazoles 3, yeast homolog 
NM_001254 CDC6 (anti)  cell division cycle 6 homolog (S. cerevisiae) 
AF015592 CDC7 (pro)  cell division cycle 7 homolog (S. cerevisiae) 
NM_002388 MCM3 (pro)  minichromosome maintenance deficient (S. cerevisiae) 3 
NM_014321 ORC6L (pro)  origin recognition complex, subunit 6, yeast homolog-like 
NM_001237 CCNA2 (pro)  cyclin A2 
NM_004701 CCNB2 (pro)  cyclin B2 
NM_001949 E2F3 (pro)  E2F transcription factor 3 
NM_001952 E2F6 (pro/anti)  E2F transcription factor 6 
M38449 TGFB1 (pro/anti)  human transforming growth factor-beta 
NM_000034 ALDOA  aldolase A, fructose-bisphosphate 
NM_000035 ALDOB  aldolase B, fructose-bisphosphate 
NM_002629 PGAM1  phosphoglycerate mutase 1 (brain) 
NM_005566 LDHA  lactate dehydrogenase A 
NM_002611 PDK2  pyruvate dehydrogenase kinase, isoenzyme 2 
NM_000365 TPI1  triosephosphate isomerase 1 



































NM_001673 ASNS  asparagine synthetase 
NM_003875 GMPS  guanine-monophosphate synthetase 
NM_005271 GLUD1  glutamate dehydrogenase 1 
NM_002079 GOT1  glutamic-oxaloacetic transaminase 1, soluble 
NM_002080 GOT2  glutamic-oxaloacetic transaminase 2, mitochondrial 
AF113132 PSAT1  phosphoserine aminotransferase 
NM_001172 ARG2  arginase, type II 
NM_002539 ODC1  ornithine decarboxylase 1 
NM_000071 CBS  cystathionine-beta-synthase 
NM_001902 CTH  cystathionase 
NM_005412 SHMT2  serine hydroxymethyltransferase 2, mitochondrial 
NM_001917 DAO  D-amino-acid oxidase 
NM_000254 MTR  5-methyltetrahydrofolate-homocysteine methyltransferase 
L07033 HMGCL  3-hydroxymethyl-3-methylglutaryl-Coenzyme A lyase 
Fold Change 




metabolism genes is hypothesized to be a response by the nutrient-controlled fed-batch 
culture to restrict the inefficient employment of potentially limited resources and re-
channel it to more critical functions. 
Asparagine synthetase (ASNS) catalyses the formation of asparagine from 
aspartate via the transamination of glutamine to glutamate (Figure 6.6).  It has been 
reported in literature that its expression, which is under the control of two nutrient 
sensing-response elements (NSRE), is increased in response to either amino acid or 
glucose deprivation (Zhong et al., 2003).  It was observed that the expression of ASNS 
was similar during the mid and late exponential phases of the batch and fed-batch 
cultures but was significantly higher in the batch compared to the fed-batch during the 
stationary phase (Figure 6.6).  The reason for the difference in expression can be 
attributed to nutrient deprivation, for example glutamine (Figure 3.3C), experienced by 
the batch towards the later stages of the culture but not the fed-batch. 
 Guanine-monophosphate synthetase (GMPS), another glutamine-hydrolyzing 
enzyme, was also found to be down-regulated in fed-batch compared to batch (Figure 
6.6).  Four other enzymes involved in glutamate catabolism (GLUD1, GOT1, GOT2, 
EPRS) were found to have lower expression in late exponential to stationary phases of 
fed-batch compared to batch (Figure 6.6).  Glutamate dehydrogenase 1 (GLUD1) 
catalyzes the oxidative deamination of glutamate to 2-oxoglutarate, one of the key 
entry point for the glutamine catabolic pathway into the TCA cycle.  GOT1 and GOT2 
are the cytosolic and mitochondrial forms of glutamic-oxaloacetic transaminases that 
are involved in glutamate catabolism.  Glutamyl-prolyl-tRNA synthetase (EPRS) is the 
tRNA synthetase that charges the glutamate molecule to its corresponding tRNA 
during protein biosynthesis.  In addition, a glutamate anabolic enzyme, phosphoserine 




compared to batch (Figure 6.6).  The down-regulation of these genes in the fed-batch 
culture is most likely a direct consequence of the low glutamine control level 
maintained in the fed-batch culture and collectively represents a lowered and more 













Figure 6.6  Glutamine/glutamate metabolism genes found to be significantly 
regulated in the fed-batch cultures.  Gene names (in italics) with gene expression 
below (see legend).  Genes represented in pathway:  asparagine synthetase 
(ASNS); guanine-monophosphate synthetase (GMPS); glutamate dehydrogenase 
(GLUD1); glutamic-oxaloacetatic transaminases (GOT1, cytoplasmic; GOT2, 
mitochondrial); glutamyl-prolyl-tRNA synthetase (EPRS); phosphoserine 
aminotransferase (PSAT1). 
 
 The group of genes involved in serine/glycine/cysteine metabolism (SHMT2, 
CBS, CTH, SARS, GARS) exhibited similar expression profiles of consistent low 
expression in all phases of the fed-batch culture but an increasing expression towards 
stationary phase in the batch culture (Figure 6.7).  These genes functioning closely 










































































glycine and cysteine metabolism in this cell culture system.  Serine 
hydroxymethyltransferase (SHMT2) catalyzes the conversion between serine and 
glycine.  Cystathionine-beta-synthase (CBS) is capable of catalyzing the conversion of 
serine to either cysteine directly or via cystathionine through cystathionase (CTH).  
SARS and GARS are the tRNA synthetases responsible for charging serine and glycine 
to their respective tRNAs.  The down-regulation of these genes in fed-batch culture 









Figure 6.7  Serine/glycine/cysteine metabolism genes found to be significantly 
regulated in the fed-batch cultures.  Gene names (in italics) with gene expression 
below (see legend).  Genes represented in pathway:  serine 
hydroxymethyltransferase (SHMT2, mitochondrial); cystathionine-beta-synthase 
(CBS); cystathionase (CTH); seryl-tRNA synthetase (SARS); glycyl-tRNA 
synthetase (GARS); D-amino-acid oxidase (DAO). 
 
 One exception to the down-regulation of metabolism genes is the higher 
expression of D-amino-acid oxidase (DAO) in the mid and late exponential phases of 
the fed-batch culture (Figure 6.7).  DAO is a flavoprotein with wide specificity for D-
amino acids which is also known to act on glycine (which does not exhibit any 
stereoisomerism).  The higher expression of DAO, especially in the mid-exponential 
































































consumption in the fed-batch cultures (Figure 5.10).  The overexpression of DAO may 
present a means to reduce build up of glycine as a waste metabolite in culture. 
 In polyamine metabolism, arginine is hydrolyzed to ornithine and urea by 
arginase (ARG2) followed by decarboxylation to putrescine by ornithine decarboxylase 
(ODC1).  Putrescine is a precursor for production of polyamines like spermine and 
spermidine which are used in DNA packaging.  Alternatively, putrescine can find its 
way into the TCA cycle as succinate via 4-aminobutanoate.  There is distinctly lower 
expression of both ARG2 and ODC1 in fed-batch compared to batch at the late 
exponential to stationary phases.  The down-regulation of these two genes involved in 
putrescine formation probably indicates lower demand for polyamine production in the 











Figure 6.8  Arginine/polyamine metabolism genes found to be significantly 
regulated in the fed-batch cultures.  Gene names (in italics) with gene expression 





























































 The lower expression of methionine synthase (MTR) in fed-batch compared to 
batch (all phases) could mean less amino acid interconversion within the cells, again 
indicative of a more conducive nutrient environment in the fed-batch (Figure 6.5, 
group I).  3-hydroxymethyl-3-methylglutaryl-coenzyme A lyase (HMGCL) represents 
the last step in leucine degradation and its entry into the TCA cycle as acetyl-CoA.  
The down-regulation of this gene in fed-batch towards the later stages of the culture is 
further evidence of less anaplerotic flux into the TCA cycle, reducing the utilization of 
amino acids for energy production (Figure 6.5, group I). 
6.2.2 tRNA Synthetase Genes (Figure 6.5, group II) 
 The tRNA synthetase genes (EPRS, GARS, WARS, SARS, YARS) were found to 
be down-regulated in the fed-batch compared to the batch, especially towards the late 
exponential and stationary phases of the cultures.  There have been reports of amino 
acid starvation up-regulating expression of tRNA synthetases in CHO cell cultures 
(Lazard et al. 1987a, Lazard et al. 1987b).  The higher expression levels of tRNA 
synthetases therefore suggest the presence of higher nutrient-related stress in the batch 
compared to the fed-batch cultures. 
 tRNA synthetases are essential proteins found in all living organism and they 
form part of the basic translational machinery of the cell.  Their main function in the 
cell is to catalyse the attachment of amino acids to their cognate tRNAs, thereby 
ensuring the faithful translation of the genetic code.  This has implications in 
bioprocessing since protein translation is a key aspect of recombinant protein 
production and tRNA synthetase expression might represent a potential area of 
interest.  Thus, our earlier observations that tRNA synthetases were down-regulated in 
fed-batch might alternatively imply that there is a general slowing down of the cellular 




obvious since the 293 cells used in this study does not express any recombinant protein 
product.  However, a separate study using a similar fed-batch strategy of CHO cells 
demonstrated that expression of recombinant interferon-γ in low-glutamine fed-batch 
cultures was not compromised (Wong et al. 2005a). 
 Similar coordinated down-regulation of tRNA synthetases have been reported 
in several other studies utilizing microarray, for example during yeast diauxic shift 
(DeRisi et al. 1997) and in an E. coli mutant that hypersecrete recombinant α-
hemolysin (Lee and Lee 2005).  This information was exploited effectively in the 
engineering of hypersecreting E. coli cells through the use of rare codons, representing 
one of the early successful attempts at metabolic engineering employing insights 
gleaned from microarray and proteomic studies (Lee and Lee 2005).  In addition to 
their basic enzymatic function, tRNA synthetases have also been reported to possess a 
whole range of other noncanonical functions in a number of other important cellular 
processes ranging from transcriptional regulation to stress response and apoptosis (Ko 
et al. 2002).  Thus, tRNA synthetases represent a class of genes with high potential as 
metabolic engineering targets for improving culture performance, such as cell growth 
and recombinant protein production. 
6.2.3 TCA Cycle and Electron Transport Chain Genes (Figure 6.5, group III) 
 The genes involved in TCA cycle were down-regulated whereas the ones 
involved in the electron transport chain were generally up-regulated in the fed-batch 
compared to the batch cultures.  This suggests the presence of a more efficient energy 
metabolism in the fed-batch cultures. 
 Three genes (IDH1, IDH3B, SUCLG2) in the TCA cycle were found to be 
significantly regulated and showed lower expression in the fed-batch compared to the 




responsible for catalyzing the conversion of isocitrate to α-ketoglutarate with the 
formation of NADH and NADPH respectively.  These nicotinamide nucleotides are 
involved in the maintenance of the proton gradient required for the electron transport 
chain ATP synthesis.  Succinyl-CoA ligase (SUCLG2) catalyzes the conversion of 
succinyl-CoA to succinate.  Even though, the rest of the genes involved in the TCA 
cycle were not significantly regulated, the down-regulation of these three genes in the 
cyclic pathway could potentially mean the overall reduction of TCA cycle activity in 
the fed-batch compared to the batch (Figure 6.9). 
   
 
Figure 6.9  TCA cycle and electron transport chain genes found to be significantly 
regulated in the fed-batch cultures.  Gene names (in italics) with gene expression 
below (see legend).  Genes represented in pathway:  isocitrate dehydrogenases 
(IDH1; IDH3B); succinyl-CoA synthetase (SUCLG2); mitochondrial ADP/ATP 
translocases (SLC25A5; SLC25A6); NADH oxidoreductases (NDUFA1; 








































































 Four of the five significantly regulated genes (SLC25A5, SLC25A6, COX6B, 
NDUFA1) in the electron transport chain exhibit higher expression in most phases of 
the fed-batch (Figure 6.9).  SLC25A5 and SLC25A6 are mitochondrial ATP/ADP 
carriers in the electron transport chain and are important components of the energy 
metabolism pathway.  Cytochrome-C oxidase (COX6B) is the terminal enzyme of the 
mitochondrial respiratory chain and catalyzes electron transfer from reduced 
cytochrome C to oxygen.  NDUFA1 and NDUFV1 are NADH dehydrogenases 
required in the first step of the electron transport chain.  Up-regulation of these genes 
represents a higher electron transport activity and elevated cellular ATP production 
through oxidative phosphorylation.  Concurrently, uncoupling protein 1 (UCP1), 
responsible for reducing the proton gradient required for ATP production through 
electron transport chain, is down-regulated in the mid to late exponential phases in fed-
batch (Figure 6.9).  This represents a reduction in the proton leakage that leads to loss 
of potential energy. 
 Taken together, these observations suggests that despite the reduced TCA cycle 
activity, there is elevated electron transport chain activities and decreased energy waste 
through proton leakage caused by the uncoupling protein indicating a more 
energetically efficient state under nutrient-controlled fed-batch conditions.  The results 
also suggest that metabolic engineering to down-regulate UCP1 could provide a means 
to improve cellular energy efficiency in cultured cells. 
6.2.4 Glycolysis Genes (Figure 6.5, group V) 
 On the whole it is not conclusive if there was a general repression or elevation 
of glycolysis in the fed-batch cultures based on just the transcriptional information 
alone.  However, four of the six genes (ALDOA, PGAM1, LDHA, TPI1) found to be 




reported in another microarray study of nutrient-controlled hybridoma cultures (Korke 
et al. 2004), demonstrating that transcriptional analysis using microarray can be used 
effectively to identify important metabolic control points. 
 Fructose-bisphosphate aldolases are enzymes that catalyzes the conversion of 
fructose-1,6-bisphosphate to glyceraldehyde 3-phosphate and dihydroxyacetone 
phosphate in the glycolytic process.  Two isoforms of fructose-bisphosphate aldolases, 
ALDOA and ALDOB, showed remarkably different expression patterns.  ALDOA 
expression shows a decreasing trend in both batch and fed-batch cultures with 
expression in the fed-batch being higher throughout.  On the other hand, ALDOB 
expression shows an increasing trend in both batch and fed-batch cultures with 
expression in the fed-batch being lower throughout (Figure 6.10). 
 There are large numbers of inherent redundancies in eukaryotic systems, 
manifested as an abundance of enzymatic isoforms and secondary metabolic pathways.  
The presence of these redundancies facilitates a certain degree of “metabolic 
malleability” that can prove useful for the cell when surviving in adverse conditions.  
Thus, such differences in transcriptional control of isozymes can potentially provide 
further insights into how eukaryotic cells maintain cellular control in the midst of a 
complex system of redundancies and backups. 
 There was higher expression of lactate dehydrogenase (LDHA) in the fed-batch 
compared to the batch at the late exponential and stationary phases of the cultures 
(Figure 6.10).  The higher expression of LDHA ties in very well with the observed 
consumption of lactate in the fed-batch cultures (Figure 5.8) and this phenomenon has 




















Figure 6.10  Glycolysis genes found to be significantly regulated in the fed-batch 
cultures.  Gene names (in italics) with gene expression below (see legend).  Genes 
represented in pathway:  fructose-bisphosphate aldolases (ALDOA; ALDOB); 
triosephosphate isomerase (TPI1); phosphoglycerate mutase (PGAM1); lactate 
dehydrogenase (LDHA); pyruvate dehydrogenase kinase (PDK2). 
 
 Four out of six of the dynamically regulated genes (ALDOA, PGAM1, LDHA, 
TPI1) were previously reported to be differentially expressed in nutrient-controlled 
continuous culture of hybridoma cells where nine differentially expressed glycolytic 
genes were detected using both cDNA and Affeymetrix GeneChip analyses (Korke et 
al. 2004).  The presence of these differentially regulated genes common to both studies 
serves to highlight the importance of these genes as potentially important 
transcriptional control points in the glycolytic process. 
Glucose Fructose-1,6-bisphosphate 
































































 Glycolytic enzymes have also been reported to be closely associated with 
cytoskeleton proteins and the reorganization of glycolytic enzymes through binding on 
the cytoskeleton has been proposed as a means of cellular control of glycolysis (Gotz 
et al. 1999; Schwartz and Beitner 2000).  β- and γ-actin (ACTB and ACTG1) were up-
regulated in fed-batch (Figure 6.12C), an observation that was also previously reported 
in proteomic analysis of nutrient-controlled, metabolically-shifted hybridoma cells 
(Seow et al. 2001).  Up-regulation of these genes in the fed-batch could be implicated 
to their role in post-translational control of glycolysis. 
6.2.5 Cell Cycle Genes (Figure 6.5, Group VI) 
 Out of the twelve cell cycle genes found to be significantly regulated (Figure 
6.11), all four of those with potentially anti-proliferative properties (GADD45A, 
GADD153, BUB3, CDC6) were elevated significantly with culture progression 
towards the stationary phase in the batch but remained at a relatively lower level in the 
fed-batch cultures.  Five of the genes (CDC7, MCM3, ORC6L, CCNA2, CCNB2) with 
closely related functions in formation/activation of the DNA replication initiation 
complex were down-regulated in the fed-batch compared to the batch cultures.  The 
remaining significantly regulated genes involved in the control of phases of the cell 
cycle also show significant differences between batch and fed-batch.  These 
differences in gene expression suggested a difference in mechanism of cell cycle 
control/arrest between the two modes of cultures which was probably due to a 
difference in the environmental trigger. 
 GADD45A and GADD153 (alternative names: DDIT3 or CHOP) are both 
members of a family of genes whose transcript levels are increased following stressful 
growth conditions and treatment with DNA-damaging agents and both have been 




also been report indicating a rapid increase in their transcript levels following 
glutamine deprivation in cells highly dependent on glutamine for growth (Abcouwer et 
al. 1999).  Thus, the absence of overexpression of these genes in the fed-batch is 
testimony that the low glutamine level used in the fed-batch is not at a limiting level 
that is detrimental to the cells (Figure 6.11).  Additionally, the reported ability of 
GADD45 to induce G2/M arrest in cells without triggering apoptosis (Mak and Kultz 
2004) presents an opportunity to harness it for biphasic production strategies whereby 
cell cycle arrest can be induced at high cell densities for improved recombinant protein 
production.  On the hand, GADD153 is widely implicated in endoplasmic-reticulum 
stress-induced apoptosis (Oyadomari and Mori 2004) and would better serve as an 
anti-apoptotsis cellular engineering target through down-regulation of its expression. 
 BUB3 encodes for a protein that functions at the mitotic checkpoint by delaying 
anaphase through binding with CDC20.  It has additionally been shown to repress 
transcription in interphase cells and mediate G1 or G2 cell cycle arrest (Yoon et al. 
2004) and its expression was maintained at a lower level in later phases of the fed-
batch compared to the batch (Figure 6.11).  CDC6 is required for initiation of DNA 
replication and for coupling the S phase with mitosis, however overexpression of this 
gene has been reported to prevent entry into mitosis through activation of a mitotic 
check-point (Clay-Farrace et al. 2003).  Overexpression of CDC6 was observed in the 
stationary phase of the batch cultures but not the fed-batch cultures (Figure 6.11).  The 
higher expression of these four anti-proliferative genes in the batch compared to the 
fed-batch, especially at the stationary phase, is probably responsible for the termination 















































Figure 6.11  Cell cycle genes found to be significantly regulated in the fed-batch 
cultures.  Gene names (in italics) with gene expression below (see legend).  Genes 
represented in pathway:  E2F transcription factor (E2F3; E2F6); transforming 
growth factor beta (TGFB1); growth arrest and DNA-damage-inducible 
transcripts (GADD45A; GADD153); cyclins (CCNA2; CCNB2); budding 
uninhibited by benzimidazoles 3 homolog, yeast (BUB3); cell division cycle 
(CDC6; CDC7; CDC20; CDC45); origin recognition complex 6L (ORC6L); mini-














































































 Five genes (CDC7, MCM3, ORC6L, CCNA2, CCNB2) related to 
formation/activation of the DNA replication initiation complex showed lower 
expression in fed-batch compared to the batch (Figure 6.11).  CDC7 is a cell division 
cycle protein with kinase activity and it has been suggested that the protein is essential 
for initiation of DNA replication and plays a role in regulating cell cycle progression.  
Down-regulation of CDC7 by siRNA in a variety of tumor cell lines causes an abortive 
S phase, leading to cell death (Montagnoli et al. 2004).  MCM3 is one of the highly 
conserved mini-chromosome maintenance proteins (MCM) that are involved in the 
initiation of eukaryotic genome replication and is a major physiological target of 
CDC7 (Masai and Arai 2002).  ORC6L is a member of the highly conserved six 
subunit protein complex origin recognition complex (ORC) which is essential for the 
initiation of the DNA replication in eukaryotic cells.  Studies in yeast have 
demonstrated that ORC binds specifically to origins of replication and serves as a 
platform for the assembly of additional initiation factors such as CDC6 and MCM 
proteins (Prasanth et al. 2002).  The coordinated down-regulation of three of the genes 
involved in the formation of the DNA replication initiation complex (CDC6, ORC6L, 
MCM3) and two other genes that work immediately upstream of it (CDC7, CCNA2) 
provides further evidence of a difference in cell cycle control (Figure 6.11). 
 Cyclin A2 (CCNA2) and cyclin B2 (CCNB2) belong to the highly conserved 
cyclin family that functions as regulators of CDK kinases.  Different cyclins exhibit 
distinct expression and degradation patterns which contribute to the temporal 
coordination of each mitotic event.  During S phase, cyclin A2 binds and activates 
CDK1 (alternative name: CDC2) or CDK2 kinases which in turns phosphorylates 
components of the DNA replication machinery such as CDC6 forming the important 




transitions (Yam et al. 2002).  Similarly, CCNB2 is known to bind CDK1 to promote 
cell cycle progression (Fung and Poon 2005).  Both CCNA2 and CCNB2 were down-
regulated in the fed-batch compared to the batch (Figure 6.11). 
   The remaining three cell cycle genes (E2F3, E2F6, TGFB1) were up-
regulated in the fed-batch compared to the batch (Figure 6.11).  E2F3 and E2F6 
protein encoded by these genes are members of the E2F family of transcription factors. 
The E2F family plays a crucial role in the control of cell cycle and action of tumor 
suppressor proteins.  Additionally, E2F3 overexpression is associated with tumor cell 
proliferation indicative of its role in promoting cell growth (Oeggerli et al. 2004).  In 
contrast, TGFB1 is a multifunctional peptide that controls proliferation, differentiation, 
and is widely reported to be implicated in growth arrest in cells. 
Because of their wide-ranging effects, the physiological significance of 
differences in expression of these genes on cell cycle regulation is not immediately 
obvious from these results alone.  Nevertheless, these differences in gene expression 
taken together with the coordinated repression of the DNA replication initiation 
machinery and anti-proliferative genes in the fed-batch serves as strong evidence of 
differences in the cell cycle regulation between the batch and fed-batch cultures. 
6.2.6 Validation of Microarray Results using qRT-PCR 
 Thirteen of the genes discussed in earlier sections were validated using 
quantitative real-time PCR (qRT-PCR).  In general, the expression profiles from both 
qRT-PCR and microarray analyses showed good coherence.  There were however 
higher fold changes detected in the qRT-PCR compared to the microarray data.  This is 
attributable to the fold changes in the microarray data being diminished as a result of 




PCR platform.  Nonetheless, it confirms that the 1.5-fold significance criterion used in 

















































































































A.  Amino Acid Metabolism and tRNA synthetases































































































Figure 6.12  Validation of microarray data using quantitative real-time PCR 
(qRT-PCR).  Expression profiles of amino acid metabolism, tRNA synthetases, 
TCA cycle, electron transport chain, glycolysis and cell cycle genes found to be 
significantly regulated in batch (▲) and fed-batch (x) cultures from microarray 
data represented by solid lines (primary axis) and qRT-PCR results represented 
by broken lines (secondary axis).  Positive values denote up-regulation and 
negative values denote down-regulation with respect to Control.  qRT-PCR 
results from average of duplicate runs.  Note:  ACTB not represented on the chip 
therefore results from qRT-PCR only (4 repeats).  Error bars represent standard 
deviation of experimental replicates. 
 
6.3 Conclusions 
 The results demonstrated that the microarray platform can effectively be 
utilized as a tool to monitor transcriptional events in mammalian cells in culture.  The 
significant regulation of genes related to some important cellular processes were 
highlighted in this study.  Genes related to glutamine/glutamate metabolism that were 
down-regulated in the fed-batch signify a lower level of glutaminolysis and represents 
a more efficient cellular glutamine metabolism.  Furthermore, the upregulation of DAO 
is probably responsible for the glycine consumption observed in the fed-batch and 
represents a potential cellular engineering target for improving glycine metabolism.  
Down-regulation of genes related to TCA cycle, coupled with up-regulation of genes 
related to electron transport chain and down-regulation of UCP1, in fed-batch is 
indicative of a more efficient metabolic state.  These results corroborated the 



















































Cellular engineering to down-regulate UCP1 could improve energy metabolism in 
cells.  Additionally, there were differences in the cell cycle regulation between the two 
modes of culture revealed by the transcriptional analysis, most notably the down-
regulation of anti-proliferative genes and genes that are related to DNA replication 
initiation in the fed-batch.  Two of the differentially regulated cell cycle arrest genes, 
GADD45A and GADD153, possess potential applications in biphasic production and 
anti-apoptosis cellular engineering strategies. 
 Further insights into the transcriptional regulatory network in its entirety may 
only be revealed with time when more genomic information becomes publicly 
available.  However, these results have managed to provide a tantalizing but albeit 
incomplete glimpse of the transcriptional machinery and some of the significantly 





7 METABOLIC ENGINEERING OF 293-HEK CELLS 
FOR IMPROVED GLUTAMINE METABOLISM 
 It was demonstrated in earlier chapters that the use of dynamic nutrient feeding 
to maintain glutamine at low levels in fed-batch cultures reduced the overflow of 
glutamine metabolism and resulted in the shift of metabolism towards an energetically 
more efficient state signified by reduced lactate and ammonia production and thus 
achieving a higher cell concentration for enhanced virus productivity (Chapter 4 and 
5).  This shift in metabolism was investigated at the transcriptional level using DNA 
microarray and revealed a cellular modulation of glutaminolysis coupled with a more 
efficient energy metabolism (Chapter 6).  It was hypothesized that genetic down-
regulation of glutaminolysis in culture could theoretically allow the cells to self-
regulate glutamine catabolism without the need for sophisticated online fed-batch 
instrumentations.  Thus, allowing them to be cultured even at the much higher 
glutamine concentrations typically found in batch cultures and still exhibit reduced 
waste metabolites formation and enhanced culture performance. 
 One possible approach to directly regulate glutamine metabolism is to 
modulate the expression of the chief enzyme responsible for its deamination, 
glutaminase.  Glutaminase exists in two isoforms, liver-type and kidney-type, which 
are products of different but related genes.  The two isozymes possess different kinetic 
properties and protein structure.  The liver-type glutaminase is associated with 
glucogenesis and urea formation, and is detected only in cells with a functional urea 
cycle.  The kidney-type glutaminase is expressed in all other organs that utilize large 
amount of glutamine, such as kidney, brain, intestine and fetal liver.  Functional 




membrane and represents the dimeric form of the enzyme (Kvamme et al., 1991).  It is 
responsible for the deamidation of glutamine to glutamate with the liberation of an 
ammonium molecule, is activated by phosphate and glutamine (hence, phosphate 
activated glutaminase: PAG), and its inhibitors include glutamate and ammonia.  
Majority of the glutamine taken up by cells in culture undergo the PAG pathway for 
generation of energy, and only a small amount of glutamine is used for biosynthetic 
purposes.  A strategy was proposed to limit glutamine uptake by directly modulating 
glutamine metabolism via the suppression of glutaminase (PAG) by engineering cells 
with permanently reduced level of glutaminase.  This will enable optimal glutamine 
self-regulation without the need for complicated process control instrumentation and 
without complete elimination of its supplementation, which may affect glycosylation. 
 In this study, 293-HEK cells were engineered via stable transfection with 
antisense fragments of the rat phosphate activated glutaminase (PAG) gene.  Antisense 
technology was identified as a feasible means to effect the permanent reduction of 
PAG as it has been shown to be a successful tool for blocking metabolic pathways by 
targeting fucosyltransferase VI, sialidase and caspase 3 in the studies by Prati et al. 
1998, Ferrari et al. 1998, and Kim and Lee 2002 respectively.  Stable single cell clones 
were isolated from the transfected populations and the antisense 293-HEK cell lines 
generated were compared to the parental cells in terms of growth, metabolism, and 
glutaminase expression.  Characterization of these transfectants revealed phenotypic 
changes in glutamine metabolism that were attributed to the repression of intracellular 
glutamine/glutamate metabolism effected by the antisense strategy.  However, 
glutamine uptake and ammonia production were unchanged and extracellular 
glutamate accumulation was significantly higher in the antisense cell lines.  Based on 




enzyme γ-glutamyltransferase (γ-GT), may be responsible for the formation of 
glutamate and ammonia from glutamine catabolism extracellularly.  γ-GT has been 
widely investigated in renal glutamine metabolism, but has rarely been implicated in 
cultured cell metabolism.  γ-GT activity in the antisense cell lines were established 
utilizing a commercially available assay kit.   
7.1 Verification of Antisense Glutaminase Transcript Expression in 
Antisense Clones 
The use of antisense glutaminase to modulate the expression of cellular 
glutaminase had been employed previously by other investigators (Lobo et al. 2000; 
Segura et al. 2001).  In these studies, Ehrlich Ascites tumor cells stably transfected 
with the antisense 0.28kb fragment of glutaminase were reported to have reduced 
proliferation and loss of tumourigenic capacity in vivo.  In the current study, both the 
0.28kb as well as a 1.6kb fragments were used in an attempt to achieve differential 
down-regulation of glutaminase expression and hence different phenotypic expression. 
To verify the antisense glutaminase expression in the transfected cells, two selected 
stable clones from each of the two transfections using the antisense fragments (293-
1.6AS and 293-0.28AS) were evaluated using RT-PCR.  Primers specific to the 
antisense transcripts were designed and used in the RT-PCR reaction.  293-0.28AS and 
293-1.6AS clones both demonstrated expression of the appropriate antisense 
transcripts whereas these transcripts were undetectable in wild-type 293-HEK (control) 
cells (Figure 7.1).  Analysis was performed after the cells were adapted to growth in 
suspension and serum-free medium.  The results showed that the cells were stably 
transfected with the antisense constructs and expressed antisense transcripts whereas 








Figure 7.1  RT-PCR using primers specific for antisense transcripts verify their 
presence in 293-0.28AS and 293-1.6AS clones but not in the wild-type 293-
HEKcontrol cells.  The cells were adapted to grow in suspension and serum-free 
medium over a course of 3-4 weeks before analysis. 
 
7.2 Verification of Reduced Glutaminase Expression in Antisense 
Clones 
To ensure that the expression of antisense glutaminase had resulted in a 
reduction in glutaminase expression, levels of glutaminase in the two selected stable 
clones (293-1.6AS and 293-0.28AS) were evaluated using Western blot analysis.  
Figure 7.2 shows the Western blot analysis of the two clones and 293-HEK (control) 
cells.  The cells were adapted to growth in suspension and serum-free medium before 
the analysis.  The duration for the adaptation was 3-4 weeks. 
The figure shows that the expression of glutaminase was suppressed when cells 
were transfected with either antisense 0.28kb or 1.6kb cDNA glutaminase fragments as 
evident from the much lighter bands when compared to the 293-HEK control.  This 
difference in band intensities were however not reflected in the actin controls 
indicating that there was equal loading of cellular proteins in each gel lanes and hence 
the repression in glutaminase was a true observation.  It was however difficult to detect 
any difference in glutaminase expression between the 293-0.28AS and 293-1.6AS 
clones from the western blot as both bands appears to be of equal intensities (taking 














Figure 7.2  Western-blot analyses showing the decrease in glutaminase protein 
after expression of antisense 0.28kb and 1.6kb cDNA glutaminase segment.  
Rabbit anti-rat glutaminase was used for detection.  293-HEK: control, 
untranfected cells; 293-1.6AS: cells transfected with 1.6kb glutaminase segment, 
and 293-0.28AS: cells transfected with 0.28kb glutaminase segment.  β-actin 
western blots were included as loading control.  The cells were adapted to grow in 
suspension and serum-free medium over a course of 3-4 weeks before analysis. 
 
7.3 Characterization of Antisense Clones 
The effect of suppressed glutaminase expression on cell growth and metabolite 
profiles was investigated next.  Cells adapted to serum-free suspension growth were 
used for the experiments, which were conducted in duplicates.  The cell growth 
profiles are shown in Figure 7.3, and Figure 7.4 shows the glucose, lactate, glutamine 
and ammonia profiles. 
In general, 293-HEK (control) and 293-1.6AS cells displayed similar 
characteristics in growth, glucose and glutamine consumption.   293-0.28AS cells 
exhibited slower growth and reached a lower maximum cell concentration than 293-
HEK (control) and 293-1.6AS cells (Figure 7.3).  The maximum cell concentration 
reached by the 293-HEK (control) and 293-1.6AS was approximately 1.5 folds higher 









Figure 7.3  Viable cell concentration profiles of suspension 293-HEK(control) cells 
(), 293-0.28AS cells (U) and 293-1.6AS cells ().  Data represents the average of 
duplicate experiments and error bars represent the standard deviation of the 
duplicates. 
 
Figure 7.4  Metabolite concentration profiles of suspension 293-HEK(control) 
cells (), 293-0.28AS cells (U) and 293-1.6AS cells ().  Data represents the 
average of duplicate experiments and error bars represent the standard deviation 












































































































































































Figures 7.4.   Upon reaching the maximum cell concentration at 100 hours, 293-HEK 
(control) cells switched from lactate production to consumption.  However, lactate 
production continued in the 293-1.6AS and 293-0.28AS cultures and reached final 
concentrations of 18 and 20 mmol/L, as compared to 13 mmol/L in the 293-HEK 
(control) cultures.  Ammonia production from 293-HEK (control) cells was also 
observed to be lower than that of the antisense cell lines.  Specific production and 
consumption rates can better reflect the changes in metabolic activities, and were thus 
calculated from the exponential growth phases of the three cell lines.  Results were 
normalized against the calculated rates of the 293-HEK (control) cells and are shown 
in Figure 7.5. 
Figure 7.5  Specific consumption (glucose and glutamine) and production (lactate 
and ammonia) rates of 293-0.28AS cells (open bars) and 293-1.6AS cells (shaded 
bars).  The rates were calculated from the exponential growth phase of the 
cultures, and were normalized by the corresponding rates of 293-HEK (control) 
cells. Data represents the average of duplicate experiments and error bars 





Overall, these observations appear to suggest that repression of the conversion 
of glutamine to glutamate via glutaminase does not reduce glutamine metabolism 
readily.  Ammonia production in the antisense cell lines was in fact observed to be 
higher than that of the 293-HEK (control) cells.  The indirect effect of reduced glucose 
consumption and lactate production as demonstrated in glutamine controlled fed-batch 
cultures (Lee et al. 2003) is also absent.  293-1.6AS cells exhibited similar growth to 
the control; however, the 293-0.28AS cells exhibited a slower growth and lower 
maximum cell concentration.  The specific glutamine and glucose uptake rates were 
also not significantly altered, although the specific lactate and ammonia production 
rates were unexpectedly higher in the antisense cell lines. 
Amino acid analysis was conducted and it showed that most of the amino acids 
consumption profiles were similar between 293-HEK (control), 293-1.6AS and 293-
0.28AS cells (data not shown).  However, glutamate, alanine, aspartic acid, asparagine, 
and proline profiles exhibited characteristic differences (Figure 7.6).  As shown in 
Figure 7.6a, glutamate was produced in 293-HEK (control) cells during the 
exponential growth phase but was consumed from 96 hours onwards.  Interestingly, 
glutamate production in 293-1.6AS and 293-0.28AS continued until the end of the 
cultures, reaching levels 5 times higher than 293-HEK (control) cells. 
Alanine production (Figure 7.6b), a characteristic of 293-HEKcell metabolism, 
was observed in the control and 293-1.6AS cultures.  The final concentration reached 
was approximately 1 mmol/L.  On the other hand, alanine concentration was 
maintained considerably lower, ranging from 0.05 to 0.2 mmol/L, in 293-0.28AS cells.  
Figures 7.6c-e also demonstrate that both the antisense cell lines exhibited similar 






Figure 7.6  Profiles of glutamate, alanine, aspartic acid, asparagine and proline of 
suspension 293-HEK (control) cells (), 293-0.28AS cells (U) and 293-1.6AS cells 
().  Data represents the average of duplicate experiments and error bars 
represent the standard deviation of the duplicates. 
 
distinguishable from that of 293-HEK (control) cells.  These differences in metabolism 






































































































































































7.4 γ-Glutamyltransferase (γ-GT) Activity in Antisense Clones 
Despite the reduced expression of glutaminase using antisense strategy, 
glutamine consumption and ammonia production remained unchanged in 293-HEK 
antisense cells.  However, extracellular glutamate formation was considerably higher, 
as compared to 293-HEK (control) cells.  This phenomenon was also observed in 
Chinese Hamster Ovary (CHO-K1) cells after transfection with the same antisense 
vector constructs (data not shown).  Therefore, the presence of an active alternative 
pathway for glutamine metabolism was suspected in the antisense glutaminase cell 
lines.  A likely candidate was γ-GT, which hydrolyses glutamine to glutamate and 
results in its extracellular accumulation, along with ammonia.  A colorimetric assay 
was used to determine the activity levels of γ-GT in the cells and the results are shown 
in Figure 7.7. 
 The activities of γ-GT clearly correlated well with glutamate accumulation; that 
is, the levels for γ-GT and glutamate were highest in 293-0.28AS cells, and lowest in 
293-HEK (control) cells.  The results show that γ-GT activities were elevated in the 
glutaminase antisense cell lines.  In particular, γ-GT activity in cells expressing the 
0.28kb antisense glutaminase segment was 5-fold higher than the control 293-HEK 
cells.  γ-GT had seemingly compensated for the reduced glutaminase activity and 
contributed to the high glutamine consumption, and high glutamate and ammonia 
production.  Since γ-GT is a membrane-bound enzyme with an extracellular catalytic 













































Figure 7.7  γ-glutamyltransferase activity of suspension 293-HEK (control) cells, 
293-0.28AS cells and 293-1.6AS cells.  1 x 106 cells were harvested at mid-
exponential growth phase for the enzyme assays.  Data represents the average of 
duplicate experiments and error bars represent the standard deviation of the 
duplicates. 
 
7.5 Summary of Metabolic Changes in Antisense Clones 
A schematic representation of the main metabolic pathways postulated to be 
influenced by the antisence strategy is presented in Figure 7.8.  The accumulation of 
high level of glutamate with low level of alanine production in the 293-0.28AS cells 
suggests that there is relatively little transamination of glutamate to α-ketoglutarate via 
alanine aminotransferase, resulting in the formation of low level of alanine (Figure 7.8, 
reactionY).  Accumulation of aspartic acid when asparagine is depleted in the 
antisense cell lines points to an inactive asparagine synthetase pathway (Figure 7.8, 
reaction Z), as compared to the 293-HEK(control) cells.  Since this transamidation 
reaction is highly dependent on glutamine as an amino-group donor, it might be 
compromised by the lack of accessibility of intracellular glutamine.  The lowered 






Figure 7.8  Schematic representation of metabolic pathways for glutamine 
degradation.  X phosphate activated glutaminase (PAG) Y alanine 
aminotransaminase Z asparagine synthetase [ aspartate  \ proline biosynthesis 
] γ-glutamyltransferase. 
 
of intracellular glutamate since glutamate is an essential precursor for proline 
biosynthesis (Figure 7.8, reaction\).  These evidences suggest that the reduction in 
glutaminase expression had resulted in a characteristic shift in the metabolism of some 
amino acids that are closely linked to intracellular glutamine / glutamate metabolism.  
The accumulation of high level of glutamate suggested that the up-regulation of an 
alternative glutamine hydrolysis pathway was likely, and it could be a reaction 
catalyzed by γ-glutamyltransferase (γ-GT) (Figure 7.8, reaction]). 
γ-GT is a transmembrane enzyme with an extracellular domain containing a 























glutamyl compounds to amino acid and peptide receptors (Welbourne and Dass 1982).  
Its main function is degradation and neo-synthesis of glutathione, which is essential for 
multiple functions ranging from antioxidant defense to proliferation (Lu 1999).   γ-
GT’s catabolic activity coverting glutamine to glutamate was first reported in rat 
kidney (Tate and Meister 1974; Curthoys and Kuhlenschmidt 1975).  However, it has 
rarely been implicated in glutaminolysis in cell culture, except for several studies 
which reported that extracellular glutamate in porcine kidney cell lines was generated 
via γ-GT (Meade et al. 1998; Welbourne and Nissim 2001).  Since γ-GT effected 
glutaminolysis essentially takes place extracellularly, high activity of γ-GT would in 
effect convert most of the glutamine extracellularly to glutamate and ammonia and 
availability of both substrates to the mitochondrial enzymes may be diminished.  This 
could well account for experimental observations in the antisense cell lines as 
described above. 
As shown in Figure 7.7, 293-0.28AS cells display the highest γ-GT activity and 
293-HEK(control) cells have the lowest γ-GT activity.  This corresponds well with the 
observed higher glutamate levels in the 293-0.28AS and 293-1.6AS culture 
supernatant.  The presence of γ-GT could also explain the failure of earlier attempts in 
quantifying the differential glutaminase activity in the control and antisense cells using 
the protocol as outlined in Lobo et al. 2000.  The live-cell assay used was based on 
glutamate measurement after catalytic conversion from added glutamine in the 
presence of phosphate.  Due to the higher γ-GT activity in the antisense cells, it 
effectively compensated for the reduced glutaminase activity and hence rendered the 
results inconclusive (not shown). 
The lower γ-GT activity in the 293-1.6AS cells when compared to the 293-




alanine and proline profiles.  A less active γ-GT could result in higher availability of 
the glutamine to the intracellular space.  This in turn would mean a higher proportion 
of the glutaminolysis could occur intracellularly and hence a lower extracellular 
glutamate level was observed (Figure 7.6a).  The larger proportion of intracellular 
glutaminolysis provides for a higher accessibility of the glutamate for the 
transamination reaction with pyruvate to form alanine, hence the alanine buildup 
(Figure 7.6b).  Presence of a higher level of intracellular glutamate could have resulted 
in the higher accumulation of proline (Figure 7.6e) when compared to the 293-0.28AS 
as well. 
7.6 Conclusions 
Antisense down-regulation of the main glutaminolytic enzyme, glutaminase, 
was achieved and phenotypic changes in glutamine metabolism was induced in 293-
HEK cells transfected with antisense glutaminase cDNA fragments.  These changes 
were manifested as differences in glutamate, alanine, proline, aspartic acid and 
asparagine profiles between the antisense clones and the untransfected cells.  These 
differences were attributed to a compensatory up-regulation of gamma-
glutamyltransferase (γ-GT) activity.  The up-regulation of this alternative glutamine 
catabolic pathway is proposed to be in response to the down-regulation of glutaminase 
expression.  Although the strategy was unable to restrict glutamine metabolism by way 
of reducing glutamine uptake and ammonia production, it was established that γ-GT 
could play a significant role in glutaminolysis in cultured cell lines, which has not been 
previously reported in mammalian cell bioprocessing.  This has important implications 
in metabolic engineering of cellular glutamine metabolism in 293-HEK cells as it 




there is a possible necessity to down-regulate both glutaminase and γ-GT should a 
more effective modulation of glutamine metabolism be required.  The significance of 





8 CONCLUSIONS & RECOMMENDATIONS 
8.1 Conclusions 
A low glutamine fed-batch platform was successfully developed for suspension 
culture of 293-HEK cells with the aim to tighten the control on glutamine metabolism 
and hence reduce ammonia and lactate accumulation.  This fed-batch system was 
implemented using a commercial medium, an in-house serum-free chemically-defined 
medium (SF-CDM) and finally an in-house protein-free chemically-defined medium 
(PF-CDM).  The PF-CDM was developed from systematic elimination and substitution 
of proteinaceous or undefined components in the medium and facilitated better control 
of the fed-batch environment in the absence of cellular dependence on exogenously 
supplemented proteins or hydrolysates. 
Reduction in glutamine and glucose consumption, as well as production of 
waste metabolites like lactate, ammonia, alanine and glycine, were observed in all the 
fed-batch cultures.  These metabolic alterations provided physiological evidence of a 
more efficient metabolic state in the fed-batch cultures.  Consequently, there were 
general improvements in maximum cell concentrations attainable in fed-batch cultures 
ranging from 4-6 million cells/mL, a 2 to 4 fold improvement over parallel batch 
cultures.  These improvements were translated into enhancement of virus titers up to 3 
X 1011 pfu/mL in the PF-CDM fed-batch platform.  These results demonstrated for the 
first time that the control of only glutamine at low levels in cultures is sufficient to 
reduce lactate and ammonia production and yield significant improvements in both cell 
concentrations and viral production. 
A transcriptional profiling study focused on understanding the transcriptional 




exponential, late exponential and stationary phases of both batch and fed-batch 
cultures.  A pathway-oriented analysis of the microarray data revealed a down-
regulation of genes related to glutamine/glutamate metabolism indicating a general 
reduction in glutaminolysis in the fed-batch cultures.  Furthermore, the analysis 
revealed an upregulation of DAO, which was probably responsible for glycine 
consumption observed in the fed-batch, thus highlighting DAO as a potential cellular 
engineering target for improving glycine metabolism. 
 It also showed repression of TCA cycle coupled with an increase in electron 
transport chain activity and a reduction in proton leakage in the fed-batch, indicative of 
a more energetically efficient metabolic state.  Cellular engineering to down-regulate 
UCP1, and hence reduce the proton leakage, could improve energy metabolism in 
cells.  There were also differences in the cell cycle regulation between the two modes 
of culture revealed by the transcriptional analysis, most notably the down-regulation of 
anti-proliferative (growth arrest) genes and genes that are related to DNA replication 
initiation in the fed-batch.  Two of the differentially regulated cell cycle arrest genes, 
GADD45A and GADD153, possess potential applications in biphasic production and 
anti-apoptosis cellular engineering strategies. 
 These results demonstrated that the microarray platform can effectively be 
utilized as a tool to monitor transcriptional events in mammalian cells in culture.   
Further insights into the transcriptional regulatory network in its entirety may only be 
revealed with time when more genomic information becomes publicly available.  
However, these results have managed to provide a tantalizing but albeit incomplete 
glimpse of the transcriptional machinery and some of the significantly regulated genes 




Genetic intervention to reduce glutamine metabolism at the molecular level 
should dispense with the need for complicated fed-batch instrumentations and yet 
provide the benefits of a regulated glutamine catabolism even in the presence of high 
glutamine levels in culture.  Antisense down-regulation of the main glutaminolytic 
enzyme, glutaminase, was achieved and reduction in glutaminase expression was 
confirmed in the antisense clones with western blots.  Phenotypic changes in glutamine 
metabolism were induced in 293-HEK cells transfected with antisense glutaminase 
cDNA fragments.  These changes were manifested as differences in glutamate, alanine, 
proline, aspartic acid and asparagine profiles between the antisense clones and the 
untransfected cells. 
These differences were attributed to a compensatory up-regulation of gamma-
glutamyltransferase (γ-GT) activity.  The up-regulation of this alternative glutamine 
catabolic pathway is proposed to be in response to the down-regulation of glutaminase 
expression.  Although the strategy was unable to restrict glutamine metabolism by way 
of reducing glutamine uptake and ammonia production, it was established that γ-GT 
could play a significant role in glutaminolysis in cultured cell lines, which has not been 
previously reported in mammalian cell bioprocessing.  This has important implications 
in metabolic engineering of cellular glutamine metabolism in 293-HEK cells as it 
emphasizes the need for consideration of γ-GT in future metabolic engineering work as 
there is a possible necessity to down-regulate both glutaminase and γ-GT should a 
more effective modulation of glutamine metabolism be required.  The significance of 





8.2 Recommendations for Future Work 
From the transcriptional profiling study, several potential gene targets related to 
metabolism and cell cycle were identified as potential cellular engineering targets in 
Chapter 6 and summarized in Table 8.1.  Despite the comprehensiveness of the public 
human genome database, about half of the differentially expressed genes from the 
transcriptional profiling study were unknown genes or do not have a known functional 
ontology associated with them.  Their role in the cellular transcriptional program 
remains unknown until more information becomes available in the public domain.  
However, through the use of more advanced techniques of data mining, more 
information can hopefully be obtained from them.  One recommendation is to employ 
other clustering techniques (eg. hierachical clustering, principal component analysis) to 
group genes with similar expression profiles and elucidate function of novel genes 
from those of known ones.    Finally, in order to verify these speculations, independent 
functional characterization of these novel genes will have to be carried out.  This is a 
large undertaking however the discovery of novel gene candidates with significantly 
important applications, eg. enhancing protein productivity, is a very real and attractive 
possibility. 
Much of the phenotypically observable metabolic changes were due to a 
concurrent regulation of a large numbers of genes (Chapter 6).  This suggests that 
metabolic engineering strategies should ideally incorporate an orchestrated co-
regulation of these genes which is not practical from a genetic engineering point of 
view if each genetic manipulation has to be conducted individually.  Thus, it is further 
recommended that the differentially regulated genes identified from the microarray 
study be screened for common genetic regulatory elements (eg. promoter motifs, 




Table 8.1  List of potential gene targets 
Gene Description Reported Function Potential Application 
UCP1 Homo sapiens 
uncoupling protein 1 
(mitochondria) 
-  Reduces proton gradient 
required for ATP production 
through electron transport 
chain. 
-  Implicated in in-vivo 
thermoregulation. 
-  Overexpression in mouse 
muscle decreases muscle 
energy efficiency and affects 
thermoregulation and substrate 
oxidation (Klaus et al 2005). 
-  Down-regulation might 
improve the overall energy 
efficiency of cells. 
DAO Homo sapiens D-
amino acid oxidase 
-  Acts on a wide range of D-
amino acids 
-  Substrate known to include 
glycine (no stereoisomeric 
form) 
-  Overexpression might 
reduce accumulation of 
glycine as a waste 
metabolite. 
GADD45A Homo sapiens 




-  Transcript levels are 
increased following stressful 
growth conditions and are 
involved in cell cycle arrest. 
-  Involved in arrest at G2/M 
transition (Wang et al. 1999). 
-  Found to be downregulated 
in a number of tumor cells. 
-  Recent report suggests ability 
to trigger growth arrest without 
apoptosis (Mak and Kultz 
2004). 
-  Biphasic production 
strategies. 
-  Gene (under inducible 
promoter) induced at high 
cell concentration after 
“growth phase” to initiate 
growth arrest into 
“production phase” to 
enhance productivity. 
 
GADD153 Homo sapiens DNA-
damage-inducible 
transcript 3 
-  Also known as CHOP or 
DDIT3. 
-  Reported increase in 
transcript levels following 
stressful growth conditions (eg. 
nutrient depletion). 
-  Implicated in TNF-receptor 
mediated apoptotic pathway. 
-  Addition to repertoire of 
candidate genes for anti-
apoptosis strategies. 
-  Down-regulation of gene 





transcriptional regulator.  This has been demonstrated in yeast diauxic shift where 7 
genes identified to share a common expression profile were all found to contain stress 
response element (STRE) motif repeats in their upstream promoter region and 6 have 
been reported to be controlled at least partially by these elements (DeRisi et al. 1997).  




of a multi-gene metabolic engineering strategy that requires only a single genetic 
manipulation of the “master regulator”.   
It was established that γ-GT plays a significant role in glutaminolysis in 
cultured cell lines, which has not been previously reported.  This has important 
implications to metabolic engineering of cellular glutamine metabolism in 293-HEK 
and even other mammalian cells as there is probably a need to down-regulate both 
glutaminase and γ-GT should a more effective modulation of glutamine metabolism be 
required.  Additionally, a transcriptional analysis of the engineered cells against the 
untransfected cells might provide a more definitive understanding of the phenotypic 
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Comparison of batch cultures in 2 L and 5 L bioreactor vessels. 
Batch bioreactor cultures were conducted in both 2 L and 5 L bioreactor vessels to 
ensure that batch cultures achieve comparable maximum cell concentrations in the 
different scales.  This is to ensure that subsequent batch control cultures may be 
conducted using the 2 L bioreactor vessel as this will alleviate the need for preparation 
of large volume of inoculum required for simultaneous batch and fed-batch bioreactor 
runs.  Batch cultures in both 2 L and 5 L bioreactor vessels achieved similar maximum 
cell concentrations (Figure A.1) and calculated specific growth rates, μ, were 
comparable at 0.025 and 0.029 hr-1 respectively.   
 
 
Figure A.1  Cell concentration profiles of 2 L (○) and 5 L (□) bioreactor batch 
cultures conducted in 293 SFM II medium.  Error bars represent standard 



























































Significantly Regulated Gene List:  Fold change > 1.5; p-value < 0.05 
 
Log2(Fold Change) p-value 

















NM_005542 INSIG1 1.295 -0.105 -0.946 1.025 0.980 0.655 0.001 0.280 0.023 0.029 0.017 0.013 
AB002437 TIGA1 -1.382 -0.603 -0.108 -1.677 -0.925 -1.017 0.001 0.000 0.297 0.000 0.002 0.000 
NM_017745 BCOR 0.787 0.606 -0.165 0.696 1.300 1.219 0.034 0.020 0.287 0.001 0.015 0.000 
AJ292757 TUBB1 0.798 -0.110 -0.621 0.683 -0.019 0.719 0.007 0.236 0.002 0.001 0.374 0.003 
AK026945 C20orf97 -2.074 -0.338 0.361 -1.851 -1.434 -1.665 0.000 0.070 0.019 0.000 0.000 0.000 
M31212 MYL6 0.864 0.448 0.139 0.985 0.772 0.729 0.008 0.001 0.287 0.014 0.023 0.000 
NM_001280 CIRBP -1.073 -0.514 0.127 -1.107 -0.781 -0.834 0.000 0.002 0.277 0.000 0.000 0.000 
NM_001614 ACTG1 0.902 0.084 0.000 1.036 0.849 0.962 0.000 0.326 0.375 0.000 0.005 0.005 
NM_001806 CEBPG -1.045 -0.408 -0.163 -1.531 -0.885 -0.690 0.009 0.000 0.099 0.002 0.027 0.000 
NM_005346 HSPA1B 1.734 0.144 -1.013 2.114 0.920 0.250 0.000 0.165 0.000 0.000 0.028 0.037 
NM_005646 TARBP1 -0.624 -0.344 -0.524 -0.767 -0.795 -0.965 0.047 0.004 0.046 0.000 0.000 0.001 
NM_006468 POLR3C -0.879 -0.383 0.222 -0.927 -0.959 -0.706 0.007 0.004 0.243 0.030 0.007 0.000 
NM_007061 CDC42EP1 -0.935 -0.220 -0.088 -0.795 -0.838 -0.581 0.000 0.000 0.139 0.002 0.018 0.000 
NM_014505 KCNMB4 -0.732 -0.247 0.780 -0.696 -0.048 -0.622 0.000 0.037 0.011 0.001 0.370 0.005 
NM_015714 G0S2 -1.494 -0.573 -0.072 -1.330 -0.957 -1.800 0.001 0.000 0.270 0.000 0.003 0.000 
L36587 - -1.655 -0.351 -0.152 -1.954 -1.843 -1.258 0.003 0.061 0.134 0.000 0.001 0.000 
AK026671 FLJ23018 -0.931 -0.534 -0.246 -0.866 -0.855 -1.126 0.002 0.016 0.043 0.000 0.028 0.001 
AL110141 - -0.950 -0.452 0.211 -1.509 -1.018 -0.715 0.034 0.007 0.059 0.002 0.002 0.000 
NM_003875 GMPS -0.773 -0.374 -0.108 -0.747 -0.913 -0.712 0.000 0.003 0.255 0.000 0.000 0.000 
NM_016947 C6orf48 -0.953 -0.449 0.315 -1.178 -0.690 -0.646 0.000 0.000 0.024 0.000 0.001 0.000 
X56197 - -0.658 -0.407 -0.060 -0.824 -0.614 -0.972 0.000 0.005 0.299 0.001 0.015 0.000 
NM_003746 DNCL1 -0.117 0.307 0.651 0.740 0.913 0.587 0.366 0.118 0.007 0.002 0.019 0.013 
NM_002128 HMGB1 0.734 0.383 0.365 0.844 0.868 0.783 0.018 0.019 0.046 0.024 0.009 0.000 
AF286598 AMOT 1.428 0.842 -0.541 0.714 0.753 0.525 0.002 0.005 0.049 0.029 0.015 0.002 
AB046781 UACA -0.606 -0.037 -0.157 -0.603 -0.667 -0.502 0.035 0.365 0.246 0.047 0.014 0.029 
AF216381 CCNB1IP1 -1.005 -0.466 0.011 -1.085 -0.831 -0.509 0.004 0.030 0.374 0.001 0.002 0.029 
AK022317 UCK1 -1.192 -0.314 0.095 -0.766 -0.472 -0.656 0.000 0.153 0.322 0.045 0.140 0.045 
AK024069 FLJ14007 -0.584 -0.293 -0.117 -0.556 -0.682 -0.618 0.004 0.007 0.317 0.070 0.033 0.000 
AK024092 CHD2 -0.689 -0.156 -0.252 -0.783 -1.034 -0.353 0.000 0.252 0.046 0.008 0.000 0.139 
NM_000169 GLA 0.781 0.519 -0.585 0.687 0.035 0.442 0.025 0.012 0.010 0.002 0.366 0.018 
NM_001673 ASNS -1.546 -0.501 -0.214 -1.454 -0.548 -0.709 0.000 0.001 0.001 0.000 0.003 0.000 
NM_001863 COX6B 0.588 0.220 -0.037 0.819 0.742 0.442 0.006 0.182 0.367 0.002 0.031 0.032 
NM_001924 GADD45A -0.732 -0.281 0.114 -0.867 -0.764 -0.639 0.001 0.003 0.234 0.017 0.021 0.001 
NM_003604 IRS4 0.979 0.462 -1.665 0.977 -0.170 0.382 0.000 0.027 0.000 0.000 0.261 0.025 
NM_003680 YARS -0.922 -0.275 0.129 -0.762 -0.226 -0.633 0.004 0.009 0.144 0.035 0.017 0.000 
NM_004083 MARS -0.783 -0.064 0.540 -0.967 -0.590 -0.196 0.003 0.325 0.043 0.006 0.003 0.170 
NM_004178 TARBP2 0.731 -0.324 0.225 1.180 0.487 0.672 0.001 0.048 0.002 0.000 0.023 0.000 
NM_005080 XBP1 -0.937 -0.287 0.287 -1.035 -0.661 -0.512 0.001 0.065 0.052 0.000 0.004 0.003 
NM_006276 SFRS7 -0.829 0.099 -0.529 -0.473 -0.738 -1.051 0.019 0.209 0.017 0.172 0.002 0.000 
NM_006738 AKAP13 0.687 -0.080 -0.336 0.905 -0.275 0.712 0.047 0.334 0.004 0.003 0.321 0.048 
NM_014522 PCDH11X 0.686 0.752 -0.325 0.275 0.705 0.234 0.012 0.008 0.120 0.030 0.008 0.051 
NM_014685 HERPUD1 -0.681 -0.138 0.616 -0.630 -0.265 0.062 0.000 0.190 0.039 0.032 0.181 0.296 
X56465 - -0.593 -0.238 0.059 -0.969 -0.654 -0.523 0.000 0.011 0.352 0.000 0.000 0.000 
D28363 - 0.934 0.397 -0.259 0.897 0.619 -0.065 0.000 0.091 0.056 0.001 0.048 0.200 
AK022745 - -0.884 -0.345 0.040 -0.904 -0.443 -0.745 0.013 0.000 0.352 0.002 0.084 0.020 
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NM_004446 EPRS -0.601 -0.225 -0.073 -0.689 -0.681 -0.449 0.000 0.006 0.288 0.001 0.000 0.000 
NM_014333 IGSF4 0.676 0.789 -0.053 0.236 0.701 0.677 0.015 0.003 0.350 0.076 0.113 0.001 
NM_018172 FLJ10661 -0.837 -0.271 -0.266 -0.438 -0.598 -0.878 0.000 0.018 0.029 0.054 0.011 0.000 
X56196 - -0.616 -0.208 -0.108 -0.804 -0.727 -0.583 0.025 0.251 0.310 0.041 0.032 0.052 
NM_005382 NEF3 0.319 0.021 -1.151 -0.577 -0.969 -0.734 0.096 0.366 0.000 0.000 0.003 0.024 
NM_014812 KAB 0.022 -0.148 -0.746 -0.523 -0.682 -0.865 0.372 0.072 0.004 0.043 0.000 0.000 
AB033085 KIAA1259 -0.336 -0.090 -0.046 -0.750 -0.936 -0.582 0.064 0.262 0.328 0.003 0.003 0.001 
NM_000532 PCCB -0.335 -0.201 0.035 -0.603 -0.620 -0.582 0.084 0.134 0.363 0.002 0.002 0.000 
NM_003605 OGT -0.931 -0.445 0.448 -1.575 -0.759 -0.694 0.052 0.001 0.002 0.002 0.016 0.001 
NM_004024 ATF3 -0.552 -0.100 0.340 -0.963 -1.829 -0.907 0.097 0.286 0.057 0.024 0.003 0.000 
NM_006472 TXNIP -0.551 0.136 -0.098 -1.967 -1.019 -0.732 0.001 0.188 0.294 0.000 0.000 0.017 
S79912 GHRHR 0.479 0.028 -0.026 0.759 0.639 0.720 0.005 0.363 0.352 0.000 0.001 0.000 
AF251188 - -0.564 -0.276 -0.170 -0.583 -0.726 -0.679 0.000 0.199 0.228 0.010 0.045 0.009 
AF086234 C6orf125 -0.524 -0.571 0.008 -0.935 -0.662 -0.824 0.003 0.003 0.375 0.000 0.003 0.000 
U00944 FLJ23018 -0.229 -0.197 -0.105 -0.988 -0.907 -0.642 0.361 0.010 0.280 0.009 0.000 0.013 
NM_001907 CTRL 0.064 0.607 0.187 0.153 1.071 0.614 0.289 0.018 0.085 0.307 0.042 0.002 
Z36811 - 0.582 0.198 -0.214 0.720 0.430 0.685 0.006 0.269 0.190 0.000 0.012 0.015 
Z36874 - 1.120 -0.076 -0.414 1.565 0.459 0.940 0.000 0.312 0.058 0.000 0.092 0.000 
NM_019096 GTPBP2 -0.701 -0.152 0.336 -0.413 -0.692 -0.707 0.009 0.185 0.104 0.029 0.001 0.001 
AB039947 APBA2BP -0.828 -0.123 0.451 -0.442 -0.553 -1.172 0.000 0.074 0.022 0.160 0.216 0.034 
AF034102 SLC29A2 0.680 0.147 -0.350 0.771 0.558 0.336 0.018 0.127 0.003 0.006 0.010 0.004 
AF052169 KCTD12 1.003 0.087 -0.642 0.538 -0.010 -0.148 0.000 0.229 0.015 0.018 0.374 0.251 
AF113132 PSAT1 -0.984 -0.270 -0.010 -1.007 -0.556 -0.219 0.000 0.058 0.366 0.000 0.027 0.117 
AF221520 OLIG2 -0.595 0.038 0.418 -0.653 -0.423 -0.152 0.001 0.351 0.031 0.010 0.005 0.058 
AK002078 FLJ23614 -0.838 -0.247 0.479 -0.680 -0.446 -0.349 0.001 0.016 0.176 0.007 0.045 0.004 
AK021747 C14orf31 -0.895 0.161 -0.339 -0.488 -0.595 0.056 0.025 0.235 0.006 0.004 0.026 0.371 
AK023963 MARK3 -0.724 -0.427 0.156 -1.072 -0.522 -0.552 0.029 0.015 0.046 0.030 0.004 0.025 
AK024524 CIDE-3 -0.898 -0.100 0.088 -0.710 -0.531 -0.362 0.000 0.304 0.334 0.013 0.001 0.123 
AK025640 SESN2 -0.919 -0.156 0.512 -0.953 -0.272 -0.027 0.008 0.118 0.002 0.000 0.043 0.329 
AL050021 SLC7A1 -0.642 -0.081 0.239 -0.813 0.085 -0.449 0.016 0.303 0.200 0.000 0.367 0.008 
AL110293 BLM 0.715 -0.266 0.163 0.692 -0.200 -0.055 0.039 0.191 0.348 0.004 0.355 0.341 
NM_000071 CBS -0.799 0.018 -0.288 -0.428 -0.407 -0.608 0.012 0.372 0.057 0.026 0.000 0.000 
NM_001096 ACLY 0.672 0.048 -0.608 0.377 -0.110 0.245 0.002 0.348 0.008 0.043 0.328 0.000 
NM_001152 SLC25A5 0.771 0.253 -0.440 0.908 0.524 0.566 0.001 0.002 0.003 0.002 0.003 0.000 
NM_001902 CTH -1.062 -0.141 0.391 -0.773 -0.219 -0.658 0.003 0.254 0.025 0.006 0.342 0.051 
NM_002047 GARS -1.171 -0.232 0.266 -1.106 -0.339 -0.501 0.000 0.104 0.035 0.000 0.081 0.011 
NM_002553 ORC5L -0.607 -0.304 0.007 0.101 -0.748 -0.082 0.009 0.115 0.375 0.371 0.017 0.291 
NM_002584 PAX7 0.857 0.551 0.059 -0.648 0.189 0.072 0.000 0.040 0.174 0.002 0.187 0.232 
NM_002898 RBMS2 0.613 0.161 -0.003 0.872 0.190 0.544 0.016 0.355 0.375 0.017 0.334 0.231 
NM_003016 SFRS2 0.698 0.322 0.354 0.824 0.572 0.544 0.000 0.058 0.008 0.001 0.077 0.003 
NM_003129 SQLE 1.091 0.184 -0.472 0.866 0.452 0.397 0.003 0.125 0.003 0.002 0.240 0.016 
NM_003234 TFRC 1.017 -0.156 0.720 0.664 0.171 -0.140 0.015 0.166 0.039 0.070 0.292 0.152 
NM_003364 UPP1 0.865 0.026 -0.268 0.588 0.304 0.317 0.018 0.370 0.192 0.050 0.160 0.101 
NM_003714 STC2 -0.621 -0.376 -0.405 -0.761 -0.871 -0.155 0.034 0.065 0.029 0.000 0.096 0.201 
NM_004095 EIF4EBP1 -1.361 -0.515 0.312 -0.939 0.162 -0.314 0.000 0.031 0.049 0.000 0.279 0.122 
NM_004184 WARS -0.688 -0.177 0.528 -0.266 -0.774 -0.408 0.000 0.045 0.004 0.037 0.000 0.003 
NM_005067 SIAH2 -0.611 -0.109 -0.441 -0.470 -0.596 -0.080 0.000 0.320 0.019 0.036 0.017 0.333 
NM_005170 ASCL2 -0.763 -0.431 -0.278 -0.640 -0.670 -0.766 0.014 0.185 0.059 0.064 0.042 0.051 
NM_005243 EWSR1 -0.612 -0.214 -0.031 -0.783 -0.416 -0.464 0.010 0.059 0.364 0.000 0.004 0.001 
NM_005412 SHMT2 -0.952 -0.222 0.290 -0.588 -0.221 -0.085 0.005 0.085 0.002 0.027 0.049 0.318 
NM_005953 MT2A 0.690 0.897 0.221 0.362 0.574 0.364 0.018 0.041 0.074 0.106 0.080 0.036 
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NM_007126 VCP 0.626 0.017 -0.004 0.719 0.106 0.088 0.006 0.374 0.375 0.013 0.026 0.366 
NM_007182 RASSF1 -0.753 -0.309 0.144 -0.094 -0.584 -0.058 0.001 0.005 0.027 0.337 0.022 0.346 
NM_007214 SEC63 -0.622 -0.044 0.020 -0.382 -0.590 -0.098 0.002 0.309 0.373 0.103 0.002 0.226 
NM_007348 ATF6 -0.672 -0.002 0.378 -0.752 -0.453 -0.471 0.002 0.375 0.017 0.000 0.007 0.045 
NM_013285 HUMAUANTIG -0.658 -0.198 -0.158 -0.272 -0.665 -0.507 0.001 0.002 0.053 0.067 0.007 0.012 
NM_014225 PPP2R1A 0.603 0.225 -0.217 0.441 0.175 0.772 0.002 0.198 0.100 0.080 0.265 0.002 
NM_014265 ADAM28 1.149 0.661 -0.050 0.571 -0.010 0.273 0.040 0.019 0.002 0.116 0.374 0.087 
NM_015848 HUMCYT2A 0.648 0.001 -0.703 0.094 0.205 1.636 0.001 0.375 0.047 0.336 0.032 0.248 
NM_015914 LOC51061 -0.709 -0.150 0.197 0.096 0.749 0.073 0.013 0.318 0.335 0.211 0.002 0.262 
NM_017679 BCAS3 -0.602 -0.121 0.244 -0.852 0.470 -0.326 0.002 0.220 0.153 0.002 0.141 0.139 
NM_018648 NOLA3 -0.729 0.023 -0.455 -0.619 -0.124 -0.066 0.025 0.374 0.202 0.002 0.321 0.365 
S67970 ZNF75 -0.899 -0.100 0.067 -0.583 -0.238 -0.366 0.000 0.222 0.329 0.032 0.316 0.108 
X62468 IFNG 0.605 -1.125 -0.407 -0.322 -0.001 -0.334 0.026 0.024 0.242 0.196 0.375 0.258 
NM_005193 - -0.709 -0.224 0.003 -0.731 -0.433 -0.374 0.013 0.271 0.375 0.000 0.059 0.222 
NM_005323 - 1.218 -0.401 0.074 1.068 0.500 0.082 0.001 0.252 0.335 0.020 0.046 0.298 
D17169 - -0.757 -0.096 0.269 -0.784 -0.109 -0.091 0.004 0.257 0.026 0.008 0.307 0.340 
NM_016236 - -0.645 -0.125 -0.136 -0.665 -0.589 -0.112 0.007 0.273 0.101 0.156 0.025 0.343 
S68954 - 0.629 0.837 0.202 0.365 0.732 0.299 0.004 0.049 0.301 0.163 0.065 0.003 
AK021897 - -0.720 -0.550 -0.181 -0.557 -0.531 -0.731 0.003 0.004 0.137 0.017 0.001 0.002 
AK022973 AXOT -0.671 -0.196 0.047 -0.341 -0.624 -0.317 0.002 0.141 0.355 0.135 0.001 0.076 
AL050288 APG4B 0.695 -0.144 0.067 1.110 0.563 0.627 0.011 0.334 0.344 0.000 0.020 0.084 
AL080200 DKFZP434F122 0.663 0.031 0.654 1.520 0.328 0.195 0.045 0.372 0.199 0.042 0.131 0.329 
AL117452 FTHFSDC1 -0.893 -0.287 -0.073 -0.659 -0.288 -0.484 0.000 0.028 0.355 0.000 0.154 0.023 
AL122079 FLJ12892 -0.711 -0.186 -0.033 -0.848 -0.272 -0.305 0.005 0.154 0.372 0.000 0.207 0.023 
AL133052 C1orf37 0.656 -0.229 0.131 1.120 0.393 0.289 0.039 0.101 0.196 0.001 0.053 0.109 
AL137269 TMEM18 -0.681 0.084 -0.083 -0.580 -0.424 -0.157 0.031 0.339 0.356 0.001 0.003 0.149 
AL389983 - -0.667 -0.173 -0.079 -0.333 -0.310 -0.695 0.009 0.217 0.304 0.104 0.060 0.000 
NM_001952 E2F6 -0.768 -0.073 -0.016 -0.682 -0.153 0.192 0.010 0.353 0.372 0.028 0.304 0.162 
NM_004039 ANXA2 0.724 0.181 0.311 0.723 0.389 0.235 0.007 0.071 0.001 0.000 0.056 0.038 
NM_005257 GATA6 0.712 0.367 0.024 0.474 -0.223 0.746 0.005 0.001 0.358 0.001 0.297 0.000 
NM_006513 SARS -0.901 -0.253 0.057 -0.765 -0.478 -0.354 0.001 0.065 0.336 0.000 0.039 0.041 
NM_007235 XPOT -1.001 -0.315 -0.245 -0.849 -0.479 -0.282 0.003 0.044 0.021 0.000 0.033 0.025 
NM_014642 IQCB1 -0.592 -0.404 0.128 -0.232 -0.419 -0.721 0.010 0.003 0.245 0.205 0.078 0.000 
NM_016107 ZFR -0.716 -0.135 0.001 -0.639 -0.529 -0.151 0.001 0.102 0.375 0.002 0.002 0.245 
NM_016284 KIAA1007 -0.628 -0.020 -0.064 -0.330 -0.618 -0.224 0.021 0.374 0.353 0.091 0.000 0.199 
U79249 LOC152185 0.796 -0.178 -0.006 0.801 -0.467 0.078 0.022 0.045 0.375 0.008 0.224 0.351 
X74070 BTF3 -0.667 -0.149 0.183 -0.637 -0.467 -0.557 0.001 0.296 0.245 0.000 0.017 0.063 
X97261 MT1L 0.972 0.889 0.150 0.453 0.661 0.096 0.011 0.015 0.215 0.030 0.171 0.304 
NM_000160 GCGR 0.127 0.769 -0.460 0.704 0.734 -0.204 0.240 0.005 0.172 0.028 0.098 0.182 
NM_000222 KIT -0.144 0.643 -1.468 -0.636 -0.048 0.489 0.042 0.042 0.074 0.003 0.372 0.010 
NM_006122 MAN2A2 -0.185 0.704 -0.185 0.833 0.116 0.085 0.258 0.006 0.151 0.027 0.240 0.295 
NM_012295 CABIN1 -0.011 -0.628 -0.582 -0.356 -0.342 0.137 0.372 0.045 0.048 0.015 0.253 0.282 
S67154 EIF4A2 0.307 -0.688 0.370 0.635 0.287 -0.311 0.181 0.040 0.060 0.022 0.237 0.268 
NM_014693 - 0.459 0.686 0.251 0.893 0.137 -0.439 0.095 0.031 0.040 0.002 0.157 0.047 
NM_014928 - 0.077 0.855 -0.196 0.688 0.058 0.091 0.341 0.037 0.153 0.019 0.323 0.149 
AK023781 - -0.206 1.700 -0.135 1.093 0.056 0.197 0.092 0.003 0.297 0.033 0.342 0.312 
AK024431 AKNA -0.372 -0.622 0.202 -0.476 -0.816 -1.243 0.226 0.006 0.218 0.153 0.056 0.001 
M91159 H3F3A 0.459 -1.101 0.730 -0.316 -0.359 -0.340 0.114 0.009 0.002 0.027 0.299 0.159 
AF076617 SLC25A6 0.374 0.066 -0.583 0.418 0.764 0.347 0.022 0.347 0.000 0.038 0.013 0.065 
AF085966 KIAA0052 -0.200 -0.435 -0.675 -0.381 -0.797 -0.393 0.309 0.001 0.043 0.001 0.007 0.119 




Log2(Fold Change) p-value 

















NM_002388 MCM3 -0.327 -0.278 -0.714 -0.469 -1.370 -0.271 0.009 0.097 0.047 0.025 0.044 0.105 
NM_003900 SQSTM1 0.279 0.374 0.850 0.380 0.149 0.982 0.199 0.074 0.021 0.058 0.331 0.003 
NM_004089 DSIPI -0.021 0.199 -0.916 -1.031 -0.313 -0.239 0.367 0.126 0.000 0.000 0.119 0.036 
NM_004211 SLC6A5 -0.163 -0.133 0.824 0.613 0.117 0.360 0.267 0.327 0.022 0.040 0.220 0.146 
NM_004864 GDF15 -0.188 -0.071 1.389 -0.407 -0.333 -0.632 0.261 0.332 0.016 0.050 0.265 0.018 
NM_020529 NFKBIA 0.263 -0.267 0.786 -0.122 0.336 0.611 0.256 0.075 0.039 0.359 0.302 0.015 
NM_004692 - -0.637 -0.169 0.730 -0.877 -0.257 -0.250 0.050 0.214 0.018 0.002 0.201 0.198 
NM_004812 - 0.120 -0.013 -0.712 0.636 0.154 -0.015 0.358 0.375 0.030 0.014 0.351 0.222 
AK000176 - -0.031 0.256 0.718 0.232 0.596 0.343 0.364 0.104 0.009 0.022 0.005 0.200 
AK026195 - 0.059 0.546 1.166 -0.031 0.736 0.087 0.367 0.274 0.034 0.368 0.032 0.373 
AL049687 LOC57821 -0.021 0.186 -0.613 -0.586 -0.046 -0.138 0.372 0.120 0.016 0.004 0.360 0.090 
D70833 - 0.421 0.575 0.640 0.562 0.714 0.384 0.118 0.013 0.016 0.121 0.020 0.173 
NM_006808 SEC61B 0.204 0.169 1.122 0.379 0.637 0.275 0.096 0.069 0.002 0.000 0.019 0.039 
NM_015960 CUTC 0.052 -0.069 -0.601 -0.872 -0.294 -0.352 0.309 0.346 0.013 0.017 0.111 0.087 
AF024705 ZNF585A -0.512 0.152 -0.351 -0.939 -0.618 -0.025 0.042 0.360 0.216 0.000 0.022 0.374 
AK021725 BMP2K -0.016 0.118 -0.070 -0.615 -0.730 -0.004 0.373 0.311 0.057 0.001 0.011 0.375 
AK023652 ZNF613 -0.187 -0.010 -0.130 -0.648 -0.581 -0.023 0.235 0.374 0.331 0.017 0.017 0.355 
AK026569 PPIA 0.358 0.124 0.034 0.583 0.631 0.241 0.021 0.233 0.298 0.009 0.004 0.069 
NM_001357 DHX9 0.488 0.347 0.408 0.597 0.630 0.893 0.001 0.066 0.037 0.001 0.096 0.003 
NM_001539 DNAJA1 0.284 0.236 0.348 0.672 0.622 0.593 0.073 0.127 0.031 0.010 0.051 0.013 
NM_002826 QSCN6 -0.259 0.098 -0.172 -1.039 -0.644 0.255 0.242 0.340 0.337 0.025 0.001 0.249 
NM_003798 CTNNAL1 -0.463 -0.014 0.380 -0.685 -0.593 -0.400 0.038 0.372 0.041 0.000 0.010 0.053 
NM_004300 ACP1 -0.407 -0.061 0.199 -0.748 -0.705 -0.494 0.032 0.281 0.099 0.000 0.006 0.026 
NM_004780 TCEAL1 -0.357 -0.128 0.022 -0.763 -0.957 -0.554 0.003 0.034 0.356 0.005 0.002 0.000 
NM_004992 MECP2 -0.414 -0.285 -0.222 -0.713 -1.060 -0.656 0.044 0.272 0.233 0.012 0.023 0.092 
NM_005870 SAP18 -0.310 -0.197 -0.488 -1.019 -0.821 -0.256 0.162 0.333 0.073 0.001 0.013 0.294 
NM_006101 KNTC2 -0.483 0.062 0.404 -0.607 -0.653 -0.131 0.016 0.362 0.002 0.032 0.010 0.236 
NM_006164 NFE2L2 -0.572 -0.005 0.188 -0.705 -0.664 -0.183 0.027 0.375 0.233 0.035 0.007 0.078 
NM_006265 RAD21 -0.190 -0.081 -0.374 -0.624 -0.606 -0.241 0.076 0.246 0.007 0.000 0.011 0.016 
NM_006756 TCEA1 -0.464 -0.146 0.133 -0.787 -0.815 -0.339 0.002 0.312 0.264 0.000 0.002 0.124 
NM_006982 CART1 -0.021 0.096 -0.495 -0.679 -0.393 0.847 0.374 0.345 0.040 0.003 0.189 0.028 
NM_007190 SEC23IP 0.526 0.078 0.067 0.772 0.045 0.732 0.024 0.318 0.360 0.015 0.373 0.039 
NM_007278 GABARAP 0.313 0.291 0.109 0.607 0.615 0.201 0.007 0.116 0.319 0.002 0.011 0.125 
NM_015571 SENP6 -0.487 -0.157 -0.083 -0.841 -0.749 -0.372 0.006 0.079 0.352 0.000 0.000 0.018 
NM_016529 ATP8A2 0.239 0.571 -0.318 1.032 0.662 -0.415 0.209 0.179 0.099 0.027 0.016 0.275 
NM_016931 NOX4 -0.009 0.080 -0.092 -0.986 -0.635 -0.267 0.375 0.351 0.346 0.017 0.005 0.100 
S81522 EEF1B2 -0.248 -0.069 -0.125 -0.643 -0.462 -0.657 0.108 0.199 0.114 0.001 0.097 0.001 
X52357 ZNF29 -0.588 -0.184 -0.425 -1.506 -1.086 -0.322 0.056 0.347 0.098 0.007 0.029 0.297 
AL359650 - 0.092 0.108 0.115 -0.618 0.267 1.090 0.343 0.296 0.322 0.027 0.276 0.008 
AF086490 - -0.557 -0.331 -0.203 -0.611 -0.608 -0.529 0.022 0.124 0.076 0.025 0.022 0.034 
AF052106 C6orf106 0.220 -0.318 -0.219 1.164 0.690 -0.299 0.165 0.233 0.320 0.033 0.020 0.157 
AK026042 NUP210 -0.199 0.410 -0.383 -0.889 -0.854 0.174 0.320 0.288 0.230 0.002 0.046 0.360 
NM_001949 E2F3 0.487 -0.005 -0.411 0.758 0.606 0.391 0.002 0.374 0.000 0.000 0.000 0.048 
NM_003071 SMARCA3 -0.082 -0.025 -0.050 -0.606 -0.622 -0.277 0.331 0.365 0.354 0.006 0.019 0.023 
NM_004204 PIGQ -0.060 0.468 0.053 -0.804 0.405 0.635 0.353 0.076 0.352 0.043 0.146 0.005 
NM_016303 LOC51186 -0.409 -0.118 -0.264 -1.030 -1.010 -0.593 0.111 0.349 0.190 0.000 0.050 0.113 
NM_018093 FLJ10439 -0.417 0.015 -0.069 -0.825 -0.781 -0.372 0.001 0.370 0.331 0.002 0.002 0.055 
U80232 - -0.643 0.010 -0.331 -1.130 -0.962 0.006 0.084 0.375 0.202 0.000 0.039 0.375 
NM_003707 RUVBL1 -0.317 -0.161 -0.225 -0.436 -0.609 -0.637 0.022 0.106 0.030 0.003 0.014 0.000 
Z70770 POU3F3 0.437 0.377 -0.328 0.185 0.827 0.731 0.024 0.065 0.081 0.261 0.045 0.026 
AK000807 - -0.201 0.389 0.266 0.676 0.681 -1.503 0.302 0.316 0.240 0.144 0.018 0.049 




Log2(Fold Change) p-value 

















AF278605 - -0.658 -0.357 0.068 -0.503 -0.754 -0.681 0.072 0.020 0.321 0.033 0.033 0.004 
AL157459 - 0.039 0.408 0.063 0.380 0.838 0.826 0.338 0.225 0.344 0.080 0.005 0.006 
AL162007 - 0.371 0.382 0.312 0.362 0.912 0.910 0.163 0.200 0.132 0.102 0.043 0.032 
NM_006392 NOL5A -0.475 -0.012 -0.110 -0.554 -0.643 -0.592 0.009 0.374 0.308 0.000 0.001 0.015 
NM_014328 RUSC1 0.182 0.145 -0.144 0.071 0.606 0.719 0.283 0.205 0.183 0.210 0.025 0.006 
AF131817 CBFA2T1 0.773 0.251 -0.372 0.282 0.350 0.699 0.042 0.102 0.132 0.231 0.150 0.023 
NM_020040 TUBB4Q 0.757 0.124 -0.362 0.968 1.623 0.609 0.050 0.354 0.074 0.007 0.084 0.200 
AF131799 SDK1 0.965 -0.117 0.805 0.282 0.332 0.660 0.017 0.356 0.042 0.109 0.080 0.231 
AK001725 VPS52 -0.664 -0.051 0.176 -0.636 -0.124 -0.213 0.000 0.357 0.276 0.038 0.335 0.167 
AK001883 FLJ11021 -0.628 -0.111 0.018 -0.632 -0.574 -0.283 0.010 0.107 0.372 0.002 0.007 0.000 
U44029 - -0.750 -0.517 -0.120 -0.081 -0.334 -0.852 0.017 0.150 0.298 0.354 0.248 0.021 
AF305072 KCNIP4 0.685 0.841 -0.138 0.825 0.129 -0.591 0.186 0.004 0.130 0.184 0.345 0.044 
AB014511 ATP9A 0.865 0.225 -0.036 -0.108 0.223 -0.350 0.011 0.125 0.368 0.346 0.345 0.009 
AB040896 KIAA1463 0.702 0.267 0.065 -0.237 0.097 -0.339 0.030 0.016 0.067 0.138 0.359 0.181 
AF015592 CDC7 -0.748 -0.291 0.067 -0.409 -0.573 -0.568 0.001 0.008 0.350 0.162 0.075 0.006 
AF017433 ZNF213 -0.734 -0.127 0.227 -0.547 -0.076 -0.314 0.039 0.325 0.294 0.013 0.364 0.076 
AF086106 VMD2 -0.618 -0.109 0.289 -0.118 -0.229 -0.166 0.024 0.275 0.043 0.254 0.323 0.288 
AF088004 CACNA1D -0.609 -0.229 0.082 -0.186 -0.078 -0.100 0.001 0.265 0.101 0.241 0.363 0.354 
AF131756 SLC1A2 1.462 0.001 0.377 0.544 0.183 -0.240 0.028 0.375 0.317 0.026 0.334 0.224 
AF147302 IREB2 -0.624 0.176 -0.143 -0.075 0.061 -0.201 0.004 0.195 0.335 0.359 0.362 0.321 
AF147326 TM4SF2 -1.751 0.001 -0.085 -0.881 -0.176 -0.322 0.033 0.375 0.079 0.327 0.246 0.078 
AF165527 DGCR8 0.720 -0.045 -0.026 0.217 0.462 0.063 0.025 0.367 0.373 0.279 0.064 0.254 
AF176705 FBXO10 -0.651 -0.427 0.044 -0.513 -0.726 -0.364 0.030 0.048 0.317 0.097 0.162 0.091 
AF205437 TRIB1 0.678 0.068 -0.039 0.165 0.538 0.181 0.027 0.252 0.287 0.309 0.046 0.182 
AF217993 MGC15523 -0.629 -0.026 0.427 0.014 -0.054 0.016 0.026 0.370 0.061 0.375 0.366 0.368 
AF261758 DHCR24 0.630 0.068 -0.526 0.342 0.186 0.489 0.044 0.278 0.005 0.107 0.330 0.063 
AF284223 DMRT2 0.588 0.579 -0.077 0.122 0.141 -0.353 0.034 0.226 0.355 0.309 0.282 0.013 
AF320293 ABCG5 -0.585 -0.063 0.105 -0.244 0.388 0.192 0.021 0.279 0.338 0.097 0.056 0.160 
AJ132084 DNAH7 1.074 0.052 -0.211 0.072 0.310 0.022 0.034 0.297 0.235 0.303 0.082 0.369 
AJ227905 CXCL12 0.825 -0.544 0.470 0.418 -0.678 -0.185 0.000 0.221 0.229 0.084 0.230 0.345 
AK021493 CREB5 -0.744 -0.254 0.488 -0.425 -0.239 -0.505 0.005 0.001 0.048 0.170 0.223 0.000 
AK021975 ALDH2 -1.435 -0.078 -0.827 -0.255 0.447 0.003 0.043 0.241 0.199 0.252 0.069 0.365 
AK022224 ACTN1 0.614 -0.108 0.194 0.486 -0.116 0.113 0.034 0.187 0.254 0.085 0.343 0.244 
AK024570 MRPL24 -0.624 -0.342 -0.071 -0.229 -0.123 -0.516 0.001 0.056 0.319 0.150 0.316 0.002 
AK025114 EXOSC2 0.800 -0.216 -0.080 0.141 -0.084 0.003 0.036 0.322 0.165 0.294 0.240 0.365 
AK025590 KCTD15 -0.689 -0.218 0.096 -0.328 -0.103 -0.252 0.000 0.026 0.308 0.095 0.224 0.003 
AK025615 BCAT1 -0.810 -0.131 0.305 0.317 -0.068 -0.281 0.019 0.104 0.043 0.350 0.365 0.001 
AK025877 ABL2 -0.601 -0.097 -0.054 0.110 -0.071 -0.112 0.009 0.348 0.339 0.128 0.364 0.336 
AK027209 TCF7L2 0.964 -0.158 -0.136 -0.029 0.379 0.186 0.022 0.307 0.086 0.161 0.057 0.280 
AL049340 YT521 0.633 0.544 -0.557 0.007 0.100 -0.381 0.042 0.304 0.210 0.375 0.317 0.077 
AL050107 TAZ 0.621 -0.050 0.077 0.553 -0.273 -0.100 0.017 0.357 0.294 0.053 0.268 0.357 
AL137423 DDX50 -0.632 -0.169 -0.175 -0.306 -0.810 -0.559 0.001 0.192 0.269 0.244 0.059 0.064 
D31763 ZNF33A -0.660 -0.012 0.143 -0.393 -0.021 -0.055 0.000 0.374 0.266 0.095 0.374 0.356 
M26663 KLK3 0.773 0.025 -0.131 -0.051 0.179 0.285 0.002 0.375 0.362 0.071 0.172 0.006 
NM_000434 NEU1 1.128 1.177 0.548 -0.049 0.061 -0.058 0.014 0.216 0.247 0.357 0.372 0.372 
NM_000508 FGA 0.617 0.052 -0.090 0.959 0.274 0.129 0.019 0.368 0.352 0.177 0.215 0.173 
NM_000557 GDF5 -0.592 -0.022 0.124 -0.492 -0.500 -0.055 0.010 0.374 0.248 0.058 0.009 0.341 
NM_000790 DDC -0.708 0.176 0.391 0.134 0.149 -0.083 0.002 0.275 0.062 0.220 0.314 0.364 
NM_000809 GABRA4 0.727 0.050 0.150 0.146 0.130 -0.103 0.024 0.301 0.342 0.131 0.321 0.330 
NM_000859 HMGCR 0.754 0.138 -0.304 -0.078 -0.157 0.143 0.022 0.346 0.105 0.069 0.351 0.354 
NM_000899 KITLG 0.608 0.068 0.152 0.050 0.077 -0.008 0.008 0.339 0.307 0.212 0.035 0.372 




Log2(Fold Change) p-value 

















NM_001172 ARG2 -0.819 -0.103 -0.033 -0.266 -0.414 -0.481 0.000 0.145 0.368 0.000 0.023 0.051 
NM_001293 CLNS1A 0.882 -0.022 0.087 0.007 0.309 -0.124 0.041 0.368 0.258 0.325 0.060 0.113 
NM_001315 MAPK14 0.883 0.093 -0.153 0.039 -0.032 -0.019 0.046 0.349 0.301 0.345 0.337 0.374 
NM_001490 GCNT1 0.678 0.072 -0.307 0.569 0.113 -0.219 0.010 0.362 0.294 0.018 0.094 0.159 
NM_001571 IRF3 -0.773 0.286 0.168 0.062 -1.021 0.474 0.004 0.114 0.124 0.104 0.147 0.026 
NM_001675 ATF4 -0.814 -0.136 -0.356 -0.285 -0.657 0.146 0.029 0.128 0.144 0.008 0.243 0.122 
NM_001817 CEACAM4 0.596 -0.179 -0.257 -0.105 0.239 0.069 0.043 0.311 0.247 0.353 0.264 0.236 
NM_002027 FNTA -0.709 -0.060 -0.091 -0.196 -0.371 -0.478 0.000 0.312 0.176 0.250 0.097 0.000 
NM_002080 GOT2 -0.687 -0.221 -0.213 -0.516 -0.280 -0.508 0.041 0.188 0.106 0.025 0.065 0.050 
NM_002106 H2AFZ 0.749 0.709 0.091 0.156 -0.052 0.143 0.009 0.110 0.193 0.339 0.369 0.200 
NM_002531 NTSR1 1.397 0.095 0.239 0.163 2.848 0.501 0.002 0.349 0.299 0.137 0.194 0.126 
NM_002570 PACE4 -0.678 0.080 -0.277 -0.140 -0.122 0.209 0.004 0.348 0.250 0.340 0.339 0.180 
NM_002719 PPP2R5C -0.635 -0.049 0.138 -0.144 -0.330 0.023 0.007 0.365 0.319 0.273 0.060 0.373 
NM_002737 PRKCA 0.583 -0.310 -0.083 0.841 -0.180 -0.245 0.035 0.271 0.162 0.196 0.293 0.107 
NM_002960 S100A3 0.647 0.007 0.023 0.312 -0.024 -0.034 0.037 0.375 0.360 0.224 0.372 0.370 
NM_003216 TEF 0.840 0.274 0.250 0.589 0.147 0.318 0.043 0.288 0.205 0.071 0.319 0.029 
NM_003904 ZNF259 -0.588 0.001 0.327 -0.400 -0.391 -0.261 0.002 0.375 0.054 0.024 0.001 0.021 
NM_003908 EIF2S2 -0.673 -0.201 0.166 -0.537 -0.403 -0.493 0.012 0.007 0.155 0.053 0.052 0.000 
NM_004044 ATIC -0.654 -0.138 0.202 -0.444 -0.345 -0.527 0.001 0.014 0.177 0.013 0.036 0.000 
NM_004306 ANXA13 0.767 0.102 0.195 0.043 0.073 0.200 0.011 0.305 0.087 0.363 0.348 0.117 
NM_004328 BCS1L -0.740 -0.173 0.056 -0.363 -0.510 -0.336 0.010 0.276 0.362 0.060 0.001 0.002 
NM_004739 MTA2 -0.648 -0.141 0.317 0.047 -0.003 0.350 0.032 0.286 0.176 0.371 0.375 0.050 
NM_005071 SLC1A6 0.747 -0.432 -0.054 0.033 -0.251 -0.447 0.049 0.281 0.350 0.374 0.336 0.127 
NM_005546 ITK 2.692 0.338 0.225 0.437 -0.073 -0.007 0.009 0.265 0.178 0.117 0.313 0.351 
NM_005562 LAMC2 0.616 0.001 -0.059 -0.174 0.205 0.257 0.019 0.375 0.362 0.359 0.123 0.044 
NM_005578 LPP -0.619 0.148 -0.052 -0.154 0.051 -0.113 0.044 0.107 0.293 0.321 0.325 0.291 
NM_005732 RAD50 -0.624 -0.308 0.062 -0.308 -0.307 -0.298 0.006 0.003 0.281 0.204 0.101 0.043 
NM_005822 DSCR1L1 0.582 0.195 0.133 0.208 0.623 -0.354 0.029 0.211 0.151 0.273 0.153 0.032 
NM_005869 SDCCAG10 -0.819 -0.195 0.084 0.058 -0.312 -0.129 0.004 0.208 0.350 0.366 0.122 0.340 
NM_005891 ACAT2 0.629 0.570 -0.265 0.561 0.283 0.099 0.001 0.022 0.106 0.024 0.195 0.266 
NM_005896 IDH1 0.668 0.051 0.005 0.295 -0.351 -0.061 0.028 0.371 0.374 0.216 0.177 0.223 
NM_006079 CITED2 -0.636 -0.180 0.100 -0.099 -0.404 -0.259 0.006 0.159 0.063 0.326 0.202 0.151 
NM_006192 PAX1 -0.726 0.213 -0.077 0.207 -0.272 0.491 0.008 0.096 0.352 0.123 0.084 0.042 
NM_006219 PIK3CB 0.617 0.109 0.063 0.203 0.181 -0.500 0.000 0.324 0.176 0.283 0.291 0.145 
NM_006260 DNAJC3 -0.831 -0.133 0.041 -0.568 -0.125 0.148 0.001 0.298 0.368 0.043 0.329 0.050 
NM_006421 BIG1 -0.930 0.188 0.300 -0.244 0.042 0.111 0.024 0.268 0.262 0.173 0.365 0.199 
NM_006441 MTHFS -0.587 -0.047 0.163 -0.336 -0.027 -0.116 0.016 0.327 0.278 0.119 0.367 0.067 
NM_006536 CLCA2 0.633 0.429 0.206 -0.089 0.110 -0.126 0.003 0.230 0.049 0.288 0.199 0.350 
NM_006660 CLPX -0.735 -0.034 0.046 -0.352 -0.253 -0.115 0.001 0.371 0.367 0.091 0.230 0.250 
NM_006665 HPSE 0.820 0.338 -0.662 0.547 0.054 0.054 0.045 0.113 0.132 0.171 0.362 0.259 
NM_006745 SC4MOL 0.706 0.241 -0.137 0.616 0.754 -0.035 0.025 0.118 0.148 0.066 0.063 0.365 
NM_006884 SHOX2 0.591 -0.298 0.303 -0.038 0.217 0.302 0.006 0.291 0.200 0.367 0.041 0.181 
NM_006980 MTERF -0.720 0.306 -0.173 -0.043 0.226 -0.400 0.028 0.171 0.267 0.371 0.118 0.138 
NM_006992 B7 -0.832 0.001 -0.262 -0.201 -0.006 0.154 0.003 0.375 0.258 0.360 0.375 0.192 
NM_012383 OSTF1 0.622 0.088 0.296 -0.167 -0.092 0.026 0.001 0.269 0.182 0.236 0.188 0.371 
NM_013328 PYCR2 -0.602 -0.097 0.279 -0.452 -0.104 -0.208 0.002 0.276 0.039 0.018 0.212 0.055 
NM_013404 MSLN 0.814 0.357 -0.060 0.165 0.263 -0.035 0.039 0.234 0.357 0.071 0.158 0.370 
NM_013451 FER1L3 0.747 0.429 -0.278 0.664 0.401 0.118 0.021 0.185 0.056 0.101 0.058 0.140 
NM_014596 ZNRD1 -0.747 -0.342 -0.169 -0.433 -0.294 -0.228 0.001 0.093 0.136 0.144 0.189 0.066 
NM_016327 UPB1 -0.591 -0.354 -0.184 -0.332 0.065 -0.066 0.010 0.095 0.207 0.124 0.365 0.367 
NM_016489 NT5C3 -0.611 -0.163 0.078 -0.465 -0.522 -0.496 0.003 0.102 0.302 0.090 0.001 0.005 
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NM_017426 NUP54 -0.628 -0.004 0.424 -0.150 -0.205 -0.358 0.004 0.375 0.023 0.194 0.095 0.039 
NM_017779 DEPDC1 -0.626 -0.516 -0.273 0.295 -0.001 -0.375 0.019 0.202 0.276 0.040 0.375 0.099 
NM_018249 CDK5RAP2 -0.608 -0.155 0.016 -0.279 -0.043 -0.253 0.003 0.185 0.369 0.108 0.322 0.049 
NM_018697 LANCL2 -0.614 -0.028 -0.570 0.351 -0.014 -0.002 0.005 0.373 0.012 0.090 0.375 0.375 
NM_019851 FGF20 -0.639 -0.324 -0.426 -0.411 -1.373 0.072 0.004 0.201 0.030 0.206 0.212 0.338 
NM_020359 PLSCR2 -0.583 -0.271 0.030 -0.427 -0.259 -0.520 0.000 0.017 0.362 0.004 0.020 0.011 
U79273 EIF4A1 0.598 0.236 0.043 0.008 0.178 -0.144 0.002 0.203 0.370 0.344 0.120 0.334 
Z11773 ZNF187 -0.839 -0.045 -0.129 -0.603 -0.596 0.069 0.014 0.369 0.350 0.212 0.148 0.088 
NM_003809 - 0.725 0.182 0.100 -0.227 0.323 -0.200 0.038 0.273 0.187 0.276 0.153 0.124 
AJ276252 - 0.821 1.026 0.375 0.483 0.321 -0.103 0.048 0.058 0.100 0.038 0.087 0.369 
AK021889 - 1.030 -0.133 -0.703 0.542 -1.047 -0.452 0.039 0.067 0.123 0.035 0.059 0.181 
AK022301 - -0.590 1.076 0.062 -0.356 -0.137 0.237 0.018 0.151 0.352 0.157 0.347 0.232 
AK024914 - -1.173 -0.452 0.238 0.180 0.022 -1.711 0.033 0.100 0.215 0.321 0.375 0.064 
AK025363 - 0.743 -0.485 0.057 0.519 0.346 0.072 0.046 0.025 0.313 0.035 0.117 0.340 
NM_005703 - -0.728 0.054 0.269 -0.174 -0.020 -0.016 0.000 0.344 0.090 0.292 0.373 0.371 
AK024526 - -0.588 0.426 -0.194 -0.404 -0.547 0.139 0.013 0.112 0.259 0.183 0.115 0.355 
AK026419 - 0.596 0.022 0.273 -0.216 0.059 0.089 0.023 0.373 0.105 0.046 0.365 0.291 
AL117447 - 0.814 0.328 -0.375 0.325 0.064 -0.347 0.040 0.294 0.097 0.227 0.350 0.142 
AL360144 - 0.982 0.001 0.268 0.154 -0.509 0.191 0.000 0.375 0.187 0.138 0.336 0.364 
NM_015923 - -0.625 -0.014 0.146 -0.629 -0.026 0.101 0.000 0.371 0.223 0.126 0.355 0.244 
NM_014641 - -0.683 -0.195 0.235 -0.167 -0.488 -0.416 0.001 0.040 0.155 0.057 0.037 0.005 
AF022793 - 0.586 0.111 0.041 0.065 1.012 -0.002 0.032 0.346 0.370 0.319 0.260 0.375 
L04552 - -0.729 -0.236 0.359 -0.134 1.038 0.011 0.025 0.095 0.273 0.281 0.235 0.221 
AF086347 - 1.962 -0.024 -0.413 0.195 -0.436 -0.302 0.042 0.371 0.228 0.014 0.248 0.181 
AF056453 - 0.623 -0.235 0.356 0.258 -0.024 -0.631 0.029 0.263 0.195 0.018 0.372 0.232 
AF086369 - 1.949 0.262 -0.271 -0.227 -0.952 -0.211 0.048 0.304 0.180 0.242 0.263 0.155 
NM_017598 - 0.584 -0.143 -0.196 0.313 -0.122 0.003 0.022 0.287 0.121 0.049 0.344 0.369 
AF083117 - -1.159 0.308 -0.025 0.288 0.193 -0.079 0.024 0.071 0.364 0.025 0.019 0.062 
NM_002450 - 0.675 0.732 0.311 0.221 0.566 0.396 0.027 0.103 0.007 0.130 0.150 0.077 
AB018337 KIAA0794 -0.637 -0.032 0.178 -0.363 -0.328 -0.229 0.043 0.337 0.171 0.112 0.121 0.216 
AB020677 KIAA0870 0.612 -0.366 -0.551 0.300 -0.232 -0.260 0.006 0.108 0.051 0.018 0.261 0.246 
AB037749 KIAA1328 -0.953 0.255 -0.498 -0.419 -0.302 -0.476 0.040 0.046 0.019 0.063 0.100 0.097 
AF035035 - 0.591 -0.026 -0.689 -0.324 -0.625 1.288 0.048 0.286 0.153 0.223 0.281 0.179 
AF074989 HYPB -0.623 -0.131 -0.154 -0.116 -0.116 0.367 0.003 0.357 0.317 0.341 0.339 0.246 
AF075082 - 1.103 -0.872 -0.514 0.248 -0.045 0.692 0.049 0.185 0.151 0.032 0.295 0.190 
AF086018 - -0.752 -0.145 -0.126 -0.401 -0.374 -0.362 0.007 0.323 0.330 0.149 0.106 0.076 
AF086115 - 0.770 0.187 -0.359 0.088 0.311 1.024 0.003 0.271 0.331 0.318 0.207 0.132 
AF086351 MGC31963 0.585 0.218 0.567 0.734 0.428 0.275 0.003 0.285 0.058 0.158 0.134 0.117 
AF086410 - 0.900 0.001 -0.189 1.006 0.152 0.009 0.041 0.375 0.351 0.064 0.359 0.304 
AF086511 - 0.834 0.295 0.379 0.007 0.260 -0.001 0.003 0.147 0.292 0.325 0.137 0.375 
AF088020 - -0.629 0.172 0.040 0.247 0.122 -0.044 0.035 0.139 0.155 0.207 0.181 0.274 
AF088054 - 0.585 0.727 -0.046 0.007 0.097 -0.247 0.030 0.115 0.144 0.325 0.322 0.304 
AF104260 PIWIL1 0.801 0.015 -1.153 0.345 -0.040 0.049 0.026 0.325 0.111 0.317 0.356 0.180 
AF131757 - 0.787 0.001 1.478 0.278 -0.237 0.124 0.045 0.375 0.103 0.008 0.326 0.224 
AK001204 C6orf166 -0.630 -0.546 -0.043 -0.436 -0.176 -0.534 0.000 0.084 0.372 0.191 0.363 0.123 
AK021990 - -0.733 -0.108 -0.457 -0.182 -0.247 0.098 0.026 0.361 0.280 0.329 0.269 0.230 
AK022101 - -0.772 0.813 -0.164 0.021 0.349 -0.328 0.007 0.202 0.062 0.372 0.056 0.225 
AK022420 - -0.655 0.166 -0.160 -0.161 -0.231 -0.177 0.024 0.176 0.285 0.325 0.193 0.042 
AK022723 C13orf23 -0.639 -0.045 0.452 -0.232 -0.392 -0.328 0.001 0.365 0.078 0.090 0.022 0.004 
AK023522 - 0.751 -0.452 -1.467 0.130 -0.054 -0.233 0.043 0.115 0.158 0.238 0.343 0.168 
AK023707 CCDC2 -0.585 -0.123 0.055 -0.371 -0.413 -0.274 0.006 0.205 0.353 0.161 0.055 0.031 
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AK024004 C6orf60 -0.723 -0.219 0.133 -0.080 -0.593 -0.309 0.003 0.288 0.270 0.354 0.091 0.190 
AK024915 - 0.718 0.001 0.404 0.042 0.375 0.041 0.048 0.375 0.256 0.319 0.109 0.367 
AK024944 - -0.588 -0.307 0.110 0.133 -0.502 -0.091 0.029 0.249 0.328 0.277 0.098 0.347 
AK026315 FLJ22662 0.864 0.175 0.247 0.181 0.066 0.062 0.031 0.230 0.297 0.226 0.120 0.235 
AK026324 FLJ22671 -0.656 0.057 -0.160 -0.406 -0.116 0.097 0.023 0.371 0.177 0.065 0.348 0.338 
AK026359 - -0.591 0.252 0.051 0.057 0.027 0.850 0.006 0.320 0.369 0.313 0.316 0.147 
AK026368 - -0.593 -0.087 -0.312 0.251 0.080 0.119 0.000 0.362 0.046 0.314 0.347 0.307 
AK026485 - 0.715 -0.297 0.268 0.055 0.017 -0.259 0.011 0.200 0.081 0.082 0.371 0.200 
AK026788 - -0.664 -0.595 0.080 0.227 -0.197 -0.228 0.004 0.121 0.287 0.089 0.263 0.251 
AK026880 - 0.619 0.167 -0.266 -0.447 0.380 0.301 0.001 0.246 0.057 0.057 0.100 0.043 
AK027232 LBH 0.666 -0.244 0.163 0.389 0.057 -0.196 0.018 0.225 0.299 0.220 0.374 0.067 
AK027251 FLJ23598 0.745 0.045 -0.279 0.073 0.219 0.172 0.025 0.317 0.065 0.318 0.265 0.094 
AL049680 LOC343068 -1.165 -0.493 0.307 -0.455 0.054 -0.251 0.000 0.001 0.017 0.132 0.360 0.049 
AL050097 DKFZP586B0319 -0.683 0.100 -0.092 0.030 0.000 0.389 0.024 0.337 0.317 0.372 0.375 0.116 
AL050297 LOC203069 -0.703 -0.339 -0.091 -0.394 -0.504 -0.539 0.003 0.034 0.326 0.216 0.000 0.024 
AL137498 - 0.685 -0.200 -0.087 0.139 0.333 -0.395 0.042 0.208 0.267 0.260 0.066 0.253 
AL359603 - 0.800 0.034 0.331 0.190 1.275 -0.056 0.044 0.367 0.150 0.155 0.166 0.195 
D17052 PTD015 -0.652 -0.280 -0.318 -0.405 0.012 -0.295 0.015 0.095 0.189 0.026 0.370 0.167 
NM_001363 DKC1 -0.718 -0.098 0.103 -0.539 -0.338 -0.508 0.001 0.298 0.263 0.024 0.072 0.001 
NM_002079 GOT1 -0.731 -0.157 -0.044 -0.437 -0.107 -0.456 0.006 0.248 0.366 0.013 0.363 0.069 
NM_002137 HNRPA2B1 0.598 0.407 -0.006 0.155 0.572 0.461 0.027 0.056 0.374 0.346 0.074 0.042 
NM_002287 LAIR1 0.672 0.558 -0.043 0.025 0.411 -0.201 0.048 0.218 0.008 0.001 0.122 0.367 
NM_003627 SLC43A1 -0.781 -0.160 0.202 -0.517 -0.106 -0.680 0.022 0.294 0.048 0.026 0.345 0.099 
NM_005566 LDHA 0.667 0.136 -0.354 0.518 0.537 0.128 0.015 0.285 0.012 0.015 0.034 0.296 
NM_006329 FBLN5 0.726 -0.065 -0.574 0.064 0.179 -0.017 0.001 0.348 0.208 0.345 0.320 0.373 
NM_006459 C10orf69 0.661 -0.381 0.983 -0.012 -0.026 0.787 0.025 0.184 0.091 0.374 0.373 0.239 
NM_014167 HSPC128 -0.684 -0.148 0.367 -0.626 -0.205 -0.501 0.025 0.108 0.118 0.089 0.042 0.030 
NM_014549 DKFZP434P211 0.818 -0.404 -0.037 -0.227 0.379 0.150 0.019 0.220 0.365 0.221 0.180 0.318 
NM_015416 HCCR1 -0.580 -0.034 0.086 -0.490 -0.312 -0.488 0.002 0.372 0.274 0.016 0.192 0.012 
NM_016360 LOC51204 -0.611 -0.114 0.247 -0.570 -0.281 -0.362 0.000 0.220 0.208 0.022 0.063 0.017 
NM_016534 FLJ39616 -0.678 -0.041 -0.099 -0.393 -0.041 -0.056 0.023 0.288 0.282 0.146 0.371 0.263 
NM_018263 ASXL2 0.619 0.148 0.235 0.166 0.561 0.275 0.001 0.289 0.045 0.135 0.088 0.028 
U50539 - 1.485 0.074 -0.171 -0.413 0.253 -0.482 0.042 0.192 0.212 0.225 0.143 0.253 
X92108 - -0.604 -1.108 -0.421 0.173 -0.322 -0.257 0.007 0.108 0.031 0.367 0.218 0.192 
AB011151 BDG29 -0.121 -0.655 -0.219 0.110 -0.295 -0.113 0.046 0.000 0.073 0.221 0.119 0.300 
AB040892 EPHA8 0.277 0.662 0.139 -0.036 0.331 0.218 0.182 0.019 0.224 0.353 0.259 0.346 
AB040948 USP28 0.048 0.650 -0.121 0.216 -0.002 0.295 0.351 0.042 0.323 0.348 0.375 0.148 
AB046857 NCOA5 -0.271 0.647 0.263 0.175 0.027 0.376 0.202 0.000 0.220 0.314 0.374 0.050 
AF000562 UPK2 0.231 1.172 0.085 0.110 0.469 0.417 0.215 0.042 0.303 0.298 0.161 0.296 
AF015041 NUMBL -0.087 -0.992 -0.115 -0.382 0.354 0.379 0.282 0.009 0.323 0.137 0.205 0.109 
AF055012 TGIF2 0.112 0.624 0.406 0.037 -0.003 0.050 0.315 0.024 0.066 0.369 0.375 0.354 
AF070524 FLJ38993 0.311 -0.870 -0.340 0.307 -0.524 -0.360 0.087 0.003 0.325 0.126 0.342 0.345 
AF079529 PDE8B 0.352 -0.580 0.531 -0.258 0.283 -0.764 0.102 0.010 0.103 0.248 0.350 0.213 
AF086287 PRKCA 0.105 0.592 0.386 -0.049 0.089 0.172 0.318 0.035 0.164 0.371 0.365 0.221 
AF086298 THSD2 0.008 -1.070 0.355 -0.140 0.120 -0.018 0.362 0.031 0.196 0.202 0.218 0.353 
AF086480 K6IRS4 0.015 -0.928 -0.230 0.257 0.432 -0.106 0.374 0.007 0.147 0.288 0.055 0.332 
AF217227 ZNF287 0.296 0.643 -0.099 -0.093 -0.206 -0.657 0.140 0.034 0.165 0.334 0.189 0.167 
AK022722 C14orf127 0.029 -0.615 -0.026 0.004 -0.282 -0.397 0.372 0.002 0.371 0.375 0.225 0.077 
AK023288 ZNFN1A5 0.170 -0.867 0.199 -0.713 -0.314 -0.113 0.360 0.024 0.002 0.143 0.183 0.275 
AK025451 BUCS1 -0.598 0.599 -0.434 -0.111 0.374 -0.065 0.100 0.049 0.080 0.122 0.009 0.144 
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AK026822 CAST 0.094 0.680 0.160 -0.381 0.306 0.331 0.335 0.036 0.074 0.016 0.207 0.240 
AK027031 ELOVL6 0.043 -0.665 -0.063 -0.003 0.296 -0.093 0.373 0.000 0.355 0.375 0.124 0.356 
D86964 DOCK2 0.217 -1.048 0.073 -0.062 0.133 0.119 0.091 0.025 0.369 0.305 0.048 0.099 
J05063 C6 -0.103 -0.593 0.045 0.474 0.083 -0.193 0.331 0.031 0.161 0.276 0.339 0.251 
NM_000078 CETP -0.346 0.720 0.042 0.467 0.081 -0.306 0.284 0.042 0.373 0.118 0.364 0.246 
NM_000141 FGFR2 0.187 -0.592 -0.063 -0.537 0.571 0.147 0.292 0.029 0.276 0.098 0.088 0.206 
NM_000256 MYBPC3 0.030 -0.693 0.077 -0.149 -0.373 -0.158 0.371 0.026 0.358 0.290 0.244 0.307 
NM_000499 CYP1A1 -0.436 -0.661 -0.133 -0.186 -0.949 -0.498 0.061 0.030 0.214 0.193 0.153 0.018 
NM_000510 FSHB 0.080 1.094 0.245 0.019 1.086 -0.062 0.369 0.041 0.099 0.367 0.072 0.207 
NM_000869 HTR3A -0.199 -0.853 -0.043 0.331 0.077 0.047 0.347 0.001 0.143 0.093 0.166 0.369 
NM_000903 NQO1 0.186 0.602 0.268 0.442 0.458 0.291 0.314 0.000 0.082 0.009 0.179 0.146 
NM_001188 BAK1 -0.344 -1.198 -0.242 0.063 0.101 -0.066 0.113 0.044 0.308 0.372 0.367 0.357 
NM_001692 ATP6V1B1 -1.115 -0.837 0.081 -0.220 0.090 -0.348 0.167 0.006 0.347 0.189 0.261 0.123 
NM_001957 EDNRA -0.436 0.629 0.265 0.447 -0.048 0.028 0.045 0.042 0.223 0.174 0.357 0.373 
NM_002185 IL7R 0.201 1.142 0.040 0.279 0.198 0.052 0.093 0.044 0.295 0.226 0.099 0.363 
NM_002411 SCGB2A2 0.099 0.730 -0.055 0.253 0.374 0.059 0.083 0.023 0.369 0.016 0.251 0.373 
NM_002611 PDK2 0.210 0.740 -0.080 0.026 0.348 0.280 0.204 0.019 0.365 0.373 0.126 0.017 
NM_003280 TNNC1 0.095 -0.737 -0.265 0.052 -0.560 0.190 0.341 0.008 0.220 0.357 0.064 0.248 
NM_004093 EFNB2 0.184 0.963 -0.046 0.135 -0.668 -0.047 0.160 0.019 0.334 0.322 0.129 0.340 
NM_004226 STK17B 0.069 0.603 0.215 -0.128 0.079 -0.305 0.023 0.021 0.291 0.188 0.336 0.252 
NM_004533 MYBPC2 0.012 -0.782 -0.389 0.531 0.008 -0.806 0.374 0.031 0.169 0.189 0.373 0.099 
NM_005374 MPP2 0.219 -0.671 0.658 0.062 -0.323 0.211 0.156 0.032 0.054 0.013 0.271 0.221 
NM_005619 RTN2 0.069 0.586 -0.225 -0.076 0.140 -0.009 0.370 0.041 0.239 0.359 0.184 0.366 
NM_005930 MGEA6 0.241 -0.631 -0.055 -0.252 0.185 -0.285 0.248 0.039 0.361 0.238 0.083 0.231 
NM_006576 AVIL -0.102 -0.633 0.039 0.190 -0.106 0.227 0.340 0.002 0.372 0.285 0.222 0.282 
NM_013381 TRHDE 0.392 0.775 -0.145 0.064 0.169 -0.333 0.131 0.025 0.307 0.207 0.054 0.212 
NM_014640 TTLL4 0.166 -0.638 -0.072 0.590 -0.173 -0.232 0.071 0.026 0.202 0.213 0.286 0.205 
NM_014807 TMEM24 0.453 -0.989 -0.842 0.255 -0.020 0.123 0.123 0.028 0.071 0.256 0.373 0.111 
NM_016590 PART1 0.419 -0.693 0.087 0.060 0.185 -0.029 0.052 0.046 0.258 0.211 0.127 0.374 
NM_017778 WHSC1L1 0.035 0.759 -0.082 -0.105 0.066 -0.255 0.364 0.024 0.310 0.132 0.355 0.261 
NM_018961 UBASH3A 0.192 0.790 -0.105 -0.561 -0.359 0.136 0.123 0.040 0.345 0.037 0.214 0.295 
NM_019888 MC3R 0.319 0.726 0.256 -0.574 -0.023 0.640 0.293 0.006 0.109 0.120 0.374 0.256 
NM_020358 RNF18 -1.153 0.652 0.272 -0.003 0.135 0.465 0.156 0.036 0.186 0.369 0.139 0.217 
U43586 KSR 0.330 -0.964 0.853 0.222 0.422 0.325 0.121 0.040 0.141 0.037 0.021 0.154 
U58514 CHI3L2 0.132 -1.198 -0.027 -0.178 0.072 -0.167 0.338 0.024 0.363 0.137 0.349 0.222 
X06389 SYP 0.297 0.802 0.313 0.261 -0.293 0.067 0.065 0.045 0.098 0.018 0.351 0.352 
X98411 MYO1F -0.219 -0.771 0.362 -0.240 0.429 0.331 0.166 0.050 0.232 0.255 0.097 0.043 
Y19188 - -0.309 -0.587 -0.209 -0.127 0.018 -0.117 0.146 0.022 0.241 0.138 0.372 0.342 
AK002199 - -0.075 -0.658 0.363 0.021 0.713 -0.271 0.317 0.035 0.112 0.373 0.268 0.282 
U92017 - -0.191 -1.003 -0.203 0.098 -0.554 -0.141 0.219 0.037 0.096 0.320 0.232 0.283 
X52005 - 0.422 0.594 0.414 0.756 1.332 -0.427 0.109 0.042 0.307 0.166 0.157 0.017 
AK022375 - 0.249 0.990 0.027 -0.320 0.356 0.116 0.226 0.029 0.326 0.132 0.204 0.245 
AK022471 - 0.022 0.599 -0.891 0.272 0.246 0.170 0.370 0.016 0.244 0.216 0.021 0.235 
AL049244 - 0.173 -1.055 -1.069 0.495 -0.533 -1.225 0.290 0.016 0.051 0.077 0.217 0.072 
NM_012457 - 0.288 -0.652 0.125 -0.199 -0.560 0.231 0.061 0.020 0.132 0.044 0.128 0.209 
AL355694 - 0.068 -2.061 0.441 -0.160 0.133 0.411 0.080 0.041 0.025 0.344 0.294 0.057 
AK026919 - 0.194 0.697 -0.493 0.147 -0.063 -0.324 0.268 0.025 0.046 0.241 0.361 0.104 
AL357201 - -0.048 0.702 0.108 0.424 -0.503 -0.062 0.342 0.023 0.364 0.130 0.297 0.352 
NM_014486 - 0.110 0.615 -0.151 0.052 0.221 0.083 0.329 0.001 0.083 0.371 0.023 0.348 
AF009287 - -0.237 0.882 0.478 -0.355 -0.216 -0.126 0.283 0.035 0.046 0.235 0.220 0.346 
M14755 - -0.684 0.832 0.321 -0.212 0.353 -0.086 0.095 0.026 0.207 0.236 0.025 0.360 
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NM_018605 - -0.087 -0.664 -0.039 0.380 0.208 0.456 0.116 0.035 0.366 0.042 0.068 0.182 
Y10206 - 0.200 1.351 0.028 0.464 0.296 0.093 0.235 0.031 0.366 0.082 0.004 0.134 
U48728 - -0.118 0.740 0.291 0.192 0.002 -0.009 0.362 0.027 0.078 0.217 0.375 0.361 
U52838 - 0.220 0.605 0.406 0.228 0.345 -1.739 0.166 0.038 0.159 0.019 0.103 0.216 
Z34290 - -0.128 -0.651 0.097 0.015 -0.037 0.829 0.188 0.004 0.295 0.000 0.374 0.053 
AF147337 - 0.079 -0.616 0.211 0.295 -0.904 -0.610 0.277 0.019 0.265 0.226 0.132 0.119 
AF009271 - -0.075 -0.653 0.195 0.520 0.576 0.181 0.233 0.035 0.309 0.019 0.139 0.122 
AF052103 - 0.228 0.602 -0.222 0.308 1.050 -0.124 0.123 0.042 0.296 0.062 0.096 0.173 
AF070632 - 0.158 -0.690 0.565 0.117 0.114 -0.166 0.289 0.032 0.066 0.327 0.289 0.034 
AF085969 - -0.019 -0.730 0.473 -0.279 -0.525 -0.083 0.364 0.041 0.121 0.163 0.194 0.186 
AF086151 - -0.121 0.613 -0.367 0.018 -0.014 -0.102 0.339 0.000 0.230 0.326 0.374 0.280 
AF131806 - 0.315 -0.750 0.104 0.913 -0.026 0.028 0.226 0.032 0.370 0.057 0.375 0.243 
AK001398 - -0.136 1.083 -0.092 0.114 0.057 0.043 0.245 0.002 0.365 0.240 0.371 0.330 
AK021561 - -0.294 -0.844 -0.037 -0.092 0.020 -0.232 0.087 0.020 0.373 0.061 0.374 0.122 
AK021601 FLJ11539 0.502 -1.546 0.310 0.107 0.397 -0.215 0.001 0.036 0.219 0.243 0.211 0.206 
AK022479 - 0.677 0.627 -0.013 0.024 0.083 -0.029 0.127 0.038 0.374 0.372 0.114 0.013 
AK022594 - 0.491 -1.089 0.030 0.432 0.281 -0.132 0.229 0.045 0.141 0.027 0.159 0.207 
AK022975 - 0.409 0.869 -0.263 0.183 -0.309 -0.208 0.155 0.047 0.163 0.297 0.293 0.334 
AK024134 PPM1H 0.094 0.748 -0.189 -0.084 -0.059 -0.247 0.349 0.049 0.091 0.334 0.366 0.008 
AK024604 - -0.360 -0.610 0.030 0.072 0.062 0.003 0.017 0.026 0.371 0.153 0.302 0.365 
AK025564 - 0.010 0.940 -0.468 0.066 0.156 0.246 0.375 0.029 0.138 0.365 0.306 0.150 
AK026720 LOC283537 0.251 0.856 0.425 -0.349 0.221 -0.191 0.178 0.016 0.172 0.297 0.230 0.022 
AK026789 - 0.328 0.644 -0.152 0.506 0.154 0.094 0.140 0.028 0.141 0.018 0.270 0.280 
AK026962 KIAA1815 0.201 0.739 0.051 -0.040 0.512 -0.325 0.157 0.018 0.334 0.359 0.295 0.242 
AL137493 DKFZp434B1231 0.088 0.600 -0.037 -0.303 0.007 0.169 0.362 0.012 0.367 0.004 0.370 0.137 
D17010 - 0.037 0.855 -0.397 -0.908 0.636 -0.095 0.363 0.031 0.215 0.156 0.146 0.296 
L13197 PLAC4 -0.361 -0.734 -0.188 -0.157 -0.558 -0.412 0.029 0.044 0.005 0.099 0.167 0.027 
M34428 PVT1 -0.351 -1.394 -0.077 -0.572 0.469 0.077 0.298 0.040 0.326 0.031 0.169 0.231 
NM_003370 VASP 0.050 0.703 -0.163 0.006 0.223 -0.218 0.363 0.026 0.341 0.375 0.267 0.175 
NM_003571 BFSP2 0.104 -0.743 0.072 0.047 -0.188 0.083 0.290 0.016 0.354 0.147 0.311 0.323 
NM_005553 KRN1 0.029 -0.692 -0.063 -0.308 -0.109 0.109 0.362 0.023 0.341 0.049 0.281 0.191 
NM_006393 NEBL 0.147 0.640 -0.183 -0.186 -0.116 0.320 0.291 0.008 0.177 0.238 0.278 0.180 
NM_007118 TRIO 0.903 0.627 -0.025 0.026 0.345 -0.113 0.194 0.035 0.373 0.177 0.184 0.315 
NM_016588 NRN1 -0.045 -0.697 -0.083 0.502 -0.163 0.111 0.249 0.036 0.342 0.176 0.266 0.037 
NM_018370 FLJ11259 -0.098 -0.601 0.423 0.489 0.070 0.055 0.343 0.023 0.033 0.141 0.362 0.337 
NM_020422 LOC57146 -0.314 0.674 0.402 -0.245 0.382 -0.387 0.235 0.034 0.288 0.299 0.020 0.277 
X81896 TMEM16C 0.798 1.198 -0.512 -0.211 -0.091 -0.142 0.159 0.030 0.352 0.160 0.372 0.096 
AB023152 MAN2B2 0.106 -0.153 -0.865 -0.011 0.119 0.226 0.273 0.281 0.046 0.374 0.276 0.086 
AB028947 KIAA1024 0.197 0.024 -0.635 0.135 0.342 0.210 0.298 0.374 0.032 0.296 0.082 0.205 
AB040889 KIAA1456 -0.173 0.297 0.706 0.104 0.423 0.228 0.134 0.109 0.040 0.019 0.057 0.026 
AF019225 APOL1 -0.052 -0.044 0.749 0.478 0.038 0.040 0.354 0.360 0.000 0.003 0.371 0.342 
AF056450 DAP 0.081 0.373 -0.689 0.162 0.528 0.134 0.341 0.102 0.049 0.297 0.043 0.280 
AF086403 TNFRSF11A 0.031 0.106 0.719 0.374 0.050 -0.061 0.364 0.240 0.030 0.029 0.373 0.202 
AF147384 C5orf12 0.302 0.388 0.695 0.083 -0.567 0.075 0.034 0.264 0.004 0.056 0.239 0.222 
AF161342 SF1 0.025 0.046 1.450 0.380 0.147 -0.073 0.374 0.267 0.009 0.159 0.113 0.137 
AF169257 SLC24A3 0.152 0.427 0.839 0.254 0.239 -0.797 0.295 0.036 0.031 0.282 0.106 0.204 
AF216292 HSPA5 0.171 -0.257 1.317 0.493 -0.095 0.062 0.058 0.053 0.000 0.000 0.134 0.356 
AK021829 FLJ11767 -0.188 0.115 -0.974 -0.079 0.367 0.237 0.167 0.359 0.049 0.328 0.116 0.221 
AK021922 PDZK3 0.485 0.180 0.775 0.141 0.163 0.612 0.000 0.257 0.042 0.206 0.328 0.237 
AK022649 FLJ12587 -0.545 -0.219 0.933 -0.626 0.103 0.054 0.134 0.222 0.001 0.078 0.221 0.356 
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AK024228 FLJ14166 -0.142 0.101 0.784 0.385 0.323 -0.098 0.364 0.257 0.007 0.289 0.037 0.153 
AK025851 KIAA0779 0.067 -0.334 0.632 -0.017 -0.166 -0.059 0.223 0.159 0.044 0.375 0.292 0.251 
AK026052 CSEN 0.387 0.940 -0.768 0.017 0.257 -0.619 0.060 0.218 0.048 0.033 0.271 0.220 
AK026225 PLD1 -0.065 -0.033 0.604 -0.040 0.372 -0.222 0.354 0.325 0.036 0.349 0.016 0.018 
AK026270 EWSR1 -0.065 0.163 0.640 0.079 0.019 0.265 0.333 0.235 0.035 0.355 0.374 0.060 
AK026840 VPS33A 0.149 0.245 -0.604 -0.203 0.011 -0.086 0.313 0.273 0.000 0.066 0.374 0.356 
AL109698 DKFZp547K1113 0.014 -0.345 1.304 -0.234 -0.064 -0.230 0.374 0.203 0.000 0.096 0.365 0.210 
AY004175 PLCB1 0.049 0.001 0.630 0.082 0.054 0.120 0.324 0.375 0.008 0.346 0.354 0.009 
D26070 ITPR1 -0.050 0.044 0.609 -0.253 0.049 -0.140 0.360 0.359 0.041 0.096 0.365 0.056 
D38169 ITPKC -0.115 -0.173 0.731 0.337 0.227 0.134 0.300 0.256 0.016 0.171 0.247 0.083 
L10284 CANX -0.038 0.073 0.898 0.110 0.240 0.232 0.322 0.338 0.002 0.233 0.214 0.222 
L39924 KPNB1 0.062 0.266 -0.822 0.519 -0.123 0.569 0.357 0.339 0.028 0.111 0.165 0.206 
NM_000183 HADHB -0.046 0.207 0.646 0.195 -0.202 0.010 0.358 0.191 0.005 0.230 0.245 0.375 
NM_000351 STS -0.196 0.018 0.733 0.061 0.315 0.078 0.152 0.375 0.000 0.352 0.060 0.168 
NM_000387 SLC25A20 0.141 0.188 -0.646 -0.290 -0.414 -0.227 0.238 0.052 0.026 0.002 0.017 0.118 
NM_000436 OXCT 0.121 -0.347 0.691 0.181 -0.211 -0.073 0.336 0.144 0.013 0.285 0.276 0.351 
NM_000493 COL10A1 -0.191 0.278 -0.687 -0.718 0.304 0.023 0.292 0.118 0.029 0.127 0.012 0.374 
NM_000714 BZRP -0.245 -0.246 -0.597 -0.259 -0.022 -0.282 0.065 0.027 0.004 0.087 0.371 0.002 
NM_001254 CDC6 -0.154 -0.167 0.640 -0.404 0.099 -0.131 0.121 0.288 0.038 0.003 0.321 0.330 
NM_001282 AP2B1 -0.233 -0.139 -0.875 0.067 -0.199 0.188 0.040 0.230 0.047 0.315 0.252 0.261 
NM_001396 DYRK1A 0.063 0.040 -0.657 -0.135 -0.100 -0.040 0.243 0.341 0.006 0.115 0.321 0.340 
NM_001417 EIF4B 0.252 -0.211 -0.904 0.089 -0.671 -0.259 0.033 0.124 0.001 0.078 0.056 0.010 
NM_001561 TNFRSF9 0.038 -0.244 0.597 0.010 -0.409 0.062 0.364 0.081 0.018 0.375 0.008 0.279 
NM_002377 MAS1 0.117 -0.169 -0.673 0.343 -0.121 -0.194 0.362 0.288 0.042 0.154 0.047 0.171 
NM_002869 RAB6A -0.234 0.249 0.594 -0.363 -0.492 0.352 0.006 0.016 0.009 0.002 0.128 0.012 
NM_002905 RDH5 0.074 0.132 -0.598 0.543 0.290 0.195 0.249 0.125 0.010 0.181 0.244 0.195 
NM_002938 RNF4 0.113 0.124 0.649 0.065 0.636 0.176 0.316 0.330 0.001 0.324 0.089 0.242 
NM_002964 S100A8 -0.077 0.821 -0.707 -0.138 -0.136 -0.288 0.345 0.185 0.032 0.193 0.332 0.216 
NM_002971 SATB1 -0.014 0.167 -0.659 -0.018 0.143 0.092 0.374 0.154 0.000 0.374 0.033 0.103 
NM_003135 SRP19 -0.376 0.007 0.624 -0.204 -0.063 -0.251 0.003 0.375 0.035 0.313 0.359 0.008 
NM_003149 STAC 0.046 -0.291 0.690 0.071 -0.152 -0.104 0.355 0.181 0.029 0.371 0.001 0.255 
NM_003220 TFAP2A 0.182 0.476 -0.824 -0.035 0.005 -0.400 0.150 0.008 0.033 0.371 0.375 0.192 
NM_003431 ZNF124 -0.510 -0.233 -1.117 -0.484 -0.539 -0.284 0.042 0.334 0.013 0.000 0.080 0.198 
NM_003524 HIST1H2BH 0.211 -0.138 -0.656 0.107 -0.144 0.070 0.041 0.121 0.033 0.161 0.320 0.228 
NM_003625 PPFIA2 -0.044 -0.134 -0.881 -0.211 0.034 -0.459 0.364 0.279 0.009 0.204 0.371 0.233 
NM_003713 PPAP2B 0.160 0.456 -0.668 -0.078 0.165 0.266 0.224 0.202 0.047 0.285 0.000 0.196 
NM_003768 PEA15 -0.505 -0.122 0.704 0.115 0.160 -0.379 0.146 0.088 0.007 0.360 0.084 0.002 
NM_003779 B4GALT3 -0.162 0.099 0.856 -0.229 0.222 0.498 0.330 0.144 0.009 0.113 0.172 0.221 
NM_003815 ADAM15 -0.095 0.213 -0.737 0.011 -0.134 0.851 0.353 0.191 0.048 0.374 0.149 0.228 
NM_003858 CCNK -0.120 0.801 0.587 -0.123 -0.102 0.052 0.308 0.175 0.024 0.248 0.312 0.164 
NM_004071 CLK1 0.150 0.420 0.873 0.172 0.127 0.339 0.189 0.027 0.014 0.301 0.349 0.112 
NM_004088 DNTT -0.470 0.000 0.755 -0.431 -0.431 0.057 0.002 0.375 0.011 0.012 0.054 0.357 
NM_004192 ASMTL -0.095 -0.019 0.702 0.293 0.324 0.087 0.333 0.374 0.049 0.065 0.244 0.358 
NM_004709 CXorf1 0.194 0.058 2.055 0.201 -1.017 -0.406 0.372 0.188 0.027 0.021 0.289 0.348 
NM_004744 LRAT 0.104 0.046 0.763 0.520 0.106 0.018 0.340 0.360 0.004 0.073 0.352 0.373 
NM_005135 SLC12A6 0.105 0.398 -0.742 0.148 0.326 0.427 0.019 0.277 0.002 0.337 0.170 0.274 
NM_005183 CACNA1F -0.014 -0.008 1.443 0.016 0.250 0.045 0.374 0.372 0.028 0.374 0.009 0.244 
NM_005219 DIAPH1 0.228 0.487 0.764 0.178 0.469 0.425 0.073 0.056 0.018 0.109 0.093 0.035 
NM_005261 GEM 0.029 0.021 -0.690 0.547 0.329 0.327 0.372 0.287 0.039 0.180 0.167 0.127 
NM_005321 HIST1H1E 0.231 -0.092 -0.806 -0.021 -0.316 0.035 0.054 0.326 0.042 0.369 0.060 0.354 
NM_005397 PODXL -0.086 0.215 -0.688 -0.139 0.063 -0.326 0.337 0.142 0.001 0.240 0.363 0.063 
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NM_005574 LMO2 -0.196 -0.119 0.614 0.139 0.275 1.044 0.275 0.167 0.015 0.141 0.313 0.205 
NM_005725 TSPAN-2 -0.272 0.489 -0.616 -0.219 -0.051 0.230 0.137 0.129 0.033 0.250 0.370 0.323 
NM_006010 ARMET 0.054 0.173 0.754 0.068 0.276 0.359 0.348 0.158 0.019 0.251 0.171 0.059 
NM_006183 NTS -0.062 -0.299 -0.616 -0.196 -0.064 0.064 0.339 0.100 0.034 0.071 0.311 0.365 
NM_006274 CCL19 -0.101 -0.115 0.935 0.222 0.071 0.351 0.291 0.357 0.006 0.016 0.140 0.248 
NM_006389 HYOU1 -0.093 -0.057 0.913 0.176 0.411 0.322 0.005 0.343 0.000 0.095 0.072 0.004 
NM_006534 NCOA3 0.020 0.174 -0.938 -0.249 -0.788 -0.221 0.375 0.352 0.016 0.327 0.090 0.342 
NM_006699 MAN1A2 -0.058 0.381 -0.718 -0.197 0.278 0.559 0.356 0.119 0.008 0.112 0.136 0.110 
NM_006803 AP3M2 0.437 -0.321 -0.631 -0.174 -0.282 0.449 0.251 0.218 0.039 0.186 0.172 0.242 
NM_006910 RBBP6 -0.540 0.085 0.800 -0.097 0.259 0.048 0.086 0.354 0.001 0.328 0.206 0.361 
NM_007256 SLCO2B1 -0.050 -0.193 0.859 0.726 0.143 -0.145 0.360 0.323 0.000 0.200 0.243 0.343 
NM_012328 DNAJB9 -0.264 -0.105 0.737 0.616 -0.232 -0.277 0.222 0.353 0.002 0.146 0.235 0.041 
NM_012395 PFTK1 0.082 0.675 0.762 0.129 0.172 -0.448 0.357 0.216 0.017 0.343 0.133 0.257 
NM_012461 TINF2 0.274 -0.002 -0.648 -0.022 0.163 0.059 0.150 0.375 0.024 0.373 0.309 0.360 
NM_014005 PCDHA5 0.064 0.431 -0.612 -0.028 -0.304 0.174 0.358 0.004 0.039 0.230 0.009 0.128 
NM_014169 C14orf123 -0.325 -0.020 0.610 -0.045 0.143 -0.013 0.003 0.375 0.017 0.368 0.332 0.374 
NM_014424 HSPB7 0.064 0.165 -0.745 0.135 0.274 -0.065 0.359 0.306 0.028 0.166 0.251 0.356 
NM_014815 THRAP4 0.397 -0.237 -0.778 -0.295 0.447 0.003 0.039 0.180 0.008 0.045 0.101 0.365 
NM_015599 PGM3 -0.202 0.003 0.711 -0.036 -0.318 0.264 0.245 0.375 0.049 0.369 0.081 0.000 
NM_016053 CGI-116 -0.221 -0.090 0.718 -0.196 0.059 -0.128 0.014 0.264 0.001 0.048 0.366 0.045 
NM_016186 SERPINA10 0.072 -0.101 -0.594 -0.409 -0.509 -0.260 0.353 0.363 0.023 0.132 0.021 0.235 
NM_016306 DNAJB11 0.115 0.140 0.778 0.412 0.135 0.257 0.212 0.197 0.007 0.193 0.130 0.030 
NM_016341 PLCE1 0.253 -0.126 -0.667 -0.046 -0.487 0.085 0.020 0.207 0.028 0.367 0.169 0.215 
NM_016399 HSPC132 -0.174 0.242 0.782 -0.119 -0.035 0.135 0.273 0.138 0.000 0.340 0.371 0.085 
NM_016509 CLEC2 -0.301 0.652 -0.715 -0.161 -0.090 0.245 0.046 0.098 0.016 0.053 0.364 0.188 
NM_016622 MRPL35 0.124 -0.095 0.643 0.012 -0.227 0.085 0.183 0.296 0.043 0.373 0.225 0.355 
NM_017729 EPS8L1 0.277 0.293 -0.657 0.204 0.219 0.092 0.321 0.111 0.032 0.072 0.052 0.346 
NM_018008 FEZL 0.393 -0.740 0.630 0.100 -0.291 -0.308 0.133 0.270 0.023 0.310 0.113 0.180 
NM_018261 SEC3L1 -0.187 0.046 -0.762 -0.299 -0.376 -0.487 0.064 0.366 0.024 0.004 0.073 0.000 
X55525 COL1A2 -0.087 -0.050 0.784 -0.010 0.157 -0.358 0.353 0.368 0.023 0.374 0.286 0.169 
X89399 RASA3 -0.062 0.619 0.622 0.365 0.153 0.071 0.326 0.249 0.046 0.281 0.140 0.326 
Z83802 DNAH12 0.102 0.174 0.627 -0.174 -0.002 0.253 0.271 0.175 0.032 0.116 0.374 0.219 
AK021434 - 0.428 0.283 -0.648 -0.217 -0.327 0.425 0.183 0.171 0.003 0.038 0.049 0.098 
AK021438 - -0.322 0.269 0.794 0.483 0.301 -0.273 0.185 0.053 0.033 0.151 0.019 0.070 
X04236 - -0.079 -0.056 0.814 -0.105 -0.214 0.444 0.321 0.201 0.049 0.259 0.213 0.031 
NM_003523 - -0.215 -0.249 -0.603 0.079 0.197 -0.207 0.276 0.021 0.001 0.279 0.201 0.003 
NM_003525 - 0.191 -0.246 -0.680 0.050 0.060 -0.083 0.091 0.044 0.012 0.311 0.351 0.344 
AK024901 - -0.142 0.055 0.616 -0.094 0.301 -0.082 0.124 0.107 0.002 0.110 0.045 0.348 
AK025076 - 0.206 0.588 -0.793 0.084 0.126 0.174 0.247 0.258 0.043 0.149 0.366 0.167 
AK024182 - 0.278 -0.240 0.581 0.177 -0.012 0.003 0.054 0.225 0.013 0.245 0.369 0.365 
AK025430 - -0.087 -1.121 0.787 0.008 0.256 0.478 0.324 0.159 0.000 0.302 0.240 0.116 
AK026318 - -0.092 0.161 0.766 0.095 0.198 -0.085 0.230 0.286 0.022 0.355 0.363 0.343 
NM_014809 - -0.168 0.027 -0.846 1.280 -0.202 -0.039 0.209 0.373 0.050 0.060 0.306 0.320 
NM_014817 - 0.094 -0.031 0.746 -0.061 0.316 -0.008 0.233 0.364 0.006 0.240 0.010 0.313 
NM_018041 - -0.024 0.086 -0.591 -0.430 0.144 0.198 0.370 0.265 0.016 0.176 0.233 0.157 
NM_016452 - -0.119 -0.059 0.691 0.029 0.109 0.435 0.324 0.360 0.036 0.371 0.239 0.317 
AF056426 - 0.012 0.097 0.979 0.077 0.159 -0.437 0.373 0.347 0.035 0.051 0.133 0.093 
AF056442 - 0.185 -0.012 0.658 0.177 0.347 -0.035 0.277 0.375 0.026 0.314 0.038 0.003 
NM_018278 - -0.154 0.289 -0.665 -0.539 0.024 0.280 0.047 0.087 0.007 0.000 0.359 0.024 
AF181286 - -0.104 -0.085 -1.184 0.203 0.154 -0.019 0.232 0.205 0.041 0.111 0.345 0.317 
AF075080 - -0.221 0.260 -0.635 -0.138 0.209 0.307 0.201 0.277 0.017 0.252 0.231 0.100 




Log2(Fold Change) p-value 

















AB002449 APG12L 0.633 0.256 0.588 -0.126 0.475 -0.219 0.179 0.220 0.003 0.363 0.173 0.317 
AB007975 - -0.546 -0.127 1.263 0.109 -1.166 -0.360 0.128 0.310 0.037 0.203 0.281 0.224 
AF052122 ADCK4 -0.012 -0.432 0.742 0.399 0.092 -0.028 0.368 0.060 0.000 0.072 0.350 0.365 
AF064839 - -0.500 0.200 0.607 -0.184 0.262 0.237 0.002 0.152 0.006 0.108 0.212 0.013 
AF070541 - 0.297 -0.647 -0.713 -0.294 -0.084 0.315 0.017 0.148 0.024 0.020 0.361 0.140 
AF075017 - -0.017 -0.574 0.629 0.225 0.286 -0.952 0.338 0.314 0.047 0.051 0.071 0.093 
AF075073 - -0.089 0.287 0.928 -0.150 -0.148 0.110 0.346 0.224 0.042 0.032 0.105 0.226 
AF086053 - -0.010 0.208 0.784 0.110 0.023 -0.227 0.306 0.306 0.022 0.171 0.374 0.126 
AF086535 NOR1 0.444 -0.138 1.060 0.628 0.355 -0.437 0.123 0.193 0.005 0.135 0.232 0.230 
AF090895 - -0.204 0.226 -0.813 -0.167 0.179 1.475 0.280 0.137 0.034 0.355 0.283 0.148 
AF147423 - -0.038 0.110 0.988 -0.104 -0.013 -0.119 0.351 0.325 0.015 0.287 0.354 0.323 
AF155654 PP784 -0.018 -0.145 0.644 -0.251 0.104 0.261 0.372 0.288 0.036 0.060 0.354 0.027 
AJ227878 - 0.080 -0.284 -0.636 -0.135 -0.751 0.044 0.357 0.222 0.032 0.227 0.217 0.307 
AJ272173 - -1.238 -0.022 0.764 -0.088 0.042 -0.263 0.099 0.373 0.003 0.352 0.370 0.027 
AK000156 RC3 -0.196 0.050 -0.699 0.009 0.079 0.008 0.237 0.349 0.042 0.374 0.331 0.375 
AK021574 - -0.032 -0.402 0.636 0.173 0.186 0.144 0.357 0.314 0.001 0.055 0.130 0.286 
AK021590 - -0.197 -0.327 0.765 -0.037 0.177 0.091 0.234 0.126 0.041 0.367 0.327 0.358 
AK021675 - 0.097 -0.064 0.646 0.124 0.186 0.156 0.341 0.349 0.013 0.286 0.304 0.161 
AK021763 - 0.120 0.036 0.625 -0.327 -0.073 -0.382 0.213 0.363 0.008 0.147 0.280 0.147 
AK021816 - 0.148 -0.168 -0.627 0.253 -0.094 0.132 0.247 0.213 0.006 0.074 0.207 0.346 
AK021959 - 0.170 0.164 0.764 0.007 0.122 -0.375 0.317 0.199 0.028 0.329 0.153 0.212 
AK022730 ATF7IP2 0.195 0.001 0.612 0.077 0.209 0.162 0.142 0.375 0.013 0.332 0.270 0.124 
AK023357 IGSF4 -0.329 0.001 0.809 -0.081 0.241 0.003 0.188 0.375 0.047 0.354 0.244 0.365 
AK023571 - -0.014 0.081 -0.731 0.229 -0.461 0.016 0.372 0.279 0.010 0.205 0.002 0.367 
AK023662 - -0.020 0.320 0.850 -0.134 0.129 0.030 0.371 0.077 0.011 0.221 0.147 0.175 
AK024517 - 0.148 -0.252 -1.162 -0.001 -0.407 0.250 0.059 0.220 0.007 0.375 0.209 0.003 
AK025113 - 0.050 -0.653 -0.601 -0.107 0.803 0.069 0.327 0.129 0.000 0.303 0.206 0.233 
AK026447 FLJ22794 0.191 0.058 -0.654 -0.082 -0.051 0.117 0.339 0.358 0.045 0.057 0.278 0.197 
AK026706 FLJ23053 -0.465 0.095 -0.720 -0.073 0.724 -0.188 0.161 0.342 0.002 0.202 0.154 0.233 
AK026748 DKFZP761M1511 -0.525 -0.492 0.699 0.489 0.325 -0.187 0.246 0.176 0.044 0.013 0.125 0.348 
AK027247 FLJ23594 0.016 0.145 -0.844 0.079 0.401 0.109 0.374 0.274 0.037 0.355 0.316 0.205 
AL050024 SOSTDC1 -0.137 -0.095 0.644 -0.446 -0.016 -0.442 0.350 0.042 0.019 0.286 0.375 0.166 
AL080215 - -0.107 0.001 -0.704 0.378 -0.072 0.003 0.243 0.375 0.042 0.223 0.331 0.365 
AL109719 - -0.117 0.273 0.780 -0.640 0.162 -0.480 0.307 0.233 0.027 0.215 0.279 0.211 
AL117235 KIAA1337 0.353 0.004 -0.678 0.071 0.314 0.079 0.106 0.365 0.000 0.255 0.096 0.197 
AL117439 C20orf26 -0.124 0.525 0.869 -0.297 -0.326 0.231 0.188 0.030 0.000 0.082 0.259 0.093 
AL137383 - 0.133 0.021 -1.126 -0.100 -0.586 0.272 0.325 0.205 0.027 0.335 0.287 0.117 
AL137429 FLJ37874 0.015 0.189 -0.619 -0.162 -0.277 0.178 0.373 0.041 0.000 0.082 0.108 0.284 
NM_001289 CLIC2 0.110 0.420 0.581 0.122 -0.928 0.047 0.074 0.293 0.021 0.326 0.188 0.364 
NM_003330 TXNRD1 0.253 0.479 0.605 0.409 0.380 0.455 0.144 0.004 0.006 0.000 0.055 0.011 
NM_004828 NCR2 0.435 -0.224 0.740 -0.172 -0.039 0.000 0.058 0.271 0.027 0.019 0.371 0.375 
NM_004878 PTGES 0.050 0.122 0.805 0.256 0.211 -0.004 0.361 0.307 0.038 0.041 0.115 0.371 
NM_005935 MLLT2 -0.587 0.603 -0.702 -0.571 0.757 -0.342 0.283 0.230 0.047 0.028 0.084 0.261 
NM_006649 SDCCAG16 0.037 -0.228 -0.798 -0.166 -0.003 0.188 0.361 0.054 0.011 0.076 0.375 0.256 
NM_014937 INPP5F -0.396 -0.210 0.651 -0.226 -0.064 -0.088 0.003 0.142 0.035 0.074 0.280 0.228 
NM_016652 CRNKL1 0.035 -0.127 0.900 -0.073 0.182 0.103 0.371 0.282 0.019 0.345 0.228 0.264 
NM_017956 FLJ20772 -0.115 -0.150 0.614 -0.125 0.117 0.058 0.217 0.251 0.017 0.265 0.331 0.347 
NM_018044 WBSCR20A -0.034 0.070 -0.663 -0.276 -0.015 0.000 0.343 0.278 0.004 0.021 0.374 0.375 
NM_018076 ARMC4 -0.046 0.301 -0.585 -0.250 0.580 -0.472 0.353 0.296 0.009 0.222 0.127 0.202 
NM_018203 FLJ10748 -0.124 -0.149 -0.914 -0.281 0.215 0.166 0.231 0.277 0.019 0.003 0.152 0.163 
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AB007925 FNBP2 -0.115 0.127 -0.105 -0.781 -0.095 -0.004 0.335 0.330 0.353 0.000 0.349 0.375 
AB018283 RHOBTB1 -0.003 0.148 0.170 -2.581 -0.044 0.243 0.375 0.272 0.347 0.011 0.361 0.217 
AB020660 KIAA0853 0.018 0.111 0.130 -0.594 -0.038 0.150 0.373 0.270 0.308 0.001 0.371 0.249 
AB032964 TCEB3BP1 0.174 -0.645 -0.391 -0.649 0.023 -0.107 0.290 0.247 0.179 0.047 0.373 0.066 
AB033022 KIAA1196 -0.196 0.073 0.207 -0.632 -0.080 -0.041 0.041 0.235 0.239 0.003 0.355 0.372 
AB037802 COG1 -0.383 -0.192 -0.023 -1.089 -0.414 -0.052 0.097 0.085 0.373 0.037 0.176 0.365 
AB037817 ZNF471 -0.043 0.525 0.169 -0.675 -0.333 0.033 0.296 0.211 0.218 0.032 0.165 0.294 
AB042562 CSNK1G1 0.028 0.034 -0.193 -0.599 -0.099 -0.007 0.365 0.351 0.086 0.003 0.340 0.372 
AB044661 XAB1 0.070 -0.005 0.043 -0.794 -0.651 -0.010 0.361 0.375 0.374 0.009 0.062 0.345 
AB045292 TMEM8 0.111 0.185 -0.148 1.081 0.255 -0.463 0.359 0.151 0.045 0.014 0.093 0.291 
AF064255 SLC27A5 0.508 -0.098 0.452 -0.655 0.291 0.021 0.000 0.267 0.003 0.001 0.134 0.371 
AF070599 PPP1R11 -0.046 -0.732 -0.024 1.246 0.124 -0.039 0.343 0.075 0.372 0.000 0.233 0.024 
AF070600 OK/SW-cl.56 0.448 -0.261 -0.471 0.665 -0.472 0.324 0.000 0.041 0.016 0.000 0.244 0.003 
AF070637 EFCBP2 -0.382 -0.103 0.148 -0.602 0.130 0.155 0.103 0.295 0.052 0.001 0.342 0.178 
AF075069 TIP120A 0.378 -0.268 0.100 -0.675 0.404 0.322 0.229 0.315 0.326 0.001 0.068 0.116 
AF079098 ATE1 0.294 0.148 -0.081 -0.732 -0.259 -0.068 0.221 0.306 0.356 0.004 0.162 0.355 
AF085734 ADPRTL2 -0.258 -0.109 0.107 -0.589 -0.150 -0.139 0.074 0.154 0.136 0.028 0.217 0.196 
AF086067 PCTK2 -0.310 0.158 -0.017 -0.816 -0.372 -0.284 0.151 0.288 0.372 0.000 0.252 0.051 
AF086176 PCYT1A -0.212 0.024 0.007 0.609 0.231 -0.182 0.244 0.195 0.373 0.049 0.049 0.277 
AF086428 ZNF585A 0.285 0.054 -0.149 0.715 0.378 -0.001 0.120 0.358 0.102 0.001 0.085 0.375 
AF113007 DKFZP586A0522 1.060 -0.293 -0.004 0.587 0.474 0.175 0.142 0.064 0.374 0.025 0.081 0.211 
AF131836 TMOD1 -0.311 0.116 -0.322 -0.703 -0.170 -0.022 0.116 0.347 0.023 0.003 0.024 0.368 
AF143880 SORBS1 0.374 -0.952 -0.323 0.869 -0.362 -0.138 0.060 0.191 0.231 0.000 0.333 0.208 
AF144700 TIMM13 -0.190 0.096 -0.006 -0.791 -0.074 -0.424 0.274 0.262 0.375 0.002 0.336 0.039 
AF174487 BOK 0.034 -0.210 -0.282 1.144 -0.216 -0.044 0.372 0.274 0.265 0.006 0.027 0.343 
AF224741 CLCN7 0.098 0.314 0.074 0.819 -0.158 -0.022 0.005 0.134 0.354 0.000 0.351 0.370 
AF255342 VN1R1 0.004 -0.056 -0.072 -0.585 -0.152 -0.005 0.375 0.372 0.238 0.012 0.342 0.375 
AF263462 CGN 0.053 0.007 -0.023 0.830 0.278 0.004 0.364 0.375 0.365 0.007 0.012 0.375 
AF264765 Parva -0.024 -0.261 0.128 0.895 -0.692 -0.145 0.340 0.283 0.206 0.028 0.194 0.298 
AF272890 ADRB1 0.302 -0.051 -0.369 0.612 -0.069 -1.127 0.125 0.368 0.131 0.025 0.373 0.132 
AF290204 DO -0.242 -0.012 -0.010 0.699 -0.728 0.135 0.275 0.374 0.336 0.001 0.203 0.189 
AJ002788 PRKCB1 0.131 -0.452 -0.181 0.773 0.340 -0.923 0.342 0.080 0.208 0.034 0.009 0.130 
AJ005273 KIN 0.008 0.225 -0.099 -0.581 0.286 -0.074 0.375 0.099 0.144 0.043 0.087 0.115 
AJ011377 TSC1 0.027 -0.092 -0.147 0.902 0.400 0.135 0.366 0.339 0.312 0.000 0.020 0.253 
AJ133115 THG-1 -0.170 -0.316 0.051 0.618 0.077 -0.358 0.202 0.360 0.369 0.050 0.202 0.258 
AJ275213 STAB1 -0.011 0.146 -0.583 -0.703 0.056 0.318 0.374 0.155 0.120 0.000 0.368 0.178 
AK001228 C6orf107 -0.331 0.118 -0.023 -0.734 -0.233 -0.340 0.113 0.258 0.373 0.006 0.192 0.019 
AK021791 PANK2 -0.123 0.302 -0.265 -0.749 0.068 -0.077 0.300 0.142 0.159 0.002 0.226 0.343 
AK021838 NCOA2 -0.125 -0.064 -0.938 -0.663 -0.558 0.075 0.303 0.357 0.217 0.012 0.013 0.363 
AK021863 RBM17 -0.241 -0.145 -0.019 -0.620 -0.465 -0.050 0.239 0.309 0.373 0.005 0.127 0.366 
AK021874 TGFB2 0.040 -0.148 -0.005 -0.595 0.295 0.025 0.362 0.316 0.375 0.027 0.050 0.369 
AK022011 DOCK9 0.013 -0.120 0.956 0.720 0.225 -0.119 0.373 0.241 0.174 0.046 0.199 0.031 
AK023128 DLC1 -0.503 0.415 -0.074 0.732 0.269 -0.290 0.020 0.208 0.356 0.044 0.286 0.032 
AK023159 LSM11 -0.142 0.320 0.201 0.646 0.287 -0.142 0.319 0.146 0.019 0.005 0.231 0.297 
AK023275 FLJ13213 -0.202 0.316 0.284 -0.648 -0.030 0.353 0.283 0.107 0.119 0.000 0.371 0.000 
AK024002 TUBA4 0.020 0.128 0.168 -0.626 -0.266 0.352 0.373 0.283 0.265 0.000 0.212 0.202 
AK024450 RHOT2 -0.363 0.201 -0.579 -0.645 -0.245 0.122 0.060 0.261 0.079 0.001 0.168 0.286 
AK024514 JJAZ1 -0.645 -0.235 -0.014 -0.593 -0.614 -0.145 0.079 0.316 0.374 0.016 0.115 0.345 
AK024813 C10orf9 -0.011 -0.174 0.119 -0.630 -0.110 0.259 0.375 0.125 0.313 0.012 0.317 0.067 
AK025110 ZNF529 -0.443 -0.125 -0.199 -0.782 -0.828 -0.375 0.069 0.350 0.201 0.027 0.059 0.162 
AK025616 FLJ21963 0.141 -0.476 0.351 -0.599 0.542 0.143 0.355 0.270 0.108 0.026 0.005 0.231 
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AK026765 AGPAT4 -0.478 -0.044 0.008 0.797 0.216 -0.565 0.218 0.368 0.271 0.030 0.312 0.219 
AL049442 FLJ14431 -0.161 -0.061 -0.198 -1.387 -0.417 -0.274 0.214 0.247 0.167 0.019 0.001 0.079 
AL080165 SEC24A -0.443 -0.157 -0.204 -0.585 -0.649 0.194 0.086 0.314 0.256 0.048 0.217 0.227 
AL110155 ANTXR1 -0.099 0.143 -0.151 0.665 0.127 0.083 0.326 0.287 0.193 0.038 0.219 0.172 
AL133068 MOV10L1 -0.121 -0.038 0.227 -0.967 -0.377 -0.167 0.324 0.366 0.199 0.014 0.142 0.153 
AY007113 AMMECR1 0.362 -0.230 0.007 1.025 -0.059 -0.143 0.238 0.153 0.375 0.023 0.365 0.159 
D29810 ESDN 0.429 -0.094 -0.068 0.976 -0.097 -0.039 0.027 0.315 0.336 0.036 0.292 0.369 
D79998 KCTD2 -0.108 -0.236 0.231 1.030 0.172 0.000 0.316 0.084 0.311 0.045 0.293 0.375 
D83778 KIAA0194 -0.067 -0.146 0.151 -0.836 0.008 0.294 0.357 0.317 0.131 0.015 0.375 0.217 
L07033 HMGCL -0.313 -0.106 0.429 0.631 -0.296 -0.256 0.073 0.336 0.284 0.040 0.070 0.042 
L40027 GSK3A 0.131 -0.071 0.213 0.781 0.463 -0.246 0.339 0.250 0.093 0.025 0.078 0.262 
M20642 MYL1 0.168 -0.090 0.111 -0.657 -0.061 -0.041 0.106 0.056 0.193 0.025 0.234 0.373 
M27877 ZNF83 -0.310 0.141 -0.260 -0.936 -0.563 0.027 0.218 0.357 0.240 0.000 0.093 0.374 
M38449 TGFB1 0.147 0.119 0.036 0.692 0.196 -0.011 0.349 0.320 0.366 0.010 0.126 0.374 
M59979 PTGS1 0.392 0.165 0.850 0.630 0.215 0.295 0.018 0.337 0.150 0.000 0.033 0.025 
M91368 SLC8A1 -0.261 0.775 0.024 0.798 0.048 0.232 0.208 0.074 0.372 0.021 0.162 0.132 
NM_000034 ALDOA 0.449 0.123 -0.085 0.609 0.459 0.136 0.043 0.333 0.298 0.012 0.089 0.324 
NM_000165 GJA1 -0.012 0.503 0.045 0.677 -0.163 -0.114 0.373 0.276 0.358 0.025 0.329 0.314 
NM_000214 JAG1 0.065 -0.419 -0.240 -0.929 0.390 0.576 0.152 0.219 0.148 0.000 0.218 0.178 
NM_000244 MEN1 0.234 0.084 -0.236 0.758 0.486 -0.006 0.133 0.353 0.094 0.001 0.096 0.375 
NM_000306 POU1F1 -0.074 -0.098 -0.185 -0.685 -0.874 -0.024 0.360 0.117 0.248 0.024 0.207 0.374 
NM_000335 SCN5A -0.439 0.631 -0.302 0.849 -0.038 -0.501 0.283 0.147 0.200 0.003 0.374 0.268 
NM_000365 TPI1 -0.493 0.091 -0.296 -0.582 -0.390 -0.069 0.069 0.366 0.008 0.043 0.192 0.297 
NM_000408 GPD2 -0.277 0.491 -0.080 -1.220 -0.627 0.492 0.187 0.043 0.334 0.000 0.259 0.041 
NM_000595 LTA 0.509 0.023 -0.629 0.648 0.099 -0.397 0.020 0.253 0.202 0.004 0.359 0.225 
NM_000598 IGFBP3 0.219 -0.142 -0.375 0.622 -0.258 -0.133 0.034 0.364 0.299 0.025 0.246 0.208 
NM_000717 CA4 -0.217 0.164 0.082 0.713 -0.249 0.366 0.241 0.238 0.153 0.004 0.080 0.203 
NM_000721 CACNA1E 0.113 0.284 0.080 -1.255 -0.064 0.220 0.322 0.269 0.350 0.036 0.363 0.233 
NM_000750 CHRNB4 -0.064 0.256 0.033 -0.856 -0.194 0.057 0.353 0.279 0.372 0.000 0.313 0.370 
NM_000811 GABRA6 -0.147 0.121 -0.060 1.230 0.346 0.133 0.295 0.226 0.366 0.018 0.362 0.369 
NM_000835 GRIN2C 0.278 0.303 -0.161 1.185 0.118 -0.040 0.257 0.209 0.321 0.020 0.305 0.328 
NM_000842 GRM5 0.390 0.308 -0.374 1.060 0.075 0.428 0.115 0.102 0.009 0.033 0.319 0.001 
NM_000864 HTR1D -0.248 -0.059 -0.010 0.634 -0.066 -0.083 0.087 0.334 0.373 0.012 0.365 0.047 
NM_000891 KCNJ2 0.555 0.471 -0.066 1.497 0.234 0.086 0.086 0.176 0.129 0.029 0.258 0.323 
NM_000954 PTGDS 0.395 -0.175 -0.095 0.735 0.280 -0.012 0.146 0.116 0.355 0.000 0.197 0.264 
NM_001093 ACACB -0.016 -0.249 -0.335 0.739 -0.247 -0.096 0.369 0.126 0.123 0.038 0.123 0.200 
NM_001185 AZGP1 -0.324 -0.521 -0.221 -0.654 0.059 -0.062 0.108 0.006 0.200 0.043 0.371 0.368 
NM_001189 BAPX1 -0.286 0.009 -0.055 -0.597 -0.267 -0.092 0.031 0.369 0.317 0.009 0.265 0.292 
NM_001206 BTEB1 0.251 0.092 -0.234 0.772 0.419 0.027 0.080 0.346 0.040 0.000 0.120 0.372 
NM_001237 CCNA2 -0.280 -0.101 -0.064 -0.704 -0.376 -0.260 0.059 0.272 0.153 0.003 0.000 0.157 
NM_001240 CCNT1 -0.076 -0.121 0.142 -0.737 -0.367 0.186 0.258 0.191 0.282 0.001 0.203 0.019 
NM_001348 DAPK3 0.064 0.232 -0.107 -0.706 -0.051 0.201 0.345 0.237 0.031 0.002 0.345 0.063 
NM_001352 DBP -0.430 0.121 0.038 -0.613 -0.738 -0.002 0.125 0.318 0.366 0.000 0.088 0.375 
NM_001360 DHCR7 0.475 0.183 -0.215 0.865 0.113 0.114 0.117 0.294 0.263 0.021 0.346 0.276 
NM_001380 DOCK1 0.092 -0.344 0.146 -0.923 0.206 0.325 0.257 0.135 0.088 0.048 0.019 0.109 
NM_001683 ATP2B2 -0.085 0.057 -0.235 -0.961 -0.737 -0.235 0.371 0.374 0.325 0.040 0.160 0.350 
NM_001749 CAPNS1 0.373 0.254 -0.019 0.892 0.205 -0.455 0.177 0.190 0.371 0.034 0.042 0.024 
NM_001780 CD63 0.497 0.333 0.205 0.625 0.170 0.368 0.045 0.030 0.045 0.000 0.320 0.000 
NM_001917 DAO -0.016 -0.048 -0.109 0.924 0.208 -0.029 0.374 0.336 0.236 0.044 0.166 0.360 
NM_001925 DEFA4 0.039 0.341 0.364 1.330 0.395 -0.244 0.374 0.158 0.183 0.038 0.044 0.133 
NM_001981 EPS15 -0.120 0.037 0.092 -0.610 -0.218 0.002 0.306 0.341 0.294 0.000 0.139 0.375 
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NM_002258 KLRB1 -0.013 0.123 0.122 -1.548 0.208 -0.182 0.374 0.341 0.330 0.032 0.134 0.149 
NM_002407 SCGB2A1 0.100 0.001 0.413 0.695 0.122 0.138 0.295 0.375 0.196 0.000 0.324 0.189 
NM_002429 MMP19 0.054 0.152 1.040 1.074 0.406 -0.229 0.360 0.131 0.193 0.001 0.013 0.228 
NM_002435 MPI -0.539 -0.114 -0.295 -0.706 -0.043 -0.179 0.001 0.296 0.143 0.002 0.369 0.218 
NM_002445 MSR1 0.162 0.206 0.154 0.765 -0.413 -0.144 0.037 0.092 0.206 0.043 0.146 0.235 
NM_002453 MTIF2 -0.264 0.080 0.055 -0.633 -0.418 -0.356 0.062 0.346 0.362 0.025 0.055 0.115 
NM_002465 MYBPC1 -0.102 0.362 -0.514 -0.973 -0.066 -0.099 0.368 0.299 0.134 0.005 0.364 0.369 
NM_002502 NFKB2 0.275 0.026 -0.288 0.751 0.390 0.084 0.091 0.372 0.048 0.001 0.193 0.350 
NM_002539 ODC1 -0.380 -0.220 0.030 -0.621 -0.623 -0.461 0.025 0.057 0.333 0.022 0.105 0.002 
NM_002540 ODF2 -0.492 -0.192 -0.148 -0.591 -0.449 -0.430 0.003 0.142 0.109 0.000 0.030 0.033 
NM_002629 PGAM1 0.499 0.214 0.245 0.615 0.340 0.332 0.007 0.183 0.046 0.012 0.097 0.080 
NM_002745 MAPK1 0.422 -0.273 -0.138 0.662 0.232 0.367 0.021 0.101 0.318 0.003 0.189 0.195 
NM_002823 PTMA 0.575 -0.021 -0.118 0.626 0.383 0.198 0.003 0.368 0.167 0.003 0.006 0.229 
NM_003118 SPARC -0.223 0.385 0.262 0.905 0.433 0.089 0.057 0.273 0.010 0.031 0.070 0.354 
NM_003221 TFAP2B -0.200 1.016 -0.074 -0.681 -0.057 0.031 0.242 0.104 0.330 0.023 0.351 0.262 
NM_003264 TLR2 0.193 0.465 0.296 0.661 -1.090 0.102 0.258 0.292 0.217 0.046 0.201 0.276 
NM_003275 TMOD1 -0.117 -0.112 -0.612 0.671 0.142 -0.067 0.227 0.221 0.163 0.010 0.246 0.277 
NM_003357 SCGB1A1 -0.392 -0.401 -0.423 -0.698 -0.604 -0.401 0.031 0.051 0.025 0.021 0.086 0.160 
NM_003401 XRCC4 -0.563 0.008 -0.050 -0.594 -0.048 -0.053 0.031 0.375 0.366 0.000 0.365 0.357 
NM_003419 ZNF345 -0.462 0.320 -0.700 -0.597 -0.289 0.237 0.035 0.253 0.093 0.000 0.004 0.144 
NM_003440 ZNF140 -0.391 -0.372 -0.407 -1.079 -1.074 -0.313 0.195 0.305 0.236 0.000 0.102 0.295 
NM_003612 SEMA7A -0.562 0.438 -0.261 -0.628 -0.957 0.119 0.040 0.005 0.166 0.000 0.162 0.324 
NM_003619 PRSS12 0.320 -0.398 -0.071 1.366 0.388 -0.204 0.035 0.316 0.370 0.034 0.256 0.323 
NM_003651 CSDA -0.556 -0.279 0.172 -0.587 -0.373 -0.512 0.002 0.002 0.034 0.002 0.014 0.000 
NM_003670 BHLHB2 0.074 -0.366 0.329 0.644 0.751 0.242 0.329 0.030 0.150 0.000 0.176 0.234 
NM_003715 VDP -0.112 0.150 0.336 -0.637 -0.153 0.179 0.260 0.192 0.048 0.000 0.261 0.250 
NM_003720 DSCR2 -0.314 -0.025 0.000 -0.665 -0.007 -0.393 0.185 0.352 0.375 0.007 0.375 0.000 
NM_003725 RODH 0.295 -0.480 0.285 0.831 0.085 -0.096 0.253 0.001 0.322 0.031 0.371 0.030 
NM_003751 EIF3S9 0.345 0.116 -0.218 0.845 0.298 0.110 0.026 0.276 0.053 0.011 0.148 0.168 
NM_003758 EIF3S1 0.247 -0.182 0.296 0.795 -0.403 -0.223 0.180 0.327 0.029 0.001 0.147 0.219 
NM_003834 RGS11 -0.210 -0.020 0.268 -0.590 0.006 0.065 0.246 0.372 0.293 0.020 0.375 0.348 
NM_003903 CDC16 -0.423 0.038 0.186 -0.632 -0.077 -0.304 0.022 0.342 0.144 0.002 0.362 0.090 
NM_003963 TM4SF5 -0.107 0.386 0.254 1.059 0.467 -0.248 0.334 0.251 0.343 0.000 0.228 0.051 
NM_003967 PNR -0.103 -0.047 0.349 -0.633 0.118 -0.170 0.321 0.356 0.127 0.007 0.183 0.233 
NM_003986 BBOX1 0.113 -0.074 -0.042 -1.275 -0.151 -0.007 0.330 0.175 0.221 0.023 0.051 0.371 
NM_004313 ARRB2 -0.177 -0.076 -0.264 -1.461 -0.185 0.241 0.107 0.349 0.078 0.000 0.173 0.024 
NM_004424 E4F1 0.088 0.299 -0.047 -0.908 -0.463 0.324 0.351 0.263 0.355 0.020 0.105 0.281 
NM_004432 ELAVL2 -0.198 0.292 -0.262 -1.573 0.060 -0.127 0.200 0.143 0.280 0.034 0.243 0.021 
NM_004449 ERG 0.402 0.226 -0.530 0.984 -0.364 -0.001 0.265 0.244 0.007 0.047 0.208 0.375 
NM_004490 GRB14 -0.214 -0.105 -0.380 -0.804 -0.169 -0.033 0.227 0.304 0.086 0.004 0.240 0.366 
NM_004580 RAB27A 0.388 0.060 -0.011 0.593 -0.299 -0.100 0.226 0.350 0.374 0.012 0.226 0.279 
NM_004625 WNT7A -0.015 0.124 0.335 -0.663 -0.154 0.175 0.374 0.361 0.150 0.000 0.165 0.029 
NM_004701 CCNB2 -0.136 0.050 -0.115 -0.639 -0.152 -0.008 0.260 0.360 0.156 0.000 0.269 0.375 
NM_004725 BUB3 -0.350 -0.115 0.142 -0.591 -0.575 -0.421 0.101 0.133 0.285 0.046 0.023 0.007 
NM_004837 GGPS1 -0.480 -0.304 -0.103 -0.583 -0.421 -0.437 0.002 0.029 0.312 0.011 0.003 0.011 
NM_004933 CDH15 0.707 0.406 -0.179 0.891 -0.015 0.775 0.104 0.277 0.329 0.043 0.375 0.251 
NM_004944 DNASE1L3 0.080 -0.128 -0.254 -0.630 -0.259 0.007 0.347 0.203 0.024 0.022 0.049 0.375 
NM_004957 FPGS -0.270 -0.021 -0.348 -0.820 -0.165 0.138 0.057 0.372 0.123 0.000 0.276 0.176 
NM_004977 KCNC3 -0.255 0.411 -0.490 -0.805 -0.475 0.149 0.297 0.221 0.050 0.001 0.062 0.359 
NM_005031 FXYD1 -0.259 0.256 -0.480 -0.821 -0.317 0.226 0.282 0.323 0.085 0.008 0.253 0.355 
NM_005033 PMSCL1 -0.544 -0.035 -0.045 -0.596 -0.254 -0.329 0.015 0.355 0.367 0.040 0.084 0.000 




Log2(Fold Change) p-value 

















NM_005147 DNAJA3 -0.465 -0.245 -0.056 -0.607 -0.023 -0.074 0.025 0.066 0.338 0.011 0.374 0.290 
NM_005194 CEBPB -0.064 -0.669 -0.506 0.820 -0.264 0.077 0.340 0.136 0.087 0.039 0.328 0.282 
NM_005275 GNL1 -0.061 -0.087 -0.061 -0.596 -0.034 0.056 0.365 0.269 0.080 0.040 0.367 0.154 
NM_005373 CDC20 -0.065 -0.284 0.082 0.900 0.035 0.208 0.342 0.286 0.345 0.024 0.372 0.305 
NM_005387 NUP98 0.096 0.164 0.132 -0.678 -0.120 0.110 0.114 0.073 0.230 0.003 0.336 0.333 
NM_005426 TP53BP2 -0.128 -0.018 0.193 -0.995 -0.446 -0.072 0.235 0.359 0.045 0.000 0.087 0.353 
NM_005428 VAV1 -0.278 -0.026 0.126 -0.583 -0.033 -0.343 0.154 0.345 0.302 0.024 0.371 0.078 
NM_005486 TOM1L1 -0.468 -0.014 0.117 -0.733 -0.511 -0.132 0.052 0.368 0.332 0.037 0.040 0.245 
NM_005674 ZNF239 -0.177 -0.105 0.116 -0.625 0.238 0.383 0.201 0.306 0.258 0.001 0.223 0.024 
NM_005704 PTPRU 0.017 0.001 0.359 0.889 0.374 -0.548 0.374 0.375 0.152 0.029 0.204 0.112 
NM_005715 UST 0.089 -0.405 -0.052 0.918 0.355 -0.027 0.109 0.004 0.369 0.001 0.021 0.357 
NM_005750 C4orf6 -0.107 -0.053 0.236 1.207 -0.064 -0.008 0.262 0.225 0.262 0.033 0.291 0.366 
NM_005804 DDX39 -0.470 -0.117 0.153 -0.598 -0.236 -0.125 0.006 0.162 0.293 0.005 0.231 0.114 
NM_005829 AP3S2 -0.208 0.346 -0.010 -0.642 0.018 -0.230 0.203 0.042 0.374 0.000 0.374 0.084 
NM_005994 TBX2 0.044 0.067 -0.068 -0.587 0.102 0.316 0.346 0.303 0.348 0.000 0.350 0.028 
NM_005998 CCT3 0.477 0.207 -0.266 0.724 0.570 0.243 0.000 0.170 0.053 0.011 0.009 0.088 
NM_006020 ALKBH -0.358 -0.086 -0.142 -0.974 -0.485 0.110 0.010 0.326 0.198 0.001 0.001 0.338 
NM_006028 HTR3B -0.033 0.055 -0.237 1.128 0.098 0.264 0.350 0.368 0.341 0.006 0.351 0.152 
NM_006052 DSCR3 -0.075 -0.218 -0.780 0.625 1.265 -0.437 0.320 0.239 0.079 0.034 0.176 0.024 
NM_006149 LGALS4 0.402 -0.057 0.086 0.598 0.103 0.787 0.117 0.366 0.306 0.034 0.321 0.175 
NM_006256 PRKCL2 0.002 0.366 -0.255 -0.594 -0.232 0.275 0.375 0.006 0.067 0.002 0.225 0.012 
NM_006350 FST 0.367 0.045 0.153 0.646 0.368 0.159 0.142 0.162 0.131 0.001 0.121 0.281 
NM_006379 SEMA3C -0.378 0.179 0.039 -0.781 0.123 0.347 0.097 0.332 0.084 0.004 0.342 0.190 
NM_006403 NEDD9 0.165 0.368 -0.593 0.581 0.344 0.072 0.360 0.094 0.206 0.018 0.184 0.361 
NM_006420 ARFGEF2 0.006 -0.163 0.106 0.724 0.114 0.054 0.374 0.296 0.365 0.022 0.366 0.328 
NM_006438 COLEC10 -0.281 -0.073 -0.042 0.772 -0.101 0.233 0.134 0.132 0.363 0.032 0.354 0.213 
NM_006447 USP16 0.168 0.134 -0.215 -0.846 -0.283 -0.315 0.288 0.153 0.050 0.000 0.208 0.184 
NM_006492 ALX3 -0.507 -0.554 -0.131 -0.652 -0.839 -0.367 0.019 0.004 0.101 0.034 0.177 0.026 
NM_006502 POLH 0.061 0.244 -0.025 -0.750 -0.167 0.417 0.341 0.204 0.370 0.000 0.331 0.012 
NM_006638 RPP40 -0.249 0.020 0.084 -0.633 0.023 -0.463 0.172 0.374 0.297 0.004 0.374 0.141 
NM_006713 PC4 0.350 0.046 0.161 -0.661 0.103 0.091 0.020 0.374 0.231 0.029 0.343 0.149 
NM_006768 BRAP -0.091 0.337 0.138 -1.350 -0.112 -0.087 0.225 0.004 0.313 0.002 0.342 0.333 
NM_006771 KRTHA8 -0.441 -0.278 -0.246 -0.580 -0.666 -0.152 0.021 0.204 0.041 0.005 0.156 0.292 
NM_006846 SPINK5 -0.304 0.161 0.575 -0.819 0.043 0.004 0.224 0.055 0.209 0.019 0.362 0.373 
NM_006871 RIPK3 -0.237 -0.320 0.154 0.809 0.241 -0.471 0.343 0.318 0.199 0.007 0.052 0.193 
NM_006885 ATBF1 0.272 0.052 -0.328 0.720 0.519 0.058 0.110 0.362 0.064 0.005 0.076 0.361 
NM_006965 ZNF24 -0.302 0.018 0.080 -0.585 -0.343 -0.393 0.211 0.374 0.301 0.034 0.106 0.104 
NM_007069 HRASLS3 0.200 0.302 0.393 0.589 0.244 0.022 0.266 0.237 0.071 0.032 0.014 0.364 
NM_007096 CLTA 0.060 0.413 -1.046 -0.614 -0.393 0.058 0.144 0.273 0.255 0.048 0.007 0.364 
NM_007105 SLC22A1LS 0.159 -0.970 1.310 0.873 -0.578 -0.025 0.176 0.094 0.115 0.018 0.248 0.356 
NM_007145 ZNF146 -0.386 0.002 0.017 -0.730 -0.418 -0.249 0.087 0.375 0.373 0.010 0.124 0.005 
NM_007180 TREH 0.952 0.011 -0.160 1.055 0.052 -0.658 0.195 0.374 0.211 0.025 0.370 0.213 
NM_007282 RNF13 -0.190 0.093 0.038 -0.666 -0.339 0.087 0.188 0.316 0.348 0.001 0.090 0.354 
NM_007352 ELA3B 0.610 -0.161 -0.150 -0.651 -0.082 0.048 0.151 0.136 0.069 0.005 0.351 0.361 
NM_007355 HSPCB 0.384 -0.070 -0.338 0.587 0.079 0.167 0.030 0.319 0.012 0.020 0.292 0.254 
NM_012079 DGAT1 -0.394 0.475 0.208 -1.146 0.228 0.741 0.192 0.151 0.089 0.031 0.236 0.188 
NM_012126 CHST5 0.196 -0.031 -0.432 0.915 -0.078 0.157 0.062 0.370 0.026 0.028 0.359 0.111 
NM_012148 DUX1 -0.267 -0.026 -0.294 -0.739 -0.044 0.123 0.006 0.370 0.118 0.003 0.347 0.220 
NM_012177 FBXO5 -0.305 -0.157 -0.105 -0.589 -0.402 -0.126 0.104 0.102 0.242 0.003 0.085 0.330 
NM_012241 SIRT5 -0.095 0.085 -0.066 -0.863 -0.321 -0.278 0.296 0.298 0.338 0.002 0.052 0.169 
NM_012400 PLA2G2D -0.198 -0.134 -0.849 0.784 -0.206 0.190 0.322 0.002 0.129 0.000 0.362 0.196 




Log2(Fold Change) p-value 

















NM_012447 STAG3 0.288 -0.058 0.082 0.879 0.028 0.284 0.146 0.371 0.095 0.004 0.374 0.330 
NM_013282 UHRF1 -0.301 -0.159 -0.073 -0.592 -0.274 0.158 0.187 0.288 0.329 0.000 0.302 0.068 
NM_013334 GMPPB -0.382 0.014 0.119 -0.731 -0.550 -0.046 0.062 0.374 0.344 0.001 0.144 0.358 
NM_013378 VPREB3 -0.062 0.021 -0.270 -0.669 -0.345 0.079 0.272 0.373 0.181 0.008 0.137 0.367 
NM_013439 PILRA -0.414 0.119 0.017 -0.588 0.074 0.316 0.065 0.075 0.304 0.013 0.353 0.054 
NM_013943 CLIC4 -0.310 -0.045 0.246 -0.874 -0.575 -0.101 0.002 0.344 0.047 0.001 0.002 0.112 
NM_014011 SOCS5 0.819 -0.305 0.101 1.623 -0.034 0.051 0.059 0.119 0.362 0.006 0.363 0.367 
NM_014070 C6orf15 0.081 0.271 -0.039 -0.811 -0.035 0.433 0.119 0.141 0.372 0.020 0.370 0.092 
NM_014183 DNCL2A 0.495 0.073 -0.268 -0.702 -0.017 0.179 0.267 0.349 0.314 0.023 0.339 0.108 
NM_014236 GNPAT 0.221 0.208 -0.019 0.923 0.155 0.535 0.119 0.169 0.373 0.010 0.168 0.122 
NM_014254 TMEM5 0.443 -0.220 -0.148 0.963 0.867 -0.402 0.055 0.295 0.180 0.031 0.205 0.119 
NM_014310 RASD2 0.071 0.045 0.270 0.692 -0.036 0.131 0.274 0.367 0.288 0.027 0.323 0.310 
NM_014321 ORC6L -0.176 0.160 -0.010 -0.740 -0.244 0.141 0.190 0.233 0.375 0.000 0.250 0.132 
NM_014379 KCNV1 0.092 0.357 -0.526 0.862 0.165 -0.074 0.130 0.100 0.103 0.022 0.289 0.127 
NM_014395 DAPP1 0.244 0.395 -0.097 -0.621 -0.633 0.062 0.101 0.301 0.344 0.039 0.155 0.236 
NM_014452 TNFRSF21 -0.215 -0.037 -0.212 -0.969 -0.038 0.153 0.230 0.361 0.220 0.044 0.329 0.317 
NM_014480 ZNF544 -0.373 0.074 0.108 -0.801 -0.298 -0.116 0.014 0.355 0.234 0.006 0.249 0.259 
NM_014571 HEYL 0.076 -0.357 -0.092 1.014 0.035 0.003 0.168 0.153 0.239 0.012 0.035 0.365 
NM_014580 SLC2A8 -0.034 -0.029 -0.150 0.994 -0.034 -0.239 0.235 0.366 0.104 0.019 0.312 0.146 
NM_014592 KCNIP1 -0.145 -0.019 -0.345 0.589 -0.349 -0.098 0.296 0.149 0.068 0.002 0.306 0.316 
NM_014618 DBC1 -0.738 -0.556 -0.321 -0.600 -0.522 0.281 0.162 0.103 0.320 0.022 0.014 0.049 
NM_015322 FEM1B -0.412 0.000 0.183 -0.757 -0.288 -0.089 0.002 0.375 0.199 0.000 0.062 0.261 
NM_015642 ZNF288 0.417 0.138 -0.114 0.587 0.188 0.166 0.216 0.282 0.347 0.045 0.297 0.040 
NM_015720 PODLX2 -0.042 0.116 -0.085 -0.622 -0.161 -0.394 0.365 0.322 0.246 0.038 0.211 0.027 
NM_016086 MK-STYX -0.427 -0.108 0.314 -0.903 -0.010 -0.355 0.030 0.191 0.027 0.028 0.375 0.041 
NM_016106 SCFD1 0.038 -0.074 -0.048 -0.590 -0.135 -0.294 0.370 0.254 0.357 0.027 0.313 0.054 
NM_016145 PTD008 0.420 0.442 0.569 0.685 0.433 0.365 0.150 0.252 0.233 0.015 0.077 0.133 
NM_016169 SUFU -0.200 -0.154 -0.453 -0.711 -0.252 0.879 0.124 0.194 0.200 0.002 0.083 0.164 
NM_016180 MATP -0.173 0.244 0.075 0.735 0.145 -0.171 0.297 0.286 0.350 0.020 0.178 0.341 
NM_016194 GNB5 -0.023 -0.219 -0.257 0.805 0.483 0.262 0.372 0.350 0.355 0.000 0.017 0.290 
NM_016195 MPHOSPH1 0.179 0.139 -0.120 -0.715 -0.378 -0.276 0.057 0.270 0.174 0.002 0.029 0.233 
NM_016262 TUBE1 -0.087 0.315 -0.274 -0.725 -0.967 0.057 0.357 0.133 0.135 0.000 0.174 0.173 
NM_016290 RAP80 -0.308 -0.075 -0.186 -0.988 0.010 -0.455 0.188 0.311 0.147 0.020 0.375 0.047 
NM_016331 ANC_2H01 -0.277 0.150 -0.200 -0.870 0.024 0.218 0.177 0.190 0.290 0.026 0.374 0.131 
NM_016540 GPR83 0.153 0.012 0.400 0.728 -0.101 -0.558 0.300 0.253 0.249 0.007 0.370 0.030 
NM_016563 RASL12 -0.029 0.001 0.296 0.704 -0.551 0.047 0.370 0.375 0.147 0.041 0.264 0.243 
NM_016585 THEG -0.236 -0.098 -0.107 -0.593 -0.432 -0.220 0.024 0.209 0.296 0.000 0.137 0.257 
NM_016940 C21orf6 -0.498 -0.015 -0.048 -1.021 -0.628 -0.063 0.029 0.370 0.361 0.001 0.077 0.369 
NM_017417 GALNT8 0.000 0.337 0.110 -0.958 -0.249 -0.083 0.375 0.030 0.329 0.013 0.250 0.065 
NM_017639 CDHJ -0.030 -0.030 -0.303 -0.851 0.218 0.356 0.341 0.371 0.106 0.000 0.050 0.222 
NM_017757 ZNF407 0.355 -0.135 -0.226 0.658 0.183 0.106 0.026 0.176 0.186 0.014 0.162 0.308 
NM_017886 FLJ20574 -0.218 -0.129 0.070 -0.728 -0.350 -0.203 0.060 0.334 0.325 0.048 0.153 0.257 
NM_018015 FLJ10178 -0.193 0.139 -0.027 -0.606 -0.085 0.008 0.230 0.254 0.371 0.012 0.344 0.374 
NM_018070 SSBP3 -0.547 -0.232 0.499 0.587 -0.135 0.265 0.102 0.179 0.073 0.013 0.306 0.036 
NM_018289 FLJ10979 -0.559 0.229 0.157 -1.702 0.153 0.412 0.027 0.069 0.208 0.000 0.339 0.195 
NM_018319 TDP1 -0.136 -0.297 -0.487 1.445 -0.228 -0.293 0.276 0.106 0.150 0.027 0.283 0.129 
NM_018416 FOXJ2 -0.208 -0.100 0.218 -0.768 -0.313 0.224 0.191 0.218 0.229 0.000 0.173 0.132 
NM_018952 HOXB6 0.108 0.169 -0.318 -0.898 -0.200 0.146 0.258 0.214 0.155 0.017 0.237 0.254 
NM_019052 C6orf18 -0.478 0.026 -0.249 -0.776 -0.087 -0.070 0.000 0.346 0.177 0.000 0.344 0.300 
NM_019087 ARFRP2 -0.571 0.348 -0.096 0.624 0.014 -0.046 0.135 0.264 0.339 0.004 0.367 0.267 
NM_020163 LOC56920 -0.191 0.232 0.338 0.596 -0.087 0.100 0.224 0.203 0.078 0.049 0.341 0.124 




Log2(Fold Change) p-value 

















S53686 TAL1 -0.237 -0.051 0.158 1.429 0.273 0.094 0.301 0.339 0.200 0.001 0.196 0.228 
U00946 PRKWNK1 -0.102 0.185 -0.049 -0.585 -0.124 0.040 0.301 0.185 0.369 0.004 0.236 0.341 
U28480 UCP1 0.128 0.272 -0.128 -0.950 -0.304 0.191 0.283 0.107 0.246 0.003 0.128 0.240 
U49349 PIK3R1 0.256 -0.119 -0.187 0.629 0.746 0.022 0.021 0.206 0.339 0.016 0.151 0.351 
U87972 IDH3B -0.029 0.042 0.115 -0.707 -0.475 -0.111 0.372 0.372 0.318 0.034 0.297 0.291 
X15183 HSPCA 0.502 0.076 -0.187 0.725 0.273 0.310 0.064 0.283 0.133 0.024 0.139 0.032 
X52343 ZNF19 -0.442 -0.419 -0.038 -0.830 0.081 0.128 0.055 0.283 0.352 0.038 0.025 0.328 
X52355 ZNF28 -0.242 -0.168 -0.233 -0.712 -0.557 -0.072 0.187 0.323 0.110 0.000 0.034 0.360 
X65231 ZNF135 -0.484 -0.004 -0.136 -0.669 -1.153 -0.619 0.027 0.375 0.324 0.007 0.070 0.158 
X78924 ZNF266 -0.148 0.139 -0.021 -1.581 -0.116 0.154 0.215 0.302 0.372 0.004 0.106 0.281 
X94440 TEAD2 -0.365 -0.032 -0.522 -1.158 -1.105 -0.436 0.262 0.374 0.190 0.006 0.085 0.308 
X99681 HOXC8 -0.340 -0.108 0.050 -0.616 0.083 0.467 0.144 0.293 0.371 0.000 0.353 0.010 
Y16752 SCGN -0.079 -0.185 -0.032 0.585 -0.129 -0.009 0.346 0.199 0.371 0.015 0.316 0.375 
Z36823 LOC201895 0.012 -0.061 -0.035 -0.679 -0.126 0.076 0.374 0.246 0.359 0.042 0.062 0.309 
Z36846 - 0.246 0.044 -0.272 0.752 0.474 0.022 0.107 0.365 0.062 0.002 0.066 0.373 
AK001857 - 0.059 -0.467 0.080 1.345 -0.570 -0.227 0.342 0.027 0.337 0.008 0.281 0.219 
Z83945 - -0.061 -0.789 -0.169 0.692 -0.411 0.165 0.261 0.211 0.278 0.021 0.342 0.222 
U80775 - -0.053 -0.077 0.404 -0.726 0.018 -0.100 0.368 0.332 0.072 0.023 0.373 0.349 
U92019 - 0.256 0.274 0.623 -0.730 -0.243 0.530 0.197 0.197 0.211 0.005 0.208 0.100 
X52221 - -0.324 -0.006 0.042 -0.676 -0.190 -0.255 0.020 0.374 0.343 0.034 0.236 0.063 
X69081 - 0.210 0.036 -0.230 0.763 0.482 0.056 0.123 0.366 0.007 0.001 0.040 0.357 
X74613 - 0.269 -0.025 -0.360 -0.597 0.052 0.066 0.271 0.369 0.109 0.035 0.366 0.363 
AK021771 - -0.136 0.021 -0.387 -1.621 0.088 -0.054 0.143 0.374 0.023 0.005 0.034 0.341 
AK022963 - 0.059 0.214 -0.017 1.007 -0.041 -0.821 0.363 0.080 0.357 0.046 0.342 0.194 
AK023167 - 0.059 -0.035 0.003 -0.583 -0.146 0.132 0.321 0.374 0.375 0.024 0.102 0.319 
AK023667 - -0.058 -0.533 0.314 0.709 0.015 0.002 0.330 0.146 0.035 0.007 0.374 0.375 
AK022371 - -0.279 0.042 -0.058 -0.621 -0.409 0.090 0.094 0.366 0.341 0.037 0.003 0.333 
NM_005311 - -0.296 -0.032 -0.562 -0.760 -0.455 0.076 0.031 0.317 0.069 0.003 0.063 0.347 
AK023920 - 0.007 -0.021 -0.453 -0.668 -0.223 0.220 0.375 0.366 0.202 0.000 0.053 0.012 
AK023936 - 0.403 0.245 0.003 1.139 0.137 0.058 0.064 0.226 0.375 0.012 0.147 0.237 
AK024108 - -0.023 0.001 0.371 0.756 0.445 0.003 0.307 0.375 0.016 0.039 0.213 0.365 
AK024185 - -0.117 0.314 -0.513 0.758 -0.643 0.298 0.372 0.282 0.005 0.000 0.243 0.102 
AL049231 - 0.148 0.012 1.053 1.393 -0.288 -0.085 0.093 0.253 0.191 0.007 0.089 0.168 
AK026385 - -0.076 0.008 -0.700 1.515 1.110 -0.224 0.312 0.318 0.176 0.050 0.113 0.224 
NM_014092 - 0.472 -0.269 0.081 0.582 1.617 -0.086 0.258 0.012 0.365 0.000 0.144 0.205 
AL109790 - -0.241 -0.012 -0.052 0.741 -0.038 -0.144 0.270 0.372 0.367 0.001 0.366 0.210 
AL353946 - 0.173 0.263 0.136 0.686 0.198 0.138 0.221 0.221 0.368 0.019 0.287 0.237 
NM_014148 - 0.167 0.093 -0.252 0.839 -0.045 -0.040 0.227 0.304 0.262 0.012 0.370 0.326 
AL117570 - 0.202 -1.468 -0.064 1.019 -0.072 -0.219 0.112 0.283 0.359 0.021 0.356 0.168 
AL122122 - 0.361 -0.079 -0.513 -0.588 0.392 -0.253 0.146 0.353 0.000 0.018 0.178 0.213 
M26880 - 0.461 -0.100 0.088 0.922 0.567 0.420 0.000 0.247 0.218 0.000 0.012 0.023 
M34572 - -0.088 -0.047 -0.242 0.686 0.181 -0.192 0.348 0.369 0.235 0.001 0.283 0.242 
AB007953 - -0.200 0.076 -0.202 -0.607 -0.473 0.034 0.144 0.341 0.223 0.000 0.050 0.370 
AB007962 - -0.412 0.070 -0.157 -0.717 -0.261 0.080 0.029 0.347 0.048 0.013 0.286 0.349 
AL137285 - -0.567 -0.608 -0.286 -0.771 -0.215 0.039 0.063 0.273 0.134 0.020 0.185 0.362 
NM_016064 - -0.192 0.056 0.419 -0.610 0.104 -0.198 0.005 0.304 0.044 0.001 0.259 0.017 
NM_014664 - 0.082 -0.498 -0.232 0.778 0.936 0.346 0.324 0.078 0.275 0.029 0.132 0.018 
NM_016171 - 0.513 -0.099 -0.022 0.601 0.459 0.270 0.001 0.135 0.370 0.000 0.000 0.004 
NM_014758 - -0.175 -0.096 0.172 0.593 -0.148 -0.040 0.166 0.347 0.210 0.041 0.315 0.370 
AF009312 - 0.911 0.409 0.214 0.690 0.276 0.184 0.247 0.126 0.247 0.013 0.017 0.162 
NM_014861 - 0.423 0.464 0.123 0.592 0.610 0.172 0.013 0.096 0.294 0.011 0.165 0.043 
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NM_018002 - -0.129 -0.084 -0.063 -0.633 -0.188 -0.048 0.231 0.175 0.362 0.000 0.279 0.343 
L23545 - -0.187 -0.062 0.028 0.760 0.051 -0.059 0.312 0.372 0.363 0.049 0.161 0.364 
NM_018084 - -0.420 -0.299 0.000 -0.614 -0.189 -0.048 0.025 0.024 0.375 0.000 0.175 0.357 
L77586 - 0.180 0.226 0.062 -0.674 -0.216 0.148 0.304 0.307 0.298 0.000 0.196 0.271 
AF088050 - 0.782 -0.081 -0.176 0.840 -0.299 -0.012 0.270 0.348 0.309 0.021 0.339 0.373 
NM_020484 - 0.020 0.226 0.203 -0.651 0.287 -0.018 0.373 0.305 0.160 0.026 0.321 0.373 
AF090405 - 0.016 -0.602 -0.034 0.585 0.007 -0.326 0.374 0.097 0.355 0.007 0.371 0.285 
S69023 - -0.292 0.047 -0.151 -0.969 -0.311 0.005 0.048 0.322 0.261 0.000 0.126 0.375 
S83307 - -0.128 -0.690 0.272 -0.777 0.126 -0.462 0.270 0.061 0.192 0.014 0.330 0.235 
U00684 - 0.755 -0.049 -0.350 1.222 0.096 0.048 0.164 0.370 0.189 0.029 0.259 0.364 
AF085897 - 0.282 0.042 -0.238 0.737 0.377 0.028 0.114 0.365 0.027 0.001 0.053 0.371 
U00925 - 0.046 -0.403 0.014 0.895 0.036 -0.729 0.371 0.221 0.375 0.012 0.328 0.213 
U03241 - 0.221 -0.074 0.126 1.193 -0.130 -0.071 0.237 0.242 0.130 0.027 0.354 0.348 
NM_018599 - -0.004 0.239 -0.140 0.595 0.634 -0.267 0.375 0.127 0.347 0.026 0.185 0.258 
NM_018624 - -0.215 0.232 -0.174 -0.876 0.053 -0.140 0.227 0.168 0.276 0.029 0.368 0.089 
Y12020 - 0.071 -0.338 0.385 0.899 0.039 0.755 0.372 0.214 0.099 0.022 0.372 0.210 
Y16708 - 0.314 -0.094 0.064 0.686 0.040 -0.604 0.065 0.344 0.352 0.041 0.369 0.103 
AF142063 - 0.847 0.125 -0.003 -0.814 0.132 0.079 0.153 0.109 0.375 0.044 0.261 0.333 
U56251 - -0.566 0.025 -0.149 -0.603 -0.076 -0.535 0.003 0.285 0.209 0.000 0.369 0.000 
U58666 - -0.192 -0.271 -0.059 -1.073 -0.032 0.175 0.185 0.191 0.363 0.000 0.370 0.285 
U62822 - 0.252 0.389 -0.114 -0.667 -0.190 0.441 0.024 0.013 0.169 0.002 0.283 0.057 
AB002319 ZFYVE26 0.332 -0.031 -0.147 -0.620 0.126 0.303 0.163 0.374 0.197 0.046 0.290 0.082 
AB002337 KIAA0339 -0.196 -0.214 -0.028 -0.611 -0.098 0.020 0.014 0.150 0.350 0.008 0.155 0.349 
AB023223 STXBP5L 0.089 0.701 -0.668 1.172 0.232 0.095 0.327 0.320 0.150 0.001 0.316 0.291 
AB033025 KIAA1199 0.342 -0.043 -0.306 0.927 -0.113 -0.014 0.160 0.370 0.114 0.045 0.358 0.369 
AB037753 KIAA1332 -0.519 0.019 0.013 -0.749 -0.447 -0.284 0.005 0.369 0.374 0.000 0.000 0.035 
AB040917 LRFN1 0.005 0.531 0.608 0.602 0.475 -0.250 0.374 0.154 0.149 0.025 0.182 0.283 
AB040938 KIAA1505 0.019 -0.277 -0.181 -0.726 -0.207 -0.399 0.374 0.073 0.006 0.000 0.252 0.230 
AF000560 LOC126208 -0.204 -0.027 -0.070 -0.678 -0.115 -0.083 0.146 0.372 0.360 0.005 0.363 0.288 
AF007147 - -0.116 0.209 0.249 0.756 0.363 0.071 0.340 0.182 0.356 0.024 0.054 0.246 
AF052127 - 0.149 0.016 -0.023 0.809 -0.031 -0.150 0.253 0.374 0.374 0.003 0.370 0.214 
AF064846 - -0.016 0.124 -0.048 -0.654 -0.377 0.320 0.374 0.231 0.367 0.003 0.217 0.130 
AF070580 - 0.371 -0.223 -0.050 0.813 -0.034 -0.164 0.202 0.082 0.370 0.001 0.374 0.097 
AF070633 IPO9 -0.250 -0.127 -0.199 -0.687 -0.368 -0.164 0.050 0.180 0.197 0.034 0.071 0.099 
AF073482 MTMR7 -0.076 0.014 -0.249 -0.845 0.228 -0.045 0.368 0.375 0.101 0.030 0.189 0.036 
AF075023 - -0.015 -0.251 0.243 0.674 -0.414 0.006 0.362 0.131 0.243 0.024 0.248 0.374 
AF075028 - 0.241 -0.570 0.050 1.406 0.335 -0.002 0.086 0.231 0.080 0.001 0.087 0.373 
AF075070 - -0.036 0.008 -0.012 -0.649 0.172 0.003 0.365 0.317 0.374 0.043 0.225 0.365 
AF085890 - 0.115 0.116 -0.033 0.655 0.064 0.101 0.353 0.238 0.358 0.027 0.360 0.308 
AF085891 - 0.049 0.182 0.135 1.071 -0.086 0.162 0.362 0.035 0.249 0.026 0.234 0.239 
AF085917 KCTD1 0.149 0.730 0.068 0.716 0.060 0.046 0.299 0.092 0.362 0.025 0.368 0.179 
AF085926 - -0.015 -0.210 0.603 0.731 0.299 0.137 0.373 0.187 0.066 0.007 0.177 0.237 
AF085960 - 0.066 0.139 0.151 0.686 0.265 -0.047 0.293 0.090 0.248 0.010 0.275 0.367 
AF085993 - 0.371 0.392 0.364 0.661 0.101 0.048 0.176 0.202 0.209 0.039 0.333 0.242 
AF086037 - -0.340 0.229 0.095 0.770 -0.193 -0.006 0.006 0.089 0.278 0.002 0.296 0.363 
AF086063 - -0.162 -0.129 -0.353 0.675 -0.079 -0.055 0.213 0.317 0.071 0.014 0.348 0.347 
AF086120 C4orf7 0.203 -1.856 -0.079 0.677 0.415 0.103 0.127 0.216 0.318 0.041 0.075 0.227 
AF086213 - -0.834 -0.251 0.038 0.668 -0.041 -0.048 0.206 0.230 0.317 0.000 0.372 0.304 
AF086342 - -0.380 -0.263 0.534 0.615 0.301 -0.071 0.266 0.063 0.046 0.003 0.213 0.282 
AF086344 HIWI2 0.240 -0.603 -0.313 0.719 -0.214 0.198 0.328 0.272 0.351 0.005 0.349 0.342 
AF086451 - 0.164 -0.232 -0.300 0.920 -0.362 0.108 0.145 0.223 0.080 0.003 0.274 0.226 
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AF086485 - -0.084 -0.507 -0.138 0.983 -0.062 -0.300 0.155 0.140 0.332 0.002 0.347 0.222 
AF090944 - -0.030 0.119 0.312 1.446 0.396 0.147 0.372 0.149 0.330 0.001 0.141 0.250 
AF119908 PRO2955 0.270 -0.044 -0.353 -0.603 -0.077 -0.146 0.263 0.356 0.029 0.035 0.317 0.110 
AF132027 - -0.302 -0.110 -0.292 -0.706 -0.827 -0.237 0.010 0.270 0.108 0.049 0.076 0.046 
AF147419 - -0.124 0.067 -0.231 0.812 0.317 0.013 0.356 0.326 0.191 0.028 0.062 0.371 
AF147791 - -0.021 0.256 -0.009 -0.814 0.153 0.023 0.367 0.147 0.374 0.003 0.119 0.367 
AF149304 - 0.072 -0.025 0.145 0.910 0.083 0.097 0.344 0.367 0.052 0.045 0.190 0.215 
AF161411 C9orf80 -0.439 0.048 -0.259 -0.604 0.040 0.377 0.140 0.362 0.109 0.035 0.002 0.000 
AF161441 - -0.466 -0.522 0.126 1.076 0.143 0.062 0.001 0.072 0.333 0.000 0.131 0.365 
AF182419 MDS018 -0.372 0.056 -0.154 -0.599 -0.408 -0.233 0.007 0.356 0.114 0.000 0.032 0.021 
AF198444 - -0.193 -0.097 -0.272 -0.586 -0.064 0.191 0.220 0.263 0.100 0.008 0.363 0.071 
AF221846 - 0.056 0.449 0.505 0.671 0.115 0.120 0.364 0.108 0.012 0.021 0.167 0.221 
AF222927 SAMSN1 -0.136 -0.121 0.206 0.639 1.261 -0.050 0.128 0.221 0.098 0.000 0.092 0.362 
AK021814 FLJ11752 0.103 0.084 -1.280 -0.853 0.074 -0.099 0.339 0.270 0.207 0.002 0.365 0.206 
AK022077 BAALC 0.169 -0.406 0.080 0.730 0.059 -0.960 0.231 0.114 0.372 0.010 0.373 0.142 
AK022158 - -1.256 -0.182 0.102 0.766 -0.191 -0.191 0.084 0.160 0.081 0.005 0.268 0.103 
AK022167 - -0.013 -0.192 0.287 -0.666 0.653 0.121 0.373 0.131 0.132 0.027 0.064 0.240 
AK022185 - -0.088 0.364 -0.113 0.645 0.306 0.003 0.360 0.170 0.355 0.000 0.270 0.365 
AK022347 - 0.483 0.426 -0.046 0.581 1.057 0.041 0.171 0.210 0.361 0.002 0.109 0.360 
AK022427 - 0.034 -0.072 -0.325 0.692 -0.508 -0.504 0.256 0.173 0.318 0.004 0.226 0.163 
AK022537 RPF1 -0.192 0.008 -0.255 -0.661 -0.083 -0.247 0.232 0.371 0.230 0.014 0.365 0.003 
AK022591 FLJ12529 0.023 0.073 -0.028 -0.701 -0.020 0.220 0.370 0.208 0.373 0.007 0.365 0.037 
AK022619 - 0.279 0.179 0.210 0.645 -0.315 0.037 0.048 0.023 0.283 0.014 0.291 0.251 
AK022680 C14orf160 -0.148 0.240 -0.467 0.795 -0.209 -0.175 0.216 0.217 0.024 0.024 0.153 0.208 
AK022877 - 0.116 -0.293 0.088 0.879 0.236 -0.260 0.319 0.057 0.342 0.003 0.063 0.071 
AK022980 IDI1 0.042 -0.344 0.227 0.790 0.214 0.079 0.369 0.092 0.326 0.000 0.103 0.337 
AK023031 FLJ12969 -0.305 0.016 0.059 -0.988 -0.316 -0.257 0.012 0.373 0.361 0.000 0.055 0.209 
AK023039 LOC339263 0.321 0.163 0.182 0.612 0.298 -0.791 0.120 0.310 0.249 0.007 0.056 0.169 
AK023072 ZNF451 -0.057 -0.296 0.246 -0.583 0.474 0.310 0.158 0.236 0.009 0.047 0.141 0.090 
AK023104 - -0.019 -0.238 0.541 0.727 0.267 0.028 0.373 0.241 0.120 0.002 0.260 0.098 
AK023150 FLJ32745 -0.184 -0.262 -0.259 -0.712 0.592 -0.243 0.350 0.225 0.319 0.045 0.140 0.286 
AK023198 - 0.776 1.160 -0.249 0.810 -0.278 0.990 0.089 0.140 0.262 0.015 0.359 0.197 
AK023283 - -0.110 -0.283 -0.101 1.200 -0.455 -0.265 0.310 0.208 0.350 0.044 0.244 0.223 
AK023309 - 0.189 -0.010 0.050 0.630 -0.361 0.063 0.161 0.375 0.372 0.021 0.324 0.267 
AK023464 - 0.181 -0.031 -0.077 0.678 0.032 0.082 0.136 0.368 0.301 0.023 0.317 0.205 
AK023501 - -0.387 0.011 -0.355 -1.307 0.218 0.117 0.048 0.375 0.247 0.042 0.306 0.363 
AK023543 - 0.356 0.409 0.062 0.724 0.310 0.660 0.132 0.218 0.287 0.041 0.278 0.211 
AK023940 - 0.053 0.260 0.333 -1.350 -0.383 -0.276 0.298 0.179 0.191 0.000 0.184 0.355 
AK024161 MGC17791 -0.132 0.488 0.374 0.609 0.189 -0.116 0.302 0.254 0.096 0.017 0.228 0.241 
AK024204 - 0.207 -0.100 0.002 0.789 0.090 0.080 0.154 0.320 0.375 0.024 0.363 0.341 
AK024244 LOC284723 -0.186 -0.208 0.285 -0.750 -0.003 0.312 0.291 0.345 0.023 0.025 0.375 0.183 
AK024303 - -0.032 0.103 -0.204 1.530 -0.074 0.044 0.356 0.282 0.258 0.000 0.373 0.245 
AK024436 DOCK8 -0.099 -0.053 -0.134 -0.693 -1.087 0.065 0.011 0.363 0.316 0.009 0.111 0.327 
AK024551 FLJ20898 -0.336 -0.192 0.444 0.958 -0.055 -0.147 0.274 0.129 0.024 0.027 0.370 0.160 
AK024613 - 0.820 0.296 -0.387 0.780 0.231 0.411 0.178 0.339 0.222 0.007 0.334 0.198 
AK024662 - -0.377 -0.174 0.276 1.344 0.328 0.136 0.315 0.368 0.238 0.008 0.085 0.223 
AK025213 C6orf89 -0.014 -0.717 0.081 0.824 0.309 0.104 0.334 0.278 0.330 0.036 0.048 0.373 
AK025308 KIAA0182 0.435 -0.531 0.160 0.587 0.085 -0.439 0.207 0.188 0.243 0.000 0.116 0.083 
AK025311 LOC91948 0.232 -0.282 0.093 -0.991 0.296 0.117 0.078 0.274 0.244 0.040 0.183 0.294 
AK025593 FLJ21940 -0.428 -0.310 0.117 -0.620 -0.415 -0.237 0.010 0.000 0.249 0.041 0.024 0.219 
AK025657 SLC35F5 -0.105 0.125 -0.097 -0.751 0.301 0.022 0.338 0.291 0.185 0.043 0.164 0.369 
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AK026238 - 0.126 0.656 -0.578 0.674 0.187 -0.184 0.206 0.230 0.339 0.000 0.321 0.280 
AK026277 FLJ22624 -0.278 0.187 0.115 -0.660 -0.028 -0.154 0.128 0.202 0.322 0.009 0.367 0.138 
AK026288 FLJ22635 -0.396 -0.063 -0.245 -0.663 -0.115 0.221 0.006 0.332 0.040 0.003 0.338 0.004 
AK026299 MGC21874 0.345 -0.658 0.180 0.588 0.336 0.074 0.261 0.188 0.313 0.017 0.079 0.347 
AK026436 - -0.307 0.419 -0.125 -0.744 -0.543 -0.563 0.121 0.000 0.273 0.000 0.016 0.023 
AK026493 - -0.426 -0.077 -0.058 -1.300 -0.024 -0.144 0.073 0.254 0.224 0.011 0.370 0.189 
AK026905 MICAL2 -0.326 -0.124 0.611 -0.717 0.053 -0.190 0.029 0.326 0.135 0.046 0.358 0.283 
AK026922 FLJ40432 0.016 0.070 0.036 0.583 0.296 0.114 0.369 0.343 0.367 0.013 0.300 0.235 
AK027129 FLJ23476 -0.002 0.333 -0.076 -0.634 0.018 0.376 0.375 0.058 0.253 0.000 0.374 0.001 
AK027199 - -0.208 -0.053 0.520 1.368 0.377 -0.055 0.298 0.367 0.077 0.018 0.058 0.028 
AK027211 FLJ23558 -0.511 0.081 -0.704 -0.895 0.066 -0.260 0.278 0.370 0.134 0.029 0.363 0.209 
AL049227 - -0.046 0.222 -0.043 0.682 0.696 -0.119 0.122 0.227 0.008 0.004 0.273 0.365 
AL049299 NPD014 0.007 -0.250 -0.413 0.828 0.124 0.219 0.372 0.361 0.105 0.000 0.243 0.133 
AL050205 LOC113251 -0.310 -0.207 -0.199 -0.638 -0.491 -0.286 0.151 0.313 0.334 0.002 0.085 0.278 
AL110104 MGC14386 -0.354 -0.230 -0.169 -0.663 -0.370 -0.364 0.007 0.063 0.081 0.025 0.132 0.014 
AL117474 - -0.291 0.495 0.092 -0.691 0.057 0.533 0.152 0.180 0.330 0.029 0.210 0.257 
AL133086 - -0.404 0.004 -0.326 0.594 -0.107 -0.119 0.214 0.375 0.233 0.018 0.355 0.240 
AL137343 NSE1 0.346 -0.249 -0.156 1.263 -0.415 -0.376 0.027 0.135 0.355 0.047 0.291 0.206 
AL137368 - -0.148 0.226 0.140 0.922 0.342 -0.055 0.254 0.275 0.228 0.038 0.091 0.367 
AL137575 - 0.220 0.026 0.056 0.616 -0.179 0.112 0.024 0.374 0.328 0.028 0.072 0.214 
AL162052 LOC90520 -0.157 -0.990 0.321 0.708 0.119 -0.303 0.339 0.052 0.238 0.046 0.287 0.246 
AL359572 H2AFY2 -0.155 0.385 -0.322 -0.742 0.165 0.044 0.281 0.319 0.124 0.001 0.272 0.245 
AL360198 - -0.506 0.007 -0.284 0.790 0.100 -0.053 0.318 0.374 0.257 0.003 0.121 0.202 
AY009951 HHIP -0.200 -0.236 -0.249 -0.695 -0.021 0.069 0.088 0.196 0.209 0.002 0.373 0.292 
D16471 - 0.187 0.185 0.344 0.796 -0.019 -0.224 0.051 0.213 0.061 0.018 0.372 0.249 
D16908 - 0.419 0.085 0.182 0.845 0.179 0.057 0.236 0.346 0.250 0.004 0.120 0.237 
D42044 KIAA0090 0.153 -0.074 -0.041 0.928 0.225 -0.074 0.323 0.347 0.365 0.030 0.184 0.189 
D87446 RW1 -0.216 0.031 0.103 -1.129 -0.109 -0.096 0.120 0.368 0.254 0.026 0.345 0.307 
D90070 PMAIP1 -0.418 0.021 0.021 -0.654 -0.472 -0.296 0.002 0.367 0.371 0.004 0.006 0.008 
NM_000254 MTR -0.576 0.008 0.074 -0.983 -0.274 -0.290 0.010 0.373 0.348 0.000 0.170 0.020 
NM_001757 CBR1 0.384 0.325 -0.043 0.592 0.458 0.477 0.033 0.116 0.359 0.008 0.230 0.003 
NM_002415 MIF 0.065 -0.042 0.113 0.635 0.468 -0.117 0.346 0.371 0.272 0.004 0.127 0.343 
NM_003171 SUPV3L1 -0.314 0.022 -0.074 -0.697 -0.133 -0.166 0.089 0.362 0.330 0.000 0.327 0.097 
NM_004676 PRY -0.163 0.156 -0.469 -0.786 0.136 0.147 0.212 0.068 0.095 0.044 0.296 0.211 
NM_005145 FLJ00058 -0.177 -0.152 0.105 0.785 0.271 -0.751 0.332 0.319 0.331 0.019 0.225 0.229 
NM_005197 C14orf116 -0.386 0.220 0.012 -0.615 -0.222 0.120 0.080 0.305 0.374 0.041 0.276 0.343 
NM_005325 HIST1H1A 0.315 -0.359 -0.015 0.700 -0.493 -0.618 0.218 0.140 0.375 0.004 0.218 0.275 
NM_005332 HBZ -0.210 0.446 -0.117 -0.687 0.048 0.075 0.128 0.097 0.360 0.030 0.258 0.234 
NM_005706 TSSC4 0.105 -0.047 -0.036 -0.656 -0.208 0.145 0.325 0.273 0.349 0.014 0.258 0.207 
NM_005885 TEB4 -0.216 -0.152 -0.265 -0.803 -0.408 0.058 0.241 0.253 0.223 0.000 0.112 0.351 
NM_006223 PIN4 -0.234 0.102 0.293 -1.065 -0.009 0.172 0.185 0.302 0.211 0.049 0.374 0.243 
NM_006382 CDRT1 0.161 0.295 0.163 -0.722 0.114 -0.025 0.150 0.151 0.114 0.008 0.270 0.368 
NM_006659 TUBGCP2 -0.071 0.102 0.077 -0.716 -0.495 0.136 0.326 0.235 0.344 0.003 0.044 0.190 
NM_006868 RAB31 -0.275 0.162 -0.341 -0.890 -0.602 0.554 0.248 0.348 0.047 0.010 0.094 0.275 
NM_006891 CRYGD -0.194 -0.019 -0.058 -0.616 -0.233 -0.006 0.278 0.373 0.341 0.043 0.173 0.375 
NM_006978 ZNF183 -0.566 -0.166 -0.161 -0.594 -0.278 -0.201 0.000 0.109 0.298 0.001 0.150 0.044 
NM_007112 THBS3 -0.125 -0.308 0.228 0.595 -0.050 -0.039 0.336 0.241 0.305 0.045 0.368 0.372 
NM_007212 RNF2 -0.419 0.201 -0.198 0.595 -0.321 -0.192 0.041 0.221 0.174 0.040 0.101 0.128 
NM_013266 CTNNA3 -0.070 -0.134 -0.408 -0.789 0.128 -0.389 0.310 0.105 0.032 0.003 0.321 0.341 
NM_013275 ANKRD11 -0.127 0.170 0.013 -0.722 -0.621 0.246 0.249 0.328 0.374 0.002 0.115 0.310 
NM_014021 SSX2IP -0.389 0.071 -0.310 -0.654 -0.563 0.112 0.025 0.291 0.053 0.013 0.001 0.285 
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NM_014563 SEDL -0.212 -0.270 -0.171 -0.648 -0.206 -0.087 0.076 0.019 0.224 0.020 0.303 0.334 
NM_014637 CHPPR -0.126 0.022 -0.280 -0.661 -0.335 0.210 0.357 0.374 0.224 0.001 0.056 0.205 
NM_014878 KIAA0020 -0.340 -0.002 -0.362 -0.760 -0.280 -0.308 0.008 0.375 0.098 0.000 0.116 0.142 
NM_015535 DNAPTP6 -0.139 0.248 0.352 -0.583 -0.298 0.229 0.139 0.102 0.014 0.000 0.225 0.031 
NM_015942 CGI-12 -0.339 0.026 -0.225 -0.586 -0.184 -0.216 0.179 0.368 0.137 0.000 0.292 0.154 
NM_015954 STRAP -0.296 -0.032 0.139 -0.642 -0.717 -0.355 0.149 0.345 0.264 0.000 0.050 0.008 
NM_016132 MYEF2 -0.056 0.163 0.089 -0.738 -0.166 0.019 0.343 0.271 0.352 0.003 0.219 0.373 
NM_016449 LOC51233 -0.095 0.441 0.185 -0.860 -0.340 -0.429 0.340 0.025 0.246 0.012 0.267 0.042 
NM_016613 DKFZp434L142 0.276 -0.161 -0.506 0.608 -0.059 -0.221 0.132 0.329 0.155 0.000 0.283 0.196 
NM_016626 LOC51320 -0.339 0.231 0.057 -0.650 -0.566 0.157 0.010 0.155 0.352 0.009 0.089 0.308 
NM_016627 LOC51321 -0.471 -0.077 0.278 -0.999 -0.247 -0.299 0.003 0.312 0.185 0.000 0.201 0.038 
NM_017432 PTOV1 0.355 0.200 0.191 -0.810 -0.731 0.139 0.112 0.043 0.244 0.044 0.191 0.228 
NM_017638 FLJ20045 0.344 -0.327 0.085 1.159 -0.292 -0.066 0.001 0.219 0.356 0.024 0.328 0.334 
NM_017775 FLJ20343 -0.414 -0.190 -0.074 -0.695 -0.397 -0.351 0.010 0.068 0.306 0.001 0.033 0.000 
NM_017816 LYAR -0.492 -0.048 -0.185 -0.904 -0.523 -0.361 0.005 0.332 0.138 0.000 0.037 0.017 
NM_017824 FLJ20445 -0.241 -0.033 -0.205 -0.659 -0.335 0.092 0.244 0.355 0.171 0.000 0.148 0.181 
NM_017847 C1orf27 -0.117 0.071 0.049 -0.685 0.166 -0.312 0.212 0.255 0.141 0.017 0.281 0.182 
NM_017928 FLJ20694 0.329 0.127 -0.016 -0.957 0.008 -0.083 0.123 0.333 0.374 0.012 0.375 0.364 
NM_017938 FLJ20716 0.358 -0.380 0.053 0.632 0.275 0.235 0.148 0.072 0.351 0.015 0.240 0.315 
NM_018011 FLJ10154 -0.019 0.407 -0.150 -2.273 -0.539 -0.070 0.358 0.002 0.062 0.026 0.020 0.000 
NM_018128 FLJ10534 0.103 0.068 -0.041 -0.750 -0.491 0.105 0.206 0.316 0.368 0.000 0.004 0.003 
NM_018131 C10orf3 0.293 0.221 -0.083 -0.656 -0.021 -0.444 0.245 0.022 0.312 0.000 0.374 0.009 
NM_018250 FLJ10871 0.863 -0.386 -0.338 -1.010 0.049 0.048 0.243 0.183 0.211 0.036 0.364 0.366 
NM_018256 WDR12 -0.238 -0.068 -0.327 -0.654 -0.454 -0.419 0.178 0.318 0.134 0.000 0.004 0.026 
NM_018286 FLJ10970 0.003 0.513 -0.010 0.739 -0.307 0.003 0.375 0.272 0.336 0.036 0.258 0.365 
NM_018352 FLJ11184 -0.708 0.362 0.054 -0.638 0.353 0.264 0.269 0.039 0.170 0.042 0.091 0.242 
NM_018433 JMJD1A 0.183 -0.239 -0.091 0.680 -0.689 -0.100 0.150 0.276 0.291 0.000 0.235 0.287 
NM_018455 BM039 -0.081 -0.057 -0.140 -0.819 -0.045 -0.120 0.342 0.250 0.088 0.050 0.359 0.104 
NM_018469 HT008 -0.192 0.157 0.119 -0.670 -0.253 -0.230 0.040 0.162 0.269 0.001 0.000 0.259 
NM_018487 HCA112 0.286 0.020 0.162 0.767 -0.567 0.702 0.279 0.364 0.200 0.037 0.213 0.191 
NM_018840 C20orf24 0.403 0.154 0.043 0.622 0.354 0.369 0.032 0.093 0.358 0.002 0.067 0.006 
NM_019027 FLJ20273 -0.063 -0.083 -0.296 -0.640 -0.613 0.202 0.309 0.239 0.249 0.007 0.148 0.200 
NM_019040 ELP4 0.182 -0.058 -0.135 0.677 0.318 0.080 0.182 0.183 0.335 0.018 0.257 0.362 
NM_020125 SLAMF8 0.042 -0.208 -0.038 -0.639 -0.165 0.376 0.368 0.286 0.357 0.047 0.334 0.220 
NM_020347 LZTFL1 -0.476 0.069 -0.055 -1.355 -0.044 -0.006 0.052 0.367 0.299 0.002 0.268 0.375 
S75762 FUS -0.294 -0.054 -0.159 -0.764 -0.427 -0.485 0.109 0.343 0.027 0.000 0.064 0.110 
U00949 - 0.104 0.119 -0.157 -0.809 0.139 -0.009 0.181 0.324 0.188 0.023 0.105 0.371 
U27143 HINT1 0.797 0.001 -0.323 0.980 -0.049 -0.469 0.148 0.375 0.115 0.024 0.375 0.047 
U61096 - 0.234 -0.639 -0.150 0.745 0.213 0.074 0.120 0.094 0.229 0.047 0.062 0.212 
U79260 FTO 0.059 0.228 -0.241 -0.829 0.362 0.197 0.338 0.166 0.090 0.003 0.190 0.251 
U81557 - -0.497 0.475 -0.947 -1.604 -1.069 -0.087 0.303 0.308 0.152 0.004 0.073 0.374 
X52341 ZNF17 -0.566 -0.097 -0.439 -1.186 -1.239 -0.459 0.100 0.369 0.142 0.001 0.067 0.279 
X69636 LOC283755 0.098 0.274 0.381 -0.854 -0.014 0.210 0.367 0.151 0.102 0.045 0.375 0.277 
X84370 - 0.164 0.275 -0.151 1.026 -0.097 -0.336 0.084 0.296 0.111 0.009 0.360 0.235 
Y11897 - 0.166 0.489 -0.018 -0.757 -0.183 0.053 0.314 0.031 0.368 0.005 0.299 0.288 
Y13808 - -0.093 0.224 -0.158 -0.820 -0.016 -0.006 0.315 0.272 0.326 0.004 0.372 0.375 
AB040925 DPP10 0.709 -0.299 -0.304 -0.396 0.990 0.030 0.219 0.262 0.266 0.320 0.023 0.264 
AB042554 KIAA1173 -0.396 0.242 -0.016 0.101 0.671 0.212 0.022 0.272 0.370 0.345 0.023 0.072 
AF027147 ZNF11B -0.331 -0.008 -0.197 -0.524 -0.597 -0.103 0.117 0.375 0.263 0.081 0.016 0.354 
AF075025 H-plk -0.167 -0.769 1.037 -0.251 0.709 -0.269 0.177 0.133 0.107 0.207 0.009 0.078 
AF084560 FADS3 -0.063 -0.099 0.224 -0.357 -0.648 -0.148 0.290 0.210 0.129 0.016 0.011 0.040 
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AF113223 SNX25 0.055 -0.088 -0.040 -0.016 1.026 0.091 0.353 0.352 0.318 0.359 0.025 0.235 
AF131748 SUCLG2 0.140 -0.114 -0.288 -0.062 -0.655 0.033 0.092 0.159 0.078 0.269 0.016 0.343 
AF147429 DDX42 -0.074 0.279 0.431 0.397 0.720 0.103 0.363 0.057 0.175 0.208 0.020 0.151 
AF148646 IMMT -0.336 -0.053 -0.322 -0.576 -0.860 0.119 0.002 0.250 0.066 0.015 0.029 0.338 
AF151802 SQRDL -0.153 0.014 0.226 -0.360 -0.604 -0.282 0.074 0.333 0.188 0.121 0.013 0.024 
AJ297349 PCM1 -0.217 -0.310 0.073 -0.356 -0.739 -0.388 0.060 0.025 0.348 0.032 0.000 0.073 
AK000803 LOC90624 0.140 -0.360 -0.378 0.214 -0.730 -0.344 0.208 0.176 0.000 0.327 0.040 0.008 
AK021524 PRPF18 -0.337 -0.442 0.114 0.381 0.822 0.003 0.227 0.219 0.155 0.134 0.032 0.365 
AK022654 NPHP3 -0.016 -0.097 0.274 -0.242 -0.634 -0.131 0.371 0.258 0.077 0.104 0.022 0.273 
AK022668 FLJ12606 -0.570 -0.232 -0.090 -0.570 -0.591 -0.568 0.034 0.094 0.307 0.002 0.005 0.002 
AK023189 HELIC1 0.021 -0.069 -0.232 0.790 -0.963 -0.143 0.373 0.285 0.093 0.124 0.037 0.310 
AK023822 ChGn -0.307 -0.126 -0.190 0.144 -0.621 -0.727 0.002 0.319 0.134 0.260 0.011 0.107 
AK024082 TLK2 0.070 0.039 0.693 0.276 0.730 0.134 0.367 0.104 0.058 0.120 0.045 0.188 
AK024560 PAWR -0.022 0.198 0.046 -0.221 -0.657 0.097 0.374 0.239 0.371 0.032 0.017 0.204 
AK024964 NFIA -0.118 -0.044 0.115 0.329 0.620 0.240 0.299 0.366 0.282 0.009 0.005 0.169 
AK025389 FLJ21736 0.004 -0.131 0.004 -0.859 -0.730 -0.146 0.374 0.288 0.375 0.164 0.017 0.076 
AK026537 GABARAP 0.073 -0.041 0.048 0.240 0.957 -0.056 0.341 0.369 0.361 0.273 0.008 0.345 
AK027239 EIF4EL3 -0.366 -0.264 0.025 -0.041 0.899 0.048 0.016 0.085 0.000 0.104 0.010 0.346 
AL049466 BAG4 -0.063 0.161 0.174 -0.381 0.768 0.404 0.315 0.254 0.241 0.277 0.038 0.025 
AL110188 ZNF10 -0.050 0.256 0.055 0.182 -1.091 -0.155 0.360 0.146 0.284 0.310 0.019 0.319 
AL110194 HMGB1 0.071 0.215 -0.123 0.112 0.723 0.116 0.362 0.147 0.350 0.290 0.037 0.350 
AL110286 SV2B -0.187 -0.111 -0.214 -0.345 -0.630 -0.465 0.161 0.323 0.052 0.102 0.033 0.062 
AL117665 GEMIN5 0.544 0.154 -0.311 -0.140 -0.584 -0.066 0.230 0.158 0.148 0.287 0.035 0.349 
AL137449 HOXB4 -0.060 -0.148 -0.152 -0.335 -0.797 -0.376 0.340 0.116 0.308 0.068 0.003 0.137 
AL157449 PPP1R9B 0.119 0.174 0.309 0.125 0.610 0.496 0.190 0.016 0.067 0.293 0.000 0.001 
D26068 WBSCR1 -0.291 -0.207 -0.099 -0.370 -0.713 -0.131 0.000 0.029 0.017 0.024 0.013 0.073 
D28450 H2AFZ 0.290 0.043 -0.052 0.651 0.593 0.342 0.167 0.352 0.332 0.058 0.045 0.035 
D43948 ch-TOG 0.143 0.109 -0.149 0.392 -0.676 -0.071 0.324 0.346 0.327 0.188 0.043 0.242 
D70835 TIZ 0.417 -0.042 0.040 0.046 0.808 0.346 0.008 0.343 0.363 0.355 0.021 0.058 
J04621 SDC2 0.827 0.347 0.188 0.530 0.816 -0.469 0.073 0.148 0.278 0.195 0.001 0.199 
M14200 DBI 0.721 0.374 -0.070 0.467 0.719 0.343 0.106 0.016 0.338 0.144 0.038 0.000 
M96843 ID2B 0.229 0.402 -0.038 0.227 1.167 0.335 0.175 0.134 0.340 0.018 0.026 0.215 
NM_000100 CSTB 0.229 0.429 0.354 0.464 0.683 0.558 0.288 0.051 0.082 0.031 0.045 0.002 
NM_000173 GP1BA 0.068 -0.326 -0.031 -0.270 0.947 0.156 0.356 0.235 0.373 0.047 0.010 0.305 
NM_000178 GSS -0.302 -0.108 0.147 -0.547 -0.719 -0.370 0.129 0.248 0.117 0.044 0.009 0.021 
NM_000319 PEX5 0.046 -0.079 -0.152 0.119 -0.703 -0.500 0.362 0.321 0.125 0.206 0.004 0.085 
NM_000421 KRT10 0.109 -0.189 0.303 -0.066 0.649 -0.193 0.124 0.296 0.155 0.348 0.005 0.221 
NM_000888 ITGB6 0.071 0.011 -0.295 0.485 0.764 0.108 0.308 0.371 0.033 0.001 0.045 0.094 
NM_001111 ADAR -0.090 0.036 -0.246 -0.365 -0.618 -0.434 0.223 0.338 0.066 0.022 0.003 0.020 
NM_001564 ING1L -0.203 0.118 -0.228 -0.256 -0.782 -0.043 0.113 0.116 0.250 0.220 0.043 0.346 
NM_001713 BHMT 0.092 0.161 -0.080 -0.629 0.587 0.369 0.345 0.333 0.298 0.122 0.030 0.218 
NM_001772 CD33 -0.103 -0.249 -0.506 -0.350 -0.934 -0.210 0.297 0.137 0.123 0.165 0.030 0.327 
NM_001890 CSN1S1 0.072 0.099 -0.114 -0.155 -0.688 0.102 0.278 0.318 0.313 0.292 0.005 0.289 
NM_002312 LIG4 -0.066 -0.072 -0.024 -0.188 -0.633 -0.022 0.363 0.348 0.372 0.178 0.006 0.373 
NM_002441 MSH5 -0.458 -0.327 0.045 -0.291 -0.598 -0.341 0.000 0.022 0.359 0.070 0.015 0.138 
NM_002568 PABPC1 -0.342 -0.377 -0.046 -0.323 -0.601 -0.144 0.029 0.013 0.311 0.069 0.007 0.257 
NM_002689 POLA2 -0.137 -0.005 -0.092 -0.220 -0.800 -0.583 0.312 0.375 0.255 0.175 0.010 0.024 
NM_002703 PPAT -0.439 -0.147 -0.323 -0.332 -0.614 -0.171 0.000 0.158 0.070 0.055 0.006 0.015 
NM_002759 PRKR 0.087 0.055 -0.178 0.169 1.082 0.322 0.202 0.361 0.200 0.303 0.049 0.050 
NM_003083 SNAPC2 -0.104 0.105 0.064 -0.056 -0.907 0.290 0.252 0.344 0.364 0.241 0.022 0.021 
NM_003137 SRPK1 -0.258 -0.016 -0.152 -0.444 -0.699 0.085 0.000 0.369 0.283 0.086 0.015 0.231 
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NM_003377 VEGFB 0.100 0.254 0.208 0.321 0.742 0.571 0.217 0.163 0.224 0.141 0.049 0.014 
NM_003463 PTP4A1 -0.318 -0.080 0.220 -0.506 -0.732 -0.185 0.049 0.269 0.213 0.091 0.004 0.086 
NM_003481 GNB3 0.126 -0.115 -0.023 -0.218 0.707 -0.607 0.333 0.353 0.374 0.292 0.025 0.095 
NM_003796 C19orf2 -0.259 -0.166 -0.257 -0.460 -0.601 -0.171 0.001 0.070 0.016 0.001 0.000 0.101 
NM_004217 AURKB -0.375 -0.311 -0.290 -0.570 -0.745 -0.355 0.007 0.000 0.062 0.003 0.012 0.010 
NM_004267 CHST2 -0.193 0.365 -0.262 -0.113 -0.752 0.266 0.098 0.217 0.143 0.303 0.038 0.108 
NM_004310 RHOH 0.229 1.438 0.033 0.185 0.596 0.302 0.202 0.078 0.372 0.131 0.019 0.113 
NM_004436 ENSA 0.297 0.238 0.024 -0.122 0.668 0.234 0.070 0.096 0.372 0.311 0.017 0.007 
NM_004516 ILF3 -0.138 -0.210 -0.428 -0.387 -1.013 -0.131 0.144 0.019 0.096 0.003 0.027 0.133 
NM_004661 CDC23 -0.076 -0.219 -0.216 -0.153 -0.663 -0.118 0.245 0.163 0.218 0.293 0.045 0.318 
NM_004715 CTDP1 -0.038 0.042 -0.061 -0.219 -0.748 0.109 0.362 0.367 0.358 0.151 0.015 0.042 
NM_004738 VAPB -0.233 0.080 -0.004 -0.200 -0.691 -0.057 0.056 0.280 0.375 0.042 0.003 0.355 
NM_004761 RAB2L 0.230 0.113 -0.117 0.078 0.842 -0.363 0.194 0.209 0.279 0.196 0.006 0.017 
NM_004861 GAL3ST1 -0.362 -0.431 0.076 0.148 0.609 0.267 0.295 0.099 0.346 0.193 0.018 0.211 
NM_004939 DDX1 -0.460 -0.030 -0.019 -0.255 -0.660 -0.223 0.010 0.305 0.374 0.250 0.008 0.055 
NM_005092 TNFSF18 -0.218 -0.051 0.124 -0.109 -2.086 0.008 0.046 0.349 0.288 0.057 0.014 0.365 
NM_005445 CSPG6 -0.199 -0.009 -0.265 -0.463 -0.637 -0.369 0.148 0.371 0.052 0.035 0.012 0.096 
NM_005497 GJA7 0.076 -0.337 -0.118 0.032 -0.617 -0.227 0.320 0.225 0.277 0.370 0.009 0.186 
NM_005531 IFI16 0.050 0.453 0.163 0.757 0.787 0.545 0.347 0.065 0.222 0.111 0.042 0.013 
NM_005576 LOXL1 0.004 -0.339 -0.130 0.505 0.932 -0.062 0.374 0.296 0.224 0.088 0.035 0.361 
NM_005629 SLC6A8 0.308 0.201 0.021 0.125 0.583 0.543 0.095 0.019 0.368 0.301 0.034 0.032 
NM_005746 PBEF1 -0.319 -0.108 -0.119 -0.524 -0.594 -0.232 0.001 0.319 0.247 0.001 0.000 0.097 
NM_005755 EBI3 -0.306 0.059 -0.041 0.277 0.774 -0.337 0.092 0.369 0.007 0.151 0.020 0.266 
NM_005771 DHRS9 -1.162 0.142 0.126 -0.004 -0.686 0.074 0.163 0.196 0.280 0.375 0.017 0.235 
NM_005875 GC20 -0.515 -0.157 0.028 -0.565 -0.598 -0.417 0.015 0.018 0.365 0.000 0.002 0.001 
NM_005966 NAB1 0.378 0.131 0.151 0.533 0.809 0.416 0.101 0.280 0.323 0.047 0.006 0.227 
NM_006016 CD164 0.452 0.490 0.189 0.380 0.658 0.557 0.025 0.062 0.282 0.144 0.040 0.033 
NM_006152 LRMP -0.012 0.495 -0.227 1.114 0.590 -0.143 0.373 0.192 0.007 0.143 0.000 0.150 
NM_006244 PPP2R5B 0.348 -0.006 -0.203 -0.147 -0.675 0.437 0.125 0.375 0.032 0.294 0.001 0.246 
NM_006399 BATF -0.079 -0.046 -0.342 -0.492 -0.613 -0.084 0.232 0.358 0.024 0.000 0.033 0.253 
NM_006511 RSC1A1 0.244 -0.222 -0.527 0.185 0.613 0.087 0.313 0.262 0.238 0.255 0.046 0.292 
NM_006589 C1orf2 0.417 0.119 0.087 0.510 0.689 0.491 0.219 0.230 0.351 0.060 0.032 0.001 
NM_006608 PHTF1 0.187 -0.018 -0.082 0.283 0.747 0.267 0.132 0.371 0.341 0.247 0.007 0.057 
NM_006621 AHCYL1 -0.093 -0.175 -0.013 -0.430 -0.758 -0.464 0.305 0.021 0.372 0.017 0.004 0.037 
NM_006839 IMMT -0.210 -0.044 -0.167 -0.327 -0.598 -0.492 0.148 0.274 0.205 0.094 0.003 0.046 
NM_007103 NDUFV1 -0.216 -0.180 -0.129 -0.421 -0.673 -0.322 0.005 0.168 0.263 0.004 0.012 0.014 
NM_012086 GTF3C3 0.045 0.058 -0.087 -0.157 -0.910 -0.226 0.359 0.339 0.352 0.339 0.002 0.253 
NM_012219 MRAS 0.346 0.368 -0.126 0.141 0.587 0.048 0.300 0.113 0.242 0.030 0.013 0.367 
NM_012280 FTSJ1 -0.159 -0.153 -0.182 -0.329 -0.648 -0.123 0.040 0.200 0.021 0.027 0.009 0.294 
NM_012341 GTPBP4 -0.550 -0.161 -0.248 -0.353 -0.706 -0.528 0.005 0.246 0.082 0.120 0.001 0.031 
NM_012414 RAB3-GAP150 0.242 -0.192 -0.122 0.233 1.247 0.073 0.114 0.283 0.342 0.122 0.008 0.127 
NM_013348 KCNJ14 -0.344 0.554 -0.144 -0.187 0.969 -0.124 0.243 0.034 0.142 0.088 0.027 0.352 
NM_013352 SART2 0.219 0.056 0.148 0.571 0.590 0.202 0.108 0.342 0.295 0.000 0.000 0.059 
NM_013391 DMGDH 0.214 0.089 0.028 -0.064 0.745 -0.128 0.252 0.356 0.370 0.358 0.034 0.141 
NM_013450 BAZ2B -0.191 0.158 -0.206 -0.270 -0.776 -0.038 0.288 0.180 0.042 0.282 0.015 0.340 
NM_014051 TMEM14A -0.009 0.430 -0.072 -0.155 0.684 0.454 0.374 0.070 0.340 0.270 0.035 0.037 
NM_014230 SRP68 -0.479 -0.207 0.097 -0.505 -0.721 -0.274 0.038 0.111 0.174 0.007 0.008 0.142 
NM_014383 TZFP 1.362 -0.245 0.074 0.007 0.923 0.056 0.133 0.352 0.240 0.325 0.002 0.172 
NM_014619 GRIK4 0.079 0.162 -0.553 -0.074 0.707 0.090 0.264 0.198 0.104 0.281 0.005 0.316 
NM_014669 NUP93 -0.213 0.000 -0.415 -0.357 -0.611 -0.135 0.040 0.375 0.000 0.024 0.019 0.192 
NM_014765 TOMM20 -0.196 0.075 -0.114 -0.130 -0.801 -0.143 0.215 0.083 0.102 0.343 0.008 0.128 
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NM_015839 FCN2 0.382 -0.233 -0.117 -0.075 0.602 -0.440 0.162 0.182 0.204 0.170 0.001 0.168 
NM_015922 H105E3 0.371 0.188 -0.031 0.261 0.601 0.179 0.048 0.099 0.339 0.020 0.017 0.091 
NM_015984 UCHL5 -0.269 -0.070 -0.068 -0.499 -0.698 -0.171 0.091 0.254 0.340 0.000 0.014 0.024 
NM_016142 HSD17B12 0.111 0.120 0.127 -0.222 -0.682 0.027 0.170 0.192 0.260 0.002 0.002 0.347 
NM_016347 CML2 0.282 -0.479 -0.412 -0.105 0.670 -0.014 0.148 0.241 0.019 0.083 0.026 0.231 
NM_017665 ZCCHC10 -0.134 -0.074 -0.051 0.115 0.619 -0.159 0.338 0.304 0.039 0.121 0.000 0.186 
NM_017754 C6orf107 -0.077 0.133 0.194 -0.073 -0.971 -0.092 0.347 0.061 0.221 0.318 0.001 0.341 
NM_018117 WDR11 -0.195 0.161 -0.086 -0.305 -0.605 -0.457 0.218 0.282 0.364 0.216 0.033 0.080 
NM_018119 POLR3E 0.206 -0.069 -0.811 0.069 -0.593 0.267 0.300 0.231 0.167 0.362 0.011 0.190 
NM_018170 P15RS -0.508 -0.008 0.146 -0.298 -0.590 -0.103 0.011 0.368 0.272 0.213 0.000 0.278 
NM_018439 IMPACT -0.253 -0.099 -0.140 -0.350 -0.813 -0.510 0.160 0.315 0.222 0.076 0.000 0.002 
NM_020128 MDM1 -0.241 0.049 -0.019 -0.427 -0.601 -0.155 0.196 0.344 0.372 0.025 0.013 0.314 
NM_020158 EXOSC5 -0.513 0.021 -0.267 -0.579 -0.644 -0.034 0.003 0.360 0.216 0.020 0.021 0.309 
NM_020402 CHRNA10 0.263 0.021 -0.031 0.018 0.698 0.286 0.343 0.360 0.351 0.372 0.019 0.141 
NM_020414 DDX24 -0.039 -0.022 -0.483 -0.301 -0.609 -0.179 0.277 0.208 0.045 0.046 0.025 0.123 
S82198 CTRC -0.107 -0.090 0.084 -0.099 0.798 0.141 0.292 0.250 0.327 0.338 0.048 0.200 
U17989 STRN3 0.586 0.192 -0.251 0.111 0.879 -0.246 0.053 0.072 0.279 0.343 0.020 0.199 
X51630 WT1 -0.434 -0.037 0.306 -0.090 0.625 0.203 0.069 0.356 0.007 0.329 0.002 0.053 
X69111 ID3 0.122 0.491 -0.054 -0.043 0.813 0.252 0.315 0.018 0.366 0.373 0.041 0.096 
X73079 PIGR -0.011 0.378 -0.571 -0.544 -0.616 0.195 0.374 0.047 0.017 0.000 0.047 0.282 
Z83947 - 0.102 0.146 -0.073 0.539 1.046 0.240 0.322 0.263 0.370 0.090 0.044 0.102 
AJ011593 - -0.481 -0.036 -0.245 0.314 0.752 0.553 0.264 0.375 0.294 0.107 0.034 0.236 
AJ227861 - 0.404 -0.428 -0.199 -0.208 0.682 0.086 0.088 0.130 0.251 0.124 0.023 0.267 
X00094 - -0.043 0.176 -0.130 0.221 0.664 -0.432 0.372 0.247 0.352 0.266 0.044 0.062 
X51779 - 0.264 0.297 0.277 0.127 0.617 -0.038 0.152 0.207 0.017 0.050 0.015 0.357 
X58060 - 0.111 0.130 0.483 0.206 0.628 0.003 0.345 0.235 0.137 0.321 0.004 0.365 
X63966 - 0.093 -0.215 0.003 0.074 0.698 0.008 0.348 0.227 0.375 0.209 0.032 0.349 
X64982 - -0.127 0.017 -0.207 -0.334 -1.491 0.012 0.110 0.374 0.333 0.138 0.021 0.370 
AK000561 - 0.281 -0.090 -0.026 0.276 0.636 -0.147 0.185 0.318 0.368 0.094 0.003 0.308 
AK024252 - 0.007 0.039 -0.079 -0.483 0.702 0.613 0.375 0.371 0.313 0.147 0.011 0.061 
AK024527 - 0.345 0.081 0.097 0.749 0.615 -0.550 0.175 0.164 0.348 0.076 0.002 0.221 
NM_013318 - -0.072 -0.171 -0.143 -0.102 0.885 0.003 0.227 0.226 0.127 0.350 0.033 0.365 
NM_014116 - 0.019 0.270 0.038 0.092 0.946 0.102 0.370 0.209 0.373 0.063 0.001 0.100 
NM_014132 - -0.518 -0.135 -0.015 -0.556 -0.640 -0.464 0.000 0.194 0.374 0.032 0.007 0.078 
NM_012107 - -0.308 -0.158 0.009 -0.336 -0.648 -0.043 0.196 0.344 0.375 0.251 0.026 0.374 
NM_015883 - 0.412 -0.444 0.204 0.132 0.599 -0.173 0.222 0.302 0.110 0.013 0.037 0.278 
M87931 - 0.127 -0.021 -0.125 -0.001 -0.728 -0.076 0.154 0.370 0.067 0.375 0.000 0.173 
D28384 - 0.315 0.182 0.334 0.384 0.600 0.302 0.012 0.261 0.049 0.026 0.037 0.168 
NM_014660 - -0.121 0.091 -0.005 -0.440 -0.668 0.100 0.278 0.353 0.375 0.035 0.016 0.347 
AF009286 - 0.039 0.475 0.159 -0.181 0.685 -0.721 0.355 0.013 0.308 0.028 0.003 0.160 
AF009288 - -0.181 0.116 -0.508 -0.366 1.066 -0.266 0.340 0.360 0.233 0.054 0.026 0.081 
AF009308 - 0.282 0.021 -0.071 0.427 0.607 0.348 0.043 0.335 0.261 0.042 0.007 0.000 
AF064851 - -0.036 -0.101 0.105 -0.188 -0.670 -0.071 0.371 0.278 0.247 0.082 0.045 0.316 
NM_017604 - -0.224 0.185 -0.291 0.213 0.713 -0.003 0.278 0.250 0.206 0.173 0.008 0.375 
U10515 - 0.001 0.625 0.188 0.355 -0.581 0.033 0.375 0.115 0.342 0.280 0.040 0.369 
U17628 - 0.269 -0.074 0.127 -0.076 -0.755 -0.017 0.038 0.258 0.260 0.327 0.005 0.358 
NM_018626 - 0.325 0.140 0.373 -0.053 1.623 0.025 0.070 0.307 0.023 0.196 0.029 0.354 
Y11718 - 0.083 -0.023 -0.579 0.334 0.856 0.340 0.351 0.370 0.219 0.175 0.031 0.261 
U46119 - -0.029 -0.036 0.173 -0.097 -0.754 -0.080 0.343 0.208 0.284 0.338 0.010 0.213 
AB018319 KIAA0776 -0.305 -0.154 -0.077 -0.474 -0.740 -0.090 0.017 0.237 0.336 0.044 0.021 0.325 
AB020626 KIAA0819 0.045 0.102 0.366 0.491 0.616 -0.106 0.364 0.357 0.053 0.063 0.035 0.030 
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AB033027 KIAA1201 -0.245 0.269 -0.155 -0.276 0.609 0.199 0.162 0.087 0.278 0.119 0.029 0.062 
AB037851 KIAA1430 -0.349 -0.091 0.063 -0.302 -0.623 -0.242 0.084 0.169 0.356 0.211 0.004 0.112 
AB046833 KIAA1613 0.075 0.079 0.279 -0.145 0.654 0.398 0.260 0.361 0.138 0.080 0.021 0.128 
AF035282 C1orf21 0.167 0.067 -0.120 -0.157 -0.634 0.003 0.290 0.363 0.320 0.350 0.000 0.365 
AF056431 - -0.288 -0.117 0.166 0.264 0.701 0.144 0.245 0.013 0.200 0.125 0.029 0.107 
AF070642 LOC253982 -0.129 0.102 0.016 -0.486 0.607 0.348 0.038 0.327 0.371 0.000 0.042 0.047 
AF083125 - -0.397 0.173 -0.103 -0.038 -0.913 -0.263 0.044 0.332 0.318 0.365 0.012 0.282 
AF086489 LOC91801 -0.115 -0.429 0.028 -0.342 -0.689 -0.118 0.039 0.029 0.352 0.044 0.012 0.276 
AF230800 - -0.097 -0.030 0.040 0.198 0.667 0.063 0.221 0.373 0.307 0.286 0.010 0.290 
AF237700 - -0.443 0.026 -0.595 -0.349 -0.791 0.243 0.092 0.374 0.187 0.002 0.001 0.280 
AF275808 SVH 0.274 0.148 -0.363 0.365 0.666 -0.072 0.166 0.200 0.245 0.236 0.001 0.318 
AK000967 PIP3AP 0.388 -0.078 0.130 0.062 0.635 0.056 0.074 0.348 0.247 0.336 0.046 0.249 
AK001433 DKFZP566F2124 -0.277 -0.045 0.034 -0.248 -0.655 -0.073 0.146 0.343 0.369 0.244 0.013 0.303 
AK002014 C6orf70 -0.657 -0.070 0.044 -0.477 -0.636 -0.424 0.098 0.364 0.370 0.311 0.028 0.136 
AK021730 - -0.404 0.334 0.115 0.032 0.649 -0.251 0.195 0.316 0.339 0.338 0.020 0.228 
AK021803 EBF 0.319 0.152 0.274 -0.007 0.740 0.247 0.090 0.223 0.287 0.280 0.002 0.044 
AK021810 - -0.026 1.009 0.060 -0.028 -0.671 -0.223 0.372 0.236 0.353 0.273 0.024 0.276 
AK022179 KIAA1414 0.129 -0.108 0.222 0.754 0.593 -0.196 0.330 0.206 0.135 0.099 0.000 0.153 
AK022181 - 0.300 0.199 0.344 0.538 0.842 0.409 0.199 0.161 0.177 0.235 0.047 0.218 
AK022212 FLJ12150 0.167 -0.001 0.072 -0.034 -0.760 0.275 0.236 0.375 0.292 0.370 0.040 0.238 
AK022361 - 0.648 -0.221 0.196 0.333 0.613 0.059 0.247 0.304 0.328 0.214 0.035 0.184 
AK022461 - 0.449 -0.039 0.030 0.073 0.737 -0.137 0.161 0.012 0.360 0.195 0.023 0.171 
AK022764 - 0.083 0.632 0.542 0.559 0.611 -0.068 0.272 0.188 0.145 0.075 0.001 0.354 
AK022971 - -0.140 -0.427 0.208 -0.192 -0.684 0.131 0.117 0.026 0.242 0.284 0.008 0.343 
AK023023 WDR26 -0.208 -0.094 -0.098 -0.078 -0.622 -0.158 0.023 0.066 0.228 0.170 0.001 0.033 
AK023048 FLJ12986 -0.475 0.359 -0.056 0.107 0.583 0.075 0.226 0.028 0.373 0.050 0.040 0.335 
AK023162 LOC90120 0.284 -0.072 0.050 0.356 0.661 0.325 0.215 0.366 0.352 0.139 0.015 0.056 
AK023636 MIR -0.233 0.093 -0.029 -0.273 -1.006 -0.130 0.292 0.259 0.367 0.123 0.003 0.240 
AK023829 - 0.076 -0.309 0.098 -0.376 -0.589 0.162 0.334 0.200 0.331 0.033 0.042 0.218 
AK023905 - 0.130 -0.305 -0.207 0.039 -0.627 -0.141 0.329 0.229 0.035 0.187 0.040 0.290 
AK025143 - 0.315 0.612 0.371 0.144 0.687 -0.228 0.013 0.257 0.234 0.014 0.008 0.194 
AK025317 - 0.067 0.203 -0.097 -0.046 -0.713 0.227 0.343 0.343 0.302 0.368 0.010 0.302 
AK025823 FLJ22170 -0.293 0.466 0.045 -0.196 0.628 -0.171 0.296 0.015 0.345 0.258 0.005 0.113 
AK025902 - 0.195 0.113 0.457 -0.181 0.822 0.195 0.199 0.301 0.087 0.257 0.006 0.200 
AK026373 HNRPA2B1 0.156 0.298 0.537 0.030 0.639 0.047 0.184 0.010 0.045 0.373 0.015 0.141 
AK026593 C16orf33 0.273 0.304 0.222 0.155 0.811 0.146 0.004 0.028 0.071 0.208 0.001 0.071 
AK026811 FLJ23053 0.331 0.131 0.096 -0.418 -0.667 -0.367 0.320 0.243 0.300 0.061 0.010 0.053 
AK026908 FLJ12517 -0.501 -0.048 -0.070 -0.481 -0.635 -0.493 0.013 0.308 0.273 0.016 0.029 0.001 
AK026995 FLJ23342 -0.036 0.313 -0.070 0.133 0.710 0.184 0.345 0.121 0.358 0.284 0.036 0.172 
AK027121 KLIP1 -0.108 -0.081 0.182 -0.479 -0.615 -0.263 0.174 0.176 0.002 0.009 0.008 0.005 
AL050145 - 0.421 0.110 0.489 -0.794 0.610 0.003 0.030 0.182 0.068 0.206 0.020 0.365 
AL133073 FLJ14904 0.016 0.145 -0.275 0.449 0.605 -0.397 0.374 0.312 0.246 0.132 0.040 0.116 
AL137450 - -0.299 -0.310 0.134 -0.551 -1.301 -0.157 0.258 0.073 0.251 0.072 0.039 0.294 
AL137597 C20orf110 -0.003 -0.171 -0.264 0.060 0.708 0.031 0.375 0.324 0.324 0.093 0.024 0.258 
AL359058 - 0.014 -0.152 -0.135 -0.285 -0.608 -0.267 0.368 0.181 0.328 0.028 0.005 0.217 
AL359563 - -0.069 -0.085 -0.408 -0.317 0.597 0.654 0.354 0.356 0.282 0.181 0.034 0.229 
AL442116 DKFZP566F0546 -0.214 -0.166 -0.178 0.160 0.803 0.061 0.284 0.230 0.219 0.226 0.020 0.363 
L19778 HIST1H2AG 0.398 -0.274 0.255 -0.003 -0.615 0.044 0.281 0.126 0.214 0.369 0.005 0.363 
L31942 - -0.201 -0.580 -0.362 -0.372 -0.716 -0.272 0.300 0.023 0.067 0.127 0.001 0.213 
NM_000035 ALDOB 0.017 0.226 0.781 -0.745 -1.405 0.102 0.132 0.190 0.173 0.205 0.042 0.227 
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NM_002894 RBBP8 -0.337 -0.014 -0.007 -0.253 -0.630 -0.166 0.001 0.373 0.374 0.122 0.001 0.162 
NM_003657 BCAS1 0.228 0.250 0.080 -0.060 0.675 0.134 0.184 0.100 0.266 0.371 0.019 0.216 
NM_004541 ZNF183 0.387 0.268 -0.130 -0.021 0.607 -0.069 0.140 0.091 0.218 0.374 0.044 0.274 
NM_006346 C13orf24 -0.400 -0.057 0.093 -0.508 -0.601 -0.562 0.016 0.301 0.343 0.001 0.001 0.000 
NM_006452 PAICS -0.121 0.044 -0.182 -0.263 -0.756 -0.028 0.344 0.351 0.255 0.292 0.044 0.363 
NM_006715 MAN2C1 0.183 0.180 -0.289 0.015 -0.648 0.671 0.138 0.223 0.096 0.373 0.046 0.202 
NM_007042 RPP14 -0.341 0.004 0.308 -0.160 -0.672 0.103 0.070 0.375 0.155 0.339 0.000 0.299 
NM_014106 FLJ20582 0.018 0.037 0.297 0.290 0.681 -0.176 0.370 0.360 0.126 0.122 0.016 0.131 
NM_014639 KIAA0372 -0.120 -0.012 -0.081 -0.467 -0.754 -0.083 0.218 0.370 0.350 0.052 0.005 0.243 
NM_014648 DZIP3 -0.521 -0.009 0.003 -0.334 -0.778 -0.015 0.012 0.375 0.375 0.224 0.008 0.374 
NM_015369 TP53TG3 0.029 -0.264 0.294 0.239 0.604 -0.054 0.365 0.202 0.026 0.215 0.034 0.362 
NM_015997 CGI-41 -0.118 0.195 -0.026 -0.216 -0.778 0.118 0.296 0.293 0.360 0.230 0.036 0.345 
NM_016019 LUC7L2 -0.394 -0.092 -0.058 -0.201 -0.588 -0.315 0.055 0.221 0.339 0.296 0.006 0.069 
NM_016140 CGI-38 0.607 -0.040 0.681 0.181 0.661 -0.167 0.119 0.265 0.118 0.219 0.042 0.234 
NM_016618 LOC51315 -0.530 0.151 0.456 -0.543 -0.971 -0.309 0.056 0.250 0.058 0.112 0.000 0.182 
NM_017732 PH-4 -0.378 -0.046 -0.215 -0.085 -0.610 -0.163 0.049 0.371 0.102 0.356 0.012 0.291 
NM_017753 PRG-3 -0.185 -0.087 -0.232 0.507 0.644 -0.384 0.238 0.345 0.224 0.116 0.005 0.124 
NM_018112 C9orf87 -0.578 0.001 0.383 -0.010 0.603 0.003 0.211 0.375 0.116 0.331 0.003 0.365 
NM_018214 LRRC1 -0.065 0.070 -0.301 -0.144 0.584 0.000 0.332 0.360 0.229 0.332 0.010 0.375 
NM_018360 CXorf15 -0.218 -0.168 -0.254 -0.146 -1.025 -0.552 0.285 0.264 0.113 0.364 0.008 0.065 
NM_018502 PRO1580 -0.155 -0.023 0.189 0.198 -0.630 -0.304 0.100 0.371 0.239 0.209 0.006 0.002 
NM_020184 CNNM4 -0.044 0.545 -0.216 0.081 0.616 -0.092 0.356 0.142 0.118 0.318 0.045 0.251 
NM_020317 NPD014 0.418 0.105 0.137 0.052 0.690 0.512 0.082 0.184 0.307 0.370 0.029 0.000 
U79293 - -0.069 -0.069 -0.033 -0.135 0.717 0.109 0.289 0.358 0.355 0.212 0.048 0.350 
X99661 DKFZp667M2411 0.222 0.135 0.216 0.118 0.589 0.004 0.128 0.275 0.211 0.201 0.005 0.375 
Y11163 RPL39 -0.080 -0.239 -0.080 0.064 0.708 -0.426 0.359 0.259 0.360 0.345 0.029 0.188 
AB033118 ZDHHC8 0.424 0.230 0.006 0.341 0.715 0.922 0.037 0.141 0.375 0.035 0.094 0.001 
AB040916 ZBTB2 0.109 0.224 -0.304 0.310 0.124 0.770 0.279 0.145 0.095 0.238 0.367 0.029 
AF007132 ABHD5 0.415 -0.301 -0.507 0.343 0.249 -0.848 0.135 0.223 0.106 0.038 0.085 0.042 
AF086183 APLP2 0.360 0.483 -0.126 -0.284 0.184 1.028 0.273 0.093 0.005 0.097 0.230 0.017 
AF178983 RBJ 0.214 0.266 1.028 -0.134 0.176 -0.633 0.134 0.239 0.106 0.340 0.258 0.035 
AF182404 SLC25A19 -0.207 0.248 -0.155 -0.112 0.066 -0.627 0.014 0.080 0.278 0.111 0.295 0.002 
AF217187 PPA2 0.260 0.169 -0.376 -0.141 -0.060 -0.666 0.083 0.002 0.004 0.173 0.292 0.015 
AF218008 FZR1 0.355 -0.231 0.199 0.327 0.475 0.603 0.052 0.129 0.185 0.166 0.072 0.009 
AJ008129 FMNL1 -0.010 -0.281 0.016 0.339 -0.256 0.692 0.375 0.002 0.372 0.052 0.029 0.000 
AJ008135 MAP3K14 0.445 -0.205 0.009 0.093 -0.431 0.620 0.152 0.083 0.368 0.332 0.115 0.002 
AK000208 MGC50844 0.347 -1.043 0.012 0.083 -0.856 -0.853 0.044 0.155 0.172 0.359 0.198 0.040 
AK000724 KPNA6 -0.393 0.035 -0.428 0.115 -0.650 -1.882 0.119 0.368 0.311 0.370 0.346 0.030 
AK000770 B3GNT7 0.067 0.350 0.210 -0.094 0.187 1.043 0.349 0.079 0.034 0.315 0.243 0.021 
AK002095 RAB11-FIP4 -0.096 0.167 0.024 -0.020 -0.108 0.651 0.329 0.325 0.367 0.373 0.361 0.002 
AK022889 ZNF408 0.387 0.279 0.066 -0.363 0.117 0.606 0.008 0.011 0.324 0.181 0.325 0.005 
AK023142 FIGNL1 -0.357 0.142 -0.112 -0.261 -0.143 -0.608 0.056 0.318 0.243 0.155 0.332 0.036 
AK024030 FLJ13855 -0.141 0.408 -0.019 0.007 0.262 0.627 0.076 0.003 0.374 0.325 0.130 0.006 
AK024361 FLJ14299 0.192 -0.062 -0.029 -0.145 0.210 0.624 0.250 0.350 0.365 0.095 0.253 0.009 
AK025362 NOD27 -0.174 -0.124 0.463 0.086 -0.010 0.653 0.117 0.310 0.137 0.266 0.375 0.007 
AK025442 TXNDC5 0.053 0.374 -0.167 -0.223 0.279 0.598 0.356 0.001 0.239 0.258 0.248 0.021 
AK026271 NUP37 -0.339 -0.139 -0.047 -0.415 -0.430 -0.643 0.023 0.184 0.344 0.159 0.000 0.000 
AK026340 ARIH1 0.165 0.083 -0.304 -0.011 -0.109 1.286 0.192 0.365 0.255 0.236 0.352 0.013 
AK026524 POLR3H 0.107 0.276 0.069 -0.051 0.428 0.595 0.302 0.230 0.359 0.348 0.223 0.031 
AL050217 DHRS1 0.426 0.181 0.347 -0.249 -0.103 -0.779 0.235 0.229 0.206 0.142 0.269 0.034 
AL133108 ATBF1 0.507 -0.202 0.234 0.147 0.128 0.815 0.205 0.305 0.291 0.269 0.090 0.009 




Log2(Fold Change) p-value 

















M21551 NMB -0.054 -0.043 -0.056 -0.020 0.442 -0.614 0.349 0.370 0.355 0.368 0.145 0.000 
NM_000166 GJB1 0.019 -0.107 0.066 0.464 0.213 -0.660 0.373 0.338 0.371 0.159 0.329 0.024 
NM_000308 PPGB 0.219 0.254 0.150 -0.067 0.683 0.612 0.180 0.105 0.119 0.319 0.063 0.032 
NM_000479 AMH 0.106 0.294 0.257 -0.105 0.273 0.867 0.289 0.018 0.062 0.256 0.213 0.000 
NM_000534 PMS1 -0.528 -0.252 -0.058 -0.303 -0.013 -0.585 0.120 0.206 0.299 0.195 0.375 0.042 
NM_001055 SULT1A1 0.374 0.393 0.227 0.405 0.443 0.607 0.017 0.098 0.137 0.003 0.155 0.001 
NM_001609 ACADSB -0.245 -0.393 -0.309 -0.091 -0.218 -0.620 0.001 0.052 0.039 0.349 0.283 0.026 
NM_002133 HMOX1 0.439 0.206 0.032 0.160 0.556 0.846 0.129 0.219 0.371 0.137 0.023 0.048 
NM_002199 IRF2 0.070 0.286 -0.461 -0.232 0.035 0.692 0.320 0.223 0.040 0.047 0.370 0.003 
NM_002202 ISL1 0.027 0.334 0.085 -0.231 0.200 0.605 0.295 0.010 0.328 0.045 0.277 0.004 
NM_002273 KRT8 -0.079 0.160 0.991 0.176 0.202 -0.585 0.348 0.232 0.163 0.115 0.178 0.030 
NM_002914 RFC2 -0.394 -0.039 0.074 -0.206 -0.286 -0.731 0.082 0.366 0.358 0.145 0.001 0.000 
NM_002979 SCP2 0.072 -0.144 -0.007 0.099 -0.222 -0.667 0.330 0.192 0.374 0.280 0.216 0.029 
NM_003108 SOX11 0.367 0.300 -0.164 0.208 0.340 0.654 0.180 0.087 0.287 0.087 0.232 0.002 
NM_003560 PLA2G6 0.426 -0.004 0.059 0.370 0.413 0.697 0.013 0.375 0.359 0.029 0.005 0.001 
NM_003764 STX11 0.063 -0.102 -0.328 -0.153 -0.195 -0.587 0.297 0.335 0.097 0.055 0.245 0.017 
NM_003943 GENX-3414 0.495 -0.015 -0.206 -0.363 -0.257 -0.598 0.132 0.372 0.276 0.036 0.163 0.003 
NM_004392 DACH1 0.078 0.179 0.287 -0.214 -0.073 0.698 0.351 0.230 0.031 0.241 0.371 0.005 
NM_004953 EIF4G1 0.449 0.141 -0.089 -0.267 -0.247 0.673 0.067 0.325 0.302 0.153 0.288 0.015 
NM_005242 F2RL1 0.266 -0.671 0.194 0.313 0.418 -1.411 0.272 0.229 0.205 0.244 0.116 0.010 
NM_006110 CD2BP2 0.036 0.080 0.260 -0.613 0.278 0.632 0.365 0.310 0.146 0.153 0.088 0.001 
NM_006235 POU2AF1 0.367 0.303 0.256 0.638 0.564 0.659 0.174 0.083 0.286 0.081 0.057 0.000 
NM_006529 GLRA3 0.442 0.190 -0.166 0.120 0.314 0.646 0.046 0.283 0.170 0.326 0.030 0.025 
NM_006639 CYSLTR1 -0.053 0.252 -0.267 -0.029 -0.087 -0.630 0.369 0.220 0.233 0.374 0.153 0.038 
NM_006876 B3GNT6 0.518 0.189 -0.338 0.415 0.435 0.654 0.059 0.268 0.027 0.166 0.075 0.003 
NM_006943 SOX12 0.271 0.180 -0.051 0.356 0.392 0.637 0.139 0.236 0.354 0.025 0.245 0.003 
NM_007031 HSF2BP -0.195 -0.017 -0.372 -0.279 0.071 0.707 0.261 0.373 0.221 0.186 0.351 0.034 
NM_007169 PEMT -0.254 -0.212 0.060 -0.113 0.056 -0.606 0.087 0.142 0.322 0.055 0.355 0.001 
NM_007185 TNRC4 -0.233 -0.023 -0.081 -0.210 -0.028 -0.712 0.134 0.368 0.242 0.049 0.355 0.004 
NM_007358 M96 -0.245 0.217 -0.156 -0.157 -0.032 0.660 0.014 0.164 0.101 0.220 0.370 0.000 
NM_012264 C22orf5 0.414 -0.014 -0.047 -0.135 -0.067 0.636 0.107 0.372 0.370 0.330 0.363 0.000 
NM_013975 LIG3 0.239 0.085 -0.068 0.042 0.037 0.750 0.257 0.358 0.359 0.366 0.370 0.000 
NM_014275 MGAT4B 0.205 -0.025 -0.021 0.333 -0.154 0.585 0.215 0.369 0.373 0.008 0.229 0.000 
NM_014384 ACAD8 -0.427 -0.297 0.061 -0.497 -0.552 -0.649 0.011 0.011 0.308 0.008 0.001 0.000 
NM_014870 KIAA0478 0.577 0.055 -0.020 0.099 0.109 0.803 0.200 0.359 0.373 0.339 0.354 0.024 
NM_015239 AGTPBP1 -0.269 0.024 0.379 -0.617 -0.183 -0.588 0.106 0.274 0.110 0.113 0.107 0.006 
NM_015908 ARS2 0.454 0.364 0.081 0.216 0.763 0.776 0.001 0.055 0.059 0.091 0.088 0.047 
NM_015911 LOC51058 -0.091 0.055 0.185 0.028 0.370 0.998 0.269 0.368 0.153 0.373 0.050 0.038 
NM_015974 CRYL1 -0.149 -0.253 -0.057 0.248 -0.090 -0.632 0.283 0.185 0.339 0.285 0.360 0.000 
NM_016093 RPL26L1 -0.306 -0.140 0.072 -0.307 -0.468 -0.583 0.030 0.001 0.254 0.028 0.062 0.000 
NM_016292 TRAP1 -0.282 -0.404 -0.189 -0.403 -1.314 -0.754 0.193 0.002 0.022 0.058 0.100 0.000 
NM_016558 SCAND1 0.463 0.403 -0.251 0.332 0.352 0.690 0.046 0.037 0.281 0.001 0.218 0.000 
NM_016929 CLIC5 -0.030 -0.014 0.039 0.134 -0.001 0.593 0.374 0.172 0.152 0.084 0.375 0.019 
NM_017897 FLJ20604 0.328 0.010 -0.201 -0.404 -0.046 -0.597 0.066 0.373 0.083 0.001 0.354 0.045 
NM_018108 C14orf130 -0.016 0.021 0.009 0.396 -0.498 0.694 0.320 0.361 0.375 0.044 0.276 0.049 
NM_018165 PB1 0.124 0.350 0.163 -0.339 0.155 0.616 0.298 0.093 0.301 0.020 0.307 0.002 
NM_020353 PLSCR4 -0.269 0.301 0.158 0.381 -0.279 -0.654 0.200 0.102 0.303 0.104 0.167 0.025 
Y11162 RPL18A -0.006 -0.116 0.182 -0.058 0.519 1.951 0.375 0.173 0.297 0.142 0.016 0.001 
AJ002969 - -0.373 -0.110 -0.017 -0.129 0.490 1.695 0.001 0.313 0.374 0.103 0.140 0.023 
U79301 - 0.126 0.079 -0.377 0.314 -0.348 -0.594 0.331 0.263 0.240 0.305 0.134 0.022 
X02067 - -0.043 -0.312 0.015 -0.200 -0.174 0.842 0.365 0.096 0.354 0.080 0.318 0.013 




Log2(Fold Change) p-value 

















NM_004908 - 0.244 0.118 -0.055 0.214 -0.253 -0.583 0.067 0.237 0.357 0.176 0.252 0.040 
AK027253 - -0.297 -0.377 0.192 0.074 -0.066 -0.633 0.169 0.316 0.104 0.315 0.301 0.031 
AK024615 - -0.075 0.083 0.265 0.120 0.227 -1.758 0.281 0.321 0.088 0.078 0.202 0.024 
NM_013307 - 0.232 0.450 -0.055 0.156 0.261 1.149 0.077 0.147 0.307 0.244 0.194 0.020 
AL137631 - 0.302 0.022 -0.225 0.049 0.171 0.670 0.033 0.368 0.091 0.119 0.090 0.000 
NM_014956 - -0.095 -0.088 -0.253 -0.276 0.090 -0.667 0.287 0.280 0.202 0.020 0.327 0.009 
NM_014590 - -0.021 -0.225 -0.107 -0.216 0.173 -0.738 0.359 0.220 0.275 0.129 0.333 0.020 
D17215 - -0.296 0.125 -0.167 -0.187 0.035 -0.840 0.139 0.310 0.212 0.161 0.361 0.013 
D55644 - -0.287 -0.135 -0.471 -0.248 -0.536 -0.674 0.039 0.208 0.110 0.142 0.220 0.045 
AB019565 - -0.075 -0.107 0.098 0.554 -0.241 1.075 0.363 0.327 0.021 0.000 0.304 0.008 
NM_016278 - -0.187 -0.046 -0.095 -1.972 -0.224 -0.590 0.294 0.366 0.305 0.108 0.137 0.001 
NM_016317 - 0.087 -0.030 0.467 0.010 0.273 -0.925 0.079 0.287 0.217 0.375 0.315 0.036 
L09078 - -0.029 0.260 -0.280 -1.576 0.302 -0.584 0.373 0.101 0.094 0.144 0.163 0.042 
L23401 - 0.050 0.085 0.104 -0.163 0.502 0.980 0.353 0.358 0.228 0.161 0.040 0.001 
AF086493 - -0.160 -0.548 0.347 0.055 -0.002 -0.947 0.267 0.261 0.135 0.366 0.375 0.048 
S39891 - 0.199 0.076 -0.195 -0.456 -0.118 -0.668 0.170 0.334 0.152 0.029 0.324 0.012 
AB046861 KIAA1641 0.078 0.355 0.157 -0.182 0.184 0.628 0.350 0.017 0.297 0.272 0.238 0.001 
AF007137 - -0.647 -0.166 -0.047 -0.515 -1.445 -0.707 0.071 0.326 0.366 0.086 0.109 0.034 
AF086255 - 0.077 -0.150 0.073 -0.183 -0.034 0.583 0.347 0.309 0.360 0.205 0.373 0.006 
AF088024 - 0.431 0.307 -0.196 -0.007 0.158 0.673 0.052 0.111 0.328 0.280 0.130 0.024 
AF129928 - 0.112 0.101 -0.154 0.236 0.129 0.599 0.155 0.347 0.209 0.233 0.286 0.016 
AF279773 - 0.134 0.033 0.133 0.058 0.041 -0.590 0.233 0.367 0.346 0.200 0.362 0.040 
AK000185 - -0.395 0.178 0.480 -0.012 -0.294 -0.713 0.000 0.045 0.132 0.373 0.073 0.049 
AK000401 KIAA1728 0.175 0.094 0.075 -0.268 0.385 0.603 0.274 0.241 0.353 0.176 0.105 0.001 
AK000422 STARD10 0.552 -0.069 0.167 0.852 0.258 0.732 0.004 0.342 0.184 0.000 0.242 0.007 
AK021614 - -0.184 -0.443 -0.049 0.100 -0.677 -2.474 0.262 0.346 0.208 0.365 0.233 0.024 
AK022239 - -0.251 0.014 0.277 0.129 -0.099 -0.926 0.144 0.000 0.128 0.286 0.366 0.044 
AK022298 - -0.101 0.187 -0.089 0.183 0.270 0.631 0.329 0.252 0.358 0.351 0.293 0.002 
AK022381 - -0.030 0.220 0.370 0.025 0.194 0.606 0.370 0.215 0.138 0.210 0.015 0.035 
AK022645 - -0.143 0.188 -0.172 0.039 0.190 0.581 0.188 0.231 0.077 0.272 0.076 0.000 
AK022681 C6orf62 0.493 0.550 0.451 0.304 0.413 0.665 0.158 0.016 0.028 0.174 0.158 0.002 
AK022849 FLJ12787 -0.088 0.279 -0.066 0.333 -0.301 -0.946 0.067 0.219 0.337 0.216 0.243 0.014 
AK023158 FLJ13096 0.086 0.253 0.501 0.513 -0.134 -0.788 0.345 0.297 0.270 0.083 0.344 0.043 
AK024488 FLJ21438 0.123 -1.423 -0.019 0.315 0.039 -0.629 0.100 0.136 0.374 0.099 0.370 0.013 
AK024842 GNPTAG -0.151 0.077 0.052 0.391 0.410 0.782 0.267 0.342 0.277 0.123 0.201 0.000 
AK024946 - -0.202 -0.101 -0.194 0.035 0.001 -0.691 0.232 0.305 0.268 0.372 0.375 0.013 
AK025215 C13orf18 0.069 0.496 -0.170 0.019 -0.044 -1.530 0.316 0.131 0.125 0.000 0.351 0.031 
AK027013 FLJ23360 0.248 0.018 -0.105 0.260 0.343 0.693 0.062 0.374 0.049 0.215 0.075 0.013 
AL049387 - -0.033 0.084 -0.064 0.097 0.320 -0.643 0.350 0.346 0.367 0.368 0.337 0.031 
AL049452 - 0.315 0.281 0.109 -0.300 -0.261 1.353 0.048 0.278 0.348 0.161 0.363 0.019 
AL137487 LOC116437 -0.127 -0.114 -0.239 -0.486 0.514 0.589 0.135 0.104 0.326 0.160 0.007 0.020 
AL157505 - 0.106 -0.553 0.277 0.028 -0.321 0.867 0.354 0.161 0.095 0.000 0.101 0.013 
AL162066 C19orf12 -0.103 -0.099 -0.142 0.141 -0.276 0.616 0.313 0.320 0.149 0.344 0.249 0.049 
AL389954 - -0.199 1.265 0.207 0.245 0.112 -0.886 0.319 0.162 0.133 0.184 0.114 0.004 
NM_000485 APRT -0.250 -0.381 -0.279 -0.232 -0.192 -0.602 0.077 0.042 0.039 0.002 0.242 0.001 
NM_000726 CACNB4 -0.375 0.001 0.014 -0.354 0.448 -0.619 0.049 0.375 0.374 0.223 0.168 0.043 
NM_001611 ACP5 0.341 -0.228 0.347 -0.138 -0.012 -0.617 0.074 0.163 0.055 0.331 0.374 0.029 
NM_002631 PGD 0.502 0.246 -0.313 0.016 -0.053 0.725 0.013 0.162 0.213 0.374 0.369 0.012 
NM_003127 SPTAN1 0.057 0.502 0.437 -0.192 0.354 -0.712 0.334 0.188 0.000 0.265 0.098 0.016 
NM_003945 ATP6V0E 0.441 0.312 0.203 0.143 0.448 0.705 0.001 0.003 0.147 0.208 0.136 0.003 
NM_005688 ABCC5 -0.383 0.058 0.069 0.365 0.136 0.678 0.027 0.364 0.351 0.206 0.326 0.004 




Log2(Fold Change) p-value 

















NM_006423 RABAC1 0.094 0.307 0.474 0.180 0.269 0.627 0.183 0.043 0.027 0.100 0.278 0.000 
NM_014157 HSPC065 0.027 0.012 0.247 0.338 -0.285 -0.732 0.372 0.373 0.158 0.113 0.292 0.034 
NM_015703 CGI-96 -0.371 -0.118 -0.151 -0.265 -0.930 -0.776 0.003 0.224 0.090 0.206 0.111 0.000 
X01448 - 0.610 0.485 0.400 -0.003 0.154 0.999 0.259 0.154 0.225 0.369 0.186 0.024 














Housekeeping Gene for Normalization of qRT-PCR Data 
Initial attempts to utilize beta-actin (ACTB), a common housekeeping gene, for 
normalization of qRT-PCR results revealed variable expression of this gene in the fed-
batch.  Gamma-actin (ACTG1) expression profile also showed fluctuations, confirmed 
by qRT-PCR, during culture progression (Figure C.1).  This was corroborated by 
reports in literature that cautioned against the generic use of common housekeeping 
genes, beta-actin and glyceraldehyde-3-phosphate dehydrogenase (GAPDH), as 
normalization controls in qRT-PCR experiments.  It was instead recommended that 
other genes with constant expression specific for the system of study be utilized for 
this purpose (Bas et al. 2004).  EEF1A1 gene expression was observed to be consistent 
in both batch and fed-batch from microarray results and qRT-PCR analyses confirms 
equal expression of EEF1A1 in the Control, batch and fed-batch samples (Figure C.1).  
It was thus adopted as the housekeeping gene for normalization of all qRT-PCR 
analyses reported. 
Figure C.1  Quantitative real-time PCR results of beta-actin, ACTB (from 4 
repeats), gamma-actin, ACTG1 (from 2 repeats) and eukaryotic translation 
elongation factor 1 alpha 1, EEF1A1 (from 12 repeats).  qRT-PCR fold change 
with respect to Control for batch (□) and fed-batch (■) represented by the bar 
charts.  Corresponding microarray fold change with respect to Control for batch 
(▲) and fed-batch (x) represented by the line graphs (note:  beta-actin not 






















































Calculations for cell yield per glutamine consumed 
 

















- 0.2 0.1 - 0.3 - 0.3 
Initial cell conc.* 
(106 cells/mL) 
0.3 0.3 0.3 0.35 0.35 0.35 0.35 
Max. viable cell 
conc. 
(106 cells/mL) 
2.53 4.49 4.10 1.51 4.11 1.67 6.65 
Glutamine conc. at 
max. cell conc. 
(mmol/L) 
0.815 0.200 0.100 0.297 0.300 0.691 0.300 
Feed volume at 
max. cell conc. (L) 
- 0.338 0.267 - 0.386 - 1.606 
Initial reactor 
volume (L) 
2.0 4.0 4.0 2.0 4.0 2.0 4.0 
1Total glutamine 
consumed (mmol) 




4.46 18.18 16.21 2.32 16.49 2.64 35.32 




700 2296 2654 527 1951 399 1090 
 
1Total glutamine consumed = [(initial conc. – final conc.)*initial reactor volume + feed volume*feed 
conc.]/[initial reactor volume + feed volume] 
 
2Total cells produced = [maximum viable cell conc.*(initial reactor volume + feed volume)] – (initial 
viable cell conc.*initial reactor volume) 
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